<SEC-DOCUMENT>0001558370-22-017554.txt : 20221114
<SEC-HEADER>0001558370-22-017554.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114070743
ACCESSION NUMBER:		0001558370-22-017554
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		49
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		221380125

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20220930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/13/2022 9:07:24 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 8e143db7-36fb-497e-9f49-a6e4d3caf13a -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:plx="http://www.protalix.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" xs:nil="true" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_5Rf5OZGRIUui7KVBnG-3-A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" xs:nil="true" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_MYDvw0JFgECXtpuniwnZrQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" sign="-" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_SD_ZzPZry0Kn3wCxqHuvyw">0.24</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" sign="-" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_ph-RG_FF60KNyDOGP_Etkw">0.48</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_nea46fNOSkqHFDBXe51eTg">0.07</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_whOWA2mtCEmlBgl3O8lO9w">0.09</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_dhtmIVfIYUWGH9gC4uv-ZA">47582733</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_kjEdenobfk2zKJAT8Z4QIw">43761769</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_rjgj7ZAm2UWpwyaBeAd0eg">49498105</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_pYAP2pu4iESAJ3e-bVKQng">45556647</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityCentralIndexKey" id="Tc_-glfFb_BQUi1hQXr-UW1Xg_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:CurrentFiscalYearEndDate" id="Tc_6ADnnZ4bZEa0hu_MENJrSw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:DocumentFiscalYearFocus" id="Tc_a14RITmB_EyJo7axC-HhpQ_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:DocumentFiscalPeriodFocus" id="Tc_kHJ2GcRpek2AN05n2ytBcA_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:AmendmentFlag" id="Tc_mCU0xgIxckCE0uVkoQwDug_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_Zw_3KOfSQU6x2J-upO1Hdg">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_TR-D_RlREEGMWjkHWnc9rQ">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_IAM58yfoSUWi7YyjTPtjww">P10Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_1vc1iVN5MUuWqVvagT41sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_oDtUP6CxnkePQUEErUteKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWdI5ZA6vUyC15HD3EjNzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o3NakbeXoEead8-t7k-62Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kCsglji7kOkuf4CbzkCjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6b9M0fMDnE-ONxperA-Nqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NsMLImWFUkKskcZiXRX0ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_csxCWMqCMUKoZEBkfV_2Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u-zmvKk_nE-TsUTpTrb0yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TSLrDFkfsUiXaEXbJNE19Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oi1iFnUfUk2j89URToy_FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li6VzojNEkm79l_inaRUZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_oaSi65tpAEmtBYUa7viC5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eR0GjrjuNk-nDafPkPNl-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf5bZps_2EenQQ2ZpXcHZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bD4jRYV9p0SrHNp39PFY8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AdqKFA4TTkyOitbYq9oh_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v6SRUqykhkq9NDJkMs8VCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_RB19xNug80KwnklS6AmRlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_7Y9PKaad7UCQjX_1X3wmIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mpZ3bzeTFkeJouERtLBqfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ULcGA7VYNkCKoZuU0B0qrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_rBqFi8FTzEq1WlKuF9bz3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_E6HX3L8o1UORIsdQUL7dMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_ivy2EExMakeWgn87BPkvjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_MXh1QMX0OECsjpG02kpLTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0crLeupio0SwfGQZ9ZvUtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_FrWFE9O6FU6tzt749aUeMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_weDWoM4FaEy6cA5rEgSlaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pveYO1f-lkC05eDMbh02IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_GM0fNZn86UWpPaTCwWm11w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-4dgoH7cSUStclwbyHvr5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_63ussK77mkmthjFePYZl1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jSgenlSB70S_SqMhXL6RSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KItA5s_IX0OM8e34BU2fSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FTvwbQ8tckqFhCmnA1b1uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ukBSADqu40uHabngZO-BlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_BukwyZ3SXUKm2PtgAfi0lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nMiBJOmnlUya-eSouKgGFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_D5y751RR1UqvCc-Q5th3_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_O1a6ViT3C0ewVHZtdm2T7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3bFqnnwhSkCeJGvIIsUgXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8IZaBt_-TE-hj4hdLTni3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kCjfzxrofkaqU5KXQCoK5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eooI9ZYRYUK3xtjGWM-3Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0XmRqyM5IkSNgT9vMbeyqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_HH1mRiFsa0qJN4a4_yJ33w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_fpSaaWnM_kqRxthhVgZ0dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sjuUQKwTikGShcjRQ3wqGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NzJ2ZKx5l0SOQAjJS-KHfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_lyC38x65I0G8pUXc-Tn39A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_IaxJhLjT5EG26liBngcw3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2022_uKl9eMIZyU6wmrR6-IFDvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_rxA6MsPFmkGcr9wRVnhiBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7H_2K0nM006KXiMtIxq9sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_7nrXjB6c6Eq4cT3hYF-X6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FZ5IV3EHuU2VQz4Oea9P-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_D2abpIHIxki6wHgQcLCQlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_TpBThY-o1UO9jj7QH2sP0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__e2stD8DXUakAd6Cgk7bXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Vftn1tQ1hUCzVmrnQgfT1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_OZrCQjIzZEa_Imuc6kFkfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FoX-isrF7k-mTWZnrW05yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P__KdEwYTE-FwaUrq-H-4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_6dFVaa8MP0mBiDmzAt8Y9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_-CFgg0SHbEuiMRjiTw4qOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0sCNP7rIoky5QN2CONKd6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_b3jRdtg_20SDBBcjXHfzTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Htz4Xmw9BUOG0UfER5r48w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_FwE5KZrKh0-_yTQHyIr5xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iwDdKv5AH0-AHSnrWhC_JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qayOenlWNEakzQ457tclgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_CpKx-mzFKEGNxFx6wijT_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainOfficersDirectorsAndOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-07</xbrli:startDate><xbrli:endDate>2022-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_GZzd7j7xTUuaSCT_sh1p-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainOfficersDirectorsAndOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_kkHU2uv0R0yTrJf1B14ytw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_QEMAQN-BDkGbFVEHLs5KjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Dh9X97v5V0KmJgH7rEd7Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_13_2022_To_10_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_46nzZWDXz0C-Ml2n7Gftvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-13</xbrli:startDate><xbrli:endDate>2022-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_QWJZhKTEsUGVicty8qY70w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2022_To_10_26_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ci7oO7k4IkeIa7oHLUkBFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wwuvWu9CNkGPR5tF60aEww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wMq9gBW5wk-NkT7WyGmXVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_S8KAN140aUmNwYXLjfuU2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3mw68fgma0ShyyRQq7AwBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_W1rR-tiQQ0WX0Mrz4mB2wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_BAHkbJYPMkyDVzUoFG5QDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_5rkf-nGdtka3BrgWc-Tu5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r9AEUZN090WxWVevOrEmew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_NS6ZViowGUycZBQ7Si9mxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2022_IeK4AGoGu0qrXYZvP3Bvig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_3n4b8unPO0K-5i9HzEyFQQ"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_6_2ecVNG4kOwBZw8VWtz7Q"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_HAxVYURivkuRqA9qj9Po-g_21_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_nmq4JRk3-EORS1MItaKcMA_9_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ITEbUeMAOE6-Yk33cXimLQ_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_AuSuHn18CUWgsioZExaEAA_35_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_thi13ixbeUuHkrsQiITRkA_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_mHwqVUwizEODPiRPsC9Dbg_22_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_7myOcM5WM0WoI1yAP70r_w_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rTnP4f7RQkGQNUF9AcRd8Q_25_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3tg0jVyZPkSbuRThcWb5oQ_32_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Vg3ciLhkvU2HwfGsU6fBMA_16_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc__yTrLzsAdUy18I39T73gtQ_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_IdjnDwkcNU2CiDqYLit86g_33_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_EepnTc1-w0y2oIaq8ImdXw_39_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_OYKLN2fRrECF_oKOrOvfaQ_24_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_bhYLgp5R10uXYjtxmQhObQ_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_T0gb_nfGqUeRzjM7fAUKPw_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_qlSyO4TcwEahO_lTGSCRZA_6_12" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_n1C5k2ZMdEuoT8DpSwmt6A_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_18eLu7jalEK2GyS3JEZ_ag_6_9" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_PZ1_rxCXYEaxToDczyclvw_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_qjIjttn8v0KRquu6KCJZJw_7_12" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_CtU7fJlFLUWK-2ZJEB02fQ_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_WaAF5qNXF0-z5XWCXH-7Ig_7_9" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_bnjj10L9rkeBXEn0PgCW6g_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gSI0-d_O5USkjePB25wk1w_8_12" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_I4Sv3meE2EW6qmi-m0GhGQ_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Yj9I9ljr_EWcICY-fdWM_g_8_9" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_93340c33_7625_4d4c_8f6f_e18378327f0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:DocumentType" id="Narr_zx-h1tHTZUWtTMSHmeH1LA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:DocumentQuarterlyReport" id="Narr_xMV-tZNFrU-eU9Ye0neZFg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:DocumentPeriodEndDate" id="Narr_3bFL7MIrAUmO4XNmFNWV2Q"><b style="font-size:8pt;font-weight:bold;">September&#160;30, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:DocumentTransitionReport" id="Narr_VfgSy4ret06xXCAbOLfmuw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityFileNumber" id="Narr_k73lkkc3REOJJmom0N62JA"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityRegistrantName" id="Narr_1QUUT5kkxEGRHxQitcKBGA"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_8arwlaZ6x0eh5iPK7CjLGQ_1_1"></a><a id="Tc_H3g3a_Kgxkm5FH2oIPoRJg_2_0"></a><a id="Tc_ZL_mnkwLkEat_4u5cOhVzQ_2_1"></a><a id="Tc_PpIyUFMkgU-DWZ8W2tSc1g_4_0"></a><a id="Tc_VlzWfpQzb02kwCqMmsCgaA_5_0"></a><a id="Tc_TvhV-QIBckyb2NCGJirSdQ_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityIncorporationStateCountryCode" id="Tc_Hsvlicwjjkaeg3L269EWrw_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityTaxIdentificationNumber" id="Narr_BxKfVRjce0GtMa6Cl1s01g"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityAddressAddressLine1" id="Narr_sitv5Zki6kq6MOTv1-xRrQ"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityAddressAddressLine2" id="Narr_VkVDMYWi30eXrfPjDz60GQ"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityAddressCityOrTown" id="Narr_QWBDTa8qJ0yPbPATIDftDw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityAddressStateOrProvince" id="Narr_LJBg_Q6i2kKc7zgS-xm6GQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityAddressPostalZipCode" id="Tc_erPekCCUoESpudkfHih9Rw_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:CityAreaCode" id="Narr_hpS_-fnBSE2EhTYBXk42wg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:LocalPhoneNumber" id="Narr_ld0-rSrvmkuXyz9WTAHKEw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_PHq3JceJBE-jIn4rv6c6pw_1_0"></a><a id="Tc_EOiwvKturEutLRSgtQ5ung_1_2"></a><a id="Tc_KL9ojx4vTkO0NtC5lyrX9Q_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:Security12bTitle" id="Tc_CrTO3okJXkK3PFT1ZKRKKQ_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:TradingSymbol" id="Tc_SOeTcccVPk2RRhS0eCqcyw_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:SecurityExchangeName" id="Tc_qpYkbw-kzEmJp5z32ZacLg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityCurrentReportingStatus" id="Narr__ALARe9TYUC3u88fdQwcTw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityInteractiveDataCurrent" id="Narr_fppt8WI7uUmVNH7OH0VNjA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_GQkfqX0i90y_BYG2agX2xQ_1_0"></a><a id="Tc_RRFUs6EeI0Ogoe_PpxcJTA_1_1"></a><a id="Tc_DMyNbrT-3kaPfA5mTI0sdQ_1_2"></a><a id="Tc_G9SSjJyGw0qtBJrsJZd17w_1_3"></a><a id="Tc_YH6ItCqZP0umGdE7JWoFog_2_1"></a><a id="Tc_zbI6FF4KUE-GEoBUaOdwLg_2_2"></a><a id="Tc_TawqUIeYQ0WJ7AVeStqs_g_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityFilerCategory" id="Tc_Sj58F-tmmEmv6zaChQLgeg_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntitySmallBusiness" id="Tc_bTwJXo1HQES0_LnonEWzpg_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityEmergingGrowthCompany" id="Tc_ZERjyU-whkiDj-Vjv6GSFw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="dei:EntityShellCompany" id="Narr_Hnc35Pwd7Uybi4N558L-nA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On November&#160;10, 2022, approximately <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_10_2022_IeK4AGoGu0qrXYZvP3Bvig" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_GLzCV75lf0ebd9urpohZLQ">50,665,598</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9944cb5a_dfb1_4dbb_bd8e_22e46e05caf4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of September&#160;30, 2022 and December&#160;31, 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Nine Months ended September&#160;30, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f275c393_200f_4cab_af06_1e5a9312cf62"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_8vY403fMxEOCbImg1d1Z8Q_1_2"></a><a id="Tc_JYiPBGX6nEWVU3rur7YdwQ_1_5"></a><a id="Tc_pYelblvxZUi12tQkK3SfVQ_3_0"></a><a id="Tc_Dkq2UK3td0igzsbGLwiXZQ_5_0"></a><a id="Tc_2Mqx3HpW5EyHN5qXoUzL-A_6_0"></a><a id="Tc_BVqCYH6ZtUyF5thO4jc5ww_6_2"></a><a id="Tc_mY60FjLKuUi1ymaGYkkrrA_6_5"></a><a id="Tc_e4XU5Ffv-UOYu2D-DuMdKw_7_0"></a><a id="Tc_IQO6Ml1mFEmryQY2mJ5NkQ_7_6"></a><a id="Tc_yafy0xpr2kGfWHlKY6fckA_8_0"></a><a id="Tc_qDIxbbsDrU-Mf7Jp0e9LWA_9_0"></a><a id="Tc_ok8RLuE83UWX6GEsizVudQ_10_0"></a><a id="Tc_PqrLZPl7-UexDlNgnFTW7Q_11_0"></a><a id="Tc_uQ2bu5HfAkiwObODWg1NUQ_11_2"></a><a id="Tc_aJrAE5xRx0WiryKqYTfOPg_11_5"></a><a id="Tc_CSb-EEhh802tQ_bEmsxEqA_13_0"></a><a id="Tc_DDU_v2itBEaIfR9dSDG0GQ_14_0"></a><a id="Tc_UlACw25VHESLFUYm-48f6A_14_2"></a><a id="Tc_Hs2H0oOk3kW5IRiYTCdizQ_14_5"></a><a id="Tc_7xuHloRyFUqK9PuA7gOTFg_15_0"></a><a id="Tc_lv0eGgCtb0ChBrpGhb7ACA_16_0"></a><a id="Tc_SSx9UVvKBkGT9VY0BxiN8Q_17_0"></a><a id="Tc_9RQyYOTAl02CgS-eRl4ozQ_17_2"></a><a id="Tc_Fdde_TfuPUmI1mL1OEzepg_17_5"></a><a id="Tc_7wTE9bkLMU6ucJoYq4q8gA_19_0"></a><a id="Tc_u2csKBzwgEeaG-twGo-bMg_21_0"></a><a id="Tc_-c_x0px0hUy7iJSq1o7Vzg_22_0"></a><a id="Tc_Cc_WN6OMIUmXVHzWh9q8dg_23_0"></a><a id="Tc_Ruml4vqdckKBKut0k-AVcw_23_2"></a><a id="Tc_kUhGwpa16kOi_hL_KKjSqA_23_5"></a><a id="Tc_VCQ8mUz2tESXyzBRPPNyJA_24_0"></a><a id="Tc_hbWGYl_mI0e11xdUCSftIA_25_0"></a><a id="Tc_gv-5nvj-rUWK7qcS_GBY4Q_26_0"></a><a id="Tc_DBHnSpi8GUqdXj_F8t8Hmg_27_0"></a><a id="Tc_evi2bgPTmU-p6eLzdBp7hg_27_2"></a><a id="Tc_T1x3eoct30yi15i5_ZUA-w_27_5"></a><a id="Tc_Q32bL3zA9EylS9csoWVnnw_29_0"></a><a id="Tc_64fPmwWm4EmpQLshPZh1-A_30_0"></a><a id="Tc_oziJuRVtuk6SaZQ-1SQsxA_30_2"></a><a id="Tc_R89e4UlrMEaLEYnhA7QqPA_30_5"></a><a id="Tc_VioEhx-gE0qHpvXSt_gkNA_31_0"></a><a id="Tc_NdpbERa2yUOcbnP27_bQAw_31_3"></a><a id="Tc_lR0lIPjBREW1skVyTUDQPA_32_0"></a><a id="Tc_awDb5c-eekSnhZBSSx80dQ_33_0"></a><a id="Tc_05S2-BZDv0uU2538i4zOog_34_0"></a><a id="Tc_W1GeYhIhMUimVOFzzRKofg_34_2"></a><a id="Tc_vBcg0YBP_U2o960L8C_sNw_34_5"></a><a id="Tc_wXPSI5k6NEexDseXE0SrYg_35_0"></a><a id="Tc_Es1kn87l3U-aTji8RpJqAQ_35_2"></a><a id="Tc_ObEZY49W7U62XyZKDjK2iw_35_5"></a><a id="Tc_uqkCL69PyUenIUTWxS1EKw_37_0"></a><a id="Tc_iKU_OI29ykGRw6A0SFUZ-g_39_0"></a><a id="Tc_5Cg_9vp360O7e2i5jsMdgw_40_0"></a><a id="Tc_IaPpymvfpEqCVbr00wHkOQ_40_2"></a><a id="Tc_dT82dHtV-kaPkYudAAQI5Q_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Ofl9_3hG2UyAGqAqfiYuOA_6_3">10,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_dTgsqtDioUexMbZyra5HpA_6_6">38,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_gUYWRHHb_0msK9mPxvLqfA_7_3">10,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_yj4dVReS1UG9xfzC_xBbYQ_8_3">8,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_GU0TuqHxPkSdLIwtOwaQIg_8_6">3,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_uawvH_eg7Uu4_WeGIt8lPg_9_3">1,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_aw4PnQm8wUinAK8Q1nPtxA_9_6">1,285</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_VCxIiSk96E6hof81eUS0Ww_10_3">14,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_RLbyw3gQmkCw48Qlop-Z6w_10_6">17,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_X5_sIb1Do0ejExaSLetsoA_11_3">45,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Qk-fUvbBFkmfUqutiVGfUg_11_6">61,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_UgVYvf2G5ESPQQc8ia1oOg_14_3">1,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_W4sPMiHNHkysK-bsHTtm5A_14_6">2,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_HNd3qDTpXk2fMkqKTu9mmg_15_3">4,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_mtaKzQsJnk-PEi8mZlySwA_15_6">4,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_2p6pYu-kGEO_AFkwdueREw_16_3">4,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_FpgT-Dl9D0uXNKeiNsOL1Q_16_6">4,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_YYJrj0D8HEGooFyUtefCEQ_17_3">56,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Y1uXdFXdd0ujfIAoJe1O6w_17_6">73,665</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES NET OF CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_wjtiHY31UUmeoFqkMqSBpw_23_3">5,639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_Ed_-EMGn70O3SXM4r4K0VQ_23_6">6,986</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_Fva7Ttx-BUexQmdZ-Kx4Kw_24_3">12,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_lIe7IWU0X0GQQ25P09keuA_24_6">16,433</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ThJakNhTpk67-BQVP6u_HA_25_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_Z7T04om8r0CuCaUtxrPKAA_25_6">1,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_P0W7ZyeUf0KmRI8wfHz3AQ_26_3">14,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_Q-mYtmZhR0eINfXBxUrVfA_26_6">8,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc__VIDpftrfEmtGuvHVgKyKg_27_3">34,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_wgrSOXc-x0WjO1mz-uhDtQ_27_6">33,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_kb8iRORtqkOFZgc7q7Cs7w_30_3">28,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_V_gJrwZ-REmNioVsVGejow_30_6">27,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_r6J4a8TQL0mPD-Y20yGlOw_31_6">11,790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_6wB0O595b0KMnaWoGLFVXQ_32_3">1,779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_o0WuplLQl0WsePbKGthceA_32_6">2,472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_SYiW7xGTuUCYX2bAjnvv_A_33_3">4,031</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_OMvQ9BsQe0iQ3Y6taAwPTw_33_6">4,376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_S3cSbeOUe0qyxYml6nsKLw_34_3">33,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_yV-x86T1REyjrDA4syw7MQ_34_6">46,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_RSwatuqNzUGT5zBwojc0eQ_35_3">68,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_UZ-ue90350GGDp6LKe6EAA_35_6">79,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_TYPzDLzmkEy_3KQLh9d0fw_39_3">11,514</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8CL8iLb6wU631bK5rPBK2g_39_6">6,036</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities net of capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_PZRKeHnDJ0-dsH_z-tA37g_40_3">56,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_xP9vfPiAz02YfCjjYWZMKQ_40_6">73,665</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8488e67_cd30_41d6_985c_7b2b2667ccf1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_sSImxuP1UE-x7872H2_Xsg_1_2"></a><a id="Tc_yIiMgNU6qUuRXFfQ0551pQ_1_8"></a><a id="Tc_Tt7KFaE7yUSFGqCO3cFPnw_2_2"></a><a id="Tc_SC83q1zLi0O6e3LQv8I3XQ_2_5"></a><a id="Tc_y-V7XE5xP0iNk3aPZc0A-Q_2_8"></a><a id="Tc_by6Uwu6-MUWY-VoeIS4YBg_2_11"></a><a id="Tc_u6ak317tBUij0tUxoiPqjQ_3_0"></a><a id="Tc_AwmGMkUzFUySaCR3K9hyfA_3_2"></a><a id="Tc_gXOaLxIvh0eogED-vUmi8A_3_5"></a><a id="Tc_KxSXAmsqEkuhYLgg3g31yQ_3_8"></a><a id="Tc_LiMwIok7zUeeOge_s81_Bg_3_11"></a><a id="Tc_yUuPTJF1IEaoQipQN5DlaQ_4_0"></a><a id="Tc_aEl_eoQ940iRf5ZPtFytJg_5_0"></a><a id="Tc_IDSmaKeiJUm6RmWqfed-qQ_6_0"></a><a id="Tc_wBQPTID6S0-N_DWfqVED4Q_7_0"></a><a id="Tc_BUnfihejQUSr9A2ZmzWuFA_8_0"></a><a id="Tc_Fsl83b8aQ0m6sDOosqgiJg_9_0"></a><a id="Tc_ww4BOG-NXESIW8ub3WD6hA_10_0"></a><a id="Tc_R7em9ujtokyRAKVKiGdchw_11_0"></a><a id="Tc_HR794zMg7kyuAVlA9H_qRQ_12_0"></a><a id="Tc_Yr0BmHWzT06J5jJILM1W1g_13_0"></a><a id="Tc_ucRMG_vI_UC2psyHeyTy4g_13_3"></a><a id="Tc_ZbCEwDPjN0yxrezd39FN9g_13_9"></a><a id="Tc_i1fx_OjmZUyTNMG7ohamHQ_13_12"></a><a id="Tc_O0mfCdSCJEyYX23eVrHtxA_14_0"></a><a id="Tc_oxq1RyHUtUixM4jwegGs6w_14_2"></a><a id="Tc_o06Yb5jAfk68z-Czqd2Etg_14_5"></a><a id="Tc_tBRFOn-zq0SBuT1bLq3yyA_14_8"></a><a id="Tc_ssxszorJ6UWoWELKE8H3ng_14_11"></a><a id="Tc_waS0glhnK0SfVzE8MmhNTw_15_0"></a><a id="Tc_oHU8MCGfsk2jkZ1Z9L5png_16_0"></a><a id="Tc_-dAn0LQgkEKXMr04ulDiFw_17_0"></a><a id="Tc_EvBNUp8uaUSivmBrp2ywWA_18_0"></a><a id="Tc_64MXUxYA9kW6sb167E_5uA_18_2"></a><a id="Tc_Dqw5b51Bn0Wzx-UPhCIhzg_18_5"></a><a id="Tc_vGy7eEnNNkazD7zDYOZY3A_18_8"></a><a id="Tc_bW-SyTGO-UaksY2XHG3HAA_18_11"></a><a id="Tc_SqiYEsEEnkWYwFEkqKX-6g_19_0"></a><a id="Tc_TN3IIvB61UmStqvTY49e6A_19_2"></a><a id="Tc_UlpfDetRF0uz65NDj-yU6g_19_5"></a><a id="Tc_zD7ZMbCS4EaLDSAnpbZr2A_19_8"></a><a id="Tc_XvUPKjlHPE6-Dx9d4BiLSw_19_11"></a><a id="Tc_sZRuXgr1hkaAtS4joPVK7A_20_0"></a><a id="Tc_EJn8-jrVfUSqKHkhvVrDbQ_20_2"></a><a id="Tc_QQbvQv1LKU-fWUjnaRKwxQ_20_5"></a><a id="Tc_9rgUMhw7PUiYY_OIbgPbMA_20_8"></a><a id="Tc_48IT6W5fXUKXv1O5R2_wxg_20_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7083359%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pveYO1f-lkC05eDMbh02IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_EZSHOwnsF0uCjOkngPu9Zg_3_3">21,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_D5y751RR1UqvCc-Q5th3_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_TcIUYR_PlkynUfKX5c48RQ_3_6">12,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_ivy2EExMakeWgn87BPkvjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-TYW6nhElUKF6mDGLEiNhQ_3_9">8,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KItA5s_IX0OM8e34BU2fSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_dIF_8dTb3kKDFOJ7FdoKug_3_12">4,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_GM0fNZn86UWpPaTCwWm11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_xit7HQzmdE-XQGubCEefWQ_4_3">17,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_O1a6ViT3C0ewVHZtdm2T7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_9T5ITSyDoUWn88sB76IITw_4_6">17,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_MXh1QMX0OECsjpG02kpLTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MxKayJPnak-7OvSiOCaxQQ_4_9">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FTvwbQ8tckqFhCmnA1b1uQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bv992tnw2UaNJ7Fq0UhRXQ_4_12">7,548</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wPfEh7lMB0i_Q_8i6PlGAg_5_3">39,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_edfP_d1Ql0ew2IoDnK46CQ_5_6">29,801</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yOB7wYTdEU242qBvwc6Y9Q_5_9">14,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_YF48IRUzjEOkUtedluU_3w_5_12">12,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_n1C5k2ZMdEuoT8DpSwmt6A_6_3">17,195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_T0gb_nfGqUeRzjM7fAUKPw_6_6">13,201</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_18eLu7jalEK2GyS3JEZ_ag_6_9">7,074</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_qlSyO4TcwEahO_lTGSCRZA_6_12">3,703</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_CtU7fJlFLUWK-2ZJEB02fQ_7_3">23,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_PZ1_rxCXYEaxToDczyclvw_7_6">22,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_WaAF5qNXF0-z5XWCXH-7Ig_7_9">7,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_qjIjttn8v0KRquu6KCJZJw_7_12">7,282</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_I4Sv3meE2EW6qmi-m0GhGQ_8_3">8,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_bnjj10L9rkeBXEn0PgCW6g_8_6">9,263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_Yj9I9ljr_EWcICY-fdWM_g_8_9">2,848</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_gSI0-d_O5USkjePB25wk1w_8_12">2,954</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_xjx9-fNKUkSq2EDRAmZsiA_9_3">10,519</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_PuqC1fUoH0ef4ydQUDxEvA_9_6">14,756</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_bS1bEpfyPkOgcFHGluAxGA_9_9">3,125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_efKIWs1db06MzLH8iL4MqQ_9_12">1,885</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_RQwaO38BxEm4hwxHjrBkGw_10_3">1,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_vk4HyRGE7k20PqhX0gGOZw_10_6">6,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_yJ853HzSG02cuXA6uzc--A_10_9">639</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_L47NrjXzMUGbctSz9wek9g_10_12">2,410</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_98cXCMwywkuOjdzwTfQhtg_11_3">1,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_dRrXZYDG-ECVNoETLI-Uvw_11_6">403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_37w64IB5HkS-gpMbRoNJaA_11_9">197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_S1bJCfcQnUuZkqV9L3TDaQ_11_12">96</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES, NET</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_9XD4gPllm0-1uyP2ukaXjw_12_3">668</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_QznMrvU8EkaLuJcZoZBUuQ_12_6">6,210</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_VTxWv498r0aPBhsjZQ0leg_12_9">442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_uFw60wrAQ0u9E63TqCU9_g_12_12">2,314</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_anByqlOInUyYo0hDG5WaNw_13_6">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3cPXCfD7Qk-vZnMgEk1raA_14_3">11,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s3sZ2DD0jkOWh9gUYZM_kQ_14_6">20,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eg2SJBeJrUi7PSB8n3ZI_Q_14_9">3,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1PixscLaQEGtybV57VOpNg_14_12">4,199</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SD_ZzPZry0Kn3wCxqHuvyw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_MuYLdn-R2UKBtpRphH99sg_15_3">0.24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ph-RG_FF60KNyDOGP_Etkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_5ftVwfeC9UOen-aznHt5ww_15_6">0.48</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_nea46fNOSkqHFDBXe51eTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_UgeAggBo-EihCwZdaOcxCg_15_9">0.07</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_whOWA2mtCEmlBgl3O8lO9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_TK71XM1vMEKqGLgYBrX6GQ_15_12">0.09</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_w8JuZnaHRkifTb5c9G8VzA_17_3">47,582,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ueCx8a7Mg0uHeQ_aXst_HA_17_6">43,761,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_KiLXB6HwU0-xEVwybacoSw_17_9">49,498,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_LBuSW30SIkyo8rS3ZMB1Ug_17_12">45,556,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_OZrCQjIzZEa_Imuc6kFkfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9m3GgFyeGkOKTsjPcMSwKQ_18_3">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_b3jRdtg_20SDBBcjXHfzTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yuH7ZF9D_UOS6PmX_nYLfw_18_6">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_TpBThY-o1UO9jj7QH2sP0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GynBVznkQk6KxCQcjPI4hQ_18_9">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_6dFVaa8MP0mBiDmzAt8Y9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aaFtaJkdn0C4LAsolG99VQ_18_12">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Vftn1tQ1hUCzVmrnQgfT1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_E96rwd8OuUKc_ShsXgj2ew_19_3">275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0sCNP7rIoky5QN2CONKd6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_E_SFV4k4zkq13CX1ROXf5g_19_6">524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_D2abpIHIxki6wHgQcLCQlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aaV5eG7DnUaezNaaBd5lnQ_19_9">114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P__KdEwYTE-FwaUrq-H-4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uKuYati1uUyEOfi412cXzA_19_12">154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__e2stD8DXUakAd6Cgk7bXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_n9GUemzmekaWQ2xsmS1kVg_20_3">1,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_-CFgg0SHbEuiMRjiTw4qOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_zrCMdVORKkWYUrY5s29hvA_20_6">1,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FZ5IV3EHuU2VQz4Oea9P-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_zycUQBq5S06lADvguNE2Hg_20_9">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FoX-isrF7k-mTWZnrW05yQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_M6lqVvPe7kGeIbShr-nlFg_20_12">344</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d89eec5e_357a_4111_86ce_812eb43d3102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_0AYlPpogw0u8Ivj22aOJeQ_1_7"></a><a id="Tc_WDQdqNILA0aCZEuSwR7CVQ_2_2"></a><a id="Tc_ZPTaitwVpUSz1J_fS5zV2w_2_4"></a><a id="Tc_MrVxPAroqUuNZNWrdsxLCg_2_7"></a><a id="Tc_Fv7nqwV-6UyXe_MASN9brw_2_10"></a><a id="Tc_RkJeUfIIT0eqB6AQ4KIFGA_3_2"></a><a id="Tc_O4y-hHYtdEGya7FqM3exDA_3_4"></a><a id="Tc_q8y4n2x2-ke8e2rE5-fmMg_3_7"></a><a id="Tc_j49kMdqGd0ive0BBOUy6xg_3_10"></a><a id="Tc_TNiH7PvW0kGw094UV3ezRQ_3_13"></a><a id="Tc_K0Hx8VaSeE6P3PAYdfc6hA_4_2"></a><a id="Tc_t7SW4AmaiEqmBP5DPBMbuw_5_2"></a><a id="Tc_FJpX3v52p0S69E4Eu2XkvQ_5_4"></a><a id="Tc_pg5aX6RLQEiXdgNbonVTzg_6_0"></a><a id="Tc_KwMIR_ToeEinvyrS8YXCxg_6_4"></a><a id="Tc_pQtuOG_U-k-4NRDiEwljKA_6_7"></a><a id="Tc_xr9pMCaBQUGy-CwkUHFntg_6_10"></a><a id="Tc_6BAgevVbxk2s8CoNycdHww_6_13"></a><a id="Tc_LuTfkgmiuUCVwlX0hbTOzQ_7_0"></a><a id="Tc_b8AC5rAN6EmjNNXPbFYiew_8_0"></a><a id="Tc_Qb-g1gM_NUGTyhQR92DqLg_9_0"></a><a id="Tc_RtMDIcW3uU6YWLHAkSky4Q_10_0"></a><a id="Tc_y6i_eKH9VEaqFTHfwNxncg_11_0"></a><a id="Tc_UUF_BeGAUUqUcyTfZVR7yg_12_0"></a><a id="Tc_JwJ9V4qZfEqUTPuVgYU7Jg_12_5"></a><a id="Tc_NkyTyId9HkCcTmEwdU9JmQ_12_14"></a><a id="Tc_q2Gk7ZWip0K1H4aAwQwqjA_13_0"></a><a id="Tc_cCJN4oQfFUi-w98H85Q2gQ_14_0"></a><a id="Tc_acWxsN-hZk6O1rr9JfK4wg_15_0"></a><a id="Tc_qyMUlUUoWEesGDMK1aLEFA_16_0"></a><a id="Tc_1GrT3LRH-EOl1aoOj-f4yg_16_4"></a><a id="Tc_O0zgDaS4-kOK1RAMCFo4hw_16_7"></a><a id="Tc_rV791VI_WUyUcmY3Fsj6hg_16_10"></a><a id="Tc_Em_QITPMr0GTW8gwWerFJA_16_13"></a><a id="Tc_sHX7uBpCEkKlcVCD5oGVaA_17_0"></a><a id="Tc_LNMhluRk30mEw2-D2CzLig_17_4"></a><a id="Tc_3zKW3MhtRUup_ZbAZydjVg_17_7"></a><a id="Tc_ZOSNz-oyaEe3-IynY5t6jw_17_10"></a><a id="Tc_RriF63rn70GH9sDAJinrCA_17_13"></a><a id="Tc_-USGoZYPe0iH6deU8ZqBqA_18_0"></a><a id="Tc_3BpOJJQUBkmJ34OJ0pp2bg_19_0"></a><a id="Tc_plvKzXIHH0q7VeMi0TtdVQ_20_0"></a><a id="Tc_YakohAOfHEyIYUqW_ZWskw_21_0"></a><a id="Tc_KeguZ1mOek-w4EcnfL-X0A_21_5"></a><a id="Tc_lqg7H0TjN02i_KeFXDARJA_22_0"></a><a id="Tc_f78GFATaPECVZ62Qxd_nIw_22_5"></a><a id="Tc_siZHN5XR1UG558UB5e3xXg_23_0"></a><a id="Tc_SmQvldfPEUafyOueErdHYw_24_0"></a><a id="Tc_aqLW8W6cRkGUcTH3T39VIg_24_4"></a><a id="Tc_Z-2zgnNO5kCAsYxw6DF9Nw_24_7"></a><a id="Tc_qXfeWJJnSUiBn1yoT0n0Vw_24_10"></a><a id="Tc_QGqzMs246kycRNfz9xbsdQ_24_13"></a><a id="Tc_F8j0IXeYYUWpEJVKS5DvcQ_25_0"></a><a id="Tc_dZ1HgNXcv0OlffHTtInB9w_25_4"></a><a id="Tc_-ekFoCmim0-2xb7qJmWkJA_25_7"></a><a id="Tc_xnyv8nIA8E2Q7uqqipkSxA_25_10"></a><a id="Tc_JLFgahbb8Uekz-UVBd73Kw_25_13"></a><a id="Tc_pbkI73OavUG1LjCPZZsQbA_26_0"></a><a id="Tc_lreCvRAIuESB7OmFFF89hg_27_0"></a><a id="Tc_OOCNn_YN90-MIRmS3JHPDg_28_0"></a><a id="Tc_uye3mKXeAk-Rh1p-Aqm-pQ_29_0"></a><a id="Tc_jQNpVABGQ0CBMaU3M8zcYg_30_0"></a><a id="Tc_xvf3EQR-Yk2gGYmLoLZa9g_31_0"></a><a id="Tc_a0-m6IkYDEWgX8ZZr8Q8VA_32_0"></a><a id="Tc_GT8Fe1RwDUaNxb6tnuWYow_32_4"></a><a id="Tc_RGM_AduFGEWvALEghPglng_32_7"></a><a id="Tc_Ga9qa76SvECB-00RnWZSUA_32_10"></a><a id="Tc_606wvgCNUkyq-Tm1PbSohg_32_13"></a><a id="Tc_djPWb1GmAUWN_NfyXjsUEw_33_0"></a><a id="Tc_wwNw73RthUmjaPPKniNsuA_33_4"></a><a id="Tc_CEg0ioSlHEW7_-b498Smcw_33_7"></a><a id="Tc_E4kOPaCJ5UqIKZZwQ1i1qw_33_10"></a><a id="Tc_b5XfuCTeLU-2CaGl4Qeyxg_33_13"></a><a id="Tc_HMjdttnaCkGhGfWJWSj68A_34_0"></a><a id="Tc_6ffykjt_30eItWFA-crPNw_35_0"></a><a id="Tc_7gJYvwOjrkaF8JWksIHrmg_36_0"></a><a id="Tc_M2nvP8Obn0Kyzxptw11MhA_37_0"></a><a id="Tc_1sq4g3Ch00K_91JB3QrpUg_38_0"></a><a id="Tc_hlGCGb20NUqL8UWkV3puaw_39_0"></a><a id="Tc_UGLE08Hw_ketwubUq7V0OA_39_4"></a><a id="Tc_yCOnQdCkUkWmGYLjxFLQxA_39_7"></a><a id="Tc_CB_Z0DWTK0-3t-a1vvPPTw_39_10"></a><a id="Tc_3vRvMklAwEKKKqVyrKkByQ_39_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_7myOcM5WM0WoI1yAP70r_w_6_2">34,765,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KGRKar0xoUmwtm9LJk4j5A_6_5">35</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf5bZps_2EenQQ2ZpXcHZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CMGnZ7Oep0WGKGlVt4RrMA_6_8">320,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eR0GjrjuNk-nDafPkPNl-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mIcl0M0QMUeYDhnUetVV2Q_6_11">347,352</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2020_7nrXjB6c6Eq4cT3hYF-X6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tXe0MMCA1keCKw7eJnnKOw_6_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_bhYLgp5R10uXYjtxmQhObQ_8_2">8,749,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_R3wJKlPAakWygqXSnMEfsA_8_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_tyJmVHjNa0-pNBV72zGKgQ_8_8">37,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ZgkYx7NcpUiYE4Bw2kovNQ_8_14">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_nmq4JRk3-EORS1MItaKcMA_9_2">1,867,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_cPTbRcieVEOAU4O1ilHpxg_9_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_91oiHKU0n0y9Eg-iczczQA_9_8">8,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_uTksoCEPNkWp5u42OIbXfA_9_14">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_W-YL_y-zPUyc6RiZbFbfEA_10_8">1,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_fJkrft4PukyyA21jA5DqYQ_10_14">1,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_YPiKBNlrMkO87pM4KJ_lgQ_11_8">781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_RyC5PoQdNkWuJscZI0vS8w_11_14">781</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_thi13ixbeUuHkrsQiITRkA_12_2">173,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Reacquisition of equity component of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_PPq59OJZ-EyHeTd1IR5Caw_13_8">12,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_B3baeuMlikq0uFyJofYr7Q_13_14">12,019</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equity component of convertible notes, net of transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_v_r3xsIAj0eD42fSIB9b8A_14_8">12,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_ybT63lB5e0WWphMjr76Eug_14_14">12,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eooI9ZYRYUK3xtjGWM-3Xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tX5Ka78j5E2pm6rz_lqnDg_15_11">20,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4WEtThlMqEW3J01lwrZabw_15_14">20,915</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Vg3ciLhkvU2HwfGsU6fBMA_16_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eeqY-m3ZiU-YUW0ep9Lz2w_16_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TSLrDFkfsUiXaEXbJNE19Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8LCe2ZU6KkaCh2aoS0xo8w_16_8">368,434</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u-zmvKk_nE-TsUTpTrb0yQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6xpW-4a_Fk6CiNMuzpCJzw_16_11">368,267</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UwYGfqxlCkGpZ00qg_Wclg_16_14">213</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AdqKFA4TTkyOitbYq9oh_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc__yTrLzsAdUy18I39T73gtQ_17_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AdqKFA4TTkyOitbYq9oh_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gjTJeEqezEGiFL1IssL4jg_17_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_csxCWMqCMUKoZEBkfV_2Hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3KLWemeVG06RqEp1SS6lKQ_17_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NsMLImWFUkKskcZiXRX0ZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SOaWnn2EmUi1CftS6s91tw_17_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_CYY-GljXhESdP1dv-9xdVQ_17_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_ITEbUeMAOE6-Yk33cXimLQ_19_2">3,841,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_5uwPQ0KnEk-9goFriGSvJw_19_5">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_lCOe0y3Dr0y5Z5D8f-zmGA_19_8">4,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_IUPJCUiZT0-lNKaZaJrtaw_19_14">4,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lGwBzCUooUWKc33CTF038A_20_8">592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_f9Br8VV0YkmPF-6Ovh63Og_20_14">592</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_HAxVYURivkuRqA9qj9Po-g_21_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_BAXt6XMF1UGOrfGOBqzkAg_21_8">954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_xfIJ_MzbKEK_S386o7fpRg_21_14">954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_mHwqVUwizEODPiRPsC9Dbg_22_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_P5P6jQKJgE2mzGjdDLYxtA_22_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_mb5g8jYmhk-30wN-tX-0fw_22_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8IZaBt_-TE-hj4hdLTni3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qD4gD_E27EqZfW7VJ0o8_w_23_11">11,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Pp-WMPNCJU-TjS2zToGNHQ_23_14">11,187</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_OYKLN2fRrECF_oKOrOvfaQ_24_2">50,158,608</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5y1nSnqiEEqfy6zyHDQrGA_24_5">50</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o3NakbeXoEead8-t7k-62Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zeMKtK-RBkmUMikY3iA97A_24_8">374,557</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWdI5ZA6vUyC15HD3EjNzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SpswBqUiwkGp_o4eZ-rlVA_24_11">386,121</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8IFasy3qMUGlJyrEoWWYlA_24_14">11,514</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v6SRUqykhkq9NDJkMs8VCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_rTnP4f7RQkGQNUF9AcRd8Q_25_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v6SRUqykhkq9NDJkMs8VCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_nrCiS1Y-XE-DdNlpzQ7UJA_25_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li6VzojNEkm79l_inaRUZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YhZ3EhcepkKHfsYBSlU8DQ_25_8">367,863</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oi1iFnUfUk2j89URToy_FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kptODVYgX0mL6B8lGviJlw_25_11">364,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2021_oaSi65tpAEmtBYUa7viC5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NjILO9nWN0WI5I4x8zenVA_25_14">3,841</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Reacquisition of equity component of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_iRU2qM9aSUySigd3KNbnDQ_27_8">12,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_SY0ra7Hs706F3C5FBfRG2Q_27_14">12,019</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equity component of convertible notes, net of transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_Ob-peZxaKkeF9-dU-GSE_w_28_8">12,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_WoykLfytokyxzBbzOpdomw_28_14">12,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_P7fcpNZZ-EyInOdxRP8bqA_29_8">344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_JvjNxrNZlkm-ufvETJjYEw_29_14">344</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_PihsPEe2U0aD07V-tIscVQ_30_8">219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_xpOE2tuRQUKYh_zHHT4q4w_30_14">219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kCjfzxrofkaqU5KXQCoK5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wTWFXxBmZUOoFXkiKY8T2A_31_11">4,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RgsnQjbavUq4BJiIjCro7w_31_14">4,199</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_3tg0jVyZPkSbuRThcWb5oQ_32_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LIPnC2DdPE64sd3NDchhog_32_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TSLrDFkfsUiXaEXbJNE19Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9luqNn20m0eS2s28mMEweg_32_8">368,434</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u-zmvKk_nE-TsUTpTrb0yQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_u5ytG0BakEK1ZunrzPY_DA_32_11">368,267</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eYI-y1XQBE-JOZdlMUcSsw_32_14">213</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bD4jRYV9p0SrHNp39PFY8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_IdjnDwkcNU2CiDqYLit86g_33_2">48,712,952</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bD4jRYV9p0SrHNp39PFY8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LX47omDL5UqlTxT2hjqP9Q_33_5">49</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6b9M0fMDnE-ONxperA-Nqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Et5b-R_OK0-u8sRHWFEMvQ_33_8">372,616</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kCsglji7kOkuf4CbzkCjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dn4gO1fkA0O2mZ-2604r7w_33_11">382,554</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2022_rxA6MsPFmkGcr9wRVnhiBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7JBrTbU5qUiyyB6h3oYM6g_33_14">9,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qayOenlWNEakzQ457tclgA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_AuSuHn18CUWgsioZExaEAA_35_2">1,445,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qayOenlWNEakzQ457tclgA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_pw7Guwmle0aRhN6-TkqufA_35_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_d4QSbIpXOEmchVx5bEpnVQ_35_8">1,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_LjbQKHzndEC4jmWbqgL34w_35_14">1,520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_pEkxcLDOoU6SGO7OdDNZ-A_36_8">298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_o-CvDYmPuUavoJH67yXGlw_36_14">298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_V2dXKXqBWUeq5UEfxZL-vA_37_8">124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_6STBZSAljkGwF88ODcTFSw_37_14">124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3bFqnnwhSkCeJGvIIsUgXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Oif1c2ZFbEqnGoi7mauoJg_38_11">3,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rlR2AEimJ0C0eMHm9-vWNw_38_14">3,567</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_EepnTc1-w0y2oIaq8ImdXw_39_2">50,158,608</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uKpjFerMJEqOAAMx4ICcBQ_39_5">50</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o3NakbeXoEead8-t7k-62Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yRGulH5T_0W-LN2z4M0S5w_39_8">374,557</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWdI5ZA6vUyC15HD3EjNzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SKP1agIYPUm8mPQTOfceOg_39_11">386,121</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_osfgZ77GXkWLxQUf1W4IYw_39_14">11,514</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Represents an amount equal to less than $1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_dl7uBDirjE6QS0BEmdnRCA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_jQ8XkMNsYUqPiCTxzMSACg">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of September&#160;30, 2022 and 2021 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_HW07niUoVUSdDPm97WCYQQ">144,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_1cmgsjsZs0yEwB6kJxw1jw">120,000,000</ix:nonFraction> shares, respectively.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1969ae3b_b04b_4ede_8d7d_86a45b16dd76"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_yUKbzu7CYUyMF2bBGiGI-Q_1_2"></a><a id="Tc_WsaSE8V0iU-ILt-gtQDgsg_2_2"></a><a id="Tc_eNHL5uG7X0Sv4zZVnYX-Mw_2_5"></a><a id="Tc_la8uUV-5ZkyKEmcxi7c2wA_3_0"></a><a id="Tc_Zxm6bWbMV0KjyKcrW60iUw_4_0"></a><a id="Tc_o52l6z6EyUq_UUe0BvcD2w_4_2"></a><a id="Tc_t0RAimkbg0a-wQ5WbTbzFA_4_5"></a><a id="Tc_Y4zLQM6N3UmoyTmDxo0rCw_5_0"></a><a id="Tc_9HCrhTik3Ue4IhHDww7jKg_6_0"></a><a id="Tc_zIk1uL4GYkmBqWjutv09sA_7_0"></a><a id="Tc_dj0I8Vk-2EaMuvNzd-q6wg_8_0"></a><a id="Tc_DPtKwxOECkek1pxs8-U24Q_9_0"></a><a id="Tc_LzJ3f9Mikku7TDUNCnTwDw_10_0"></a><a id="Tc_LdJwf2_wWEO7srwJ-ECHHw_11_0"></a><a id="Tc_IHYVYcEM8EKFnDYXlwsjyQ_11_3"></a><a id="Tc_ohO-qpvhWkSNV9-xtD8xMA_12_0"></a><a id="Tc_BFq19ypQukqlWrda_VhzMw_12_3"></a><a id="Tc_4XT5MUDJi0qrOhts05cMFQ_13_0"></a><a id="Tc_BydsFOlkLkWo7Jdlk1NTtg_14_0"></a><a id="Tc_LGeKw-i2OUiCIOqk3jTuHg_15_0"></a><a id="Tc_rX4dfUjCY0Kj1_x1p2KwlQ_16_0"></a><a id="Tc_TMn0oswyakmgQALG8RiXFw_17_0"></a><a id="Tc_vHmOuwcav0SOtfgNSxxwpQ_18_0"></a><a id="Tc_uJ4f_k8t6k6LM89vQzD6kQ_19_0"></a><a id="Tc_zdjqIZdtQEirhYM5Kt3oSA_20_0"></a><a id="Tc_4g8M_DEji0GRVOPJJcWeBw_20_3"></a><a id="Tc_9oNWULlCUEujaMp62GR9ng_21_0"></a><a id="Tc_v_0t2NxIJUyxnY-ocMgPnw_21_2"></a><a id="Tc_-Ot5LAd84EuoNcfAwxzalg_21_5"></a><a id="Tc_f5mpUqid3Uq1dtgf04hxIg_23_0"></a><a id="Tc_qka9Nt-9-kqsUwyKM2Rbaw_24_0"></a><a id="Tc_WDwzm_yW6kisg12FkRlNDQ_24_2"></a><a id="Tc_KhEQNP5n30aZIqp42yvEmw_24_5"></a><a id="Tc_qXABme8XPEu3RUUAVFV10A_25_0"></a><a id="Tc_-cOE1j8z2kmovTrBaFMTHQ_26_0"></a><a id="Tc_jwEH_JgXY02lgfMHGNEUUg_27_0"></a><a id="Tc_cl0WNuUchEiTgqhhpSHfWQ_27_3"></a><a id="Tc_63lxOBMiVUaFjf6kBhDpMA_28_0"></a><a id="Tc_WDPC4q1c_kWCb2MRmE8tqg_28_3"></a><a id="Tc_G4yGMjhhzECT3G9B8G_nSw_29_0"></a><a id="Tc_QIRgR82Y6E2pFfJeflqcXQ_30_0"></a><a id="Tc_N2wHg3n73Em9gcZMVx6dwg_30_2"></a><a id="Tc_V2uFcav3e0WIU0531nk08g_30_5"></a><a id="Tc_wzJVQI4MYUiAJu-vuAK1pw_32_0"></a><a id="Tc_5-6SMAJlgEqWlM_j8z4oAw_33_0"></a><a id="Tc_0bOMtmLxeEOux7Xg9tMrNg_33_3"></a><a id="Tc_-pe28xLwxU-2BmVRKw0psA_33_5"></a><a id="Tc_doaXWIU380GjqwiojciEyQ_34_0"></a><a id="Tc_b1T4jqy6VUKbOXkyOU2qdA_34_3"></a><a id="Tc_SNfGQfcbzUC7N1hrX5a74Q_35_0"></a><a id="Tc_QIWsBRYX2UCL8Qfgftu2nA_35_3"></a><a id="Tc_nWuVkXkZq06luwM3tiDC4g_36_0"></a><a id="Tc_aU4IHnsxO0OKQhlpO7Xv2g_36_2"></a><a id="Tc_vWKUkIej60SVQOsOFGTgbw_37_0"></a><a id="Tc_Ncr3dn2NfEGAbN0RyCBtZQ_37_6"></a><a id="Tc_BAUD45vBk0uKKp1oyvww5g_38_0"></a><a id="Tc_kyk2eCSC9EG4cjddWYocHg_38_2"></a><a id="Tc_rTqws0aoREmyIMEt9f0P0Q_38_5"></a><a id="Tc_wUvqUnyNg02-JJKoGfmDzQ_39_0"></a><a id="Tc_Tv7Q0p_-9ESAngKlOT4D3g_39_2"></a><a id="Tc_wkEO5qaqm0KAaGYEHw8ehA_39_5"></a><a id="Tc_ZZQmvUrMSUyTHh92_7I3Yg_40_0"></a><a id="Tc_n4OI-0nuFUKXbqlewDhb2w_41_0"></a><a id="Tc_B6Hl8U_jiUGfLtDdPm34uA_42_0"></a><a id="Tc_9rkitQKsA0aksRgBvhieKA_42_2"></a><a id="Tc_MX3CqCMPwk-8q51n6saIog_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_und9JNrMq0Wpan1HiBx4Zw_4_3">11,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_SUgayADK2UqxZlziqSiYqg_4_6">20,915</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_so5Pf5GFEEy6RsKTNHMBAQ_6_3">1,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_rPHuO55oHUGcGwH01AhGwA_6_6">1,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_XfraYtw6MEGW0Kk3xMBW_w_7_3">811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_O4fkfoU8VkaW_9QCLaWJgA_7_6">859</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_1911ZquTo0GJe5BQsyqtxw_8_3">1,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_iq8YVkI2P0CkTz_cxKhZLw_8_6">118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_6F8Xc_h2Ck-44jFkVauUNQ_9_3">391</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_FuEeyAa5LUiIUA_480SdlA_9_6">100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_V8xX1m1dl0-nLlJSV8hZaQ_10_3">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_JRAsaNkXukWTaXKOlITptQ_10_6">75</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_k1F78r-GDEa57alkdKuLIA_11_6">51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss on extinguishment of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_mk43WsM4iE2QiN_fx6Zz_A_12_6">831</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_6OgvB-oh1UuEpHKT9aXLIg_13_3">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_Xodw0bCoukOeBmWOpddDtA_13_6">2,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in contracts liability (including non-current portion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_8paqUBBu_UK9JlVTaTuTxQ_15_3">5,547</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_ATRTQe1hAkmUF8N_kW9zug_15_6">13,945</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_VlyWizq-bkuhdEmexg5Mqw_16_3">5,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_SEQY8tWjeE6BjxkNCDlPEA_16_6">4,075</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_q0uoV8HLGkKeo0Iuq8ipdA_17_3">30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_UWQsajy2wUiOS5Rf-nMOkQ_17_6">168</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_cSp6UH4TKUCzvSf20RviTA_18_3">3,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_hWJvIybNzEqlXLedP5ijZg_18_6">1,648</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_3eoLl999a0uE3duiKqrOpw_19_3">4,438</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_qCPguKFn1Ee4V3_HRGD0vw_19_6">1,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_lt14_SqQh0irlPIF47sS2g_20_6">51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_hV8ko67q10SGZbRo4gMplA_21_3">22,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_m_DVSFqa0k6ku3XReqXCsQ_21_6">5,198</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_6U-GTyFlckWP_qgDMu-Euw_24_3">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_aHHuv8tgpEmmlDiZ1TVgVQ_24_6">37,835</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_xK_1MLv9Mky3R02cq6JuXA_25_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_2NnXUMsYzkO4X33_L460DQ_25_6">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_i2we3Zq-Z0mQjKOcGL4yrg_26_3">415</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_I-DMJ1uHvkmMVZJBfHk58A_26_6">1,011</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_BjSr7bBh6EqujICF3Y7Rbw_27_6">53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_zPquRW_LEki0Rb4LIsBVBQ_28_6">359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts paid (funded) in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_W5TvRX_aUkWWxmTdSNC_Fw_29_3">427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_gQBT22reBEm-M4G_-acXTg_29_6">81</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_L7u--7LnSkSMUsOB9R0cHw_30_3">9,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_ympvYt_Lc0-QJP5CRKDKeg_30_6">18,515</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment for convertible notes redemption and transactions costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_W1Bkfb_TOUWnWlDvZoW1sQ_33_6">25,990</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_RSIyUKY3AUG2Ge8n_n8I8w_34_6">4,086</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_2wa6P2AHOk-FCM8KoqawJQ_35_6">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_rjC-jG41ikuBoCxZJlDaBg_36_3">4,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_FNbpIszMpUyL4ajGxHYdPQ_36_6">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_jZwnrtdOJEWWj0g81spgtg_37_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_0y1XOPCgcE-NoFg69KNB2A_38_3">4,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_aLq1MqgMZE6IffkjFrrwHw_38_6">16,124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_cvSDSkXu1keo-Iy9tTzsMw_39_3">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_nsNQ7Kvb3kCu1uMynxoDTw_39_6">34</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DECREASE IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_BZb-irv9rU6FgXncSmGNXg_40_3">28,265</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_kgR-P5nbeECTyNVQ2vh_rw_40_6">7,623</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_pQUYs3QBjEujjcG5hYd2vg_41_3">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2020_7nrXjB6c6Eq4cT3hYF-X6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_6PBbo82BQ0O-U5rOBXBqYg_41_6">18,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_JxMgTLfLCEmjAlrrRC0bgw_42_3">10,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Hit-50D2HkmekcppCUzdSQ_42_6">10,642</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_V5OClBhBj0CUMELktZB9rA_1_2"></a><a id="Tc_H8596c0sUEO4JcDgmvCIMg_2_2"></a><a id="Tc_n45KK7qUeEicw-fIupFERg_2_5"></a><a id="Tc_TaOaXkVmp02QOpUXU7-oQw_3_0"></a><a id="Tc_iDn3fAwGpEi775nuKsa0Ew_4_0"></a><a id="Tc_qY6JyTLcV0WQo3pPo5p1-Q_4_2"></a><a id="Tc_plMSYas_EUytEnXzjb3rlQ_4_5"></a><a id="Tc_aRH7p0yMxkW0oOiNDmg1yQ_5_0"></a><a id="Tc_wAYcLb3HtUGwWFhaqBvo6g_5_2"></a><a id="Tc_bo__NyEwmEC7rDbmGwf1Yg_5_5"></a><a id="Tc_ghXwhg1Rt0mLzTk19qz5uw_6_0"></a><a id="Tc_T9XK5_I7q02HzXQbtgA2XQ_6_2"></a><a id="Tc_dpgAw4oD6k2CwLdQ4kioqA_6_3"></a><a id="Tc_d3NNw_TmT06po3jsa_baxw_6_5"></a><a id="Tc_5ihAgCtOpUmfzyZ16tD7eA_8_0"></a><a id="Tc_utmB45wY60mnep0LY7Fj7g_9_0"></a><a id="Tc_oZHf_sjEWEenniu2ndY3kA_9_2"></a><a id="Tc_-5IspjRgCEaD4kJPlPSR8Q_9_5"></a><a id="Tc_45UKCS6wq0-3Tn90NI5sOw_10_0"></a><a id="Tc_xaqB1qC8J0WnGgDrG93tVg_10_2"></a><a id="Tc_nS3hpegqHEqeFExWpAjK2w_10_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_b6c6TzAAMkeRYzJ4TVvKbQ_4_3">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_B7mXlaprYkG9BKHIbF1U4w_4_6">387</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_rrNgfABxzEuEWpf3gzVBvg_5_3">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_LvRMQeGMZEqcO0j0q1jCtA_5_6">309</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Transactions costs in connection with the exchange of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" scale="3" id="Tc_cP87xFECJkWg69RujBiPfg_6_6">774</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_Csh57hkiZkKFdq1qVG3v1A_9_3">2,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_XfzTcCdk_0aZQdZ5eCN_6w_9_6">3,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_Iqi26jmaRkqqfFsP5SLaTA_10_3">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_UATxAef26ECCmgTA-f8w8g_10_6">445</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_YJbpsfEshEGcuSugvqRu_g" continuedAt="Tb_YJbpsfEshEGcuSugvqRu_g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_Ri8qS6iMRU2_XmJtduzsxg" continuedAt="Tb_Ri8qS6iMRU2_XmJtduzsxg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 Phase&#160;III clinical program includes three separate studies, referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. In addition, the Phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On November&#160;9, 2022, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), resubmitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) a biologics license application (&#8220;BLA&#8221;) for PRX-102 for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, includes the final two-year analyses of the Company&#8217;s phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102 (the &#8220;<i style="font-style:italic;">BALANCE </i>study&#8221;), which were completed in July 2022, and long-term data from the Company&#8217;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 to the European Medicines Agency (&#8220;EMA&#8221;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#8217;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternation treatment for adult patients with Fabry disease. The submission was supported by the 12&#8211;month interim data analysis generated from the <i style="font-style:italic;">BALANCE </i>study. Data generated from the Company&#8217;s completed phase&#160;III <i style="font-style:italic;">BRIDGE</i> clinical trial (the &#8220;<i style="font-style:italic;">BRIDGE</i> study&#8221;), the Company&#8217;s phase&#160;I/II clinical trial in naive or untreated patients, and from the Company&#8217;s extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA includes data from the Company&#8217;s completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage (the &#8220;<i style="font-style:italic;">BRIGHT</i> study&#8221;) to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_YJbpsfEshEGcuSugvqRu_g_cont1" continuedAt="Tb_YJbpsfEshEGcuSugvqRu_g_cont2"><ix:continuation id="Tb_Ri8qS6iMRU2_XmJtduzsxg_cont1" continuedAt="Tb_Ri8qS6iMRU2_XmJtduzsxg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of the Company&#8217;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7H_2K0nM006KXiMtIxq9sA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_RPt2DDYQRU62gQfZ0yIQDg">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_4BUPV6Fg9kK-r1fyiHpRbQ">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_NRMsIbDPfUyPE-dWTLIODg">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_3HDMzFrIR0uAQbC3b6d1VQ">13.8</ix:nonFraction>&#160;million. As of September&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_G_g56DQMmkWLBHrysfc_vg">15.6</ix:nonFraction>&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_FwE5KZrKh0-_yTQHyIr5xg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_RFU60S1LzEC0Wm768K0U5A"><ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Htz4Xmw9BUOG0UfER5r48w" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_gYlPS88PVEqstvsnCvggHw">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_qUrxS0DELk2GgkQuFLAI4g">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_K5ozBnhhpEiNlu38nXGTBw">10.0</ix:nonFraction>&#160;million per year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_h48aN9U8zUaCSNssI4BjUw">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_s3ONBNXOzkuZ29vgWTNy5A">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_O2USIXmUuU-a7GuKpO6aXw">7.5</ix:nonFraction>&#160;million per year, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_VP_fYfvDoEWMW1Qlxkk5pQ">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_S8KAN140aUmNwYXLjfuU2Q" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_GECO7avwe0SiRvpGwYoS3g">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3mw68fgma0ShyyRQq7AwBQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_3Pd79iVMAEOJeUyfKITImg">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wwuvWu9CNkGPR5tF60aEww" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_i4qkWrMZT0ygcjRujv_Z_Q">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wMq9gBW5wk-NkT7WyGmXVA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_UYV6PHztD0uoUBzIvlxzbg">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_YJbpsfEshEGcuSugvqRu_g_cont2" continuedAt="Tb_YJbpsfEshEGcuSugvqRu_g_cont3"><ix:continuation id="Tb_Ri8qS6iMRU2_XmJtduzsxg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_NS6ZViowGUycZBQ7Si9mxQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_86dyIn3gtUCgFiwVsZdE0Q">10.0</ix:nonFraction>&#160;million payment to the Company in the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r9AEUZN090WxWVevOrEmew" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_7wB6naf8lEmHxL6xswf8YQ">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) under the initial Exclusive License and Supply Agreement (the &#8220;Pfizer Agreement&#8221;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_5rkf-nGdtka3BrgWc-Tu5Q" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_t7QPcoLFAU2c9DaoYp_RwQ">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The novel coronavirus disease (&#8220;COVID-19&#8221;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_W1rR-tiQQ0WX0Mrz4mB2wg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_AnTZrCvQUk2Fe5qRz0H3ig">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_W1rR-tiQQ0WX0Mrz4mB2wg" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_3oVU---160KOAGOOhZlydQ">7.5</ix:nonFraction></span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_Aa6rexGZbkaKfxVNmZsvTQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_hVOIBFE_RkGmz5l7llkb3A" continuedAt="Tb_hVOIBFE_RkGmz5l7llkb3A_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_YJbpsfEshEGcuSugvqRu_g_cont3" continuedAt="Tb_YJbpsfEshEGcuSugvqRu_g_cont4"><ix:continuation id="Tb_hVOIBFE_RkGmz5l7llkb3A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">not include <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_Rb9S1U42FkyR6mC94pBnlw">33,922,624</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_F_ZUvHwY10OBJRxyQj8M5w">33,295,154</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2022, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_pyWn_rqPR06AEa-Pyy9BCw">27,962,842</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_AIbyXx1F9EOIExuL7l55Xw">26,847,081</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_IaxJhLjT5EG26liBngcw3w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_llWVDVcbjkqCjQK5PGKyyQ"><ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_IaxJhLjT5EG26liBngcw3w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_aPMRnZQXT06f4SvapTWl8A">7.50</ix:nonFraction></ix:nonFraction>% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_xh1bRm0L5UKyrVUGnwwVuQ" continuedAt="Tb_xh1bRm0L5UKyrVUGnwwVuQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_3n4b8unPO0K-5i9HzEyFQQ" contextRef="As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Dh9X97v5V0KmJgH7rEd7Iw" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_GuiCDyV5ykCq9CNc2g2HRw">two</ix:nonFraction> performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_YJbpsfEshEGcuSugvqRu_g_cont4"><ix:continuation id="Tb_xh1bRm0L5UKyrVUGnwwVuQ_cont1"><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_TFNjPldp7UKvfgWrI26cuQ_1_2"></a><a id="Tc_YBHvf93CAEOpBIC6M1pFPA_1_5"></a><a id="Tc_SvK87geUQEK2tarJ-AQCKQ_2_0"></a><a id="Tc_K2aQDAsTukSVbvhkIpgIZA_2_2"></a><a id="Tc_PZ0ybeSdBEut2j2vW7XzSg_2_5"></a><a id="Tc_fdolVm5xykyWc3Taj1xiAQ_3_0"></a><a id="Tc_P1isG5RbCkakS-wkJCsaqQ_3_2"></a><a id="Tc_6J0kL03420me0oXgKG-0Pw_3_5"></a><a id="Tc_cyFrzM8z9kOT2vw3HpKILg_4_0"></a><a id="Tc_oJhYy5LgnUi7xwYrpv3o5w_5_0"></a><a id="Tc_Dngae57meEOuJaeLeSTGuw_6_0"></a><a id="Tc_l_FZQiL_P0-VrGzyde1bfw_6_2"></a><a id="Tc_B19lx4SO40CCFSmGOuOFdg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_0rROMhs5yUKYXdSh3nzpYw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_MKwPLLA64E-8LZ0CbMdc4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_SNbibtJdJUCfk3pR8CT63g_3_3">3,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_lMwaNDS0KUeSQnkdeckE2A_3_6">3,166</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_uveb0I0CcEyoL6iH3Go_kg_4_3">2,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_tzvd7DmcikeePD3KdwPYcQ_4_6">3,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_mbxzAIBomkuWnsvUiR4O9A_5_3">8,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_hG1hTdLa1kCRQyJB2sgVFA_5_6">11,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_zahFTfabn0mF98SR09PIXg_6_3">14,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_JVvcAwfEgUqVJo5fb96pXQ_6_6">17,954</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_cIHhyw-00kWzFIRQxC7I5w_1_5"></a><a id="Tc_F5B7c61oSkOjsw2FFUysIw_2_0"></a><a id="Tc_-W7LXlqkI0ydwpv1eM6uhA_3_0"></a><a id="Tc_tzkVFDMLV0GfiYOyXRe5Mw_4_0"></a><a id="Tc_v0YP0kBpB0qJTBST0vI6NQ_4_6"></a><a id="Tc_Nz8IVLXR-kWbQBf-tg0OSA_5_0"></a><a id="Tc_1AnYF4jmIECq19UXu7vh0Q_5_6"></a><a id="Tc_s6C2Cm2rNEaVYdehToTWZg_6_0"></a><a id="Tc_WcwC9G5v3UmruBjBErqlEA_6_6"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_pk1VPtFh3UCkuewwPXK1rQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of September&#160;30, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of September&#160;30, 2022, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_3cme8TQWb0uuWwkHHBva4A">28.75</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_S2Y0b5ZTZkmPW2GU9ojF9g">30.9</ix:nonFraction>&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0XmRqyM5IkSNgT9vMbeyqw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_xu_ttNOxXUyCW9-c5VBGyw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_HH1mRiFsa0qJN4a4_yJ33w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc__ZGQz-Q560-IAR0-3jwQeQ_2_5">1.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_6_2ecVNG4kOwBZw8VWtz7Q" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NzJ2ZKx5l0SOQAjJS-KHfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_RLyurxSGOkujZeQsjW2Uhw_3_5">1.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_fpSaaWnM_kqRxthhVgZ0dQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_y5Ywga-qgUabhJgCK9fx7g_4_5">4.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sjuUQKwTikGShcjRQ3wqGA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_e6HeHGqNkUKLEXK-ReKaOQ_5_5">75.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_lyC38x65I0G8pUXc-Tn39A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_3exXkAOOmUutXdqPwrW3sg_6_5">14.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_A9UqZ417H0Gb5smIpU4PuQ_1_2"></a><a id="Tc_zI_3XaEMnUGMsRC4lWkHqw_1_8"></a><a id="Tc_HM_MIf2hPEuVJ6nrl1TShA_2_0"></a><a id="Tc_l9h7x9ihvEOBhF7a6jiglQ_2_2"></a><a id="Tc_rcM5NJxgaEuZnRDv4uGpOg_2_5"></a><a id="Tc_4ybyZWMLEk6yUzHd551R_w_2_8"></a><a id="Tc_i8i5G-LNPEqJB9pFixpuZQ_2_11"></a><a id="Tc_VPawXDnD6UGF0yyC7J62Ng_3_0"></a><a id="Tc_UyusOCMMfkWu6guVzU_ARw_3_2"></a><a id="Tc_F6Ru9RD4gkOW_xN2sVtDFA_3_5"></a><a id="Tc_uSTF3O7as0CxZZ_tCqk75g_3_8"></a><a id="Tc_KiHcc88LWEajUbDCtcY2CQ_3_11"></a><a id="Tc_4Pp3fuObMUell0bP-JPs9Q_4_0"></a><a id="Tc_I5jITMrad066zETuAbAURw_4_2"></a><a id="Tc_pgpccNvNgUma4GfpAoZhfg_4_5"></a><a id="Tc_1yZKO1Zi0EqzegRJMLXt1g_4_8"></a><a id="Tc_zDHTzVGs8ECxxhfDOlCIsw_4_11"></a><a id="Tc_2KkskZNRCUGiVmQN7hGAGw_5_0"></a><a id="Tc_1VYzUhfW_0mZNJARqk-eeA_5_2"></a><a id="Tc_KSUQZKL1P0S4xs5TqepJIQ_5_5"></a><a id="Tc_ikifzPr1pUOm7tDBvXszWQ_5_8"></a><a id="Tc_WFmp3sPKrE-sw5_HDE7ZLQ_5_11"></a><a id="Tc_gI_JVo-ODUK2nbrRM3Xm4A_6_0"></a><a id="Tc_tanu0t_a60Sotbi69fBqGA_6_2"></a><a id="Tc_jLxLZYKtUk6WmAE-arijRA_6_5"></a><a id="Tc_IH8pZvAabUOoel7Vh3bzUg_6_8"></a><a id="Tc_VetbGuu1cEaWEqV6L9Ajbw_6_11"></a><a id="Tc_B8uoTmqEYUuE5QgpuG-F-g_7_0"></a><a id="Tc_frh4pxnMqEq1aYL2ssusFA_7_2"></a><a id="Tc_NQmcssK7_kmGH-jO65lcQw_7_5"></a><a id="Tc_xcfzi-hSake1eA_GPolYsQ_7_8"></a><a id="Tc_ia8oMDzMJ0KrA0sG5lxtWQ_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="plx:RevenueDisclosureTextBlock" id="Tb_R7YaULuqk0iif382_B2mVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_HJo-5E27hE-2oJacYOcBhA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.9pt;"><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:bottom;width:40.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ULcGA7VYNkCKoZuU0B0qrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3aApgYNfzEOB4ZRktHlqDA_3_3">4,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-4dgoH7cSUStclwbyHvr5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yoqEzBiy40StRdu-alcfDA_3_6">1,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0crLeupio0SwfGQZ9ZvUtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wkA3Hr2gx0-br9C9a2E00g_3_9">11,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ukBSADqu40uHabngZO-BlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_7wQKkNagFEi0Ep2JDzSZcQ_3_12">7,883</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_E6HX3L8o1UORIsdQUL7dMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_uyqiw41Xj0GymmCNpAJS_g_4_3">1,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jSgenlSB70S_SqMhXL6RSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_mNM3BrX8TEaq3zGyFhMK4g_4_6">3,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_weDWoM4FaEy6cA5rEgSlaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_LeRj3wYB2kmS8TKzlLu5Ww_4_9">7,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nMiBJOmnlUya-eSouKgGFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_IQaIOzSFp0mORkYHV_Kung_4_12">4,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_rBqFi8FTzEq1WlKuF9bz3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_8RdYwoUDqEu8tnzs3AUbZw_5_3">2,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_63ussK77mkmthjFePYZl1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_XG2VqIXYwE-OYcTpmpfKCg_5_6">171</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_FrWFE9O6FU6tzt749aUeMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_LPFqt4ekoEa3NB-nvgcVQw_5_9">2,781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_BukwyZ3SXUKm2PtgAfi0lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_P8uI-_5Smkm3o2YOnOyLxw_5_12">189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_ivy2EExMakeWgn87BPkvjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bcQo-y4wa0-0rnLQVBk5cw_6_3">8,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KItA5s_IX0OM8e34BU2fSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-3oz1Qf2TkC_9U6f4yFagg_6_6">4,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pveYO1f-lkC05eDMbh02IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Xclba8Z4q0GNleTzUXt-UA_6_9">21,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_D5y751RR1UqvCc-Q5th3_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_0JD-vWFSc06skTRrZKxuUQ_6_12">12,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_MXh1QMX0OECsjpG02kpLTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_arTf3lozzEmt7I9t2D_-kA_7_3">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FTvwbQ8tckqFhCmnA1b1uQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_t88abspYtUKaUx69sqhxeA_7_6">7,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_GM0fNZn86UWpPaTCwWm11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Tdl7xBwsaECDGWJUTyCI8g_7_9">17,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_O1a6ViT3C0ewVHZtdm2T7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_fuIiPlHxakuXDTurIo8wYg_7_12">17,541</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_o_wbBkSYlU6dJZTCknE1ag" continuedAt="Tb_o_wbBkSYlU6dJZTCknE1ag_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; SHARE CAPITAL</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;30, 2022, the Company held its 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_6_30_2022_rxA6MsPFmkGcr9wRVnhiBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_jCd5bgYm9kyI8oxwEsATZA">120,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_8_2_2022_uKl9eMIZyU6wmrR6-IFDvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_r4R02ZrYQEOIo4IgLAwBrw">144,000,000</ix:nonFraction> (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on August&#160;2, 2022.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Stock based compensation</b></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On February&#160;25, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_oDtUP6CxnkePQUEErUteKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_Q-tQfECEFU2WVCV46bIkkA">637,531</ix:nonFraction> shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_oDtUP6CxnkePQUEErUteKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_g5k5lGhrJkiE2KlCus6_pg">523,000</ix:nonFraction>.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_1vc1iVN5MUuWqVvagT41sw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_FPXxvNz5MU6q9wCUPO52Nw">121,951</ix:nonFraction> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_1vc1iVN5MUuWqVvagT41sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_JQ6W7Tu5VEebAWAmpwDPWg">100,000</ix:nonFraction>.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June&#160;30, 2022, the Company&#8217;s stockholders, among other matters, adopted amendments to the Plan to increase the number of shares of Common Stock available under the Plan from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_7Y9PKaad7UCQjX_1X3wmIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_f67nnpjx7kKOI1iPsPPneQ">5,725,171</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_RB19xNug80KwnklS6AmRlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_PbKHoomVqU-btTfJSJX98A">8,475,171</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares and to amend certain other terms of the Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June&#160;30, 2022, the Company granted </span><span style="-sec-ix-hidden:Hidden_Zw_3KOfSQU6x2J-upO1Hdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_y__ZEe8fgEqyBdBR1-S96A">40,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock to a new director serving on the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_QEMAQN-BDkGbFVEHLs5KjA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_IlOsrubOTES2ftl-7wPWLg">1.09</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share and vest over a </span><ix:nonNumeric contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_TD7EUWxoPki89QexLLiv-Q"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg" contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_fAhm8lm22E2EYMnAe9mM7g">16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. Vesting of the options granted to the director is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_QEMAQN-BDkGbFVEHLs5KjA" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_65pXLzKZ30iLIMjy4v3Syg">32,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On August&#160;1, 2022, the Company granted <span style="-sec-ix-hidden:Hidden_TR-D_RlREEGMWjkHWnc9rQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_l-yYUr9g3U-c7zaxkaU30g">160,000</ix:nonFraction> shares of Common Stock to a new employee of the Company under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_kkHU2uv0R0yTrJf1B14ytw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_7FW1xmNx3EmqgbAQcSRNGg">1.06</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_s6KjabaNz0W-6zus78VulQ">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg" contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_5OICmi3ZNEKf0N21WY3-8g">16</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_kkHU2uv0R0yTrJf1B14ytw" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_F2zJKj1wWU29HU3Ws6He6w">124,000</ix:nonFraction>.</p></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_VXduNrvLckqm9D1cTUUPWw_1_0"></a><a id="Tc_gxurl36tXkSowDvkY5jERg_2_0"></a><a id="Tc_Ibf9n-g4_EWdIFpqrkuPmQ_3_0"></a><a id="Tc_ZUhCk_ZvX06ao7pSFsFT8w_3_3"></a><a id="Tc_4GINESHhzUi7dQKlY81ltA_4_0"></a><a id="Tc_UMeZdBF22Uedp42ufwvPXg_4_3"></a><a id="Tc_8xOCANJFjkibEgOBV0_9Pg_5_0"></a><a id="Tc_yNj77f-y8EazUIAePno8PQ_5_3"></a><a id="Tc_u1-gsXdxpEydfKDXwQhZ1Q_6_0"></a><ix:continuation id="Tb_o_wbBkSYlU6dJZTCknE1ag_cont1"><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On September&#160;7, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, <span style="-sec-ix-hidden:Hidden_IAM58yfoSUWi7YyjTPtjww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_IgEOe0BT0EafEvMdbj1kng">3,280,000</ix:nonFraction> shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers, directors and other employees under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_GZzd7j7xTUuaSCT_sh1p-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr__FFCTlH2KEuyzKdhwopi7g">1.03</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_c0kv3_C8_UyEiNGNLwyO3A">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg" contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_tw0So6hprUi7hYpEgGSdZA">16</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options granted to executive officers and directors is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="As_Of_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_GZzd7j7xTUuaSCT_sh1p-A" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_DAqI2HJqfk-4mNoVpc65aQ">2.5</ix:nonFraction>&#160;million.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><span style="background:#ffffff;">The fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_vtkGUUeMak2EPx72q3jGOw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mpZ3bzeTFkeJouERtLBqfA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_PERS53waJkO8vJqFPGVZYA_1_2">1.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w" contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mpZ3bzeTFkeJouERtLBqfA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_fX5iwZZNjEWEpJ-fu_pXLg_2_2">1.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_RBxXLZXdpUWP6rCj2Ca55g_3_2">3.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_vYYAnqKCQUu7stDPNSzhAg_4_2">85.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_k9Ji8coPBUyYAocIiLpYSw_5_2">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_pYzP7OjHl0qnwQudx7raJw_6_2"> 6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the nine and three months ended September&#160;30, 2022, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_9_lLD4kCwUiDAd4_7k1YZQ">3,841,479</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_CpKx-mzFKEGNxFx6wijT_g" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_wqts_cYMfk2M9voVkbElJw">1,445,656</ix:nonFraction> shares of Common Stock, respectively, under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q" decimals="-5" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="6" id="Narr_jl78AfJAYE2sWV2w-KBE5w">4.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_CpKx-mzFKEGNxFx6wijT_g" decimals="-5" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="6" id="Narr_FYWeAOdeEECsH-9dwErF9Q">1.6</ix:nonFraction>&#160;million, respectively, in connection with such sales.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:CommitmentsDisclosureTextBlock" id="Tb_Xb_AHrGTM06qKOP3T-GG_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; COMMITMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of <ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_BAHkbJYPMkyDVzUoFG5QDA" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_VfYjBAyhvk-MPDnwaY97Qw">seven years</ix:nonNumeric> upon mutual written agreement prior to expiration of the initial term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_jiyaq4WzcUCBldI257BBNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During October and November 2022, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g" contextRef="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iwDdKv5AH0-AHSnrWhC_JA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_b9MGIeoLXEGGhN4R-w_WDg">506,990</ix:nonFraction> shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iwDdKv5AH0-AHSnrWhC_JA" decimals="0" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="0" id="Narr_PSsx75_sLUSFAEmKjFrTzA">530,442</ix:nonFraction> in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On October&#160;13, 2022, the Company collected approximately <ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_10_13_2022_To_10_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_46nzZWDXz0C-Ml2n7Gftvg" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_Qn31QENUDUGqHb68e9jO1w">1.7</ix:nonFraction>&#160;million from sales to Brazil. In October and November 2022, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_QWJZhKTEsUGVicty8qY70w" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr__oFTAXL0MkyoPgZl6hcL7w">2.3</ix:nonFraction>&#160;million, in the aggregate, from sales to Pfizer. On October&#160;26, 2022, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA" contextRef="Duration_10_26_2022_To_10_26_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ci7oO7k4IkeIa7oHLUkBFA" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_avRuuJw2-UK9s7bpAvCmHA">1.2</ix:nonFraction>&#160;million from expense reimbursements in connection with its collaboration with&#160;Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d30392ac_01a9_43ad_9a1c_c82bad98e7fb"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2021. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA will find that the resubmitted BLA for PRX-102 is incomplete or not properly reviewable at the time of submission and, accordingly, refuse to file the resubmitted BLA or request additional information;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the acceptance by the FDA of the resubmitted BLA for PRX-102, and the timing, progress and likelihood of final approval by the FDA and the EMA of the resubmitted BLA and of the MAA, respectively, for PRX-102, and, if approved, whether the use of PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the COVID-19 outbreak and variants which may adversely impact our business, preclinical studies and clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our other product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to maintain and manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents and short-term<span style="direction:rtl;"> </span>bank deposits; </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies and institutions;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug product to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>and the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On November&#160;9, 2022, we, together with Chiesi, resubmitted the BLA for PRX-102 for the potential treatment of adult patients with Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement, in each case with Chiesi.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make adjustments again in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete all three of the clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic and its variants on our business as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our extension trials, expected timelines and costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.64pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20220930x10q005.jpg" alt="Graphic" style="display:inline-block;height:229.64pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:226.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20220930x10q006.jpg" alt="Graphic" style="display:inline-block;height:226.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20220930x10q007.jpg" alt="Graphic" style="display:inline-block;height:116.18pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">PRX-102 is our lead product candidate and we expect it to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease was approximately $1.9&#160;billion in 2021, is forecasted to be approximately $2.1&#160;billion in 2022, and is forecasted to grow at a CAGR of approximately 10% from 2020-2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102 for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a CRL in response to the initial BLA. In preparation for the BLA resubmission, we and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, includes the final two-year analyses of our <i style="font-style:italic;">BALANCE </i>study, which were completed in July 2022, and long-term data from our open-label extension study of PRX-102 in adult </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102. The initial BLA included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study, interim clinical data from our <i style="font-style:italic;">BRIDGE</i> study and safety data from our on-going clinical studies of PRX-102 in adult patients receiving 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On February&#160;7, 2022, we, together with Chiesi, submitted the PRX-102 MAA to the EMA, and the EMA and subsequently validated the submission. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission. The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease. The submission was supported by the 12&#8211;month interim data analysis generated from our <i style="font-style:italic;">BALANCE</i> study, which was released in June 2021. Data generated from the completed <i style="font-style:italic;">BRIDGE</i> study, the phase&#160;I/II clinical trial in naive or untreated patients, and from the extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA includes data from the completed 12&#8211;month switch&#8211;over <i style="font-style:italic;">BRIGHT</i>&#160;study adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage to support an additional potential treatment regimen for patients with Fabry disease. As part of the EMA review process, we and Chiesi received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year <i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of the long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our clinical development program is designed to show that PRX-102 has a potential clinical benefit in adult Fabry patient populations when compared to currently marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs. Providing a meaningful improvement in the health and quality of life for Fabry patients being treated with PRX-102 represents a significant potential market opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, all of which have been completed. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102, which was a dose range study in ERT-na&#239;ve adult Fabry patients. In the phase&#160;III clinical program, we are studying two potential dosing regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety, offering an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">alternative to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and provide a better quality of life for Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients that completed the <i style="font-style:italic;">BALANCE, BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Currently, 126 subjects that participated in our PRX-102 clinical program have opted, with the advice of the treating physician, to continue PRX-102 treatment in one of our long-term, open label, extension studies. Such extension studies include 97 patients in the 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks extension study (PB-102-F60) with a total cumulative exposure of approximately 400 patient years (10 subjects that completed an extension study from the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II study, 18 subjects that completed the <i style="font-style:italic;">BRIDGE</i> study; and 69 subjects that completed the <i style="font-style:italic;">BALANCE</i> study), and 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study in the 2&#160;mg/kg every four weeks extension study (PB-102-F51) with a total cumulative exposure of approximately 110 patient years. Two of such subjects are being treated with 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The pivotal </span><i style="font-style:italic;">BALANCE</i> s<span style="background:#ffffff;">tudy was a 24</span>-<span style="background:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background:#ffffff;">102 in adult Fabry patients with deteriorating renal function that was </span>designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta (Fabrazyme)<span style="background:#ffffff;">. The last patient received the last treatment in this study</span> in October 2021, and topline results from the study were announced in April 2022. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study has since been completed (July 2022), and the final analysis confirmed the positive topline results and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>for at least one year with an estimated glomerular filtration rate (eGFR) slope at screening worse than -2&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta. <span style="background:#ffffff;">Approximately 40% of the enrolled patients were female.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of eGFR slope between the agalsidase beta and PRX-102 treatment arms. eGFR is considered a reliable and accepted test to measure kidney function and stage of kidney disease. Additional parameters evaluated include: cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry Clinical Events, pharmacokinetics and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the September 2021 Type A End-of-Review meeting, the FDA, in principle, agreed that <span style="letter-spacing:-0.1pt;background:#ffffff;">the proposed analysis of the </span><i style="font-style:italic;letter-spacing:-0.1pt;background:#ffffff;">BALANCE</i><span style="letter-spacing:-0.1pt;background:#ffffff;"> study demonstrating non-inferiority to agalsidase beta to be included in the data package for the PRX-102 BLA resubmission has the potential to support the approval of PRX-102 for the treatment of Fabry disease. Given the changed regulatory landscape in </span>the United States with the full approval of agalsidase beta in March 2021 based on clinical endpoints<span style="letter-spacing:-0.1pt;background:#ffffff;">, the primary analysis of the </span><i style="font-style:italic;letter-spacing:-0.1pt;background:#ffffff;">BALANCE</i><span style="letter-spacing:-0.1pt;background:#ffffff;"> study was changed from superiority to non-inferiority, as demonstrating superiority is no longer required under FDA guidelines. </span>The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study compared the eGFR annualized changes (slope) between the two treatment arms in the intent-to-treat (ITT) analysis set (77 patients). The study met its pre-specified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The median (95% confidence interval) of the eGFR slope in the PRX-102 arm was -2.514&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.788, -1.240) and -2.155 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.805, -0.505) in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians (95% confidence interval) is -0.359 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.444, 1.726). The prespecified non-inferiority margin was met. The final results of the per-protocol&#160;analysis set (72 patients) are consistent with the ITT results, with an even smaller difference in medians (95% confidence interval); -0.118 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.450, 2.213). Additional sensitivity and supportive analyses investigated mean eGFR slopes using other statistical models. These models yielded results similar to the primary analysis and confirming non-inferiority of PRX-102 to agalsidase beta. These results supported the robustness of the methodology used for comparisons of treatment effects in the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The study population (ITT analysis set) was composed of 47 males (61.0%) and 30 females (39.0%), with a mean (range) age of 44.3 (18-60) years. The mean duration of prior treatment with agalsidase beta was<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>approximately six years. At baseline, mean (SD) eGFR was 73.69&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (20.32) and median eGFR was 74.51&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>; mean (SD) eGFR slope was -8.10&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year&#160;(5.92) and median eGFR slope was -7.25&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (4<span style="direction:rtl;">0</span>.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 (21.2%) patients in the PRX-102 arm experienced a total of 13 events compared to six (24.0%) patients experiencing a total of 51 events in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti-PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA-positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA-positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA-positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment-related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Considering that in the trial, patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 have opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every two weeks in the long-term open-label extension study (PB-102-F60, NCT03566017).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa (Replagal; marketed by Takeda Pharmaceutical Company Limited (acquired Shire&#160;Plc)) for at least two years and on a stable dose for at least six months. The trial was completed in December 2019. Patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE </i>study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">et</span>. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">al</span>., in 2019, and most patients achieved a stable status post-switch.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 24.75pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.05pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;margin:0pt 5.2pt 10pt 0pt;">Baseline characteristics of the 20 patients that completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were<span style="vertical-align:super;"> </span>51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 18 have opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every two weeks in a long-term open-label extension study (PB-102-F60, NCT03566017).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIGHT</i> study was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four&#160;weeks for 52 weeks (a total of 14 infusions). The trial, which was completed in June 2020, enrolled 30&#160;adult patients (24&#160;males and 6&#160;females) with mean (SD) age of 40.5&#160;(11.3)&#160;years, ranging from 19 to 58&#160;years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV&#160;infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><a id="_Hlk64553510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We announced final results from the <i style="font-style:italic;">BRIGHT</i> study in March 2022. The results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><a id="_Hlk64641068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30&#160;patients received at least one dose of pegunigalsidase alfa, and 29&#160;patients completed the one-year study. Of these 29&#160;patients, 28 received the intended regimen of 2&#160;mg/kg every four&#160;weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg pegunigalsidase alfa every two weeks per protocol at the 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Overall, 33 of 183 total treatment-emergent adverse events (TEAEs) reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs lead to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36&#160;nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05)&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every 2&#160;weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four&#160;weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study (PB-102-F51, NCT03614234) of the 2&#160;mg/kg PRX-102 every four&#160;weeks dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete all three studies. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45 million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we and Chiesi amended the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term. The Letter Agreement changes the obligations of both us and Chiesi under the License Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amends certain provisions of the License Agreements to reflect the appointment of Chiesi as a supplier of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen and liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $1.5&#160;billion and $1.6&#160;billion in 2021 and 2022, respectively, and to grow at a CAGR of approximately 8.6% from 2020-2027.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Alidornase alfa is our chemically-modified plant cell expressed recombinant human DNase I, administered via inhalation. Recombinant human DNase I enzymatically cleaves DNA but its activity is inhibited by actin, which is present in the blood and other target organs. PRX-110 is designed to be less susceptible to actin inhibition and have higher affinity to DNA, thus enhancing enzymatic activity. In-vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA, compared to dornase alfa (Pulmozyme</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;">, currently the only commercially available DNase therapy), even more so in the presence of actin. We are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of severe gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndromes, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Severe gout is generally described as a state of gout in which there is a presence of monosodium urate crystals with any of the following: frequent recurrent gout flares, chronic gouty arthritis, subcutaneous tophi or disease elements of gout seen via imaging. It is estimated that approximately 2-5% of the gout population is considered to have chronic refractory disease, and we believe the frequency of severe gout is even higher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. However, we believe that new effective, safe therapies are needed to treat severe gout and chronic refractory gout regardless of treatment history. One treatment option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients that have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis, induce strong immunogenic reactions and have other major side-effects. In particular, 89% of patients treated with Krystexxa developed an immunogenic response associated with a failure to maintain normalization of serum uric acid levels over a 6-month therapy cycle. In addition, a recent phase IV study demonstrates that co-treatment with Krystexxa and methotrexate increases efficacy and tolerability in patients with uncontrolled gout. Krystexxa is no longer marketed in the European Union for commercial reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of severe gout which we are designing to lower uric acid levels while having low immunogenicity and increased half-life in the circulation. Pre-clinical data demonstrates stable PK profile and long half-life, low immunogenic risk and high specific activity supporting the potential of PRX-115 to be a safe and effective treatment for severe gout. Preliminary results of the first stage of one-month multiple dosing toxicity studies of PRX-115 in two species show no indication of safety concerns and our current development plan goal is to initiate a phase&#160;I clinical trial in the first quarter of 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of September&#160;30, 2022, we hold a broad portfolio of over 80 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 30 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Presentations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The five poster presentations listed below were available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities. The program was supported by Kidneys for Life, a Registered UK Charitable Organization (Manchester, UK), and took place May&#160;29, 2022 through May&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The four poster presentations listed below were available at the <span style="letter-spacing:-0.1pt;">Society for the Study of Inborn Errors of Metabolism (SSIEM) 2022 Annual Symposium held from August&#160;30, 2022 through September&#160;2, 2022</span> in<span style="letter-spacing:-0.1pt;"> Freiburg, Germany.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="letter-spacing:-0.1pt;">Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease: 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-label Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="letter-spacing:-0.1pt;">Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease: Results from the Phase 3 Open-label, BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="letter-spacing:-0.1pt;">Tolerability and Infusion Duration (ID) of Pegunigalsidase Alfa (PA) in Patients (pts) with Fabry Disease (FD): Data from 5 Completed Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="letter-spacing:-0.1pt;">Long-term Safety and Efficacy of Pegunigalsidase Alfa: a Multicenter Extension Study in Adult Patients with Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international customers and markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended September&#160;30, 2022 compared to the three months ended September 30, 2021 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $8.8&#160;million during the three months ended September&#160;30, 2022, an increase of $4.3&#160;million, or 96%, compared to revenues of $4.5&#160;million for the three months ended September&#160;30, 2021. An increase of $3.4&#160;million in sales to Pfizer, resulting from timing differences, and an increase of $2.4&#160;million in sales to Chiesi was partially offset by a decrease of $1.5&#160;million in sales to Brazil resulting from timing differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $5.4&#160;million for the three months ended September&#160;30, 2022, a decrease of $2.1&#160;million, or 28%, compared to revenues of $7.5&#160;million for the three months ended September&#160;30, 2021. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $7.1&#160;million for the three months ended September&#160;30, 2022, an increase of $3.4&#160;million, or 91%, from cost of goods sold of $3.7&#160;million for the three months ended September&#160;30, 2021. <span style="background:#ffffff;">The increase in cost of goods sold was primarily the result of the increase in sales of goods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the three months ended September&#160;30, 2022, our total research and development expenses were approximately $7.4&#160;million comprised of approximately $4.9&#160;million in subcontractor-related expenses, approximately $1.7&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.6&#160;million of other expenses. For the three months ended September&#160;30, 2021, our total research and development expenses were approximately $7.3&#160;million comprised of approximately $4.8&#160;million in subcontractor-related expenses, approximately $1.6&#160;million of salary and related expenses, approximately $0.1&#160;million of materials-related expenses and approximately $0.8&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total increase in research and developments expenses was $0.1&#160;million, or 1%, for the three months ended September&#160;30, 2022 compared to the three months ended September&#160;30, 2021<span style="direction:rtl;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $2.8&#160;million for the three months ended September&#160;30, 2022, a decrease of $0.2&#160;million, or 7%, compared to $3.0&#160;million for the three months ended September&#160;30, 2021. The decrease was primarily due to a decrease in salary-related and selling costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net were $0.4&#160;million for the three months ended September&#160;30, 2022, compared to financial expenses, net of $2.3&#160;million for the three months ended September&#160;30, 2021. <span style="background:#ffffff;">The decrease resulted primarily from lower interest and debt amortization costs due to a decrease in our outstanding notes from an aggregate principal amount of $57.92&#160;million of 2021 Notes to an aggregate principal amount of $28.</span>75&#160;million<span style="background:#ffffff;"> of 2024 Notes, and an increase in the exchange rate of New Israeli Shekels for U.S.&#160;Dollars over the period.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nine months ended September&#160;30, 2022 compared to the nine months ended September&#160;30, 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $21.2&#160;million during the nine months ended September&#160;30, 2022, an increase of $8.9&#160;million, or 72%, compared to revenues of $12.3&#160;million for the nine months ended September&#160;30, 2021. The increase resulted from an increase of $3.4&#160;million in sales to Pfizer, an increase of $2.9&#160;million in sales to Brazil and an increase of $2.6&#160;million in sales to Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $17.8&#160;million for the nine months ended September&#160;30, 2022, an increase of $0.3&#160;million, or 2%, compared to revenues of $17.5&#160;million for the nine months ended September&#160;30, 2021. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $17.2&#160;million for the nine months ended September&#160;30, 2022, an increase of $4.0&#160;million, or 30%, from cost of goods sold of $13.2&#160;million for the nine months ended September&#160;30, 2021. <span style="background:#ffffff;">The increase in cost of goods sold was primarily the result of the increase in sales of goods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the nine months ended September&#160;30, 2022, our total research and development expenses were approximately $23.7&#160;million comprised of approximately $15.1&#160;million in subcontractor-related expenses, approximately $5.4&#160;million of salary and related expenses, approximately $1.2&#160;million of materials-related expenses and approximately $2.0&#160;million of other expenses. For the nine months ended September&#160;30, 2021, our total research and development expenses were approximately $22.1&#160;million comprised of approximately $14.1&#160;million in subcontractor-related expenses, approximately $5.3&#160;million of salary and related expenses, approximately $0.5&#160;million of materials-related expenses and approximately $2.2&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">The increase in research and developments expenses of $1.6&#160;million, or 7%, from the nine months ended September&#160;30, 2022 compared to the nine months ended September&#160;30, 2021 resulted primarily from a $1.0&#160;million increase in subcontractor-related expenses in connection with regulatory submissions for PRX-102, and a $0.7&#160;million increase in materials-related expenses<span style="direction:rtl;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $8.6&#160;million for the nine months ended September&#160;30, 2022, a decrease of $0.7&#160;million, or 8%, compared to $9.3&#160;million for the nine months ended September&#160;30, 2021. The decrease resulted primarily from a decrease in professional fees and salary-related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net were $0.7&#160;million for the nine months ended September&#160;30, 2022, a decrease of $5.5&#160;million, or 89%, compared to $6.2&#160;million for the nine months ended September&#160;30, 2021. <span style="background:#ffffff;">The decrease resulted primarily from lower interest and debt amortization costs due to a decrease in our outstanding notes from an aggregate principal amount of $57.92&#160;million of 2021 Notes to an aggregate principal amount of $28.</span>75&#160;million<span style="background:#ffffff;"> of 2024 Notes, and an increase in the exchange rate of New Israeli Shekels for U.S.&#160;Dollars over the period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Our sources of liquidity include our cash balances and bank deposits. At September&#160;30, 2022, we had $20.8&#160;million in cash and cash equivalents and short term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">During the year ended December&#160;31, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60. During the nine months ended September&#160;30, 2022, we raised gross proceeds equal to approximately $4.4&#160;million from sales of common stock under our ATM program through the sale of 3,841,479 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, of a substantial majority of our then outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of our common stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of common Stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the Indenture dated as of August&#160;24, 2021 between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent, or the 2024 Indenture. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature on September&#160;1, 2024, unless earlier purchased, converted, exchanged or redeemed, and are guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries. <span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of September&#160;30, 2022, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short-term bank deposits as of September&#160;30, 2022 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $22.4&#160;million for the nine months ended September&#160;30, 2022. The net loss for the nine months ended September&#160;30, 2022 of $11.2&#160;million was increased by a $5.5&#160;million decrease in contracts liability, a $4.4&#160;million decrease in accounts payable and accruals, a $5.7&#160;million increase in accounts receivable and other assets and an increase of $1.1&#160;million in financial income, net (mainly exchange differences), and was partially offset by a $3.4&#160;million decrease in inventories and $1.5&#160;million in share-based compensation. Net cash used in investing activities for the nine months ended September&#160;30, 2022 was $10.0&#160;million and consisted primarily of net investment in bank deposits. Net cash provided by financing activities was $4.2&#160;million resulting primarily from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $5.2&#160;million for the nine months ended September&#160;30, 2021. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the nine months ended September&#160;30, 2021 of $20.9&#160;million was increased by a $4.1&#160;million increase in accounts receivable and other assets and a $1.6&#160;million increase in inventories, and was partially offset by a $13.9&#160;million increase in contracts liability, a $2.6&#160;million of amortization of debt issuance costs and debt discount, $2.0&#160;million in share-based compensation and a $1.1&#160;million increase in accounts payable and accruals. Net cash used in investing activities for the nine months ended September 30, 2021 was $18.5&#160;million and consisted primarily of a net increase in bank deposits. Net cash provided by financing activities was $16.1&#160;million resulting from the sale of common stock under our former ATM program and from our public offering of common stock, net of the convertible notes and promissory note payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates given the receipt of the CRL from the FDA discussed above, we expect to incur additional expenses in connection with any resubmission. We cannot anticipate the costs or the timing of the occurrence of such costs. In addition, to the extent we need to obtain additional financing in connection with this process or with any additional clinical testing that may be required, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v)&#160;payment of interest on our outstanding 2024 Notes. We </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">believe that our cash and cash equivalents and short term bank deposits are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts, combined with those of Chiesi, to file for resubmission with the FDA and to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. On July&#160;2, 2021, we entered into the Sales Agreement in connection with a new ATM program, as amended on May 2, 2022, pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million. On the same date, we terminated our former ATM program. As of September&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $15.6&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. Currency fluctuations during the nine months ended September&#160;30, 2022 resulted in $1.0&#160;million recognized as a financial income. We do not believe currency fluctuations have had a material effect on our results of operations during the nine months ended September&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of September&#160;30, 2022 and December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9b4c0d00_75a4_4f05_9aa8_2e415e016c80"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and approximately 65% of our expenses and capital expenditures, as well as the repayment of our 2021 Notes in 2021, are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 31% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.315</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.255</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.230</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.543</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.229</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.110</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5a32759e_5a74_480e_8c2b_45fce53eb63c"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September&#160;30, 2022 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4b630537_1066_49ba_916f_ffdd013d7a89"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d06ddd6e_f9f5_47bb_a0a1_6ec9d55b2394"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">Except as set forth below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 and in our Quarterly Reports for the three-month periods ended March 31, 2022 and June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;"><b style="font-weight:bold;">Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products, if approved.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">Increasing healthcare expenditures have been the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would result in changes in the U.S. healthcare system are continuously introduced or proposed in the U.S.&#160;Congress and in some state legislatures within the United States, including reductions in the pricing of prescription products and changes in the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products. Legislation and regulations that reduce reimbursement for our product candidates could adversely impact how much or under what circumstances healthcare providers will prescribe or administer our product candidates, if approved. This could materially and adversely impact our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our products, if approved. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales, upon approval, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, on September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The U.S.&#160;Department of Health and Human Services, or the HHS, plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. These initiatives recently culminated in the enactment of the Inflation Reduction Act, or the IRA, in August 2022, which will, among other things, allows HHS to negotiate the selling price of certain drugs and biologics that the Centers for Medicare &amp; Medicaid Services reimburses under Medicare Part B and Part D, although this will only apply to high-expenditure single-source drugs that have been approved for at least seven years (11 years for biologics). The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price beginning in October 2023, penalize drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges.</p><a id="_f9ad971f_2b7a_4e22_a819_fe4e9ed02dfb"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7eec34dc_1253_475d_a1be_0c42559aa930"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_966e3751_9a3a_4eca_8883_8a8569ef5519"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_456f122b_a221_47f7_9a57_c06b953e1e11"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_11a4c9d6_778c_4de5_9fb0_1794b2af99ac"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/tm205240d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fill/Finish Agreement effective on August&#160;29, 2022 made by and between Chiesi Farmaceutici S.p.A and Protalix Ltd.</span></a> </p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.2&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement dated August&#160;29, 2022 from Chiesi Farmaceutici S.p.A to Protalix Ltd.</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#8224;&#160;&#160;&#160;&#160;&#160;The registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation&#160;S-K. The registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb42ea3a_7937_40ba_a34c_13018e511030"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2022</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2022</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>plx-20220930xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:07:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;">       Exhibit 10.1</b></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:127.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">CONFIDENTIAL</font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_textHF_1_214"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">  </font></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXECUTION VERSION</i></p><p style="font-family:'Garamond';font-size:12pt;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;background:#ffffff;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. Such identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Garamond';font-size:8pt;font-style:italic;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:8pt;font-style:italic;line-height:1.19;padding-left:35.45pt;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.45pt;"></font><font style="display:inline-block;width:310.3pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;">__________________________________________________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>FILL/FINISH AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;">________________________________________________</p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">by and between</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.45pt;"></font><font style="display:inline-block;width:49.65pt;"></font><font style="display:inline-block;width:42.55pt;"></font><font style="display:inline-block;width:42.55pt;"></font><font style="display:inline-block;width:42.55pt;"></font><font style="display:inline-block;width:42.55pt;"></font><font style="display:inline-block;width:42.55pt;"></font><font style="display:inline-block;width:42.15pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">CHIESI FARMACEUTICI S.p.A.</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-left:0pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">and</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">PROTALIX LTD.</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FILL/FINISH AGREEMENT</b></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">THIS FILL/FINISH AGREEMENT</b><font style="font-family:'Times New Roman','Times','serif';"> (this &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) is effective on August 29, 2022, and is made by and between:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Garamond';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">CHIESI FARMACEUTICI S.p.A</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">., </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">a company incorporated under the laws of Italy with offices located at </font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_2"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Via Palermo 26</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">/A</font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_3"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Parma</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, 43122 Italy</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chiesi</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supplier</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Garamond';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_Ref175639464"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">PROTALIX LTD.</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O. Box 455, Karmiel 2161401, Israel (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;).</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Garamond';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(A)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Protalix is the owner of or has been granted the Intellectual Property Rights pertaining to the Drug Substance, Drug Product and Licensed Product (as used throughout herein, as defined in the applicable License Agreement);</font></td><td style="width:1.45pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Garamond';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(B)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Protalix and Chiesi are parties to (i)&#160;that certain Exclusive License and Supply Agreement dated October 17, 2017; and (ii) that certain Exclusive U.S.&#160;License and Supply Agreement dated July 23, 2018 ((i) and (ii), collectively</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreements</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">,&#8221; and each, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which Protalix granted to Chiesi</font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_6"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, among other rights, an exclusive </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">license to certain Intellectual Property Rights with respect to the commercialization of the Licensed Product</font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_7"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> worldwide</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">;</font></td><td style="width:1.45pt;"></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Garamond';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(C)</td><td style="padding:0pt;"><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_10"></a><a name="_cp_text_1_8"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">P</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">rotalix now desires to conduct a technology transfer of the Fill/Finish manufacturing process, including a technology transfer of analytical methods, for Drug Product </font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_9"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to Chiesi </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and purchase the Fill/Finish supply services for Drug Product from Chiesi hereunder;</font></td><td style="width:1.45pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Garamond';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(D)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Chiesi now desires to </font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_12"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">receive such technology transfer of the Fill/Finish manufacturing process for Drug Product and </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">perform Fill/Finish </font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_14"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">supply services for Protalix </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with respect to: (i) the commercial supply of the </font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_16"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Drug </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Product; (ii) the conduct of any Extension Studies (as defined in the applicable License Agreement) in accordance with the License </font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_25"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Agreements; and (iii) otherwise in connection with exploratory development and lifecycle extensions for the Drug Product; and</font></td><td style="width:1.45pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Garamond';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(E)</td><td style="padding:0pt;"><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_30"></a><a name="_cp_blt_2_29"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Parties have agreed to enter into this Agreement to set forth the terms and conditions on which </font><font style="font-family:'Garamond';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_28"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Parties will conduct the technology transfer of the Fill/Finish manufacturing process to Chiesi, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier will so conduct the Fill/Finish activities, and Customer will supply to Supplier the Drug Substance in connection therewith.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">NOW, THEREFORE, </font><font style="font-family:'Times New Roman','Times','serif';">in consideration of the mutual covenants and agreements provided</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="font-family:'Times New Roman','Times','serif';">herein, </font><font style="font-family:'Times New Roman','Times','serif';">the Parties agree as follows:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref214424447"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">DEFINITIONS</b></td></tr></table><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Certain capitalized terms used herein but not defined below are defined elsewhere in the Agreement. &#160;Unless otherwise specifically provided in this Agreement, the following terms shall have the meanings set forth below.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceleration Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in the preamble. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any entity directly or indirectly controlled by, controlling, or under common control with, a Party to this Agreement, but only for so long as such control shall continue. For purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by&#8221;, &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means (a) possession, direct or indirect, of the power to direct or cause direction of the </font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise), or (b) beneficial ownership of at least fifty-percent (50%) of the voting securities or other ownership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of an entity, it being understood and agreed that for purposes of clause (a), neither ownership of voting securities or other ownership interests of an entity nor membership or representation on (if less than half of the members of) an entity&#8217;s board of directors shall, by themselves, be presumed to constitute the power to direct or cause direction of the management or policies of such entity.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Laws</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_38"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_39"></a>&#8221; means all laws, statutes, rules, regulations, codes, administrative or judicial orders, judgments, decrees, injunctions and/or ordinances of any Governmental Authority, and common law or other legal requirements of any kind, whether currently in existence or hereafter promulgated, enacted, adopted or amended, in any country or jurisdiction that are applicable to the conduct of Fill/Finish activities in respect of the Drug Substance and Drug Product, or to a Party&#8217;s performance of its obligations hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Standards</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means good practice requirements and guidelines of any country or jurisdiction applicable to a Party&#8217;s performance of its respective obligations hereunder, including, but not limited to, cGMP.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.7</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.7(c)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.8</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bulk Drug Product</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means unlabeled vials of Licensed Product that have been filled and crimped, but have not completed the testing contemplated by clause (b) of the definition of &#8220;Fill/Finish&#8221;. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.9</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a day other than a Friday, Saturday, Sunday, or bank or other public holiday in New York, New York, Parma, Italy or Karmiel, Israel.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.10</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">cGMP</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all applicable good manufacturing practices including, (a) the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principals and guidelines of good manufacturing practice, (b) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Sections 210, 211, 600, 601 and 610, (c) EU Current Good Manufacturing Practice for Medicinal Products Eudralex Volume 4, (d) the principles detailed in the ICH Q7A guidelines, and (e) the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.11</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chiesi</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supplier</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; have the meaning set forth in the preamble. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.12</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Claims</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.13</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercially Reasonable Efforts</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_42"></a><a name="_cp_text_1_43"></a><a name="_cp_text_4_44"></a><a name="_cp_text_1_45"></a><a name="_cp_text_28_46"></a>&#8221; means, with respect to the efforts to be expended by a Party with respect to the objective that is the subject of such efforts, reasonable, good faith efforts and resources to accomplish such objective that such Party would normally use to accomplish a similar objective under similar circumstances, all as measured by the facts and circumstances at the time such efforts are due. &#160;It is anticipated that the level of effort constituting Commercially Reasonable Efforts may change over time. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.14</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all information or data of a proprietary or confidential nature regarding a Party&#8217;s business, operations, products, services, technology, layout, and/or equipment, including, without limitation, business, </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">financial, technical, clinical and scientific information, whether in oral, written, graphic, machine-readable form, or any other form (</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_54"></a><a name="_cp_text_1_55"></a><a name="_cp_text_1_61"></a> that data and information disclosed orally or visually are confirmed in writing by the disclosing Party within thirty (30) days after the date of such disclosure), disclosed and/or made available by or on behalf of a Party to the other Party or its Affiliates, and its and their respective Representatives as a result of or in connection with this Agreement and/or the Parties&#8217; discussions pertaining to this Agreement (whether prior to the execution hereof or thereafter). Notwithstanding the foregoing, unmarked information and un-confirmed information will be considered Confidential Information under this Agreement if a reasonable person familiar with the Drug Substance and the Drug Product and given the nature of information and the circumstances of disclosure would consider such information to be confidential. Such information shall not be considered to be Confidential Information of a disclosing Party to the extent that such information is: (a) as of the date of disclosure known to the receiving Party or its Affiliates (other than pursuant to the License Agreement(s)) and free from any obligation of confidentiality, as demonstrable in any tangible medium in existence at the time of disclosure; or (b) wholly disclosed in published literature, or otherwise is or becomes generally known to the public through no breach by the receiving Party of this Agreement; or (c) obtained by the receiving Party or its Affiliates from a Third Party free from any obligation of confidentiality to the disclosing Party; or (d) independently developed by the receiving Party or its Affiliates without use of or reference or access to the disclosing Party&#8217;s Confidential Information.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.15</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108642272"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Critical Regulatory Inspection Deficiency</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.11</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.16</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer Indemnitees</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.17</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.18</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Damages</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.19</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dependency Event &#8211; Inspection Deficiency</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.12</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.20</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dependency Event</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.8</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.21</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;19.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.22</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Notice</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;19.2(a)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.23</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Drug Product</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means unlabeled vials of Licensed Product that have undergone Fill/Finish, but not Labeling and Packaging.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.24</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Drug Substance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the Compound (as defined in the applicable License Agreement) component of a pharmaceutical drug product.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.25</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_66"></a><a name="_cp_text_1_62"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">DS Cost</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">&#8221; means, with respect to an applicable given quantity of Drug Substance hereunder, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_67"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and as determined in accordance with GAAP, consistently applied.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.26</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_69"></a><a name="_cp_blt_2_68"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.7(c)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.27</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DP Purchase Order</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.28</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the date indicated above.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.29</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excess DS Consumption</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.30</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finish</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_71"></a><a name="_cp_text_1_72"></a><a name="_cp_text_4_73"></a><a name="_cp_text_1_74"></a>&#8221; means the fill and finish, bulk packaging, testing and release of Drug Product to be performed by Supplier hereunder, including (a) filling the Drug Substance into vials and (b) testing, including in process release to Labeling and Packaging and ongoing stability testing of the Drug Product. &#160;For the avoidance of doubt, Fill/Finish shall not include any activities included in the definition of Labeling </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_76"></a><a name="_cp_text_1_82"></a>and Packaging. </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">When used as a verb, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finish</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means to conduct Fill/Finish, and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finished</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has a correlative meaning.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.31</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_84"></a><a name="_cp_blt_2_83"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finish Licenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all licenses, permits, approvals, authorizations and consents necessary for, or required by Applicable Law to be maintained by Supplier for, its performance of Fill/Finish activities at its applicable facility(ies) hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.32</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_86"></a><a name="_cp_blt_2_85"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure Event</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.33</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forecast</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;6</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.34</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authority</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any court, agency, department, authority or other instrumentality of any national, supra national, state, county, city or other political subdivision.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.35</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ICC Rules</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;19.2(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.36</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.4(a)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.37</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.4(a)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.38</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Alternate Source</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;3.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.39</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means know-how, trade secrets, Patent Rights (as defined in the applicable License Agreement), trademarks, service marks, trade names, design rights, copyrights (including rights in computer software) and any rights or property similar to any of the foregoing in any part of the world, whether registered or not, together with the right to apply for the registration of any such rights, and all rights or forms of protection having equivalent or similar effect, in any part of the world.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.40</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_88"></a><a name="_cp_blt_2_87"></a><a name="_Toc495297285"></a><a name="_Toc495298556"></a><a name="_Toc495328147"></a><a name="_Toc495799991"></a><a name="_Toc495949539"></a><a name="_Toc495949813"></a><a name="_Toc515906086"></a><a name="_Toc515993405"></a><a name="_Toc519751987"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">June Forecast</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;6</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.41</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labeling and Packaging</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> means the final product labeling and packaging of the Drug Product, including materials to be inserted such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying the Drug Product.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.42</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreements</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; have the meaning set forth in the recitals.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.43</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lost Drug Substance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.44</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintenance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintain</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; shall mean all necessary actions and works for retaining or restoring the applicable equipment, or pieces thereof, to carry on the operation of such equipment in proper condition and compensating for normal wear and tear or as agreed to in writing by the Parties.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.45</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_90"></a><a name="_cp_blt_2_89"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Materials</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any materials of any nature, except Drug Substance, that are used by, or are necessary for, Supplier to conduct Fill/Finish hereunder. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.46</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_92"></a><a name="_cp_blt_2_91"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Conformance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.47</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OOS</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any non-conformance in relation to quality acceptance levels, defined from a regulatory point of view (e.g., pharmacopoeias, registration documents).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.48</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means Customer (or Protalix) and Supplier (or Chiesi) (collectively), and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means either Customer (or Protalix) and Supplier (or Chiesi), as the case may be.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.49</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_96"></a><a name="_cp_blt_2_95"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Processed Drug Substance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.50</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Requirements</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the written specifications for Drug Product, as specified in the written dossier for such Drug Product to be provided by Customer to Supplier as of the Effective Date in connection with the Tech Transfer Plan, as the same </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">may be updated from time to time in accordance with the QA, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;5.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.51</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Schedule</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the written Drug Product schedule to this Agreement, entered into by and between the Parties (or any or their Affiliates) in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_field_47_98"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_99"></a><a name="_cp_text_4_100"></a><a name="_cp_text_1_101"></a> which sets forth the particulars for the Fill/Finish of Drug Product under this Agreement, including, all specifications (including, by form or dosage, as applicable), Materials and price for the Drug Product, and which is subject to amendment from time to time during the Term pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_103"></a> hereof.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.52</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; have the meaning set forth in the preamble.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.53</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QA</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, individually or collectively as applicable, QA1, QA2 and QA3.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.54</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality Agreement 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QA1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means that certain Amended &amp; Restated Quality &amp; Technical agreement dated February 28, 2022, by and between the Parties, that defines the regulatory case vis-&#224;-vis Regulatory Authorities in connection with the supply of Drug Substance, the Fill/Finish of Drug Product hereunder and the certification of finished product, when Supplier is the sponsor of clinical trials or the manufacturing authorization holder (MAH), as such agreement may be amended from time to time. QA1 is attached as </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.55</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality Agreement 2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QA2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_113"></a>&#8221; means the quality agreement to be entered into by the Parties (as contemplated in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">) that defines the regulatory case vis-&#224;-vis Regulatory Authorities in connection with the supply of Drug Substance, the Fill/Finish of Drug Product hereunder, packaging for clinical trials and the certification of finished product when Customer is the sponsor of clinical trials, as such agreement may be amended from time to time.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.56</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality Agreement 3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QA3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the quality agreement to be entered into by the Parties (as contemplated in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">) that defines the quality roles and responsibilities of each Party in connection with the Fill/Finish of Drug Product hereunder, as such agreement may be amended from time to time.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.57</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recall</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;14</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.58</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authority</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, in respect of a particular country or jurisdiction, the Governmental Authority having responsibility for granting Regulatory Approvals </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(as used throughout herein, as defined in the applicable License Agreement) </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in such country or jurisdiction.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.59</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_119"></a><a name="_cp_blt_2_118"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Inspection Deficiency</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.10</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.60</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remaining Vials</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.61</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representatives</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, such Party&#8217;s Affiliates and its and their respective officers, directors, employees, authorized consultants, contractors, and agents.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.62</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shortage</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;8.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.63</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supplier Indemnitees</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.64</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supplier Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.65</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tech Transfer</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.66</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tech Transfer Plan</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.67</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;18.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.68</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Theoretical Yield</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to each batch of Drug Substance supplied by Customer, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.69</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any person or entity other than Chiesi, Protalix, or any of their respective Affiliates.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.70</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.4(a)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.71</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Product Claim</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.72</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.7(c)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.73</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Triggering Event</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.74</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref214424453"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">CONSTRUCTION</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and mean include, includes and including, without limitation; (b) definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms; (c) references to an agreement, law or instrument mean such agreement, law or instrument as from time to time amended, modified or supplemented; (d) references to a person are also to its permitted successors and assigns; (e) references to an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;, or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; refer to an Article or Section of, or any Exhibit to, this Agreement unless otherwise indicated; (f) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;; (g) the word &#8220;any&#8221; shall mean &#8220;any and all&#8221; unless otherwise indicated by context; (h) the use of the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and/or&#8221;; and (i) references to &#8220;days&#8221; shall mean calendar days (unless Business Days are expressly specified), and references to &#8220;months&#8221; or &#8220;years&#8221; shall mean calendar months and calendar years, respectively. &#160;The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall be applied against a Party. &#160;Except as otherwise specifically stated to the contrary in this Agreement, each Party shall bear its own costs of entering into and performing its obligations under this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref107749261"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Specific terms and conditions for the Fill/Finish of designated Drug Products are set forth in the Product Schedule attached as </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and Product Schedules to be entered into by and between the Parties in the form that is substantially similar to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Any number of Product Schedules may be executed pursuant to this Agreement during the Term.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Exhibits and the Product Schedules form part of this Agreement and have the same force and effect as if expressly set out in the body of this Agreement. &#160;Any reference to this Agreement includes the Exhibits and the Product Schedules. &#160;Any breach of any Exhibit or Product Schedule shall be deemed as a breach of this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_127"></a><a name="_Ref109058855"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Parties acknowledge and agree that the execution and implementation of this Agreement does not constitute </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Solely to the extent that a Party&#8217;s </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (with respect to this Agreement, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Triggering Event</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), causes </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_153"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">SUPPLY OF DRUG PRODUCT </b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref214420825"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">During the Term, Customer hereby appoints Supplier to perform, and Supplier shall perform, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_156"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Fill/Finish </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_161"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and supply of Drug Product for Customer, including as described in Recital (D) above, and Customer shall purchase such Drug Product from Supplier, hereunder, in each case subject to and </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_167"></a>in accordance with the terms and conditions set forth herein (including the Product Schedules). &#160;For the avoidance of doubt, subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;18.5(b)</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(iii)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsection 2(g)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Part B</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, this Agreement shall not be construed as a requirements contract, or as an exclusive contract, and shall not be interpreted to obligate Customer to purchase a minimum </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">volume of Drug Product from Supplier (except with respect to the Minimum Batch Size in any applicable License Agreement).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_187"></a><a name="_cp_blt_2_186"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_185"></a>Supplier shall not subcontract Fill/Finish (or any portion thereof) to a Third Party without obtaining the prior written consent of Customer (such consent not to be unreasonably withheld, conditioned, or delayed). &#160;Each Party shall ensure that each of its Affiliates and permitted subcontractors accepts and complies with all of the applicable terms and conditions of this Agreement as if such Affiliates or permitted subcontractors were parties to this Agreement, and each Party shall remain fully responsible and fully liable for its Affiliates&#8217; and permitted subcontractors&#8217; performance under this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108897313"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Contemporaneously with the execution of this Agreement, the Parties have executed a side letter to the License Agreement with respect to establishing an alternative source for Fill/Finish (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Alternate Source</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">TECHNOLOGY TRANSFER; EQUIPMENT</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108269153"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_189"></a><a name="_cp_text_1_192"></a><a name="_cp_text_1_194"></a><a name="_cp_text_4_195"></a><a name="_cp_text_1_196"></a>Customer shall transfer such technology and technical information to Supplier as is necessary and reasonably useful for the Fill/Finish and supply of Drug Product hereunder, including process development, process validation and process optimization and all applicable analytical methods and inspection procedures, to secure the establishment of Fill/Finish and quality control of the Drug Product at Supplier&#8217;s manufacturing facilities (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tech Transfer</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) in accordance with the Tech Transfer Plan and this Agreement.&#160;<a name="_cp_text_1_198"></a> The Parties shall, at Supplier&#8217;s reasonable request, establish a joint project team, which shall discuss and propose updates and amendments to the Tech Transfer Plan for mutual written approval by the Parties (not to be unreasonably withheld, conditioned or delayed). &#160;&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tech Transfer Plan</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, collectively, the written technology transfer plan with respect to the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_200"></a> Drug Product mutually agreed by the Parties in writing and the written technology transfer plan with respect to the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_202"></a><a name="_cp_text_1_204"></a><a name="_cp_text_1_210"></a> Drug Product to be mutually agreed by the Parties in writing as soon as reasonably practicable after the Effective Date, which set out the details and activities for the Tech Transfer, including the time schedule, documentation, information, reports, costs, equipment, and technical assistance, as the same may be revised from time to time in accordance with this Agreement. &#160;The initial Tech Transfer Plan with respect to the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Drug Product is attached and incorporated as </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and any written amendments thereto signed by both Parties shall amend and modify the then-current Tech Transfer Plan and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be updated accordingly. Upon </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> the initial Tech Transfer Plan with respect to the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Drug Product, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be updated to incorporate such Tech Transfer Plan. &#160;After the completion of the Tech Transfer and the above activities, the joint project team will be dissolved and replaced with an Operational Team. &#160;The Parties shall allocate sufficient resources to perform the above activities. &#160;Customer shall remunerate Supplier for its reasonable activities and any start-up costs as agreed by the Parties in advance and in writing to the extent provided in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Part B</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Supplier may not use Customer&#8217;s technology for any purpose other than the Fill/Finish hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Customer is responsible for ensuring that Customer&#8217;s technology transferred to Supplier pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref103376604"></a> in accordance with the Tech Transfer Plan does not infringe any Third Party&#8217;s Intellectual Property Rights.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier shall be responsible for obtaining and Maintaining all equipment required for the Fill/Finish and supply of Drug Product hereunder. &#160;Title to such equipment shall be in Supplier&#8217;s name. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">QUALITY AGREEMENT</b></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_246"></a><a name="_cp_text_1_249"></a>The Parties shall negotiate in good faith and enter into both QA2 and QA3 within </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of the Effective Date (or such extended period as mutually agreed by the Parties in writing). Upon execution QA2 and QA3 shall each be attached to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If there is any inconsistency between QA1, QA2 and QA3, a Product Schedule or an Exhibit, on the one hand, and the body of this Agreement, on the other hand, the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall govern. &#160;Notwithstanding the foregoing, in the event of a conflict between any of the provisions of this Agreement and either QA1, QA2 or QA3 with respect, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the provisions of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, shall govern, (b) </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, shall govern, and (c) </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, shall govern.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109070626"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Parties shall, at any Party&#8217;s reasonable request, establish a joint project team, which shall discuss and propose updates and amendments to the Applicable Standards or Product Requirements for mutual written approval by the Parties (not to be unreasonably withheld, conditioned or delayed).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref103361239"></a><a name="_Ref109841306"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">FORECASTS AND ORDERS &#8211; DRUG PRODUCT</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 36pt;"><a name="_Ref214420681"></a><a name="_Ref245651646"></a><a name="_Ref246409953"></a><a name="_Ref492398936"></a><a name="_Ref246555251"></a><a name="_Ref247093415"></a><a name="_Ref244598063"></a>Within <font style="background:#ffffff;">[***]</font><a name="_cp_text_1_251"></a><a name="_cp_text_1_256"></a><a name="_cp_text_1_257"></a><a name="_cp_text_1_261"></a><a name="_cp_text_1_263"></a> after Protalix&#8217;s receipt of the forecast provided by Chiesi pursuant to any applicable License Agreement, Customer shall provide Supplier with a non-binding rolling Forecast for Customer&#8217;s and its Affiliates&#8217; requirements of Drug Products during the following <font style="background:#ffffff;">[***]</font> (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forecast</u><a name="_cp_text_1_267"></a>&#8221;), which Forecast shall be based <font style="background:#ffffff;">[***]</font><a name="_cp_text_28_268"></a> submitted to Protalix under the applicable License Agreement. &#160;The Forecast will be allocated per quarter. &#160;The Forecast submitted in June each year (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">June Forecast</u>&#8221;) shall, however, cover <font style="background:#ffffff;">[***]</font> under the License Agreements, and include an <font style="background:#ffffff;">[***]</font><a name="_cp_text_1_273"></a><a name="_cp_text_1_274"></a> for each quarter if the term of the Product Schedule continues for the following year. &#160;With respect to any given Drug Product, additional details regarding Forecasts for such Drug Product may be set forth expressly in the applicable Product Schedule.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">FORECASTS AND ORDERS &#8211; DRUG SUBSTANCE</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109841378"></a><a name="_Ref109059067"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_277"></a><a name="_cp_text_1_278"></a><a name="_cp_text_1_295"></a>, the Parties shall consult with a view to develop a mutually-agreed upon strategy for maximizing Supplier&#8217;s Fill/Finish commercial production yield of Drug Product(s) from the Drug Substance. &#160; &#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 72pt;">If, <font style="background:#ffffff;">[***]</font><a name="_cp_text_1_300"></a><a name="_cp_text_1_304"></a>, Supplier&#8217;s aggregate Fill/Finish commercial production yield of Drug Product(s) from the Drug Substance during such period is <font style="background:#ffffff;">[***]</font> of the Theoretical Yield, as calculated <font style="background:#ffffff;">[***]</font> from <font style="background:#ffffff;">[***]</font><a name="_cp_text_1_309"></a> (such excess consumption, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excess DS Consumption</u>&#8221;), the Parties will promptly, and in good faith, meet to collectively evaluate the underlying cause of such Excess DS Consumption and discuss proposed corrections where appropriate<a name="_cp_text_4_310"></a>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 72pt;">In the event of<a name="_cp_text_1_311"></a> Excess DS Consumption, <a name="_cp_text_1_329"></a><font style="background:#ffffff;">[***]</font>. &#160;For the avoidance of doubt, for purposes of calculating the Excess DS Consumption, any <font style="background:#ffffff;">[***]</font>. &#160;Further, it shall not constitute a <a name="_cp_text_4_332"></a>breach of this Agreement by Supplier <a name="_DV_M420"></a><a name="_cp_text_1_333"></a>if Supplier&#8217;s actual yield of Drug Product from Drug Substance <a name="_cp_text_1_335"></a>hereunder is <font style="background:#ffffff;">[***]</font> of the Theoretical Yield. </p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108269204"></a><a name="_Ref108723974"></a><a name="_Ref246410926"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">On the Effective Date, or such later date that is at least </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Customer shall deliver to Supplier a firm purchase order (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DP Purchase Order</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_339"></a>&#8221;) for the Drug Product for the first Commercial Quarter (as used throughout herein, as defined in the applicable License Agreement) covered by the initial Forecast and for at least </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_342"></a>, all of which shall be based on Chiesi&#8217;s purchase orders and forecasts for Drug Product (submitted to Protalix under the applicable License Agreement) for </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Thereafter, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Protalix shall deliver to Chiesi a DP Purchase Order for the first Commercial Quarter covered by its Forecast and for at least </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_343"></a>, all of which shall be based on Chiesi&#8217;s purchase orders and forecasts for Drug Product (submitted to Protalix under the applicable License Agreement) for </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;DP Purchase Orders shall be in writing and no verbal communications or e-mail shall be construed to mean a commitment to purchase or sell. &#160;Each DP Purchase Order delivered by Protalix to Chiesi pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be binding on Chiesi unless Chiesi notifies Protalix in writing of its rejection thereof within </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of receipt of such DP Purchase Order; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_349"></a>Chiesi may only reject DP Purchase Orders that are </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each DP Purchase Order</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> accepted by Supplier in accordance with this Agreement is non-cancellable by Customer</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_350"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, unless otherwise </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_351"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">agreed in writing by Supplier in each instance.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_354"></a><a name="_cp_text_1_355"></a><a name="_cp_text_1_357"></a> &#160;With respect to a given calendar year during the Term, Supplier agrees to have available Fill/Finish production capacity to supply Customer with quantities of Drug Product in aggregate for such calendar year at least </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, for purposes of clarity, Supplier will have no such obligation until the calendar year immediately following the calendar year in which </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">), but shall not be required to maintain Fill/Finish production capacity in excess thereof; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, for clarity, that, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the available Fill/Finish production capacity of Supplier shall be </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Upon reasonable request of either Party, the Parties agree to discuss in good faith the potential for Fill/Finish of any such excess quantities of Drug Product.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108269222"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_359"></a>DP Purchase Orders may be delivered electronically or by other means to such location as Supplier shall designate. &#160;Nothing in any such DP Purchase Order or written acceptance shall supersede the terms and conditions of this Agreement, the License Agreements, or the QA. &#160;All DP Purchase Orders, confirmations of receipt of DP Purchase Orders and other notices contemplated under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be sent to the attention of such persons as each Party may identify to the other in writing from time to time in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21.8</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108870941"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier shall use its inventory of the Drug Substance in accordance with the order of allocations reasonably specified by Customer in writing (in conjunction with delivery of the applicable Drug Substance), and the Parties shall work together in good faith to review and resolve any reasonable concerns with respect to such use of Drug Substance.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">DELIVERY OF DRUG PRODUCT</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108660705"></a><a name="_Ref108269282"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_362"></a>During the Term, Chiesi shall perform the Fill/Finish and deliver the resulting Drug Product for Customer </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Except as otherwise specified herein, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that a failure by Supplier to detect a latent defect in such inspection and release conducted upon its receipt of Materials provided by its suppliers shall not be a breach of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;8.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_379"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_398"></a><a name="_cp_text_1_397"></a><a name="_cp_text_1_400"></a>Title to the Drug Product shall transfer to Chiesi upon </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and, in any case, not later than </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_401"></a> after </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Drug Product, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that at or prior to such time Protalix shall have invoiced Chiesi for such delivery of Drug Product pursuant to Section 4.6(a)(i) of the License Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_408"></a>Supplier will label and package all Drug Product as &#8220;Brite Stock&#8221; for bulk storage, including batch number(s) identification by batch number printing on each vial, in accordance with the QA; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, that any Drug Product shall be retained by Supplier until each of Supplier and Customer has successfully completed its part of the release activities relating to such Drug Product pursuant to the applicable Product Requirements, the QA or the terms hereof.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref495013251"></a><a name="_Ref108269313"></a><a name="_Ref109841471"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In the event that the Materials or manufacturing capacity required to perform Fill/Finish and to supply Drug Product required hereunder are in material short supply (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shortage</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), Supplier shall notify Customer of such Shortage as soon as practicable after Supplier becomes aware of such Shortage or of circumstances that are reasonably likely to result in such a Shortage and the Parties shall promptly meet to discuss the Shortage (which discussion may be conducted through the Operating Committee). &#160;Supplier shall provide to Customer a written plan of action stating in reasonable detail the proposed measures to address such Shortage and the date such Shortage is expected to end. &#160;Supplier shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> to minimize the duration of any Shortage. &#160;During any such Shortage, Supplier shall; </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_424"></a><a name="_cp_text_1_425"></a><a name="_cp_text_1_429"></a><a name="_cp_text_1_431"></a><a name="_cp_text_1_432"></a><a name="_cp_text_1_433"></a>Supplier shall promptly communicate any anticipated deviation from the amount of Drug Product(s) or delivery date previously specified in the corresponding accepted DP Purchase Order, in order to enable Customer to take necessary action to mitigate the effects thereof. &#160;Such notice shall include the reason for the anticipated deviation (i.e., the shortfall or delay) and provide an indication of the anticipated extent or duration of the same. &#160;In any such case, either Party may request that designated technical personnel from each Party undertake discussions regarding </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref103362257"></a><a name="_Ref108872991"></a><a name="_Ref103362937"></a><a name="_Ref214420770"></a><a name="_Ref103362476"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">DELIVERY OF DRUG SUBSTANCE</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_448"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">During the Term, Customer shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_435"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">supply and </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">deliver the Drug Substance </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_437"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to Supplier </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_439"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in a timely manner </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and in the quantities</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_442"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (a) that satisfy Supplier&#8217;s requirements (as agreed to by the Parties in writing in advance) to Fill/Finish the quantities of Drug Product ordered by Customer under DP Purchase Orders submitted to, and accepted by Supplier, from time to time </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_443"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in accordance with the terms of this </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_444"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Agreement and (b) of additional backup and replacement quantities of Drug Substance as specified in the applicable Product Schedule</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.5</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, if applicable), </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.5</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, if applicable), </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.9</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.10</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> For clarity, Supplier would remain responsible for </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, if applicable. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_447"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">All Drug Substance must be delivered to Supplier </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_449"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> in advance of the manufacturing commencement date for the applicable Drug Product, and the Parties agree to coordinate in this regard. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108278814"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_454"></a><a name="_cp_text_1_456"></a><a name="_cp_text_1_457"></a><a name="_cp_text_1_458"></a><a name="_cp_text_1_461"></a>Upon receipt of any Drug Substance at Supplier&#8217;s facility in accordance herewith, Supplier shall perform a visual inspection of the Drug Substance as contemplated by the Product Schedule and/or the QA. &#160;If such inspection reveals that any delivery of the Drug Substance is patently damaged, short in quantity or if there are apparent discrepancies between the delivered Drug Substance and the Customer&#8217;s Manufacturing Certificate of Analysis, Supplier shall promptly </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> notify Customer of the same and Customer shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> promptly provide to Supplier replacement Drug Substance therefor (</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, for clarity, that Supplier may utilize any backup inventory of Drug Substance as necessary to meet production timelines in accordance with this Agreement, which utilization shall be subject to the pre-approval of Customer (not to be unreasonably withheld, conditioned, or delayed), and the Parties shall work together in good faith to review and resolve any reasonable concerns with respect to such use of Drug Substance).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108902950"></a><a name="_Ref109059111"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In the case of any (a) Non-Conformance (including any latent defects) of Drug Substance discovered following its delivery to Supplier by Customer hereunder after the notice period set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or (b) Drug Substance that is consumed, damaged, lost or rendered unusable in the course of Fill/Finish production of Drug Product by Supplier hereunder (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Processed Drug Substance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), then in each case ((a) and/or (b)), (y) Customer shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> promptly provide to Supplier replacement Drug Substance therefor (</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, for clarity, that Supplier may utilize any backup inventory of Drug Substance as necessary to meet production timelines in accordance with this Agreement, which utilization shall be subject to the pre-approval of Customer (not to be unreasonably withheld, conditioned, or delayed), and the Parties shall work together in good faith to review and resolve any reasonable concerns with respect to such use of Drug Substance), and (z) </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109069319"></a><a name="_Ref109059389"></a><a name="_Ref109069909"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In the case of any (a) Drug Substance or (b) Drug Substance contained in Bulk Drug Product, that is damaged, lost or stolen while in the possession of Supplier hereunder (e.g., during storage) (but excluding Processed Drug Substance) (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lost Drug Substance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), (y) </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; and (z) Customer shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> promptly provide to Supplier replacement Drug Substance therefor (</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, for clarity, that Supplier may utilize any backup inventory of Drug Substance as necessary to meet production timelines in accordance with this Agreement, which utilization shall be subject to the pre-approval of Customer (not to be unreasonably withheld, conditioned, or delayed), and the Parties </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall work together in good faith to review and resolve any reasonable concerns with respect to such use of Drug Substance). &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109059258"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In the event that replacement of Drug Substance becomes necessary under this Agreement, or Non-Conformance, damage, loss of Drug Substance otherwise occurs (or Drug Substance is otherwise rendered unusable), the Parties shall conduct a root cause investigation with respect to the same, as contemplated by the QA, including using applicable lab testing and analysis, and, in the case of any differences in the results of the Parties&#8217; initial root cause analysis, work together in good faith to resolve the same as promptly as practicable. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier&#8217;s use of the Drug Substance received from Customer shall be limited to the Fill/Finish of Drug Product for Customer hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref109069278"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">DEFECTS, SHORTFALL, DAMAGE TO DRUG PRODUCT</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108276045"></a><a name="_Ref214421894"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Without limiting the provisions of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;8.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, in case of any material damage, defect </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or shortage, as compared to the requirements under this Agreement (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Conformance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_466"></a><a name="_cp_text_1_467"></a>&#8221;), in or of the Drug Product supplied to Customer hereunder, Customer will promptly give Supplier a written notice thereof in accordance with the QA. &#160;Without limiting Customer&#8217;s other audit rights hereunder, Customer shall also have a reasonable opportunity to </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_468"></a> from time to time as contemplated by the QA. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109069932"></a><a name="_Ref109059429"></a><a name="_Ref108277325"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In the event of any Non-Conformance with respect to the Drug Product Fill/Finished by Supplier hereunder, Supplier shall replace such non-conforming Drug Product with conforming Drug Product, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108280839"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If the Parties do not agree as to the cause of an alleged Non-Conformance of Drug Product for which Customer has provided notice in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the Parties shall promptly discuss and in good faith attempt to resolve such dispute; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Supplier shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> to </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> replace such alleged non-conforming Drug Product to try and avoid any possible out-of-stock situation. The Parties shall use </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> to resolve the dispute in the case of Non-Conformance or OOS, within </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> unless otherwise agreed in writing by the Parties. If the dispute is not resolved by the Parties in such period or such other period as the Parties may agree to apply to an independent expert mutually selected by the Parties for determination of the cause and/or existence of such alleged Non-Conformance. The expert shall be mutually agreed upon in writing by the Parties and engaged by Customer. The results of the expert&#8217;s determination shall be based on </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and shall be final and binding on the Parties (absent manifest error or fraud), </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_465"></a>.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref108270146"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">INVOICES</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Each delivery of Drug Product hereunder shall be accompanied by an invoice. &#160;Supplier shall invoice for the Drug Product at the price that is determined in accordance with the applicable Product Schedule. &#160;Customer shall issue payment against such undisputed invoices within </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of the invoice date. &#160;Supplier shall include the following information, where applicable, on all invoices: the type, description, and quantity of the Drug Product delivered; the date of shipment; the prices; any applicable taxes, transportation charges or other charges provided for hereunder; and the applicable purchase order number.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">All invoices will be raised in Euros, and Customer agrees to pay all sums due in this currency.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Customer may withhold payment of that portion of any charges that Customer reasonably disputes in good faith subject to the following:</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">if Customer disputes any charges, Customer shall so notify Supplier and provide a description of the particular invoice(s) in dispute and an explanation of the reason why Customer disputes such invoice(s);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">neither the failure to dispute any charges prior to payment nor the failure to withhold any amount shall constitute, operate or be construed as a waiver of any right Customer may otherwise have to dispute any such invoice(s) or recover any amount previously paid; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Customer shall pay the remaining, undisputed charges in accordance with the terms of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;11</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If an undisputed invoice is not paid within this timeframe, penalty interest shall be charged to the Customer. &#160;Penalty interest shall be equal to the lesser of (i) the maximum rate permitted by Applicable Law, or (ii) </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> per month, computed monthly from the payment due date as indicated in the invoice and until complete payment is received.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref103362868"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">TAX MATTERS</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref492408306"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.2</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VAT</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;It is understood and agreed between the Parties that any payments made to Supplier under this Agreement are exclusive of any value added or similar tax imposed upon such payments, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref495991254"></a><a name="_Ref495352402"></a><a name="_Ref495792456"></a><a name="_Ref495922173"></a><a name="_Ref518656707"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Tax</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Payments made by Customer to Supplier </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_521"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">pursuant to this Agreement </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_522"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall be made </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_530"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;If Supplier disputes either the requirement to deduct such tax withholding or deduction from such payment, or the amount of such withholding or deduction (including where Supplier, acting in good faith, considers that less onerous taxation arrangements are available to the Parties), the Parties shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, independent accounting firm of reputable stature with relevant taxation expertise in the relevant jurisdiction to provide its professional opinion as to existence of, and the relevant amount in respect of, such tax liability. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and such independent accounting firm&#8217;s determination as to the existence of, and amount of, such tax liability shall be binding on the Parties, in respect of the application of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;12.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> to such payment (unless an applicable Governmental Authority later determines the requirement and the amount of such withholding or deduction, in which case, such determination by such applicable Governmental Authority shall be binding on the Parties in respect of the application of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;12.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> to such payment). &#160;For the avoidance of doubt, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_531"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to the extent Supplier </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_532"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">disputes either the requirement to deduct such tax withholding or deduction from such payment, or the amount of such withholding or deduction, and unless either an applicable Governmental Authority or a </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> independent accounting firm has otherwise determined the existence of, and amount of, such taxation liability in respect of such payment </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_533"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in accordance with </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_534"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the terms of this </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_535"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;12.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;In each case, Customer shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Supplier an official tax certificate or other evidence of such payment of such deduction or withholding tax if Supplier might be affected under this </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_field_47_536"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;12.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_537"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding the foregoing, if as at the date on which a payment from Customer to Supplier under this Agreement is due and payable, Supplier has not yet made available to Customer the certifications needed to reduce the amount of the withholding tax under Applicable Law</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_539"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, then Customer shall not be responsible </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> for any withholding tax higher than </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.4</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each Party shall provide the other with reasonable assistance to enable a reduction in, elimination of, or the recovery, as permitted by Applicable Law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_544"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such recovery to be for the benefit of the Party bearing such withholding tax or VAT. &#160;Each Party shall provide reasonable notice to the other Party </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of the notifying Party&#8217;s intent to withhold any amount in respect of taxes, and the other Party shall provide to the notifying Party any tax forms that may be reasonably requested by and necessary for the notifying Party not to withhold tax or to withhold tax at a reduced rate under Applicable Law (including an </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">applicable income tax treaty). &#160;Each Party further agrees to provide reasonable cooperation to the other Party, at the other Party&#8217;s expense, in connection with any official or unofficial tax audit or contest relating to payments made by a Party to the other Party under this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_cp_blt_2_530"></a><a name="_cp_blt_1_551"></a><a name="_cp_blt_2_550"></a><a name="_Ref103369073"></a><a name="_Ref109247267"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">QUALITY, AUDITS, AND REGULATORY MATTERS</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108269331"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In conducting the Fill/Finish hereunder, Supplier shall apply its quality control procedures and in-plant quality control checks on such Fill/Finish in the same manner as Supplier applies such procedures and checks to products of similar nature manufactured for sale by Supplier. &#160;In addition, Supplier and Customer shall each comply with all Applicable Laws, the QA, the Product Schedule, Applicable Standards and the Fill/Finish Licenses in its performance hereunder. &#160;Supplier shall Fill/Finish Drug Product under this Agreement in compliance with Applicable Standards and the Product Requirements.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref401932319"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier shall ensure that it, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, obtains and maintains throughout the Term the Fill/Finish Licenses and other Regulatory Authority certificates, permits, licenses or approvals that it (or the relevant Affiliate) respectively requires for the performance of Fill/Finish hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Parties agree to cooperate in attempting to resolve all product quality complaints as set out in the QA and will test and release Drug Product in accordance with the test methods as set forth in the QA to ensure that Drug Product conforms to the requirements set forth in the last sentence of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">For clarity, at the time of the Agreement, Supplier will be responsible for only the following testing with respect to release of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_553"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Drug </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Product hereunder: </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_555"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Parties will in good faith use </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> to transfer to Supplier all </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">other testing of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_556"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Drug </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Product for release </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_561"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Following completion of such transfer</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Supplier will be responsible for all testing for release and stability </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_563"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">as contemplated by the QA for Drug Product Fill/Finished by Supplier for Customer hereunder. &#160;Upon Supplier&#8217;s request, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Customer will support the testing </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_565"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">at a back-up </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">testing lab.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_566"></a><a name="_cp_text_1_567"></a>Supplier shall notify Customer in advance of, and obtain its prior written approval before, implementing </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_569"></a><a name="_cp_text_1_571"></a>. The Parties shall, at Supplier&#8217;s or Customer&#8217;s reasonable request, establish a joint project team, which shall discuss and agree on the details of such changes and program of their implementation (not to be unreasonably withheld, conditioned or delayed). &#160;All approved changes will be implemented in accordance with the provisions of the QA, as applicable, and except as otherwise set forth this Agreement, as between Chiesi and Protalix under this Agreement, all associated costs and expenses of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier shall prepare and maintain accurate records and books relating to the Fill/Finish performed hereunder in accordance with Applicable Law and the QA. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108897432"></a><a name="_Ref107752111"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Customer shall have the right to conduct, at its sole expense at a frequency defined in the QA, during normal business hours (at times mutually agreed by the Parties) and subject to a </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> prior written notice to Supplier, a general quality assurance audit and inspection of Supplier&#8217;s records and production or testing &#160;facilities relating to the Fill/Finish of the Drug Product for Customer hereunder, including storage of Drug Substance and the Drug Product in the course thereof. &#160;Representatives of Customer shall have access during audits to those areas of the facility where the Fill/Finish with respect to the Drug Product, including storage of Drug Substance and Drug Product in the course thereof, are performed, all documents, records, reports, data, procedures, regulatory submissions, and other information required to be maintained by the relevant </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_577"></a>regulatory authorities by Applicable Laws corresponding to Supplier&#8217;s Fill/Finish of Drug Product hereunder. &#160;All audited documents, data, reports, procedures, regulatory submissions, information and records, as well as anything visually observed or learned during such audit or while present in the facility, will be treated as Confidential Information of Supplier, and Customer will not be permitted to remove or copy such Confidential Information without Supplier&#8217;s prior written consent.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.7</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108897434"></a><a name="_Ref109936994"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_579"></a>Supplier shall permit Customer to conduct &#8220;for cause audits&#8221; as </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_583"></a><a name="_cp_text_1_587"></a> to address significant product or safety concerns as discovered through the audits conducted by Customer under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.6</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Any deficiencies identified in an audit or inspection by Customer pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be handled and remediated in accordance with the QA. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.8</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109069707"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier also agrees to allow the FDA and other relevant Regulatory Authorities to conduct any inspection/audit that any such Regulatory Authority requires, and Supplier agrees to cooperate with and provide such documentation or assistance as may be requested by the FDA or any other Regulatory Authority, as the case may be, in connection with such inspection/audit. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.9</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109075841"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier shall, subject to Section 13.12, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***],</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> correct each deficiency identified by the applicable Regulatory Authority in an audit or inspection described in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.8</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (excluding in each case Regulatory Inspection Deficiencies, which, for clarity, shall be treated in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.10</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.10</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109059495"></a><a name="_Ref108903007"></a><a name="_cp_text_1_621"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In the event that any Regulatory Authority shall determine</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_593"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (and notifies Supplier in writing)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, as a result of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_595"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">inspection (conducted under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.8</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above), that Supplier is not </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> with Applicable Laws (including cGMP) with respect to </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_597"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier&#8217;s performance of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Fill/Finish activities </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_599"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">for </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Drug Product hereunder (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Inspection Deficiency</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;),</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> [***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.12</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Supplier shall cure such Regulatory Inspection Deficiency </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_2_565"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.11</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108870350"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">With respect to any Regulatory Inspection Deficiency that: </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Critical Regulatory Inspection Deficiency</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Supplier shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. In the event that a Critical Regulatory Inspection Deficiency occurs </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, either Party may </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> upon written notice to the other Party, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that: </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.12</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108987526"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier is not responsible for any inspection deficiencies contemplated by </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.7</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.9</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.10</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (including any Regulatory Inspection Deficiency) or </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.11</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (including any Critical Regulatory Inspection Deficiency), in each case, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> such inspection deficiency, Regulatory Inspection Deficiency or Critical Regulatory Inspection Deficiency is caused by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_634"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> compliance with Customer&#8217;s written instructions with respect to the Fill/Finish process transferred to Supplier pursuant to the Tech Transfer or Customer&#8217;s breach or failure in </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">its performance hereunder, including delays in performing reviews or providing approvals or information, technology, instructions, documents, or other items (including Drug Substance) required to be supplied by or on behalf of Customer hereunder (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dependency Event &#8211; Inspection Deficiency</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.13</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier shall keep Customer apprised of the status of all interactions and communications with the FDA and other Regulatory Authorities, including, no later than </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_637"></a>, notifying Customer in writing of, and providing Customer with copies of, any correspondence, communications and other documentation received from the FDA or other Regulatory Authority relating to the Drug Substance, Drug Product, or conduct of the Fill/Finish hereunder (including without limitation any general cGMP inspection applicable to the facility) as contemplated by the QA. &#160;Supplier shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_641"></a> to consult with Customer in advance of any meeting or discussion, either in person or by telephone or videoconference, with the FDA or Regulatory Authority in connection with the Drug Substance, Drug Product or conduct of Fill/Finish hereunder. &#160;As </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_643"></a><a name="_cp_text_1_650"></a><a name="_cp_text_1_653"></a>requested by Supplier, Customer shall promptly review and comment on any proposed response of Supplier to any Regulatory Authority.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.14</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108269481"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_654"></a>During </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Supplier will permit </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_656"></a> to observe and consult with Supplier during the conduct of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_657"></a> in respect of the Drug Product. &#160;With respect to the foregoing, Supplier will provide </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_658"></a><a name="_cp_text_1_661"></a><a name="_cp_text_1_662"></a> with reasonable access to the portion of Supplier&#8217;s facility used to conduct such </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_663"></a><a name="_cp_text_1_664"></a> in order to observe such </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_665"></a><a name="_cp_text_1_667"></a>. &#160;Supplier will provide Customer with sufficient advance notice of each such </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> accordingly, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that in no event will this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.14</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_669"></a> be deemed to require Supplier to delay or reschedule any such </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.15</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">During any visits to or inspections of Supplier&#8217;s facility, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> will abide by all Supplier policies and procedures in force at Supplier&#39;s facility.</font><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;"> </sup></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">14.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref108899376"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">RECALLS OR OTHER CORRECTIVE ACTION &#160;</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 36pt;"><a name="_Ref96316678"></a>In the event of any required or voluntary recall, withdrawal, field alert or similar action for the Drug Product (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recall</u>&#8221;), such Recall shall be handled in accordance with the License Agreements and QA. &#160;For clarity, as between the Parties under this Agreement, the Parties&#8217; respective responsibility, if any, for the costs and expenses of any Recall <font style="background:#ffffff;">[***]</font>, and (b) this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;14</u> does not modify (and shall not be interpreted as modifying) any provisions of the License Agreement relating to any recall, withdrawal, field alert or similar actions, including Recalls. &#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">15.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref103363600"></a><a name="_Ref108269627"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_cp_text_28_680"></a>CONFIDENTIALITY </b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">15.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_689"></a><a name="_cp_text_1_687"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_688"></a><a name="_cp_text_1_690"></a>Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that for the Term and for </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> thereafter, each Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose any Confidential Information furnished to it by the other Party pursuant to this Agreement, in a manner no less protective than the actions it would customarily take to preserve the confidentiality of its own similar types of confidential information (but in any event using no less than reasonable care). </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">15.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_701"></a><a name="_cp_text_1_691"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">P</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ermitted Disclosures</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_692"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_693"></a><a name="_cp_text_4_694"></a><a name="_cp_text_1_695"></a><a name="_cp_text_4_696"></a><a name="_cp_text_1_697"></a>. Notwithstanding the foregoing, each Party may disclose the other Party&#8217;s Confidential Information (a) to such Party&#8217;s employees, consultants (including, for greater certainty, financial advisors), Affiliates, agents, contractors, or permitted sublicensees who are bound by obligations relating to confidentiality at least as restrictive of those contained herein and who have a need to know such information in connection with such Party&#8217;s performance of its obligations or practice or enforcement of its rights under this Agreement, (b) to Regulatory Authorities in connection with any regulatory approvals required for the Drug Product pursuant to the License Agreements or in compliance with Applicable Laws, rules and regulations, including any requirements under or pursuant to the Food and Drug Administration Amendments Act of 2007, or (c) pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_field_47_698"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_699"></a><a name="_cp_field_47_700"></a> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">15.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_717"></a><a name="_cp_text_1_703"></a><a name="_Ref107999169"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">erms of Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_704"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_705"></a><a name="_cp_text_4_706"></a><a name="_cp_text_1_707"></a><a name="_cp_text_4_708"></a>. The Parties agree that the material terms of this Agreement will be considered Confidential Information of both Parties. Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_710"></a> below, no Party shall, without the prior written consent of the other Party, disclose in any manner to any Third Party the material terms and conditions of this Agreement, except for terms or subject matter which has been the subject of prior public disclosure or has been mutually approved for such disclosure and except as set forth below. Supplier acknowledges that Customer or its Affiliates may be legally required to file this Agreement as an exhibit to filings with the U.S.&#160;<a name="_cp_text_4_711"></a>Securities and Exchange Commission. In addition: (a) either Party may disclose such terms as are required to be disclosed in its publicly-filed financial statements or other public statements, pursuant to Applicable Laws, regulations and stock exchange rules (e.g., the rules of the U.S. Securities and Exchange Commission, the NYSE American, the NYSE, NASDAQ, or any other stock exchange on which securities issued by either Party may be listed); </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_712"></a> that such </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">15</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_713"></a><a name="_cp_text_4_714"></a><a name="_cp_text_1_715"></a><a name="_cp_text_4_716"></a><a name="_cp_text_1_718"></a>Party shall provide the other Party with a copy of the proposed text of such statements or disclosure (including any exhibits containing this Agreement) sufficiently in advance of the scheduled release or publication thereof to afford such other Party a reasonable opportunity to review and comment upon the proposed text (including redacted versions of this Agreement) and the disclosing Party shall reasonably consider such comments in good faith and (b) either Party shall have the further right to disclose the terms of this Agreement under a confidentiality obligation no less protective than those set forth in this Agreement, to any potential sublicensee, acquirer, merger partner, investor, business partner or potential providers of financing and their advisors.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">15.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_719"></a><a name="_Ref107999181"></a><a name="_cp_text_1_720"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">M</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">andatory Disclosure</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_728"></a><a name="_cp_text_1_721"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">otification and Consultation</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_722"></a><a name="_cp_text_1_723"></a><a name="_cp_text_4_724"></a><a name="_cp_text_1_725"></a><a name="_cp_text_4_726"></a><a name="_cp_text_4_727"></a><a name="_cp_text_1_729"></a>. In the event that a Party is required by Applicable Law (including rules of an applicable stock exchange), or pursuant to legal, governmental or self-regulatory organization proceedings (including by court order or judicial or administrative process) to disclose any part of the other Party&#8217;s Confidential Information (including material terms or conditions of this Agreement), the Party required to make such disclosure shall (i) promptly notify the other Party of each such requirement and identify the documents so required thereby, so that the other Party may seek an appropriate protective order, confidential treatment or other remedy concerning any such disclosure and/or waive compliance by such Party with the provisions of this Agreement and (ii) consult with the other Party with respect to taking legally available steps to resist or narrow the scope of such requirement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_730"></a><a name="_cp_text_1_731"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">L</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">imited Disclosure</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. If, in the absence of such a protective order, confidential treatment request, other remedy or waiver by the other Party, such Party is nonetheless required to disclose any part of the other Party&#8217;s Confidential Information or any material terms or conditions of this Agreement, such Party may disclose such Confidential Information of the other Party or material terms or conditions of this Agreement without liability under this Agreement, except that such Party shall furnish only that portion of such Confidential Information or material terms or conditions that in its good faith judgment, after consultation with legal counsel, it is legally required to provide.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_cp_text_1_732"></a>REPRESENTATIONS, WARRANTIES AND COVENANTS </b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_756"></a><a name="_cp_blt_2_755"></a><a name="_cp_text_1_741"></a><a name="_Ref108002795"></a><a name="_Ref108269559"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_743"></a><a name="_cp_text_1_744"></a><a name="_cp_text_1_746"></a>Each of Customer and Supplier hereby represents and warrants to the other Party as of the Effective Date (or covenants as set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_field_47_747"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;16.1</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(g)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(h)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(i)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(j)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> below) as follows:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_757"></a><a name="_cp_text_1_758"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">It is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation, as applicable. It has the requisite corporate power and authority to conduct its business as presently being conducted and as proposed to be conducted by it.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_761"></a><a name="_cp_text_1_759"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_760"></a><a name="_cp_text_1_762"></a>It has the requisite corporate power and authority to enter into this Agreement and to perform its obligations hereunder. All corporate actions on its part, necessary for (i) the authorization, execution, delivery and performance by it of this Agreement, and (ii) the consummation of the transactions contemplated hereby, have been duly taken.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_766"></a><a name="_cp_text_1_763"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_764"></a><a name="_cp_text_4_765"></a><a name="_cp_text_1_767"></a>Assuming the due authorization, execution and delivery by the other Party, this Agreement constitutes a legally valid and binding obligation of such Party, enforceable against it in accordance with its terms (except in all cases as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting the enforcement of creditors&#8217; rights generally and except that the availability of the equitable </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">16</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">remedy of specific performance or injunctive relief is subject to the discretion of the court or other tribunal before which any proceeding may be brought).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_776"></a><a name="_cp_text_1_768"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_769"></a><a name="_cp_text_1_770"></a><a name="_cp_text_4_771"></a><a name="_cp_text_1_772"></a><a name="_cp_text_1_777"></a>There is no contractual restriction or obligation binding on such Party which would be materially contravened by execution and delivery of this Agreement or by the performance of its terms. &#160;There are no governmental filings or consents necessary for the execution of this Agreement. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_778"></a><a name="_cp_text_1_779"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Such Party is not debarred, and such Party in relation to the Drug Product or Drug Substance, as applicable, is not using, has not used, and will not use in any capacity the services of any person debarred, in each case under Subsection 306(a), (b) of the Generic Drug Enforcement Act of 1992, or any non-U.S. equivalent law to the foregoing.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(f)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">There is no litigation, proceeding or investigation pending or, to such Party&#8217;s knowledge, threatened against such Party in any court or before any agency or regulatory body which would reasonably be expected to materially adversely affect such Party&#39;s ability or right to carry out the transactions contemplated by this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(g)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108658820"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">During the Term, each Party shall promptly notify the other Party in writing upon learning of any actual or threatened investigation, inquiry, action or proceeding by or before the FDA or any other Regulatory Authority with respect to the conduct of Fill/Finish activities hereunder. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(h)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_786"></a><a name="_cp_text_1_782"></a><a name="_Ref108902465"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_783"></a><a name="_cp_text_1_784"></a><a name="_cp_text_4_785"></a><a name="_cp_text_1_787"></a>Each Party shall (i) comply in all material respects with applicable anti-bribery laws and the Chiesi Anti-Bribery Policy, attached to the License Agreements, and (ii) adopt, implement and keep for the Term, reasonably adequate measures aimed at preventing the commission, even attempted, of conduct in violation in any material respect of anti-bribery laws by its Affiliates, directors, representatives, employees, and/or consultants involved in the performance of this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_790"></a><a name="_cp_text_1_788"></a><a name="_Ref108269552"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_789"></a><a name="_cp_text_1_791"></a>Each Party and its Affiliates, directors, representatives, employees, and/or consultants involved in the performance of this Agreement, in performing their obligations under this Agreement shall not, directly or indirectly:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_794"></a><a name="_cp_text_1_792"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_793"></a><a name="_cp_text_1_795"></a>offer, transfer, promise or pay money, commissions, compensation or any other benefit (including gifts, entertainment, or any other similar benefit, even low value or non-material benefits, unless they can be considered as low value courtesy benefits) in favor of public or private parties, in violation of applicable anti-bribery laws, the Chiesi Anti-Bribery Policy and/or with the intention of or as a condition to obtaining illegal benefits in favor of Customer or Supplier;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_796"></a><a name="_cp_text_1_797"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">direct a Third Party to carry out the activities set out in subsection (i) above;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_798"></a><a name="_cp_text_1_799"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">give, transfer or promise money, commissions, compensation and rewards in kind (including gifts, entertainment or any other similar benefit, even low value or non-material benefits, unless they can be considered as low value courtesy benefits) to the other Party&#8217;s directors, legal representatives, employees or whoever acts on behalf of such other Party, in violation of any applicable anti-bribery law and beyond the limits set forth within the Chiesi Anti-Bribery Policy.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(j)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_802"></a><a name="_cp_text_1_800"></a><a name="_Ref108658828"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_801"></a><a name="_cp_text_1_803"></a>Unless to the extent this provision would be a violation of any Applicable Laws, Customer shall promptly notify Supplier at the following Supplier e-mail address: groupcompliance@chiesi.com, and Supplier shall promptly </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">17</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">notify Customer at the following Customer e-mail address: dror.bashan@protalix.com, if such Party becomes aware of:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_804"></a><a name="_cp_text_1_805"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any request, promise, offer, or donation of money, commission, compensation or rewards in kind (including gifts, entertainments, or any other similar benefit, even low value or non-material benefits) made to public officers, private parties or the other Party&#8217;s directors, legal representatives or employees (or whoever acts on behalf of such other Party), in relation to the activities prohibited under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;16.1</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(i)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_808"></a><a name="_cp_text_1_806"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_807"></a>any gift, entertainment or any other similar benefit, even non-material benefits, carried out by either Party in breach of the provisions of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;16.1</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(i)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_810"></a><a name="_cp_text_1_811"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any investigation, administrative suit, law suit or other procedure involving such Party in relation to corruption, bribery or any other similar harmful act to the public treasury.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(k)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_822"></a><a name="_cp_text_1_816"></a><a name="_Ref108658916"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Each Party hereby acknowledges and agrees that Customer&#8217;s Background Intellectual Property and Customer Intellectual Property, to the extent licensed under this Agreement, constitute intellectual property as defined in Section 101 of the United States Bankruptcy Code subject to the provisions of Section 365(n) of the United States Bankruptcy Code; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_817"></a><a name="_cp_text_1_818"></a><a name="_cp_text_1_823"></a> that no decision is made at this time with respect to any potential acceptance or rejection of this Agreement pursuant to the United States Bankruptcy Code at any time. The Parties further agree that Supplier, as licensee under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over Customer or its assets subject to Supplier&#8217;s compliance in all material respects with all of its obligations thereunder. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Customer under the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over Customer or its assets, Supplier will be entitled, subject to Applicable Laws, and at Supplier&#39;s sole cost and expense, to a complete duplicate of (or full access to, as appropriate) any such Customer&#39;s Background Intellectual Property and Customer Intellectual Property and all embodiments of such intellectual property, and same, if not already in its possession, will be promptly delivered to Supplier (or, as appropriate, Supplier will be promptly provided access thereto) (A) upon any such commencement of a bankruptcy proceeding with respect to Customer upon its written request therefor, unless Customer elects to continue to perform all of its obligations under this Agreement, or (B) if not delivered under (A) above, following any such commencement of a bankruptcy proceeding with respect to Customer and the rejection of this Agreement by or on behalf of Customer upon written request therefor by Supplier.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_824"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Supplier hereby: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_833"></a><a name="_cp_text_1_825"></a><a name="_Ref109248709"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_832"></a>represents, warrants and covenants to Customer that: (i) Supplier shall conduct, and shall use reasonable efforts to cause its Affiliates assigned responsibilities hereunder to conduct, all its activities contemplated under this Agreement in compliance with all of the provisions and requirements of the QA and in material compliance with all Applicable Laws, and (ii) the Drug Product delivered to Customer hereunder shall have been </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_835"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">covenants to Customer that it will inform Customer promptly in writing of any event, circumstance or condition, which in the reasonable judgment of </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">18</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_837"></a><a name="_cp_text_28_838"></a>Supplier, may adversely affect (i) Supplier&#8217;s ability to conduct the Fill/Finish hereunder or (ii) the suitability of the Drug Product for incorporation into Licensed Product for commercial sale in the Field worldwide. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_2_848"></a><a name="_cp_blt_1_850"></a><a name="_cp_text_1_851"></a><a name="_Ref246865250"></a><a name="_Ref492494199"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Customer hereby represents, warrants and covenants to Supplier as follows:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109248712"></a><a name="_cp_blt_1_854"></a><a name="_cp_text_1_852"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that (i) Customer shall conduct, and shall use reasonable efforts to cause its Affiliates assigned responsibilities hereunder to conduct, all its activities contemplated under this Agreement in compliance with all of the provisions and requirements of the QA and in material compliance with all Applicable Laws, and (ii) the Drug Substance delivered to Supplier hereunder, shall comply with all registered specifications for the Drug Substance, Product Requirements, and Applicable Standards and the QA; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_855"></a>it has, and will maintain throughout the Term of this Agreement, appropriate Regulatory Approvals for the Drug Substance and it has notified Supplier of any special requirements in respect of recordkeeping that may be necessary to comply with Customer&#8217;s adverse event, Drug Substance, Drug Product, defect or Recall procedures and that it shall notify Supplier of any hazards to the health or safety of any personnel of Supplier or the possibility of cross contamination of any other products being supplied or stored by Supplier and Customer shall keep Supplier so advised throughout the continuance of this Agreement, whether such hazards or possibilities are inherent in the Drug Substance, Drug Product or otherwise;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_858"></a><a name="_cp_text_1_856"></a><a name="_Ref108637125"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)&#160;it has the right to grant the license to Customer&#8217;s Background Intellectual Property and Customer Intellectual Property granted to Supplier hereunder, (ii)&#160;to its knowledge, Supplier&#8217;s practice of Customer&#8217;s Background Intellectual Property and Customer Intellectual Property as contemplated by this Agreement will not infringe any Intellectual Property Rights of any Third Party, and (iii)&#160;<a name="_cp_text_4_857"></a><a name="_cp_text_1_859"></a>it has not, as of the Effective Date, granted, conveyed or otherwise transferred, and will not, during the Term, grant, convey or otherwise transfer, in each case, whether directly or indirectly, any rights or license to any Third Party in a manner that conflicts with such license granted to Supplier by Customer hereunder; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_866"></a><a name="_cp_text_1_860"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_861"></a><a name="_cp_text_1_862"></a><a name="_cp_text_1_867"></a>the Tech Transfer, upon completion thereof in accordance with the terms of this Agreement, will be a complete and accurate transfer to Supplier of all know-how with respect to the Fill/Finish process for the Drug Product, except as would not constitute a material and adverse effect on the ability of Supplier to perform its Fill/Finish obligations hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_870"></a><a name="_cp_blt_2_869"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_868"></a>EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY, AND EACH PARTY DISCLAIMS ALL, REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE DRUG SUBSTANCE AND THE DRUG PRODUCT, OR ANY OTHER MATTER RELATED TO THIS AGREEMENT, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref112431530"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_cp_text_1_871"></a>INDEMNIFICATION; LIMITATION OF LIABILITY</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref244628703"></a><a name="_Ref245628294"></a><a name="_Ref245628326"></a><a name="_Ref245628350"></a><a name="_Ref245799197"></a><a name="_Ref245799465"></a><a name="_Ref245799543"></a><a name="_Ref247350566"></a><a name="_Ref247350679"></a><a name="_Ref247350719"></a><a name="_Ref247350797"></a><a name="_Ref247353396"></a><a name="_Ref247355111"></a><a name="_Ref247361414"></a><a name="_Ref519638008"></a><a name="_Ref519752447"></a><a name="_Ref519752448"></a><a name="_Ref519752449"></a><a name="_Ref492288908"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> by Supplier</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Supplier shall indemnify, defend and hold Customer, its Affiliates, and their respective Representatives (collectively, the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer Indemnitees</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">) harmless from and against any and all claims, suits, proceedings or causes of action (</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Claims</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">) brought by a Third </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">19</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Party against such Customer Indemnitee, including any damages or other amounts payable to such Third Party and reasonable attorneys&#8217; fees and costs of litigation (collectively, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Damages</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_879"></a>), in each case to the extent resulting from or arising out of: (a) Supplier&#8217;s breach of this Agreement or its covenants or breach of any of its representations or warranties; (b) Supplier&#8217;s failure to comply with Applicable Law; or (c) the gross negligence, fraud, or willful misconduct of Supplier or its Affiliates, or their respective Representatives in the performance of this Agreement; in each case,</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;"> </i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_882"></a>to the extent not resulting from or related to Customer&#8217;s breach of its obligations under this Agreement or its, its Affiliates&#8217;, or their respective Representatives&#8217; gross negligence or willful misconduct or otherwise subject to Customer&#8217;s indemnification obligations pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> below.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref403990702"></a><a name="_Ref519261243"></a><a name="_Ref519752442"></a><a name="_Ref519752443"></a><a name="_Ref519752444"></a><a name="_Ref519752445"></a><a name="_Ref519752446"></a><a name="_Ref494885144"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Customer shall indemnify, defend and hold Supplier, its Affiliates, and their respective Representatives (collectively, the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supplier Indemnitees</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_884"></a>) harmless from and against any and all Claims brought by a Third Party against such Supplier Indemnitee, including any Damages, in each case to the extent resulting from or arising out of: (a) Customer&#8217;s breach of this Agreement or its covenants or breach of any of its representations or warranties herein; (b) any claim of infringement or misappropriation of any Intellectual Property Right of any Third Party to the extent such claim arises with respect to the Drug Substance, Drug Product, Customer&#8217;s Background Intellectual Property or Customer Intellectual Property; (c) Customer&#8217;s failure to comply with Applicable Law; or (d) the gross negligence, fraud, or willful misconduct of Customer, its Affiliates, licensees or sublicensees, or their respective Representatives; in each case,</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;"> </i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_885"></a>to the extent not resulting from or related to Supplier&#8217;s breach of its obligations under this Agreement or its, its Affiliates&#8217;, or their respective Representatives&#8217; gross negligence or willful misconduct or otherwise subject to Supplier&#8217;s indemnification obligations pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_906"></a><a name="_cp_blt_2_905"></a><a name="_Ref404000645"></a><a name="_Toc492289868"></a><a name="_Toc495297446"></a><a name="_Toc515993564"></a><a name="_Toc519752147"></a><a name="_Toc519854187"></a><a name="_Ref108635559"></a><a name="_Ref109841908"></a><a name="_Ref403989645"></a><a name="_Ref492402809"></a><a name="_Ref519752437"></a><a name="_Ref519752438"></a><a name="_Ref519752439"></a><a name="_Ref519752440"></a><a name="_Ref519752441"></a><a name="_Ref108269586"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Product Liability Claims</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall govern the allocation of liability, as between the Parties under this Agreement (without limiting the applicable License Agreement(s)), with respect to any Third Party product liability Claim for property injury, bodily injury or deaths resulting from the Drug Product (a </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Product Claim</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">). </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref403994406"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Supplier shall indemnify and hold harmless the Customer Indemnitees from and against any and all Damages which a Customer Indemnitee may incur or suffer arising out of any Third Party Product Claim solely to the extent </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, that Customer shall not be entitled to indemnification pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (y) to the extent such Claim or Damages is/are subject to Customer&#8217;s indemnifications obligations under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and (z) for any amount to the extent that Protalix has been indemnified for such amount under Section 13.3(b) of the applicable License Agreement(s); </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;The indemnification provided pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be the sole and exclusive remedy of Customer for any and all Damages arising out of a Third Party Product Claim.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108635568"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defense Procedures</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; Procedures for Third Party Claims</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_28_903"></a>. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_2_907"></a><a name="_cp_blt_1_915"></a><a name="_cp_text_1_909"></a><a name="_Ref109841937"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">For purposes of this Agreement, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_910"></a><a name="_cp_text_1_911"></a>&#8221; means a Claim asserted by a Third Party (in no event to include any Affiliate of either Party) against a Party or any of its Affiliates, or any of their respective directors, officers, employees, consultants, contractors, sublicensees and agents. In the event a Third Party Claim is asserted with respect to any matter for which a Party or any of its Affiliates, or any of their respective directors, officers, employees, consultants, contractors, sublicensees and agents (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) is entitled to indemnification hereunder, then the Indemnified Party shall promptly notify in writing the Party obligated to indemnify the Indemnified Party hereunder (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_912"></a>&#8221;) thereof; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_913"></a>, that no delay on the part of the Indemnified Party in notifying the Indemnifying </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">20</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_914"></a><a name="_cp_text_1_916"></a>Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_925"></a><a name="_cp_text_1_917"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_918"></a><a name="_cp_text_1_919"></a><a name="_cp_text_4_920"></a><a name="_cp_text_1_921"></a><a name="_cp_text_4_922"></a><a name="_cp_text_1_923"></a><a name="_cp_text_4_924"></a><a name="_cp_text_1_926"></a>The Indemnifying Party shall assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the Claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. The Indemnified Party shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Third Party Claim that the Indemnifying Party is defending as provided in this Agreement. &#160;Notwithstanding anything to the contrary contained herein, an Indemnified Party shall be entitled to assume the defense of any Third Party Claim with respect to the Indemnified Party, upon written notice to the Indemnifying Party, in which case, the Indemnifying Party shall be relieved of liability under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.2</u><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">, </i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, as applicable, solely for such Third Party Claim and related Damages.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_929"></a><a name="_cp_text_1_927"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_928"></a>Neither Party will enter into any settlement of any suit involving a Third Party Claim that materially affects the other Party&#8217;s rights or obligations without the other Party&#8217;s prior written consent (which consent shall not be unreasonably withheld, delayed or conditioned). The Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be unreasonably withheld, delayed or conditioned), effect any settlement of any pending or threatened litigation in which the Indemnified Party has sought indemnification hereunder by the Indemnifying Party, unless such settlement involves solely monetary damages and includes an unconditional release of the Indemnified Party from all liability on Claims that are the subject matter of such litigation.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108269591"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_28_932"></a><a name="_cp_text_1_934"></a>. &#160;The Parties shall maintain insurance with creditworthy insurance companies in full force and effect during the Term and, with respect to &#8220;claims made&#8221; policies, for a period of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_935"></a><a name="_cp_text_1_937"></a> after expiration or termination of this Agreement as follows: worker&#8217;s compensation (if applicable), general liability, employers liability, clinical trial liability and product liability insurance coverage in such amounts and with such scope of coverages as are adequate to cover such Party&#8217;s obligations under this Agreement and as are customary in the industry for companies of like size and activities. Upon written request, each Party shall provide evidence of such insurance to the other Party and ensure that the other Party will receive no less than </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> notice of any cancellation or material change in such coverage.</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_944"></a><a name="_cp_blt_2_943"></a><a name="_Ref519752434"></a><a name="_Ref519752435"></a><a name="_Ref519752436"></a><a name="_Ref244628830"></a><a name="_Ref246510674"></a><a name="_Ref492481284"></a><a name="_Ref492494235"></a><a name="_Ref492391027"></a><a name="_Ref108269945"></a><a name="_Ref108900892"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclaimer of Liability for Consequential Damages</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUE SUFFERED BY SUPPLIER, CUSTOMER OR ANY OF THEIR RESPECTIVE AFFILIATES. &#160;THE FOREGOING SENTENCE SHALL NOT LIMIT THE </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_938"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">EXPRESS </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTIONS </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;"> </i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">AND </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> OF THIS AGREEMENT OR LIABILITIES RESULTING FROM A PARTY&#8217;S BREACH OF THE CONFIDENTIALITY OBLIGATIONS UNDER </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, BREACH OF </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, WILLFUL MISCONDUCT, OR FRAUD.</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">21</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.7</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_947"></a><a name="_Ref109069995"></a><a name="_Ref108900899"></a><a name="_cp_text_1_945"></a><a name="_Ref108269706"></a><a name="_cp_text_1_948"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">L</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">imitations of Liability</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. EXCEPT WITH RESPECT TO A PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, OR </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, AS APPLICABLE, BREACH OF </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> OR </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, OR GROSS NEGLIGENCE </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, WILLFUL MISCONDUCT OR FRAUD, IN NO EVENT SHALL:</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109817273"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">SUPPLIER&#8217;S TOTAL LIABILITY UNDER THIS AGREEMENT, INCLUDING FOR ALL CLAIMS OF ANY KIND, WHETHER IN CONTRACT, TORT OR STRICT LIABILITY, ARISING OUT OF THE PERFORMANCE OR BREACH OF THIS AGREEMENT, FOR ANY DRUG SUBSTANCE, DRUG PRODUCT, OR REPLACEMENT OF DRUG SUBSTANCE OR DRUG PRODUCT, OR FOR COST OF RECALLS HEREUNDER, EXCEED, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109069406"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109069245"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109068701"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(v)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109811078"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; AND</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109398216"></a><a name="_Ref109070004"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109070019"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">CUSTOMER&#8217;S TOTAL LIABILITY UNDER THIS AGREEMENT, INCLUDING FOR ALL CLAIMS OF ANY KIND, WHETHER IN CONTRACT, TORT OR STRICT LIABILITY, ARISING OUT OF THE PERFORMANCE OR BREACH OF THIS AGREEMENT, EXCEED </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109817277"></a><a name="_Ref109842018"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;">Supplier be required to reimburse Customer for </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;">;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"> </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 72pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PROVIDED</u> THAT <font style="background:#ffffff;">[***]</font>; THE FOREGOING LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.8</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_962"></a><a name="_cp_text_1_956"></a><a name="_Ref108269946"></a><a name="_cp_text_1_963"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">N</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">otwithstanding anything to the contrary herein, Supplier </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_957"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall not be liable </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_958"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">for any Non-Conformance, or delay, with respect to </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_961"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Drug Product </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">arising hereunder, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that such Non-Conformance or delay is caused by the Drug Substance, a Force Majeure Event </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, defective Materials supplied by Customer (in the condition in which the same were supplied by Customer hereunder), compliance with Customer&#8217;s written instructions, or Customer&#8217;s failure to: (a) comply with its responsibilities or (b) take actions or provide instructions required to be taken or provided (as applicable) hereunder (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dependency Event</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.9</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.10</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref109085034"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">EXCEPT AS EXPRESSLY SET FORTH IN </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, SUPPLIER SHALL HAVE NO LIABILITY TO CUSTOMER WITH RESPECT TO DRUG SUBSTANCE HEREUNDER, AND IN ALL SUCH CASES, CUSTOMER IS RESPONSIBLE FOR ALL DAMAGE TO OR LOSSES (INCLUDING RENDERING UNUSABLE OR CONSUMPTION) OF DRUG SUBSTANCE UNDER OR IN CONNECTION WITH THIS AGREEMENT.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">18.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref214420987"></a><a name="_Ref214421697"></a><a name="_Ref214422865"></a><a name="_Ref103365931"></a><a name="_Ref103371383"></a><a name="_Ref103372784"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">TERM AND TERMINATION </b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">18.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref406245444"></a><a name="_Ref429601372"></a><a name="_Ref108270040"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This Agreement shall continue in force from the Effective Date until December 31, 2025 (such period, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), unless terminated earlier in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;18</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_965"></a><a name="_cp_text_1_967"></a><a name="_cp_text_1_971"></a>. &#160;Thereafter, Customer and Supplier may extend the initial Term one time (1x) for an additional period of seven (7) years, upon mutual written agreement prior to expiration of the initial Term. </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">22</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">18.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Unless otherwise specified in the applicable Product Schedule, each Product Schedule shall continue in force during the Term, unless terminated earlier in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;18</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">18.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref107763022"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This Agreement may be terminated immediately (in whole or in part) by either Party upon notice to the other Party: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref108900692"></a><a name="_Ref107763015"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in the event of a material breach of this Agreement by the other Party and such material breach is not cured (i) within thirty (30) days after written notice thereof is delivered to the breaching Party, or (ii) in the case of a breach that cannot be cured within thirty (30) days, within a reasonable period not exceeding ninety (90) days after written notice thereof is delivered to the breaching Party, so long as the breaching Party is making a good faith effort to cure such default; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_2_980"></a><a name="_cp_blt_1_984"></a><a name="_cp_blt_2_983"></a><a name="_Ref108899427"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_982"></a>if the other Party shall file in any court or agency, pursuant to any statute or regulation of any country, a petition in bankruptcy or insolvency or for reorganization or for an the appointment of a receiver or trustee of such other Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, that is not dismissed within sixty (60) days, or if the other Party shall propose or be a party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of its creditors; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_990"></a><a name="_cp_blt_2_989"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_985"></a><a name="_cp_text_1_988"></a>in the event that both of the License Agreements expire or are terminated.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">18.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_991"></a><a name="_Ref110095752"></a><a name="_cp_text_1_992"></a><a name="_Ref214422924"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This Agreement may be terminated by either Party in accordance with </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">18.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_996"></a><a name="_cp_blt_2_995"></a><a name="_Ref108272244"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_994"></a>Without prejudice to any other rights or remedies which either Party may have under this Agreement, upon the termination (or the applicable portion thereof) or expiration of this Agreement:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1003"></a>Supplier shall: (i) return any remaining inventory of Drug Substance and Drug Product to Customer </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_1008"></a>; and (ii) promptly make available to Customer copies of all batch records and documentation relating to the Fill/Finish activities in respect of the Drug Product and shall store the originals or electronic copies of such documents and records according to cGMPs in accordance with Supplier&#8217;s internal quality procedures and Applicable Laws, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1009"></a> that Supplier shall not be required to store such records/documents beyond the duration required thereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1023"></a><a name="_cp_text_1_1015"></a><a name="_Ref108272245"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_1016"></a><a name="_cp_text_4_1018"></a><a name="_cp_text_1_1019"></a><a name="_cp_text_1_1024"></a>Supplier will invoice Customer in respect of (i) Fill/Finish performed in accordance with the terms and conditions of this Agreement up to and including the effective date of such termination or expiration in full, for all completed Fill/Finish, and, for partially completed Fill/Finish, a sum calculated on a pro-rata basis (determined in good faith by Supplier)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, (ii) any out-of-pocket or other costs incurred by Supplier on behalf of Customer hereunder pursuant to the applicable Forecast; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that Supplier shall use its reasonable efforts to mitigate such costs following the termination of this Agreement, and (iii) the TT Reimbursement Fee, in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (as applicable).&#160; All such amounts are due and payable by Customer upon invoice delivery.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1037"></a><a name="_cp_blt_2_1036"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1026"></a><a name="_cp_text_1_1035"></a>Each Party shall: (i) immediately cease all use of any property of the other Party, including any Intellectual Property Rights of the other Party, under this Agreement; and (ii) within thirty (30) days of such termination, at its own expense, return to the other Party or destroy any Confidential Information of the other Party in its possession, custody or control, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, that a </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">23</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Party may retain one (1) copy of the other Party&#39;s Confidential Information in the confidential files of its legal department in order to ensure compliance with its obligations set forth in this Agreement and that Supplier may retain Confidential Information of Customer to the extent necessary for Supplier&#8217;s performance under the License Agreements (and, for clarity, subject to the confidentiality, non-use and non-disclosure obligations therein).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">19.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref214427676"></a><a name="_Ref112431546"></a><a name="_Ref214427511"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">GOVERNING LAW AND JURISDICTION</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">19.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref246329424"></a><a name="_Ref246865165"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This Agreement shall be governed by and construed in accordance with the substantive laws of the State of New York, without regard to conflicts of law rules. &#160;The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">19.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref495795145"></a><a name="_Ref515979898"></a><a name="_Ref515979959"></a><a name="_Ref519752428"></a><a name="_Ref519752429"></a><a name="_Ref519752430"></a><a name="_Ref519752431"></a><a name="_Ref519752432"></a><a name="_Ref492398958"></a><a name="_Ref492398959"></a><a name="_Ref492398960"></a><a name="_Ref492473926"></a><a name="_Ref494877827"></a><a name="_Ref245214660"></a><a name="_Ref246329427"></a><a name="_Ref246865166"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction and Dispute Resolution Process</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;With the exception of those matters referred for resolution by an independent expert under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;10.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, or as otherwise specified elsewhere in this Agreement, any dispute, controversy or claim arising out of or relating to this Agreement, or the interpretation or breach thereof, including disputes regarding the existence, validity or termination of this Agreement or the scope of the agreement to arbitrate herein (each, a </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">), shall be determined in accordance with the provisions of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref483623643"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;19.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref483879844"></a>:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1039"></a><a name="_cp_blt_2_1038"></a><a name="_Ref109842154"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If any Dispute arises, either Party may provide written notice of the Dispute to the other Party and request negotiation between the executive officers of each Party (</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Notice</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">). &#160;Within </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref483880258"></a> after the delivery of a Dispute Notice, the executive officers shall confer in person or by teleconference to attempt to settle the Dispute. &#160;All communication between such executive officers shall not be construed as an admission or agreement as to the liability of any Party, nor be admitted in evidence in any related arbitration, litigation, or other adversary proceeding.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1041"></a><a name="_cp_blt_2_1040"></a><a name="_Ref494872299"></a><a name="_Ref515913259"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If, within </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> after the delivery of a Dispute Notice, the Parties are unable to resolve the Dispute in writing, upon written notice by any Party to the other Party, such Dispute shall be determined exclusively by arbitration in London, England, before a panel of three (3) arbitrators in accordance with the Rules of Arbitration of the International Chamber of Commerce (</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ICC Rules</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">), except as modified herein;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1043"></a><a name="_cp_blt_2_1042"></a><a name="_Ref109842180"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In any arbitration commenced pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;19.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">There shall be three arbitrators, one of which shall be nominated by Customer and another of which shall be nominated by Supplier, as provided in the ICC Rules. &#160;The third arbitrator, who shall serve as the president of the tribunal, shall be jointly nominated by the two Party-nominated arbitrators within </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of the date of confirmation of the second arbitrator by the ICC. &#160;Any arbitrator not timely nominated as provided herein shall be appointed by the ICC Court.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The seat of arbitration shall be London, England. &#160;The language of the arbitration shall be English. &#160;The Parties agree that the award rendered by the arbitral tribunal shall be final and binding and enforceable against the Parties and their respective assets in any court of competent jurisdiction. &#160;Unless determined otherwise by the arbitral tribunal, each Party shall pay its own costs and expenses in connection with the arbitration, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Any arbitration hereunder shall be confidential, and neither the Parties nor their agents shall disclose to any Third Party the existence or status of the arbitration, any information made known or documents </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">24</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">produced in the arbitration not otherwise available to them or in the public domain, or any awards arising from the arbitration, except and to the extent that disclosure is required by Applicable Law or is required to protect or pursue a legal right.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">For any proceeding in aid of arbitration or for preliminary relief to preserve the status quo or avoid irreparable harm prior to the appointment of an arbitral tribunal, each Party irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the courts located in England, and waives, to the fullest extent possible, any objection to the laying of venue in such courts. &#160;The arbitral tribunal also shall have full authority to grant provisional remedies and to direct the Parties to request that any court modify or vacate any provisional, temporary or preliminary relief issued by a court hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(v)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In any action pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;19.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and in any action with respect to any arbitration award obtained pursuant to this Agreement or to the enforcement of such an award, the Parties agree to accept service of process in the manner provided for notices in this Agreement, and to waive any other requirements for service of process in any jurisdiction to the fullest extent permitted by law.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:108pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Each Party shall continue to perform obligations hereunder, when any bona fide Dispute is pending.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">20.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_Ref108899016"></a><a name="_cp_text_1_1044"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">INTELLECTUAL PROPERTY</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">20.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1047"></a><a name="_cp_text_1_1045"></a><a name="_Ref109233158"></a><a name="_Ref109842217"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">B</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ackground Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_1046"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1048"></a>. Except as the Parties may otherwise expressly agree in writing, each Party shall continue to own its existing Intellectual Property Rights, as well as the foregoing developed or acquired by such Party outside of this Agreement (collectively, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref245274546"></a><a name="_Ref519752414"></a>&#8221;), without conferring any interests therein on the other Party. During the Term, Customer shall not, and shall cause its Representatives not to, assert any Intellectual Property Rights comprising Customer&#8217;s Background Intellectual Property against Supplier, its Representatives or permitted sublicensees for performing Supplier&#8217;s obligations and exercising Supplier&#8217;s rights under this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">20.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1059"></a><a name="_cp_text_1_1049"></a><a name="_Ref109842252"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">C</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ustomer Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_1050"></a><a name="_cp_text_4_1051"></a><a name="_cp_text_1_1052"></a>. Except for Supplier Intellectual Property, Customer shall own and retain all right, title and interest, including, without limitation, all Intellectual Property Rights, in and to all inventions, discoveries, improvements, know-how, information, and data that are made, conceived, reduced to practice, created, written, designed or developed by or on behalf of Customer and/or Supplier in the performance of Fill/Finish (collectively, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;); Supplier agrees to assign, and hereby assigns, to Customer all right, title, and interest in and to the Customer Intellectual Property. Customer hereby grants to Supplier a non-exclusive, non-transferable (other than in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_field_47_1053"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21.6</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_1055"></a><a name="_cp_text_1_1056"></a><a name="_cp_text_4_1057"></a><a name="_cp_text_4_1058"></a><a name="_cp_text_1_1060"></a>), royalty-free license, with the right to grant and authorize sublicenses (through multiple tiers), during the Term, under any and all Customer Intellectual Property that Customer has provided to Supplier, or is otherwise necessary or reasonably useful, for the purpose of performing Supplier&#8217;s obligations and exercising Supplier&#8217;s rights under this Agreement.</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#160;</u></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">20.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1063"></a><a name="_cp_text_1_1061"></a><a name="_Ref109842283"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">S</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">upplier Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_1062"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1064"></a>. &#160;Supplier shall own and retain all right, title and interest, including, without limitation, all Intellectual Property Rights, in and to all inventions, discoveries, improvements, know-how, information, and data that are made, conceived, reduced to practice, created, written, designed or developed by or on behalf of Supplier in the performance of Fill/Finish to the extent (a) generally applicable to Supplier&#8217;s </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">25</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">business and not specific to the Drug Product or Drug Substance and b) the practice of which does not require any use of Customer&#8217;s Confidential Information (collectively, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supplier Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">20.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1075"></a><a name="_cp_text_1_1065"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_1066"></a><a name="_cp_text_1_1067"></a><a name="_cp_text_4_1068"></a><a name="_cp_text_1_1069"></a><a name="_cp_text_4_1070"></a><a name="_cp_text_1_1071"></a><a name="_cp_text_4_1072"></a><a name="_cp_text_1_1073"></a><a name="_cp_text_4_1074"></a><a name="_cp_text_1_1076"></a>Except as otherwise expressly provided herein, nothing contained in this Agreement shall be construed or interpreted, either expressly or by implication, estoppel or otherwise, as (a) a grant, transfer or other conveyance by either Party to the other of any right, title, license or other interest of any kind in any of its Intellectual Property Rights, (b) creating an obligation on the part of either Party to make any such grant, transfer or other conveyance or (c) requiring either Party to participate with the other Party in any cooperative development program or project of any kind or to continue with any such program or project. &#160;Nothing in this Agreement shall modify, or be deemed to modify, the allocation of ownership, and corresponding rights and licenses granted between the Parties, under the License Agreements, with respect to any Intellectual Property Rights and/or inventions thereunder. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"><a name="_cp_blt_1_1077"></a><a name="_Ref112431551"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">MISCELLANEOUS</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1080"></a><a name="_cp_blt_2_1079"></a><a name="_Ref519752423"></a><a name="_Ref244598042"></a><a name="_Ref492398957"></a><a name="_Ref492406121"></a><a name="_Ref214427485"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1078"></a>. &#160;Neither Party hereto shall be liable to the other Party for any losses or damages attributable to a default under or breach of this Agreement that is the result of war (whether declared or undeclared), acts of God, acts of governments, revolution, acts of terror, fire, earthquake, flood, pestilence, riot, accident(s), shortage of or inability to obtain material equipment or transport or any other cause beyond the reasonable control of such Party (each, a </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure Event</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">); </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that if such a cause occurs, then the Party affected will promptly notify the other Party of the nature and likely result and duration (if known) of such cause and use its Commercially Reasonable Efforts to avoid or remove such causes of nonperformance as soon as is reasonably practicable. &#160;Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall promptly recommence. &#160;If the event lasts for a period of longer than </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the Parties shall meet and work diligently to implement appropriate remedial measures.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1082"></a><a name="_cp_blt_2_1081"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;If and solely to the extent that any provision of this Agreement shall be invalid or unenforceable, or shall render this entire Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not affect the enforceability or validity of the remainder of this Agreement or any of its provisions; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the Parties shall use their respective reasonable efforts to mutually agree to replace the invalid provisions in a manner that best accomplishes the original intentions of the Parties.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1088"></a><a name="_cp_blt_2_1087"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1084"></a><a name="_cp_text_1_1086"></a>. &#160;Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. &#160;Neither the waiver by any Party of any term or condition of this Agreement nor the failure on the part of any Party, in one or more instances, to enforce any of the provisions of this Agreement or to exercise any right or privilege, shall be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach hereof. &#160;Except as expressly set forth in this Agreement </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, all rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1090"></a><a name="_cp_blt_2_1089"></a><a name="_Hlk519092704"></a><a name="_Ref107749473"></a><a name="_Ref108036026"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreements; Amendments</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This Agreement, together with the Product Schedules, and the QA, sets forth the entire agreement and understanding between the Parties as to the subject matter hereof and supersedes all agreements or understandings, verbal or written, made between Customer and Supplier before the date hereof with respect to the subject matter hereof. &#160;None of the terms of this Agreement shall be amended, supplemented or modified except in writing signed by the Parties.</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">26</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1100"></a><a name="_cp_blt_2_1099"></a><a name="_Ref519752422"></a><a name="_Ref492398955"></a><a name="_Ref492398956"></a><a name="_Ref492486809"></a><a name="_Ref495941091"></a><a name="_Ref244629614"></a><a name="_Ref245628177"></a><a name="_Ref245628202"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The provisions that are expressly designated as those that survive the expiration or termination of this Agreement, the provisions of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;17</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;19</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1091"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;8.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.9</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.10</u><font style="font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with respect to deemed Triggering Events, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;13.11</u><font style="font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;18.5</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, as well as any other Sections or defined terms referred to in such Sections or necessary to give them effect, shall survive termination of this Agreement and remain in force until discharged in full. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1102"></a><a name="_cp_blt_2_1101"></a><a name="_Ref515894395"></a><a name="_Ref516056783"></a><a name="_Ref495011683"></a><a name="_Ref495168315"></a><a name="_Ref519752418"></a><a name="_Ref519752419"></a><a name="_Ref519752420"></a><a name="_Ref519752421"></a><a name="_Ref108034983"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment; Binding Effect</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref244626914"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Neither this Agreement nor any rights or obligations of either Party to this Agreement may be assigned or otherwise transferred by either Party without the consent of the other Party; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, either Party may, without such consent, assign this Agreement, in whole or in part: (i) to any of its respective Affiliates; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that such assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (ii) to a Third Party successor to all or substantially all of the assets of such Party whether by merger, sale of stock, all or substantially all of a Party&#8217;s assets or other similar transaction, so long as such Third Party agrees in writing to be bound by the terms of this Agreement. &#160;Notwithstanding anything to the contrary herein, nothing herein shall prevent Customer or Protalix Parent from engaging in any merger, consolidation, reorganization, sale or purchase of stock, or sale or purchase of assets, or undergoing any Change of Control.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Any purported assignment in violation of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21.6</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be void. &#160;Any permitted assignee shall assume all obligations of its assignor under this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.7</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1110"></a><a name="_cp_blt_2_1109"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Contractor</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The relationship between Customer and Supplier is that of independent contractors. &#160;Customer and Supplier are not joint venturers, partners, principal and agent, employer and employee, and have no other relationship other than independent contracting parties.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.8</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1112"></a><a name="_cp_blt_2_1111"></a><a name="_Ref519752416"></a><a name="_Ref519752417"></a><a name="_Ref244606269"></a><a name="_Ref244629638"></a><a name="_Ref492398953"></a><a name="_Ref492398954"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each communication and document made or delivered by one Party to another under this Agreement shall be made in the English language. &#160;All notices, consents, approvals, requests or other communications required hereunder given by one Party to the other hereunder shall be in writing and made by registered or certified air mail, facsimile, express overnight courier or delivered personally to the following addresses of the respective Parties:</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">If to Customer:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';">Dror Bashan </font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">P.O. Box 455, </font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">Karmiel 2161401, Israel</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">with a copy to: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';">Eyal Rubin</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">If to Supplier:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Executive Officer</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-size:12pt;"><a name="_cp_text_1_1114"></a></font><font style="font-family:'Times New Roman','Times','serif';">Via Palermo 26</font><font style="font-family:'Times New Roman','Times','serif';">/A,</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">Parma, </font><font style="font-size:12pt;"><a name="_cp_text_1_1116"></a></font><font style="font-family:'Times New Roman','Times','serif';">43122 </font><font style="font-family:'Times New Roman','Times','serif';">Italy</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">with a copy to: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';">General Counsel; and </font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">Head of Global Corporate Development</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Notices hereunder shall be deemed to be effective (a) upon receipt if personally delivered, (b) on the tenth (10th) Business Day following the date of mailing if sent </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">27</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">by registered or certified air mail and (c) on the second (2nd) Business Day following the date of transmission or delivery to the overnight courier if sent by facsimile or overnight courier.  A Party may change its address listed above by sending notice to the other Party in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;21.8</u><font style="font-family:'Times New Roman','Times','serif';">.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.9</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1120"></a><a name="_cp_blt_2_1119"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third-Party Beneficiaries</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of either Party. &#160;No Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.10</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1122"></a><a name="_cp_blt_2_1121"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective heirs, successors and permitted assigns.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.11</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_2_1129"></a><a name="_cp_blt_1_1135"></a><a name="_cp_blt_2_1134"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_1133"></a>. &#160;This Agreement may be executed in any number of counterparts (including via digital or electronic signature), each of which, when executed, shall be deemed to be an original and which together shall constitute one and the same document. &#160;Signatures provided by facsimile transmission or in electronic format shall be deemed to be original signatures.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.12</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_1_1137"></a><a name="_cp_blt_2_1136"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Headings in this Agreement are included herein for ease of reference only and shall have no legal effect.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">21.13</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc495297469"></a><a name="_Toc515993587"></a><a name="_Toc519752171"></a><a name="_Toc519854211"></a><a name="_Toc247356234"></a><a name="_Toc247356367"></a><a name="_Toc247358904"></a><a name="_Toc247366092"></a><a name="_Toc492289953"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equitable Remedies</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Parties agree that irreparable damage may occur in the event that a Party breaches </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of this Agreement. &#160;It is accordingly agreed that, without limitation of other remedies which may be available to a Party for breach of this Agreement by the other Party, the Parties shall be entitled to seek an injunction or injunctions to as a result of breaches of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of this Agreement and to enforce specifically the terms and provisions of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;15</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;20</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of this Agreement.</font></td></tr></table><p style="font-family:'Garamond';font-size:12pt;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Signature Page Follows]</font></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:0pt;text-indent:0pt;margin:0pt 0pt 6pt 108pt;"><a name="_cp_blt_2_1146"></a><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;">28</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:11.91%;padding-right:11.91%;position:relative;"><div style="margin-top:30pt;min-height:19.85pt;width:100%;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">CONFIDENTIAL</font></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXECUTION VERSION</i></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 6pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b> the Parties hereto have caused this Agreement to be executed by their duly authorized officers as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-10.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">CHIESI FARMACEUTICI S.p.A.</font></p></td><td colspan="2" style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">CHIESI FARMACEUTICI S.p.A.</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font></p></td><td style="vertical-align:top;width:42.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Alberto Chiesi</font></p></td><td style="vertical-align:top;width:5.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">By:</font></p></td><td style="vertical-align:top;width:43.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Ugo Di Francesco</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Name:</font><font style="display:inline-block;width:6.68pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Alberto Chiesi</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Title:</font><font style="display:inline-block;width:12.17pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">President</font></p></td><td colspan="2" style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Name:</font><font style="display:inline-block;width:6.68pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Ugo Di Francesco</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Title:</font><font style="display:inline-block;width:12.17pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.91%;margin-right:11.91%;margin-top:30pt;page-break-after:always;width:76.18%;border-width:0;"><div style="max-width:100%;padding-left:11.91%;padding-right:11.91%;position:relative;"><div style="margin-top:30pt;min-height:19.85pt;width:100%;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">CONFIDENTIAL</font></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><font style="display:inline-block;width:42.5pt;"></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXECUTION VERSION</i></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b> the Parties hereto have caused this Agreement to be executed by their duly authorized officers as of the date first written above.</p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-10.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">PROTALIX LTD.</font></p></td><td colspan="2" style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">PROTALIX LTD.</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font></p></td><td style="vertical-align:top;width:42.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Dror Bashan</font></p></td><td style="vertical-align:top;width:5.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">By:</font></p></td><td style="vertical-align:top;width:43.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Eyal Rubin</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Name:</font><font style="display:inline-block;width:6.68pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Dror Bashan</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Title:</font><font style="display:inline-block;width:12.17pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">President and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;"><br></font><font style="display:inline-block;width:22.5pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Chief Executive Officer</font></p></td><td colspan="2" style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Name:</font><font style="display:inline-block;width:6.68pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Eyal Rubin</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Title:</font><font style="display:inline-block;width:12.17pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Sr. Vice President and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;"><br></font><font style="display:inline-block;width:22.5pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"></font><font style="margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.45pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.91%;margin-right:11.91%;margin-top:30pt;page-break-after:always;width:76.18%;border-width:0;"><div style="max-width:100%;padding-left:11.91%;padding-right:11.91%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 35.45pt;"><a name="_cp_text_1_1148"></a>Exhibit 1</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 35.45pt;">Product Schedule for FILL/FINISH of Pegunigalsidase Alfa Vials</p><p style="font-family:'Garamond';font-size:12pt;min-height:15.0pt;margin:8pt 0pt 0pt 42.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';background:#ffffff;">[***]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:0.0pt;margin:8pt 0pt 0pt 0pt;"><font style="font-style:normal;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.91%;margin-right:11.91%;margin-top:30pt;page-break-after:always;width:76.18%;border-width:0;"><div style="max-width:100%;padding-left:11.91%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Exhibit 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Quality Agreement</p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:0.0pt;margin:8pt 0pt 0pt 0pt;"><font style="font-style:normal;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.91%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:76%;border-width:0;"><div style="max-width:100%;padding-left:11.91%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-top:8pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><a name="_cp_text_1_1330"></a>Exhibit 3</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Tech Transfer Plan</p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:center;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-top:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Garamond';font-size:11pt;min-height:15.0pt;text-align:center;margin:8pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Garamond';font-size:8pt;font-style:italic;min-height:15.0pt;margin:8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.91%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:76%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>plx-20220930xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:07:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-weight:bold;white-space:pre-wrap;">      Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="display:inline-block;width:108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">CONFIDENTIAL  </font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXECUTION VERSION</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 0pt -4.5pt;"><b style="font-weight:bold;background:#ffffff;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. Such identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 0pt 198pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 0pt 198pt;">Via Palermo 26/A,<br>Parma, 43122 Italy</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">August 29, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">Protalix Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">2 Snunit Street, Science Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">P.O. Box 455</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">Karmiel 2161401, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Re:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Additional Matters Related to the Fill/Finish Agreement and License Agreements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">Dear Dror:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">Protalix Ltd. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix</u>&#8221;) and Chiesi Farmaceutici S.p.A. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chiesi</u>&#8221;) are parties to (a)&#160;that certain Exclusive License and Supply Agreement dated October 17, 2017 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ex-US License Agreement</u>&#8221;); and (b) that certain Exclusive U.S.&#160;License and Supply Agreement dated July 23, 2018 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">US License Agreement</u>&#8221;) ((a) and (b), collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreements</u>,&#8221; and each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u>&#8221;), pursuant to which Protalix granted to Chiesi, among other rights, an exclusive license to certain Intellectual Property Rights with respect to the commercialization of the Licensed Product worldwide (as such terms are defined in the applicable License Agreement). &#160;In addition, Protalix and Chiesi have entered into that certain Fill/Finish Agreement contemporaneously herewith dated August 29, 2022 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finish Agreement</u>&#8221;), pursuant to which Protalix appoints Chiesi to perform, and Chiesi agrees to perform, Fill/Finish (as used throughout this <font style="font-size:12pt;"><a name="_cp_text_1_2"></a></font>Agreement (defined below)), (i) in the context of the Fill/Finish Agreement, as defined in the Fill/Finish Agreement, and (ii) in the context of the License Agreement(s), as defined in the applicable License Agreement) supply services for Protalix and Protalix agrees to supply Drug Substance to Chiesi for such purposes, thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt;">By signing <font style="font-size:12pt;"><a name="_cp_text_4_3"></a></font>this letter <font style="font-size:12pt;"><a name="_cp_text_1_4"></a></font>agreement (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) below, Chiesi and Protalix each hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">1.</font><a name="_Hlk111125852"></a><font style="font-size:11pt;">(a) With the express intent of modifying their obligations under Section 4.13 of the License Agreements</font><a name="_cp_text_1_5"></a><font style="font-size:11pt;"> solely with respect </font><a name="_cp_text_4_6"></a><font style="font-size:11pt;">to the </font><a name="_cp_text_1_7"></a><font style="font-size:11pt;">Selected CMO, </font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;">, pursuant to Section 15.4 of the License Agreements, Chiesi and Protalix each hereby agree as set forth in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1</u><font style="font-size:11pt;">. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(b) Promptly, but in any event within <font style="font-size:12pt;background:#ffffff;">[***]</font> following execution of this <font style="font-size:12pt;"><a name="_cp_text_1_11"></a></font>Agreement, Protalix will nominate (i.e., provide to Chiesi the name <font style="font-size:12pt;"><a name="_cp_text_1_12"></a></font>(and proposed site(s) and lines) of) <font style="font-size:12pt;background:#ffffff;">[***]</font> third party tier 1 fill/finish contract manufacturing organizations (that Protalix reasonably believes would be suitable candidates for Fill/Finish of Drug Product) for inclusion as potential alternate/secondary source candidates for the Fill/Finish of Drug Product under the License Agreements (each a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CMO Candidate</u>&#8221;) and provide Chiesi with a copy of the <font style="font-size:12pt;"><a name="_cp_text_1_13"></a></font>formal quote (which may be <font style="font-size:12pt;background:#ffffff;">[***]</font>) therefor <font style="font-size:12pt;"><a name="_cp_text_1_15"></a></font>(and any updates thereto) from each CMO Candidate. <font style="font-size:12pt;background:#ffffff;">[***]</font>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:always;width:81.18%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="margin-top:30pt;min-height:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">August 29, 2022<font style="display:inline-block;width:34.97pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>CONFIDENTIAL </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">Page 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(c) The first CMO Candidate proposed by Protalix would be jointly evaluated in good faith by the Parties for suitability and reliability, including, without limitation, customary quality audit, technical evaluation of equipment and financial evaluation<font style="font-size:12pt;"><a name="_cp_text_2_16"></a><a name="_cp_text_2_17"></a><a name="_cp_text_1_18"></a><a name="_cp_text_2_19"></a><a name="_cp_text_1_20"></a></font> (each consistent with such party&#8217;s customary practices and procedures), within <font style="font-size:12pt;background:#ffffff;">[***]</font> following the Effective Date (as defined in the Fill/Finish Agreement) that is <font style="font-size:12pt;background:#ffffff;">[***]</font>, provided that, for the avoidance of doubt, <font style="font-size:12pt;background:#ffffff;">[***]</font> would be considered a Pre-Approved CMO (as defined below) <font style="font-size:12pt;background:#ffffff;">[***]</font>, each conducted in good faith by the parties hereunder in accordance with their customary practices and procedures. &#160;Protalix and Chiesi would each bear their own costs in performing such nominations, evaluations and selection. &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(d) Each CMO Candidate which both (i) has submitted a quote to Protalix (with a copy provided by Protalix to Chiesi pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (b)</u> above) and (ii) is determined <font style="font-size:12pt;background:#ffffff;">[***]</font> as a result of the above evaluations, would constitute a pre-approved Fill/Finish alternative source (each a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Approved CMO</u>&#8221;) (the date of such pre-approval, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CMO Candidate Pre-Approval Date</u>&#8221;). &#160;<font style="font-size:12pt;"><a name="_Hlk111125788"></a></font>For clarity, pre-approval for each Pre-Approved CMO shall apply only to the particular line(s)/facility(ies) of such Pre-Approved CMO for Fill/Finish of Drug Product that were evaluated by the parties and determined to be <font style="font-size:12pt;background:#ffffff;">[***]</font>, and not to other lines/facilities thereof that were not the subject of evaluation or determined not to be <font style="font-size:12pt;background:#ffffff;">[***]</font>. <font style="font-size:12pt;"><a name="_Hlk111128351"></a><a name="_Hlk111129127"></a></font>The pre-approval <font style="font-size:12pt;"><a name="_cp_text_1_32"></a></font>or rejection of each CMO Candidate shall be documented <font style="font-size:12pt;background:#ffffff;">[***]</font> in a written notice <font style="font-size:12pt;"><a name="_cp_text_1_33"></a></font>(signed by an authorized representative of such party) provided to <font style="font-size:12pt;background:#ffffff;">[***]</font>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(e) In the event that the foregoing initial evaluation process does not result in a Pre-Approved CMO (the date of such event, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CMO Candidate Rejection Date</u>&#8221;), the Parties shall promptly repeat the process described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses (c)</u> through <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</u> above for the second CMO Candidate proposed by Protalix and, if applicable, the process described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses (b)</u> through <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</u> above for each subsequent CMO Candidate proposed by Protalix, provided that (i) with respect to the second CMO Candidate proposed by Protalix, such <font style="font-size:12pt;background:#ffffff;">[***]</font> nomination period will be reduced to <font style="font-size:12pt;background:#ffffff;">[***]</font> measured from the CMO Candidate Rejection Date, and (ii) with respect to any subsequent CMO Candidate(s), Protalix and Chiesi must <font style="font-size:12pt;"><a name="_cp_text_1_58"></a></font><font style="font-size:12pt;background:#ffffff;">[***]</font>.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(f) No later than <font style="font-size:12pt;background:#ffffff;">[***]</font> from <font style="font-size:12pt;"><a name="_cp_text_1_59"></a></font>the CMO Candidate Pre-Approval Date, Protalix will begin to diligently negotiate <font style="font-size:12pt;"><a name="_cp_text_1_60"></a></font>(in a reasonable, good faith and customary manner consistent with industry market terms) with such Pre-Approved CMO (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Selected CMO</u>&#8221;) the terms on which the Selected CMO will serve as an alternative source for Fill/Finish under the License Agreements. &#160;Upon completion of negotiations in a manner reasonably satisfactory to Protalix<font style="font-size:12pt;"><a name="_cp_text_1_61"></a></font>, consistent with the foregoing and compliant with the requirements of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (g)</u>, enter into a definitive agreement with the <font style="font-size:12pt;"><a name="_cp_text_1_62"></a></font>Selected CMO <font style="font-size:12pt;"><a name="_cp_text_4_63"></a></font>(the effective date of such agreement, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Selected CMO Agreement Date</u>&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(g) From and after <font style="font-size:12pt;"><a name="_cp_text_2_67"></a></font>the<font style="font-size:12pt;"><a name="_cp_text_1_68"></a></font> selection of such Selected CMO <font style="font-size:12pt;"><a name="_cp_text_1_70"></a></font>as contemplated by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (f)</u> above, Protalix will diligently establish and Qualify (including, without limitation, in compliance with <font style="letter-spacing:-0.05pt;">all applicable Law, GMP, Product Specifications and the then-current Regulatory Approvals </font><font style="font-size:12pt;"><a name="_cp_text_1_71"></a></font><font style="letter-spacing:-0.05pt;">(and as otherwise required by a Regulatory Authority) </font><font style="letter-spacing:-0.05pt;">for the Licensed Product in the Territory (as each of the foregoing capitalized terms is defined in the applicable License Agreement)) </font>such Selected CMO as an alternative source for Fill/Finish under the License Agreements, <font style="font-size:12pt;background:#ffffff;">[***]</font>. &#160;The terms &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Qualify</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Qualification</u>&#8221; <font style="font-size:12pt;"><a name="_cp_text_1_78"></a></font>(and variations thereof) means to complete or completion of (as the context requires) <font style="font-size:12pt;"><a name="_cp_text_1_93"></a></font><font style="font-size:12pt;background:#ffffff;">[***]</font>, provided <font style="font-size:12pt;"><a name="_cp_text_4_94"></a></font>that the <font style="font-size:12pt;"><a name="_cp_text_1_95"></a></font>foregoing shall not limit, or be deemed to limit, Protalix&#8217;s regulatory obligations under the License Agreements applicable to preparing, seeking and obtaining Regulatory Approvals or establishing or qualifying an <font style="font-size:12pt;"><a name="_cp_text_4_96"></a></font>alternative source of Fill/Finish<font style="font-size:12pt;"><a name="_cp_text_1_97"></a></font>, including, without limitation, Section 3.6(d)(iii) of each License Agreement and cooperating with Chiesi for same (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Regulatory Responsibilities</u>&#8221;). With respect to such negotiations with such Selected CMO (as described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clause (f)</u> above) and the corresponding establishment and Qualification thereof as an alternative source for Fill/Finish, as between the parties, Protalix will be responsible for such negotiations, establishment, and Qualification, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that (x) the definitive agreement with such Selected CMO must be consistent with the requirements of the License Agreements, and (y) Protalix will provide Chiesi, until completion thereof, regular <font style="font-size:12pt;background:#ffffff;">[***]</font> updates, </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:always;width:81.18%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="margin-top:30pt;min-height:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">August 29, 2022<font style="display:inline-block;width:34.97pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>CONFIDENTIAL </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">Page 3</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">through Protalix&#8217;s and Chiesi&#8217;s respective operational teams, with respect to the progress/status of such negotiations, establishment and Qualification, and the Parties agree to discuss accordingly. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(h) From and after <font style="font-size:12pt;"><a name="_cp_text_1_98"></a></font><font style="font-size:12pt;background:#ffffff;">[***]</font>, Chiesi will <font style="font-size:12pt;background:#ffffff;">[***]</font> after receiving from Protalix <font style="font-size:12pt;"><a name="_cp_text_2_107"></a></font>the<font style="font-size:12pt;"><a name="_cp_text_1_108"></a></font> <font style="font-size:12pt;background:#ffffff;">[***]</font>. &#160;As between the Parties, Chiesi will be responsible <font style="font-size:12pt;"><a name="_cp_text_1_109"></a></font>(subject to, and without limiting, Protalix&#8217;s performance of the Protalix Regulatory Responsibilities in accordance with the License Agreements) for <font style="font-size:12pt;background:#ffffff;">[***]</font>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that Chiesi will provide Protalix, until completion thereof, regular <font style="font-size:12pt;background:#ffffff;">[***]</font> updates, through Protalix&#8217;s and Chiesi&#8217;s respective operational teams, with respect to the progress/status of such <font style="font-size:12pt;background:#ffffff;">[***]</font>, and the Parties agree to discuss accordingly. &#160;<font style="font-size:12pt;"><a name="_Hlk111622993"></a></font>Upon establishment and Qualification of such Selected CMO as contemplated hereunder, and completion of the <font style="font-size:12pt;background:#ffffff;">[***]</font>, the applicable Selected CMO shall constitute the Initial Alternate Source (as defined in the Fill/Finish Agreement). &#160;For the avoidance of doubt, <font style="font-size:12pt;background:#ffffff;">[***]</font><font style="background:#00ff00;">.</font> &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(i) With the express intent of modifying their obligations under Section 4.13 of the License Agreements solely with respect to such Selected CMO, pursuant to Section 15.4 thereof, <font style="font-size:12pt;"><a name="_cp_text_1_116"></a></font><font style="font-size:12pt;background:#ffffff;">[***]</font>. Protalix shall <font style="font-size:12pt;"><a name="_cp_text_1_117"></a></font>(a) promptly <font style="font-size:12pt;"><a name="_cp_text_1_118"></a></font>(upon Protalix&#8217;s receipt thereof) provide to Chiesi a copy of <font style="font-size:12pt;"><a name="_cp_text_1_119"></a></font>the Selected CMO&#8217;s invoice submitted pursuant to such <font style="font-size:12pt;"><a name="_cp_text_1_120"></a></font>definitive agreement, and, <font style="font-size:12pt;"><a name="_cp_text_1_121"></a></font>(b) promptly <font style="font-size:12pt;"><a name="_cp_text_1_123"></a></font>upon the payment due date for such invoice <font style="font-size:12pt;"><a name="_cp_text_1_125"></a></font>thereunder, provide Chiesi either a <font style="font-size:12pt;"><a name="_cp_text_1_126"></a></font>written confirmation of its accuracy, or <font style="font-size:12pt;"><a name="_cp_text_1_127"></a></font>written final corrections to <font style="font-size:12pt;"><a name="_cp_text_1_129"></a></font>such invoice and <font style="font-size:12pt;"><a name="_cp_text_1_131"></a></font>upon a reasonable written request of Chiesi, use Commercially Reasonable Efforts to provide reasonable supporting documentation for the same, <font style="font-size:12pt;"><a name="_cp_text_1_133"></a></font>including, without limitation, as provided by the Selected CMO) therefor, <font style="font-size:12pt;"><a name="_cp_text_1_138"></a></font> provided that (x) <font style="font-size:12pt;background:#ffffff;">[***]</font>, (y) <font style="font-size:12pt;"><a name="_cp_text_1_140"></a></font><font style="font-size:12pt;background:#ffffff;">[***]</font>, and (z) <font style="font-size:12pt;"><a name="_cp_text_1_141"></a><a name="_cp_text_1_147"></a></font><font style="font-size:12pt;background:#ffffff;">[***]</font>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">(j) <font style="font-size:12pt;background:#ffffff;">[***]</font>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">2.</font><font style="background:#ffffff;">[***]</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">3.</font><font style="font-size:11pt;">In accordance with Section 15.4 thereof, the following definitions are hereby added, in the appropriate alphabetical order, to Article 1 in both License Agreements:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;width:270pt;"></font><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 36pt 0pt 36pt;"><font style="letter-spacing:-0.05pt;">&#8220;&#8220;</font><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finish CMO Agreement</u><font style="letter-spacing:-0.05pt;">&#8221; means (i) the </font><font style="font-size:12pt;background:#ffffff;">[***]</font><font style="letter-spacing:-0.05pt;"> Agreement; and (ii) </font><font style="font-size:12pt;"><a name="_cp_text_2_161"></a></font>any other agreement between a Fill/Finish CMO, other than Chiesi or <font style="font-size:12pt;background:#ffffff;">[***]</font>, and Protalix with respect to the performance of Fill/Finish services<font style="letter-spacing:-0.05pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 36pt 0pt 36pt;"><font style="font-size:11pt;letter-spacing:-0.05pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 36pt 0pt 36pt;"><font style="font-size:11pt;">&#8220;&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finish CMO</u><font style="font-size:11pt;">&#8221; means (i) </font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;">, (ii) Sections </font><a name="_cp_text_1_163"></a><font style="font-size:11pt;">4.2(a)(i)(solely as the identified recipient of &#160;Drug Substance required to be delivered by Protalix), </font><font style="font-size:11pt;">4.7(b) (</font><a name="_cp_text_1_164"></a><font style="font-size:11pt;">for (i) and for </font><font style="font-size:11pt;">last sentence only)</font><a name="_cp_text_1_166"></a><font style="font-size:11pt;">, </font><font style="font-size:11pt;">4.12(b)(ii</font><a name="_cp_text_1_167"></a><font style="font-size:11pt;">) and 6.7(a</font><font style="font-size:11pt;">) of the License Agreements,</font><font style="font-size:11pt;letter-spacing:-0.05pt;"> </font><font style="font-size:11pt;">Chiesi, or any of its Affiliates, and (iii) any Third Party, or any of its Affiliates, in each case, (i) &#8211; (iii), to the extent such Person is performing Fill/Finish services under contract to Protalix.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">4.</font><font style="font-size:11pt;">In accordance with Section 15.4 thereof, each instance of &#8220;</font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;">&#8221; in (a) Sections 1.49, 4.2(a), &#160;4.7(b), 4.12(b)(ii) and 6.7(a) of the Ex-US License Agreement, and (b) Sections 1.55, 4.2(a), 4.7(b), 4.12(b)(ii) and 6.7(a) of the US License Agreement, is hereby deleted in its entirety from such License Agreement and replaced with &#8220;Fill/Finish CMO&#8221;. </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">5.</font><font style="font-size:11pt;">In accordance with Section 15.4 thereof, each instance of &#8220;</font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;"> Agreement&#8221; in Sections 4.2(a) of each License Agreement is hereby deleted in its entirety from such License Agreements and replaced with &#8220;Fill/Finish CMO Agreement.&#8221;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:always;width:81.18%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="margin-top:30pt;min-height:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">August 29, 2022<font style="display:inline-block;width:34.97pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>CONFIDENTIAL </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;">Page 4</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">6.</font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;">, the Parties acknowledge that </font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;"> (each, as defined in the applicable License Agreement) that Protalix is required </font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;"> under the License Agreements, and </font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;">.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">7.</font><font style="font-size:11pt;">Except as expressly contemplated herein, this </font><a name="_cp_text_1_172"></a><font style="font-size:11pt;">Agreement </font><font style="font-size:11pt;">shall not be construed to otherwise modify, waive, impair or affect any other terms, provisions or conditions of the License Agreements or Fill/Finish Agreement. &#160;For the avoidance of doubt, Chiesi and Protalix each do not release the other Party or any third party (including, without limitation, </font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;">) from any obligations, including, without limitation, any obligations expressly created by this </font><a name="_cp_text_1_174"></a><font style="font-size:11pt;">Agreement </font><font style="font-size:11pt;">or any obligations, rights or claims arising under the License Agreements, </font><font style="background:#ffffff;">[***]</font><font style="font-size:11pt;"> Agreement or Fill/Finish Agreement, all of which are hereby expressly preserved. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">8.</font><font style="font-size:11pt;">This </font><a name="_cp_text_1_176"></a><font style="font-size:11pt;">Agreement </font><font style="font-size:11pt;">will be governed by and construed in accordance with the substantive laws of the State of New York, without regard to conflicts of law rules. The provisions of the U.N. Convention on Contracts for the International Sale of Goods will not apply to this </font><a name="_cp_text_1_178"></a><font style="font-size:11pt;">Agreement</font><font style="font-size:11pt;">. &#160;No amendment, modification or waiver of any term or condition of this </font><a name="_cp_text_1_180"></a><font style="font-size:11pt;">Agreement </font><font style="font-size:11pt;">will be effective unless in writing and signed by both parties. </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">9.</font><a name="_cp_blt_1_187"></a><a name="_cp_text_1_184"></a><font style="font-size:11pt;">T</font><font style="font-size:11pt;">his Agreement may be executed in any number of counterparts (including, without limitation, via digital or electronic signature), each of which, when executed, shall be deemed to be an original and which together </font><a name="_cp_text_4_185"></a><font style="font-size:11pt;">shall constitute </font><a name="_cp_text_1_186"></a><font style="font-size:11pt;">one and the same document. &#160;Signatures provided by facsimile transmission or in electronic format shall be deemed to be original signatures</font><a name="_cp_text_1_188"></a><font style="font-size:11pt;">.</font><a name="_cp_text_1_183"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt;"><font style="font-size:12pt;"><a name="_cp_text_1_190"></a></font>[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:234pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:198pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;text-indent:0pt;margin:0pt;"><a name="_cp_text_1_194"></a><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:always;width:81.18%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;"><font style="display:inline-block;width:108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">CONFIDENTIAL</font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXECUTION VERSION</i></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b> the Parties hereto have caused this Agreement to be executed by their duly authorized officers as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-10.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">CHIESI FARMACEUTICI S.p.A.</p></td><td colspan="2" style="vertical-align:top;width:50.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">CHIESI FARMACEUTICI S.p.A.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">By: </p></td><td style="vertical-align:top;width:36.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">/s/ Alberto Chiesi</p></td><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">By:</p></td><td style="vertical-align:top;width:37.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">/s/ Ugo Di Francesco</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Name:</font><font style="display:inline-block;width:45.97pt;"></font><font style="font-size:11pt;">Alberto Chiesi</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Title: President</font></p></td><td colspan="2" style="vertical-align:top;width:50.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Name: Ugo Di Francesco</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Title: Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:78.82%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt;"><font style="display:inline-block;width:108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">CONFIDENTIAL</font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXECUTION VERSION</i></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b> the Parties hereto have caused this Agreement to be executed by their duly authorized officers as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-10.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">PROTALIX LTD.</p></td><td colspan="2" style="vertical-align:top;width:50.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">PROTALIX LTD.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">By: </p></td><td style="vertical-align:top;width:36.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">By:</p></td><td style="vertical-align:top;width:37.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><font style="white-space:pre-wrap;"> /s/ Eyal Rubin</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Name: Dror Bashan</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Title: President and</font><font style="font-size:11pt;"><br></font><font style="display:inline-block;width:22.5pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">Chief Executive Officer</font></p></td><td colspan="2" style="vertical-align:top;width:50.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Name: Eyal Rubin</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:22.5pt;"></font><font style="font-size:11pt;">Title: Sr. Vice President and</font><font style="font-size:11pt;"><br></font><font style="display:inline-block;width:22.5pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:9.41%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:78.82%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>plx-20220930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:07:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>plx-20220930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:07:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>plx-20220930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:07:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>plx-20220930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:07:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20220930x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220930x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ',!#@# 2(  A$! Q$!_\0
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M_P"%'U*?=!_Q$7+O^?,__)?_ )(_1NBOSD_X:#^(O_0VW_YK_A1_PT'\1?\
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M+O\ GS/_ ,E_^2/T;HK\Y/\ AH/XB_\ 0VW_ .:_X4?\-!_$7_H;;_\ -?\
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M3_AH/XB_]#;?_FO^%'_#0?Q%_P"AMO\ \U_PH^I3[H/^(BY=_P ^9_\ DO\
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M@ Q3QR _W6!KYLU+PUK?AV-9=0L(A"0#YF]?3)Z^E/U#1&TR&TDU1ETLW?\
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MQ'JSQASY5OF)3QD9SSUKYG\:^$KSP-XHU#0[XJUQ9R%"Z]&'9A]17UZ/VIO
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MZBDK6<J$,(/(EB/S'JV'%0^+?BE\$?$-U>>)K[2KK6-;N(0GV257 W*#C^(
M=AFM7*OY]>AX[P?#D>=1=-R2CO-J-N75Q:O[W,;G@;X,> (?@MJ%Q=W%H\\T
M+1WNM,HD:V<$!E1CD  C&1UKG=9\!0ZO^S?H4&E064]W=7T5K!<BT43/NG90
MQDZXQ@GVK+^%/QG\"6WPMUGPIXGBN+*WNIYY/L]JC,IC=MP16!R,=/PIY^.G
MAOP_\'= TG2+F2;5M+U"*X2V>,@-&DY;:6/JG'XTI1J<[WW1T0Q63SPD=:<4
MZ$T[/WKW6EM+OJNK9IK^QQH@1=*?QACQ*T/G"W$:[<>NW.=N>]8_A;]E/3[[
MPCJ%_KVN2:+>V%Q)%<NRJT,:HW+]>FWD?45W?_#1WPNDU:/QB\5\/$:6IM1"
M(VSM/)7KMZ]ZY&^_:#T#Q%\'_%MC?3M;Z]JS3M':I&2HW'Y!N^@'-+FQ%NO]
M/_(*F%X6A*\>1VC*R4G9I)6YM=)7T5M3@/C[\";?X0+I-U8ZH^HV5_N4>:@5
ME8 'MU!!JG^S9X 7Q[\3;%+F$3:=8?Z7<*ZY5L?=4_4X_*NK_:5^+'ASXB>&
M_"]IHEV]Q/9%C.KQE=N44=_<5<_9V^*W@[X3>#-8NK^=Y?$%RS,MLD1.54?(
MF[MDUU*5146WJSY=X3*GQ&E3G&.'C:3UTTBFTFWK[W0ZS]K/X<:3=^#[/Q/H
M%G:P#3YVMKG['$J*5W%3D*!RKC%0?#+]F/2_#W_"*ZYXBUN&/5+F5)4TN>-6
MBE)7/E<GYC@^G:M"P_:;\#^.O!^M:)X@L#X>AND>,1PQ^8K;P27& ,,&Y^O-
M-TW]HSX>ZWHGAFX\1)=?VYHTBF(1(P19 NPR#!P5(YP:Y8^VC#V=GN?855P_
MBLP_M%U8-RBK)MQ2E%ZMK=.UK)[M,T/B7\!_#?Q&^(NKV=M<#1M2L]*AFAM+
M2%$BDR9,,0,=P 3]*\K'[.-A:_#GP_JVH:N]EKFLS)%#;R[4B4,Q())YX09/
MO71:W^T#H</[0^G^)].NY9=!?3TLKM_+(/WG)^7OC(J#XI?M >'?$7Q2\(75
MLLE]X7T=O/F3R\;I&R,[#UV@#\S505:*C%;?E:_YG!CI\/XAU\344'-3<=]U
M)QM/1_95]4;:?L9Z'?:;)'8>+);G45CWB18%:$DYP,@_US7.> ?V7](\3?#U
M==U;7I='N4N9H+@LBF*/RY63/)[XKUV+]JSX>IJQVZE?^2T?\4!$49] !SD^
M_I7FS_&WPE'\'=;\/K?R/J-Q>W,L2"%L,CW+.IS[J0:E3Q#T=^AV5\%PO3FI
MT_9M*,].;1M6Y?M7OOMN7+#]ESPWX6^)^A6VIZH=3T6_@DD@AF7:99D*?NS@
M\@AB?^ FH?BK\"_"OB'XM6FF:1K=EH;20L]]:!$C2S1$B6/:O );=G\S4WCW
M]H7PG=:_X U#3[B:\CTB9FNU$14JI0+D9ZU<?XX_"NU^+,/BN 7<US>6KPW=
MS) 2(VQ$(RJGI@(P./6A.M=2=^O_  ":D.'G3J86G[)1]I!N\M;-*]FG=V=U
M:]DK^1S_ (\_9)T[1_!>HZUH.OSWTUA&TCQ3P@++MZ[2/;..HI?#W[)&ES^&
M-$O=;\4'3]0U-D,4 1=C;EW"-23DM@$_A7<Z]^TQX$UGPKXBTV+4[[SKB"2*
M%[J$_.64XP!T':NU\&6L7CCP3X-GUK0;@W6G&&YMF20>4KJA59-P/(P>GK4^
MUK17O76J.REDO#^,Q3^IPC/W=E)N*?-:[LW9VV[GA]Q^R#'=?$>70[+5YH])
MMK*.ZN+N:,%]SLX"*!P?N9]JC^)7[(8\/:"VJ^'M7DO5A=1/!>1^60I."P/M
MG/TKTOQU\>=+^&/QLO+'4Q)-IMSIT*326_+V\H+D<=\AA]./>N+^*7[17@^?
MPQ)HVB3:OK+7CA;F6XNYE"PE@7 );J1D#CC-5">(ERM;'%B\!PO0I8F$^53B
MY*W,TT^BBM?R?F-U']CW1=)T=OM7B*^COEA\PSK9E[<-Z?+DX_\ UU\MW< M
M;J:$2),(W9/,C.5;!QD>QK[*T3]ICP1X?TY9D\0ZWJ$*0"-=,O8%D<,.G[S
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M4_V:?&_C?Q_K.N:9;V3V%Y*KQ-)=!6("*O([<@URO_#'WQ%_Y]=/_P# Q?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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MYRM^G^78OU?]:+_@_P!;]%J_Q@T/1H[.:4RR6UQIC:J9HP"(X045<\]79PH
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MZ<YKU3XRE%T*PA)P1 M<Q\'$_MKQ3XG9;1K58C'E7'))+9)J[\9[W?-80@Y
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M;^OO_P F']?E_FCT:BH[>=+J".:)MT<BAU.,9!&14E( HHHH **** "BBB@
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MJ7O-W_JW+_\ (H\,\$_"3Q!X<\7^'=0NHH7BBTK5ENVBF!6&XNKF.9(E!Y(
M##<!CCMFI_#OPRU_3HOA"LUFB'P]-=/J.)D/E![>1%Q@_-EF'3->V452=E9?
MUJW^HGJVWU_RL>=^(O!^J:A\:?#OB&"!6TJST+4+&:4R*"LLLENT8VYR<B-^
M1P,5QNG?"SQ-:Z?\*XEMHH9]!NKZ6]8RHPA$EO.D9QGYOF=>!GK7NU%+[/+_
M %NW^H=6_P"MK'S7:?";Q5<Z[X NI_#LL=UHE_/-JFIWFJ1S&??;31[H$#G$
M99UR"$(^4!2 2.J\%_#/7]'M_A.MW9HC>'S?&_Q,C>5YD+JF,'YLEATS7M5%
M.^EA-7/"?!7PK\1Z-XR\*ZA=V:1VMAJ&MW%PXG0E4N2/). <G..W3O4ME\+_
M !#!IW@J(V<:R:9XMN-6NAYR?);O]HVOUY/[Q.!SS[5[C10G:WE;\'<;U37>
M_P"*:_4^;M5^%7BW5+S2!/H$EWJ%CXJM]5N-7GU./R'M5N=_^CP[\J0A&5*K
M]UL%B:9_PIKQQ$7?3XK:QO1_PD!@N9I4=(WNG!MV*\Y![\''<=J^E**2T5O7
M\4E^@[Z\WI^#;_5GS'J_P?\ $VMS7,]EX6N-,#^%=0TDMJ>K1W-S-<RQ@)EA
M(PV$YYW?4+7I6E>!=8M?&7P_U"2W46ND:#)8WC^:I*3%(@% SD\JW(XKU*BJ
M3M_7^+_Y)_@0U=)?UT_^11YGJNC>(/"WQ,U3Q+I&BOXBM]6T^&T,$=W% ;>6
M)F(9C(1\A#\E=Q&/NFL76O"/BNRG\=V]CHD.I+XPB0BY6\016$IME@=9=^UF
M0;=RE%).2"J]:]FHJ+)JS]/D];&B;3YEO_D>"7'P=U^TT7XBZ;;0K=IJ6E:9
M8Z?*\R@W#00"-R<GY>1_%6?\>O"VK:=%XK\1BUC>P'AJTL8V:4 -.EWO*$=0
M,$<XQ7T74=Q;Q7<+13Q)-$WWDD4,I^H-4VW+FZ_\!K]2(I15NFGX6_R/$_$O
MP]\1?%?[7J%UIX\--%HATZTM[FX24W$S2QREF,18"+]TH&?F.YB5&,&O\0/
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M_5_D>4:?8M C2%XY(W"8:-LC()./6DA0YF4<EK4\?5A52R<VPG;8Q4F%5;'
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MF!8 =3]![5X7X(\->(O#FE_#R230;UI[:QU:R,,EN^V&667,*R@#,:,%^\<
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M&VF5G"KGMGN1CTS6KH'CC2=?\%VOBB.[BATF:V^U-.[C9$H'S;FZ?+@@_2O
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MJBV>NZG;7'C*QOY)=6MDAD,<<,BM.UND,?DJ&V\L,G@G'%$5S-)Z:KY7Y?\
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MKB2-8D)4N< F6,9Q^-<2=)2C8WG&HHMZ&??>=<:OJK)!)(0=HVJ3GGM^5/\
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M.^%XX_$$$R,LEFMH]R6C8'&0,CZYSQ7)1O.I/U-JEH0@_(WO"MG% JV>%DD
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MHZ-T8'J#5.3<G+O?\;_YD)))1?0\]^-D$WBSX,ZPNCV\^HR7EO&]O%!"S22
MLI&$QGISC%>;:KX)U:3X>_&&)-#NVO\ 4-566T46K&6X58H-K)QE@"&P1T(-
M?1L,*6\211($C10JJHP !T I]+9NW7_-/]!W>E^AXIX;67P?XB\6V>O^&M4U
MV;6=1AO+%[;3&N8IHO*C55>4_NXC&RMQ*R>JYS7(V'AW6O#GBG0O$=WH>J/I
MNF^+=6GN5MK*2:=89X'CCE6)%+NA8@$H#C.>F2/IFBA-K7RM^7^0K:6_K9_Y
MGS/X0TS6=*UZQ\6:EX=UD:-;^(-5FEL?[/>2YB$Z*(;H0 %W VLOR*2!)G&
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M><'BO1:**38!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I/[U?[O,IJS:\VON=CZG%Q$P)$B$#J0PJ'4;UK&SGFCMY+V6)-XMH&02/[
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M ,N>,4/2_E_]M_\ (_B$=4GW_P#M?_DOP/KEYXX_OR*O^\P%97_"5Z:?%/\
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M?18S+;V\2D*QNNK=!Q6IXZL_MGQ>U2'(7S($!8]OEK*M$^SV4;AE<BXR0.V
M:\#$Q?UB[VU_]*1Z-+^ K>1Z#X#@EN+V-I@/^/2X4E>G"X%><OXPA^'/B7_A
M'Y8@USK @D7!)V OC''?BO<OAO%_;?@^75C;"$7&F2+D# 5N5_I7AWBWPM<Z
MK\<?"$?]GF8)8VLCW6W.P*,GG\*^PA1C>,I;GS?M79Q07PT"R^*]_);1W<FH
MVGF@VTN#$"R#)/?!]*V_@S%>^.Y5?4].GCEMVD\MS:F**.($;57(_E3[KX>:
MKXO^).H:G8316L'VGS9)YU)\QL *H [ "OJ/PCI7D:9 DP1IE4!V5=H8^PK9
MRYMC-=R?P9X?:)$+J0  !FO6-&L2B*. /:N<T>V ('2NVTZ$+&!CBFE83=R&
MZA X!.:QI+4>;D\FN@NP,D;<$BLN2+G^M5<13G7]V1P,5E36JN>.E;4T7R^_
MK58P9S6;0T8K6 'ICWJ"2P!4Y K>>V![57DMQSZU+07.;O\ 2(-2TR>RF7<K
MJ1GZBO(-:^#TUOY@@U&]=\C:6D)^6O=IK?CC@UCW=O('R>E0T4CY$\0Z%J'A
MSQUX=>!9);BTNA* [X).Y>??I73:]IW@6V\57WB2_OIY8[6U8O8^7L985R6W
M>@SGIZ5Z-<?"Z:X\<'Q!<:G),D3EHK9UR%''&?3(S7S7\2-3FT[Q9X_V,J/'
MHGF)N&0<.1S[4G!3CRM%*3B[H]%GO=1\3ZKI&JF-+BQDOH3;M:L'BC@'W  .
M0,8ZT_X/6\1^-'Q1GDX+&&%?J<'^E>,? GQ-+8>(='LC*\B:C*)$C;=\G[S&
M5]N#@>U>U>$]=FT#Q!XWNDD202^(["T.$!P) P(YZ=*YZ=%TI-ON=,JJFK6\
MB#XD1#_A)4R?^6:+GV*M_C7"+8-=HD$:&222>-451R20P _,UZ%\18R/$X1L
M_P (_0UJ?##0K31M+OO&6KK_ *+IC_Z'&_2>XP=H'J!D5\AB*3JXJ4>FOZ'T
MM"?L\/%K>R,CXM7,GP\\+:#\.(BGVB<KJFK2(V<RL<)&/8!1^0]:B_:8NI[6
M_P#!TMO*T4R12LCH<$'"<BN#\6ZK>>)/%<6IWS^9=W3>;(Q]3*_ ] ,8_"NW
M_:4;??>$5SR+>8_^@UZ*J)T*O)LDK>AAR<M:DI;MML\AT^:<0_:UE=+K^T78
M2JQW!EC0YS]374:#-]EN;YY+AGU"2ZMQ<2DY^]YAV_7@Y/O6!HJ#^R()<X/]
MI7'/TB@_QI]D9(=/UN1@5D6]M&#>^V<C^5>?";C)2\CJJ14ERE;4+96N-9P"
M0;I""1CC$E9^JIMMH@.GV;G_ +ZK9U*Y%S<:E<A01/+$YQVR'_Q-96M ?9UV
M?,!;@9_X$*UO[VGD8RVMZC_VA+,0^#/""@$;G?(_[9K_ (U:N=+^U?$KP]&1
M\D%BLK?\!)(_4"G_ !X26\\.^#(T7?F608R.!LBK>OH!9^.[ZZ.$2ST-F#-P
M,\FOJ+727H> MOO//;[4C<ZEJ,Z2DF2Z\P+CJ3TK]IOV1F9OV;? )?[W]G#.
M?]]J_$>/ L&F"Y(;?NS["OVW_9%.?V;/ )_ZA_\ [.U<&"=ZU1G7BE:$3UB3
MI6-J7W&^AK9DZ5C:E]QOH:]L\PU-(_Y!L'T/\S5RJ>D?\@V#Z'^9JY0 4444
M %%<YXD^(?A[PCK.BZ5J^I)97^LRF"PA>-SYSCMD @?\"(J?5?&^B:)XCTG0
M;V_2#5]5#FSM2C%I0@RQR 0,>Y%&X;&Y6-XI\+VWB[3/[/O)[F*S9@9HK>0(
M)U[H_!RI[@8K8)P,U7T[4(M4LHKJ%9DBD!*BX@>%QSCE' 8=.X% $T4201)'
M&H5$ 55'0 =!3ZIS:Q96^J6VFR7427]RCRPVY;YW1,;F ]!N&3[BK,L@BC=V
M#%5!8[5+'\ .3]!1YA;H/HJ"RO(]0M(;F)95CE4,HFB>)P#ZHX#*?8@&IZ "
MBBB@ HI"<#-9OA[Q)IOBK3OM^E7(N[3S'A\P*R_.C%6&& /!!% &G115&XUR
MQM=16PDN4^W- ]RMLN6D:-2 S!1R1D@?4T 7J*@LKN._M(;F(2K'*@=1-$T3
M@'^\C@,I]B 14] !1110 4444 (1D$=*I:)H]MX?TFUTZS4I;6Z!$#')/J2>
MY)R2?>KU% !115/2=8LM=L5O-/N8[RU9G19HFW*2K%6 /LRD?A0!<HHHH **
M** "BBJ5QK-C::G9Z=-=11W]XLCV]NS?/(J8WD#T&Y<GW'K0!2M_".GVOB^\
M\2H)/[3N[2*RD)?Y/+C9F7 ]<N>:VJ*0D $DX H#K<6BJ>E:O9:Y9)>:?<QW
MEJY95FB;<I*DJ<'V((_"KE !116=XB\0Z?X3T*_UG5KD6>F6$+7%S<%681QJ
M,LV%!)P/04!OHC1HJI<ZI;VNEOJ#>;+;+%YW^CP/*[+C/RH@+,<=@"?:K*.)
M$5AD!AD;@0?R/2@5[ZCJ*S-/\2:;JFKZGI=K="6_TTQB[A"L#$77<G)&#D<\
M$UIT#"BBB@ HHHH Q+GPCI]UXPLO$KB3^T[.SEL8B'^3RY&1FR.YRB\UMUF:
MOXDTW0KO3+:^NA;SZE<?9;1"K'S9=I;;P#CA2<G XK3HZ6_KO^H=?Z]/T"BF
MR.(T9SDA1D[02?R')K&TGQEI.M:O-I5K<2?VE!;17DMK-;R0R)%(65&8.HQD
MHW'7CD4 ;=%8FO\ C/2?"\%W/JL\MG;6B1R2W#VTIB =]B@.%*L=W5021D$@
M BI9/%6EP2PQ3W!M9)[O[#"MU$\)GFVEML>\#?PK'*Y& >>#0!K4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KWBZ:?2[G35U#35ABGNHRJAB_W.1R17WKJ%@ V-N<U\Z_M$^$_&/B2&73M
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MP7UZ77;V]US5=4:6YAGOWE1Y!;R^9MB+%8_+8[?D"]<')JUI'C745^&WPO\
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MS D2I"=HP1PVU<@].,UV6B^//$$WB6V\%7&H-)KUIK,QN[HPH#+IP!EB;&W
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M^?X<W_R+!*[MUT_'E_\ DD?4E4[_ %FPTIH5O;ZVLVFW>6+B94+[5+-MR><
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MRL&)"X4G)R5('J0?2M*O+?A1I9^('@3P?XJ\0W4NHZV]C"\DHVI&[JS-N"*
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M9.W#?+GC%1R?![PK+IJ6;6=V=ES]L6\_M.Z^V";;LW_:O-\[.WY?O]..E'_
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M=;_BV_U7J>1^&_B!XQ_X1SPKXHO?$DE\FH^(9=(FTMK.W2 P?:I8E;<J"3S
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MZ 7D_P#\731^S]X"!S_87/\ U^3_ /Q=>B44[L+(\_7X"^!4.1H0SZ_:IO\
MXNIU^"?@Q  NC8QZ7,W_ ,77<T47861Q)^#'@XG/]D'_ ,"IO_BZ8WP3\&-U
MT;_R:F_^+KN:*+A9'"_\*1\% Y_L;G_KZF_^+KK])TJUT/3H+"RB\FU@79''
MN+;1]22:MT4@L,<55GBW U<(S3&3.:!F?#</9DKM+H3TSTI7UH+_ ,L'_,58
M>W!YP/RJNUH#V'Y4 ,_M\?\ /N_YBD_X2 ?\^[_F*4V(]!^5)]B'H/RH /\
MA(!_S[O^8H_X2 ?\^[_F*/L0]!^5'V(>@_*@ _X2 ?\ /N_YBC_A(!_S[O\
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M'Y4?8AZ#\J #_A(!_P ^[_F*/^$@'_/N_P"8H^Q#T'Y4HL0>P_*@!RZX&/\
MJ'_,5(=2:1<)&5)[D]*C6S /0?E4Z6^,<#\J ([>'!YS15Q$ [44 2T44F:
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M\T9H ;L]J4+BES1F@ QBBEHH C+XIAE'K5.:Z"CK^E4I-0"D\_I0!KF8#O\
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MU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H$X/\
M^NL#^TU]?TI1J8]?TH W_-'K^M.60&L%-1!/7]*M07@8CG]* -A6XI<U5CF#
M#K4F\#O0!(6P:8T@]:K33A>]4IKX*>OZ4 :GFCU_6D\\?Y-8;:D!W_2F_P!I
MKZ_I0!O>>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::
M^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFO
MK^E &_YX_P FCSQ_DU@?VFOK^E']IKZ_I0!O^>/\FCSQ_DU@?VFOK^E']IKZ
M_I0!O^>/\FCSQ_DU@?VFOK^E']IKZ_I0!O\ GC_)H\\?Y-8']IKZ_I1_::^O
MZ4 ;_GC_ "://'^36!_::^OZ4?VFOK^E &_YX_R://'^36!_::^OZ4?VFOK^
ME &_YX_R://'^36!_::^OZ4?VFOK^E &_P">/\FCSQ_DU@?VFOK^E']IKZ_I
M0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4
M ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFOK^E
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M_IK,HH T_P#A)=6_Z"-S_P!_31_PDNK?]!&Y_P"_IK,HH T_^$EU;_H(W/\
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M^$EU;_H(W/\ W]-'_"2ZM_T$;G_OZ:S** -/_A)=6_Z"-S_W]-'_  DNK?\
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ME&);F3.U6=4' )/+$ < ]35VZ\(ZG::=+?&.">TB($DMK=13B// W;&./QH
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M75O^@C<_]_36910!I_\ "2ZM_P!!&Y_[^FC_ (275O\ H(W/_?TUF44 :?\
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M&<Y)&<UQP\0:B$T]/MDNVP)-J,_ZK)R<?C4EEXIU73DD6WO7C620RL, _/\
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M"R+:69CBMF\Y5*JY )X)&,>]27-VM]XXU+17M;4:;]BE_<K"HPRP%PP.,@Y
MK@KGQIK5W;36\NH2-#,,21@* _(.3@<G('/6J8U[4!J,E^+I_MDBLC3=R"NT
MC\N*72W];%'2?#+,MWKEK"P6^N=*GBM?5GP"5'N5#"L+0=%U+5-0DAL0T,T<
M;O)(S&,1H%.[<W88X_'%9L$\EM,DL3M'*A#*Z'!4^H-:E]XOUC4K:2WN+^1X
M9,&10 N__>( S^--]_+_ #_S$NQW1DTW0/\ A'K6/[3)%/;QRR6\.F1W NF;
M[R[VD!)[8 XJ[IZ01V"+;12P6XMM6$<4XPZ+L.%8>HZ5YO8^+-7TVU6VMKZ2
M*%,[ ,$IGKM)&5_"H8?$.HV\*Q1W<BQJLB!<_P +C#C\11+6_G?\0CI;Y?@;
M?PU=8]<O&>,2HNG71*$D!AY3<9'-99U>#[1;R6&E0VMS'(KJRN\FXCL58D&J
M6F:K=Z-=?:+.8P3;2FX '((P1@]B*O\ _"8ZMOC<7*J\;!U98(U(8=#D+3ZI
MBZ-'H>N:7#IUSI'V;3[>/[=J$+:FJX?[-,2I\CI\HY)Q^':J4TSZIXI\3Z3>
M64$&G6\=R8XU@">04SL8$#//'US7$Z)XFNM-U-)I;B9[>2YCGN4'S&3:X;//
M?K5GQ'XVU'6KS4 MY-]AN)G98W #%"Q*JQ')P.V34O;[_P!/Z12_R_4[EGM[
MWQ7H&BRV\":?_9MO.\<<"[II/)##)X))('&1G\:RDU&PU6WG22TU#6I8[F-H
MU72XX!&=W,99)&X8<8Q7"3ZO>W-U!<R7,C7$"(D<F<,BJ,* ?8"K5]XJU;4D
M5;B^D=5?S %PN7_O' &3[FJOK?\ K<GI;^MCN+]4UN.YGLU34;>VNXWDTV:R
M\BZ@4OCRU*Y#>F,Y]J==I'KC32VDL,]M;WD+26=W9"">U4R;=H(RK#H",_A7
M"WOBO5M0C"3WTCJ&#G&%)8="2 ,GW-+=^+=7OE59KZ1P'$G  RPZ$X')'O26
MEOZ[#>IV_C!QX9L?M6E00K-=ZG=)<2^2K[-C@)&,C &#G'?-6-46'0=/\17E
MM96\-VUO82E&C5OL\D@;?M!Z?_7K@+;Q7JUI+<217L@:XD\V7< P9_[V",9]
MZJRZU?3I>))=22+=LKS[CGS"IR"?IDTNEA]?Z[F[XY"30:!>^7''<7>GB28Q
MJ%#L)'7.!QG %<K5BZO[B]CMXYY6D2WC\J(-_ N2<#\2?SJO3[B[!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'T[\*N/!6D_]<Z[9SF/\*XGX5?\ (DZ3
M_P!<Z[5_]7^% 'F'QM.?!T__ %VC_G7SY7T%\;/^1.G_ .NT?\Z^?: .J^&&
MT>-;'>"4V39"G!QY+UJ^&FTR^T+Q+9Z3#=6M_)9-*SW<JRH\*,&=1M5=K' Y
M(/3WKCM%UBXT#4HKZUV>?'N \Q=RX*E3D?0FK[^,+P6-S:VT-I8QW*[)3:PA
M&=?[I/7''2AZKY M[G:^'_#MK>7=GIU]INFV,,UHS>5+-OO7;RRPD&T?+R,X
M..*PKXV7A>WT2$:5;:C]JMUN)WF!+2;B?E4_PX]N]4K3XBZO931SQ"U^U)&(
M?M+0*9&0#&TGZ<55L?&FH6%O;1!;>?[,2;=YX0[0Y_ND]*?7^O,.AUMA!'JO
MAK3M(-K'907.M_9CYJ RQ*=O\6!\PSC.*BUFT\/+_;5H]SI47V=)!:)9P7/V
MA9%/ =FB"G.,$DXYKD5\5:@+&:U=UE66?[3YDBYD63^\K=0:GO\ QMJ6H0W*
M/Y$<ETNVXGBA"R3#T9AUSW]:E_U]R!:?UYL[22TTF;X@Z?H2:-:1V@C1I&"D
MO(Q@W')STR>GM57PCHEO.V@V]YINFVUO>, [WLNZXN0S8W1JHW*.PXZ\YQ7'
MKXMU%=?360Z?;D 4-L&W 38./I5K3O'NJ:9]B:(6S3V:A(+B2 -)&N<X!/:J
M5KZBUL5;#3!)XL2QCM)-0471C%LC[&E 8\;NW3K787&BV=YHUU/-;Z4EQ!>0
M*L>FON**S8*.P^5OKDUPMMK=W9ZR-4@D$5X)3,&4<!B23QZ<]*TI/'.H-8R6
M<<=I;6TDBRM'! %!=3D&E'1*XY:MV.HU*UTN]\0>*-)BTFUM;:QCF:"2($2*
MR'KNSR#Z5;TX6/AGXA:-HL.EV\\<?D%[I@3+)(Z*^\-V +<#I@5P/_"3WW]I
M:C?[T^T7XD$YV#!#G+8':K]A\0=6TYK22,V\ES:J$AN985:5%'1=Q[=J%HE?
M^MPEK>W];&3<W4MEK<UQ YCFBG9T8=00W%>AZI/::C#HJVL1LI_%#K)?2@C"
MA7V,J^@9@6/U%>832M/*\C\L[%C]35VYUR[NK?3H7D 73U*6Y48*@L7Z]^2:
M(Z))_P!?UH.6K;1W&JV7AY)M6LI;K2HXXD=;9+2WN?M"2+TW,8@#GODXJQIW
MA^UN9VL+S3M-T]/L3.+=IO,O=PCW!R5'!/7!Q@5Q]WXXU.[CN ?(CFN%"S7$
M4(660>[#U[^M3Q?$35H99)E6U%S)'Y4EQY"^9(NW;@GZ4NE@ZF[8:=IVI:;9
MP:9;Z;>3FUQ/9W):*\,V"2R,1M(X& #[8K/\:WS2^%_"T)MX(C]F<EDC 88D
M88SZ>OO67%XXU.&*%08&G@B\F*Z:(&9$Z8#51N]?N;[2K73YQ%)%;9\J0I^\
M4$DD;O3)IO7^O42T_KT.@U NGPMT@6W$#W\WVLKWD 7RPW_ <XJ#P=HU[XAF
MTZQN'E309+Y4=B?D$A4G ]RH/2LC1_$E[HD4\,#));3X\VWG0/&Y'0E3W]ZF
MO?%NI7C6>)$M8[1M\$5L@C1&_O #O[TUO<72WJ=5>0^'YK?44:ZTI+B%E:S7
M3K>Y$@8.!L<O$ 01GDGKBK'Q)_Y!6H_]AI__ $2M<E>^-=1O8)XL6\ N&#SM
M!"$:8@Y&XCKSSBJ^K>*;_6H98KIT9);@W+;4 ^<J%S^0J>EOZW7^177^NQNV
M#V"?#<&_AN)D_M([1;RK&0?+'4E6JKX3M]-U;Q&--33YI+6^3R TKB26W;_G
MJ" HPO4^P-9NG^)KG3],.G^1:W-J9?.V7$0?#8QD?A3E\574(NA;06MD;B$P
M.UO"%.PGD ]L]#[575O^MB5M;^MSM!I&EZ9K.L6<FD1W,.E:8TB-+D&Y<%2)
M20?NG/&.U+X+TK2_%7]FWMYIMO$8[TV\L4*[$F0QLPX]01UK%\,>/);&WO!=
MSQB6+37M;1GBW%R64A&X.1C/7BLM/'6IP7%G+;_9[5;1F>*&&$+&&8$$D=S@
MTG_7WL:_K[D=%I46FZKHFHZU+!I.F/%,EM#'/%*T* @G)5%8EN,9(Q0L/A?^
MT(9?M%DTTMFP9EMY_L<<^["L0R!MI'H" :X_2/$%WHT=Q%#Y<MO< "6"= Z/
MCH2#W'K5P>-]4%V9M\7EF'[/]F\H>3Y?7;LZ8SS1_7X =0-,TZVNTFU"VTRU
M^T6A%K>Q%I;&60-@LRJ"5],$=>U-E\/0NNH3SZ?91JVF&:">SEWP2,'"F1/[
MI'0CL17.#QUJBL%7R%M1$8/L8A'D["<D;?KSFHI_&6I3I)'NBCA:W^RB&.,*
MB1YW$*.W/.:/Z_,/Z_(ZV73M+MO',7A7^RH9+,[(&N<$SLS(#YF[ZG..F*BF
MATW1K3PI;C2K2YDOMXN9IE)9P)V08YX..X]JYQ?'>JJB'=";E(O)6\,0,X3&
M,;_IQGK6?+X@O)ETQ7=2-.&+?Y>GSE^?7DFFNEQ= \26,6F^(-2M(01#!<21
MH"<G 8@5FU8U"^EU.^N+N<@S3NTCD# ))R>*KU*NDKE/<****8@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?\ ",ZQ_P! J]_\!W_PK[;HH ^)/^$9UC_H%7O_ (#O_A1_PC.L?] J]_\
M =_\*^VZ* /B3_A&=8_Z!5[_ . [_P"%'_",ZQ_T"KW_ ,!W_P *^VZ* /B3
M_A&=8_Z!5[_X#O\ X4?\(SK'_0*O?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#
MO_A1_P (SK'_ $"KW_P'?_"OMNB@#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW
M_P !W_PK[;HH ^)/^$9UC_H%7O\ X#O_ (4?\(SK'_0*O?\ P'?_  K[;HH
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M?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?] J]_P#
M=_\ "OMNB@#S+X8V\MKX/TR*:-XI53#(ZD$?4&NQ?_5_A45S_P A&;_?_I4K
M_P"K_"@#S7XQ6<]]X4FBMH)+B4S1G9$A9L9]!7A7_",ZQ_T"KW_P'?\ PKZX
MTC_D+?\  3_*NCH ^)/^$9UC_H%7O_@._P#A1_PC.L?] J]_\!W_ ,*^VZ*
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M&=8_Z!5[_P" [_X4?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\
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M#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK[;HH ^)/^$9UC_H%7O\
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MQN+&&YB)E WJP<?,,C(/&.>M:DGP?T[_ (5]H?A*&[GALM)EMY8I< NWE.&
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M_"HKG_D(S?[_ /2I7_U?X4 0:1_R%O\ @)_E71USFD?\A;_@)_E71T %%%%
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MSB<@0V+3!8\\D[B<;STXZ<=*5D.\F;/A[Q'%KB2/')!*@<J/L\PF"X./F9>
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M!P5%7*SDK>?Y?YF:NEKY?FOT,*Q_:A@U%=:O(/#5P-(T2S2ZU&YDNE$L;MN
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MMJ7A;5#9SKI2SP7%C(!M&JWKNK#'9'5F'8,">#5)7<5WM\KJ_P" GHI/M?\
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MP5D#R%AN(*JP)."<US?P\^%=YKS2#Q)X5O;E+'PC=PV::CI\BI%<"]E,2HK
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M0,9'<4F[*_S&E=V^1Z_17A'@W]I0WOPHN_$FJZ6\U]I=OI[7BV[!%FDN0G*
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M[QSY385?3DC(KI/!G[0-CX_\4/IFB:;]JM8Y4CDE:]B2Y0-&L@E-LQ#F(A@
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MYT:]>T;3)KMKS4UA1UC#6Y52T989#-Q@=*CT#]G71M%?7O-U"YO8];TM=.O
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MTZ:_NB+:8-!Y:H=J!HQYF2Y&0>WO6MHWAOP]X=T^^\-W?BV?4KS6X2@&HWL
MN&B*; (8T1$  SR$R3RQ8U'XB^&/ACQ=HFB6D^K3I;6UI)IUE-;7,69 X3)!
M*D.P\H'&,=<@BD]]/+];_C8%LK_TM/\ @E#_ (:4\'FVCF0:C+EKA98XK0NU
MOY'E>:9-I(  FC/4]:LW?[0OA.Q6!9C?K<374EJ+4VI\X,B)(Q*YZ;)8V&,D
MAAQUK!T#X.>!8[K688?%MSJEZT=S'?!KVUWPB<0+(2D<:B/_ (]4P, #+<=
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M+^[15VO&(V/*DE9(R!R5(SBO=*IJUB$[A1112*"BBB@ HHHH **** "BBB@
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M3*0P'9.U>H3?!3PI/:K'):W;W"W*W@U ZA<?;1*JE0WVC?YGW25^]T.*JI\
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MRI[T?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\
M/=:ROLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']
MKV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z -7^U[/\
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M_P#GNM']KV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z
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DU&V;I*IK)6U0>M31VZ#UH GN)5NI%V\JN>314L,0'%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20220930x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220930x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '%!#@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#],/$GCW2_
M"NN:%I-]YWVO69F@M?+3<NY1D[CGBF:K\0M)T;QMHWA:X\_^U-5CDDM]D>8\
M(,MN;/''M7FWQYN8]/\ B1\*KNX816Z:E*K2,< $H ,FF>,S'??M2?#](I [
MVUC>22*G)4&/C/IFNVG1C)0;ZJ?_ )*FU^2.&M7E!S2Z<EO^WFD>Y5AOXMM$
M\71^'3;W9O'MS<B<0GR H.,%^F[VKY,?0M1U+P!\0O%C>)M9AO=%UJX-E!%=
M$1)AQU'?KTSBO2M,\2:K+\7M%G^T33R/X0-T;?>=DDNT'.W.,DTWAU&/,W?1
M_P#I/,0L4Y/E4;:I+_P-19]"T5\2W%I=WWP63X@7'C+5%\0:C?B.>W6[VPG]
MZ1Y83L0!VKU_P1KLL7QO\217>H.+:/PU;SB.68[%/&Y\$X'N:*F%Y%)\VL;W
M]4D_U%3QJFXKETE:WHVU^FQ[W17Q0WC;Q)_PHGP=8Z==7%S-K&KW4$LIO?)>
M11(VU/.;[N<]:]8_9I'BO2==\1Z)KFR*PMD1XK.768=0N+5R>5<H=PW Y^8#
MI53P;A&3<EI?YVW".-4IQBHO7\+WM^1ZCX_^*7A_X;6\+ZQ<2&>?/DVEK&99
MY<==J#K5#X??&SPS\2+^?3]-DNK74X5\QK'4+<P3;/[P4]N:X?5)[2R_:HMV
MUHH!/I(72C/@)OS\P7/&XG\:K6WQ-U.S^-\>D:OX%T[3=3O+:Y^SZI#?I--)
M#$C.N54?+NP."0>:B-*+IWM=M-[I;7^_;4J=>2J/6R4DMF][?=O9=#WZBOA/
MPUK?Q"UN:T\:0S&*2;4C$;^[\100V[#?@P_9G(P<<#G)KT_4/"EW\0_BS\1+
M.]U[5M-L[+3H)UM;"Z*+YNTD'/H"#P,9JYX3V?Q26B;?E:W^9%/&^U^"#W27
M2][K]/,^G:R/%?BK3?!6@7>LZO<?9K"V ,DF,]2 !CU)(%?(.J^./%_B3X>_
M#G0[:>YOY=3,R3!+Y;.2YV,55/.;H<#\:C\0Z5XCOO@+XVLO$4[>7HE];2V<
M,&L17TD1+['BF:,DD#.0& Y^E6L%9VE);V_\F42%CU.W+!ZJ_P [-I'US<^-
M;*VUW2M*,%Y)-J41EAFC@+1*!_?;^$UT%?.HT]O!7Q#^&NE:=?WUQ9?V=/*5
MN;EI#(2,_,>_M7/^!]'/C[3=:\=:Y\0;SPWJMCK,ENLKW*K:6T:, J/&Q"G=
MG')K/ZO%ZIZ=_P#MZRT+6*DK)QO)VT_[=YGJ?2?BSQ/9>#/#M]K6H^9]BLHS
M++Y2[FVCT'>O,]+_ &I?"VL7%I%;:/XE87+JD<ITIO+^8X!W9QCGK6U\>W$G
MP/\ $[+*LX-@Q$J]'X'(^M<9\(M.^+O_  C?A63^U_"W_"._9X"8?(F^T^1@
M<9QC=C\,TJ-.#A*4^CMO;IZ,O$5:D9QC3ZIO:_;S7<][5MZAAT(SS2U\P:QX
M4N?'GQ:^)-M<^(-6L++3[6.:*WL;DQKO"Y!/M[#%8%KXDUGQSX6^#WAS5-?N
M["PUM[M;Z]@E\N6;R6(C3?V)X%$<+SI-2WM]S3?Y)BEC.1RO'177JTTOU/K'
M6M5BT/2KK4)XY98;:,R,D";W('95[FFZ%K$/B'1[/4K>.:&&ZC$J)<)LD4'L
MR]C[5\O:6;KP_P")_B[I<'B&^U6WL-(402SW!9XB.V1QN'3(I/LFH>,->^#6
MD/KFI6-O?Z+<-=26MP5DE 4'DG//N>:I85/:6]G?RY92_0F6,<=7'9M6\^:,
M=_\ MX^L:*^09/%WB#X?_#7XEZ9IVJW=Y_96KI8VES=2[I8HWX)WG^=+\,[S
MQWX#\17C31B"RFT6>_:QN_$,%_-(P3<DZ(&#A21C@$<]:7U3W92YE9*Z\].;
M\GYC^N6E&#@[MV?6VO+^?H?7M,GE$$,DK E44L0HR3@=J^(OA]J7Q!FU7P[X
MJC<H-1O LEU>^([<17:[OFC6W8@JWL.:])\#>%KCQ;\2_B1J=]K>J)!HNH9M
M+.&Z98MQB.=P[CIQ14PGLD^:2T3;^32_45+&^U:48/5I+INI._\ Y*>_>$_%
M-KXQT9-2M(+JWA=V01WD)BDRIP?E/:MFOCQM0U;4_@IX)2/6+VUNKKQ"T#7:
M3-Y@4OCJ3S]#6\9M4^$?CSXA:/I.L:CJ%I%X=_M.(:A,9GCG+%2P)_$XIU,*
MDY6>U[+TL_U%3QC<8.4=U&[_ ,3:6GR/J6N=\=>.++X?:)_:E_:WUW!YJQ>7
MI]N9Y,D$YVCMQUKY6U31Y=!\%> ?$%MXSU.]OM;U&"2Z@DNR8Y6)YVJ.0!W'
M2OLNLJM!4;-N^K7;:U_S-Z&(=>Z2MHFNN][?D>/^&_VHO"?BK6(--L-.\0-/
M+,MN6?36"1N3CYSGY?QKV"OGCX8:Q<^']$^,&I6<?FW5KJ,TL2>K!"17$QV]
MUX8\ >$OB39>,M1O_$FJWD*W%M+<[X+CS&P\2Q]BO3CTK=X>$Y)0T^'SUDKK
M_ASFCB:D(MS][XO+2#L_5[:'U[7.>*/'FF>$-2T2QO\ SO/U><VUMY2;AO R
M=QSP,5X']@F^+OC'QS/KOB;4- /A\A;*TL[GR5B&W/F./XAFL^V\6:EXR\-_
M!/5=7?S;UM4N(VN&&/-";E#_ (A0:B&&UCS/M?YIM:_(TGB])<J[V?G'?0^K
MZ*^*_$$FNZ)KVI^*]0UG5+NS@U$>7K^@:E%=VD2;L>6]ON&".G)S[5]FV%W'
M?V-O<Q/YD4T:R(^,;@1D''XUC5H>SA&=[W_#9F]+$>TG*%K6_'6Q/1117,=8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH X[Q]\1X?!5QI>GP6$VL:YJKLEEIUNP4OM
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M-?U>\U.]UG2/!%GJ=A;)<RQQM=!K@QRF-& 8L(TX(P=W3I6:?N\[[7^5F_\
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MWC30;RS77]<TBZTZQM?L\<6FZ?Y4MR1@"29V)(8 =$P"2<CI7H]%).W]>O\
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M)Z\R]?Q3_-(\R\+?#WQ]I5G#8W?BC28K6TM6M[>6QTM?.E;;A'E,FX9''"@
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M\JIC,14^*;+M[K6H:E.9KJ]N+B4]7DD+$TW3YY&U"US(Q_>KU8^HJI5C3O\
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M=3I]RB7JH#DVSM&%G'O$7X.>E<)H'[7VFWTG@DW^CWMK;^(8+R1V2SNGFC>
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M78Z1P$[8S&/FRH!^4YKZ)\0^!=#\5ZCIE_JE@+F\TUV>UF$CQM&6^\,J1D'
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M#%)\F]CRQ .,GDXKJM!^#G@[PSJ-E?Z;HR6UU9/*]L_GRL(3("'VJS$ ')X
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M#'::->&_L(A+)B"?.=X^;)//0Y%8/B#]EGX5^*K&.SU7P?:WEM'=3WRQO/,
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MH *L:=_R$+7_ *ZK_,57JQIW_(0M?^NJ_P Q2>PUN?K7X?\ ^0#IO_7M%_Z
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MP6LT,.N^%929H=Q4^5)#D!T8J#\V1E>G->VT5<I.>KWNW\VK"24=MK6_%O\
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M.T8&3FNBNM N?"_C;QCX>U_X*ZI\0=;U_6HK_2M<6,16HB^0KYEX/GM]A7.
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M_$S1];\8^*/B5K%AX<U@6NJ^";9+9&T^56:3J8@I7.\=UZCTK&?X*ZCHNM_
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ML[3PCJ^E>$(+(I_:'B?PW;Z5J E# +&'A;$R8!.<#IUKZ[JI)))KJ3%MMI]
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MY+^U/_R)VG?]?7]*]:\/_P#(!TW_ *]HO_0!7DO[4_\ R)VG?]?7]*^)PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>E,KZ ^8"BBB@04444 %%%% !1110 445-9V<^H7,=M:PR7%Q(P5(HE+,Q]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF$_4_=_7% 'T/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFR!%5Y(@SD#&X^IKB/H"CH_PZB%Q]MUF7^T+HG<(C_JT_#O79(BQJ%50JC@
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M?H1D5/7(?"C4O[1\#Z>2?GA!A/\ P$D#],5U] !1145S.MK;RS,"5C4L0.N
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M:W.F6F?M%P24$7^\& (_+FE*E.-[K1?\,.-:G*R35WTZ]SJJ*Y+P=\6?"/Q
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M7]$>_45Q4/QG\%W'B0:!'KT#:P;@VOV01R;_ #?[OW<?CT]ZC;XW^!5\4?\
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M/Q;\87/CR!'TV_T-(=%DN8]Z,P4^9''Z.6YQUKQ[X;> I/'UE'I]C%)!=+X
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MN&9YWTJU:1G^\6,2Y)]\UTE%).R:]/PO^=Q-7:?:_P"/+^5OQ"BBBI&%%%%
M!1110 4444 %?G_^TI<?:/C-XA;!&UT3GV11_2OT K\^?VBO^2Q^)/\ KN/_
M $$5V87XV>#G'\"/K^C/-Z***]0^0"BBB@ HHHH **** "OTH^&?_)/?#O\
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MD8/H17FFB_'/XHG4O"J26MO=S:AXMU336LH[Q"MS%%%(5B9S;@Q+&54[E!+
M$D=B).]OZW2_4/L\W];-_DCZ_HKA_A9\2V^(MIJZ76E_V/JVD7KV%[9K<?:$
M21>ZR;5W ^NT?2OG.]_:S\7_  _^(GQ8COO#>H^,_#?A[4;1/,MF@MH]*MGB
M!=BVW=(Q8Y"G/U%+[7+Y7^6G^:#IIWM\]?\ (^Q**^?S^T?I^E^-_&4]Y+J3
M:'I&@6^KK$9(#"0X!PBB(2!CG'S2,/0"L*Q_:[US5;_2-&U#X<ZEX1O=>TR]
MO[&\O+V.51'%#OCD4!/F+9Y5L;>.N:4O=5_*_P"?XZ,:UM\OQM_FCZ=HKY'^
M!/[77B#4K7P-IGC+PSJ4T?B&=K*+Q7*\$<4]QDX40H!\O^UQ]*[S]JOXK>)O
MA7+\/IO#GVB<ZCK8M;K3[6*)I+R/RR1$#(#MR<<@C'K527+:_5I?.Z7KU(3O
M?R5_S_R/?**\%\)_M/:EXFT;Q5"_P[U2R\:>'RIF\,O?0%W5ONN)SM0+ZGM[
MUP.O_MH^(-0^%'C[4-)\$'2/&7A>6&&[L)M1ANX[:.4';/O0 /C&"HZ$CW%2
M]+^E_D_^'^74N*YFEW=OG_7W]#ZXHKYE3]K+Q-!INAZ=:_"_4_$/BY]-34M5
MTZUOX4%G"0,2;]I#ENH4"L;QK^T[XNTKXT^'X_#OA_5M?T34O"']K#PMY45K
M.L_G,"\KR+N3:JD$ D9Q@'.:IJSL_/\ !-_H]11]Y779/[VE^J^1]9T5YE\/
M_C]X:\;_  ZTSQ5=7=IX=%\'1;+5+V.)A*O#1AF(#$'TKQCX:?M>^))+'XEZ
MSXX\*266E:%JIL;$6<\<C-*=JI: #EGY#%\X._@<4GI)Q?17_)?K_6@+WHJ2
MVO;\_P#(^M**\1^&O[2S>)O$%QH7C7PE=?#?5EM&U"!-4O8I89K8=7\T;0I
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MOAGPWX"OVTB+PIH6IQWPUB&=VNKN**4RPQ& H%C.[;N?>V0O"C/!]E7WTO\
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M+J%XX8E7J0ID(WGV7)KQ_P 6_M'^*9M4UFZ\,Z'+=:&/"4>M6<KRPH8V<O\
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MOB-\.=?TK5-*@T/4A#H#:5/;7%[)$/--U-*KAA&>%$@XQSDCC&:TE\5UY_\
MM]O_ &TQBO=:?:/YPO\ ^W'HG@_X\Z)XVURQTW3[6YW76G2:AYD@ $>QMK1L
M.H8&N(MOVCK[6_&WA::TTB:T\)7EAJ=S>2SRQ!E-M,(V?[V<+M)QWWC'0U'X
M?^!?BSX=:IHNKZ&VF:U?BPN+/4(KR=[9 \K[S)&0KY /&TCD=Q6;HO[.GBFS
MT#PQI]^^FW30V6L:=J1BN'C"I>3^8LL7R'<0 ,H<=>O'(]-5Y_?[UOE\.O\
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MME>>)#.J&:1=21Y+H2R0_9BGS ,6(E#;=H'!ZU,=7&/73_VS_.7];G1OI?\
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M#CS+FY<(B9(49)X&20/QKXWO+_7+7P/X\\=#Q3X@;6=(\2O%8Q'59_LL40E
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M_P#H+UT=I_J$^@KG/B""=/T['/\ IT?_ *"U=':_ZA/H* .;^*/_ "(6K_\
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M))&VU?NJY1AO4>C9%;T/PE\)VWBNV\1P:/';ZM;:=_9,,L,CHD=KG(B6,,$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\[>
M(?V2[7Q'\2;_ %:2]6TT&Y?SS;0C]X7/+ =@,YKZ)HJXSE#X3GK4*==)5%>Q
M@^$? VB>!M.2RT:PBM(@,%E'SO[L>IK>K#\7^-]!\ Z/-JGB'5;;2K&)2S2W
M#XSCT'4GV%?"WQX_X*,7=^+G2/AM;&Q@.4.M72@RGWC3HOU.?PJ6[ZLVC%15
MHJR/L#XN_'WP7\$]+-UXEU:.&X9<PV$1WW$W^Z@YQ[]!W-?GO\=_V[O&'Q0-
MQIOA\OX7T!B5V0M_I$J_[;#IGT'YU\X:YKVH^)M5N-2U:^GU&_N&W2W-S(9'
M<^Y/-4*10^65YY&DD=I)&.6=SDD^I-,HHH **** "BBB@ KNOA;\;/%_P=U9
M+WPUJTMJN<R6KDM!*/1DZ5PM% 'Z>? C]OWPG\0OLVE>+MGA777P@FE;_1)F
M]G_A)]&QUP,U]60S1W$2R1.LD;#*NIR"/8U^"]>W_ S]KGQS\$)(;2UO3K'A
MY2 =)OF+QJO_ $S/5/PX]J /UZ>-9%(89!KG-8\'07<AN(&:WN!R)(S@@UYS
M\$?VM? OQL@B@M+T:1KI4;]+OG"OGOL;HX_(^U>UT <E8Z_J&D.MOJD37,?0
M7,:_-_P(?X5/+=ZAK_R0;[&U)Y;^-A_2NC>)'^\H/X4JHJ#  % &9IGA^VTT
M$J-SGJS<DUJ 8Z52UG7+#P]827NI7<5E:H,M)*V!^'K7SC\3/VLR/-L/"$.#
MRIU&=<_BB]/Q.?I0![OXU^(>@_#^P^U:S?QVVX'RX0<R2'_94<FOEKXF?M0:
MWXK,MGH8;1M-.5W@_OI![GM^%>.ZQK5]X@U"6^U*[FO;N4Y>:=RS'\3V]JIT
M .EE>>1I)':21CEF8Y)/N:;110 4444 %%%% !6[X3\;ZUX)OUN]'OY;20'E
M5.48>A'0UA44 ?7?PS_:JTK7O*L?$R+I-\<*+H?ZAS[_ -W\>/>O>+>YBNX$
MF@D2:)QN5T.0P]0:_,RN[^'7QF\2?#:95L+LSZ?G+V-P2T1^@_A/N,4 ??<D
M:RH4=0Z$8*L,@UYWXO\ @W8:SON-,86%T>=F/W;'^E5/AM^T'X;^("QV[RC2
M=4/!M;AAAC_LMT->H Y&1R* /(?A=\.+[1_$=Q=ZK;>5]E&V'/(=C_$#WP/Y
MUZ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'P!_P %(_A7K:7>F^.+:ZNKO0B%
MM;JV+EH[63^!PO0!LXSZX'>OA.OW7\3^&M.\8^'M0T35[9+S3;Z%H)X7'#*P
MP?Q]Z_'O]HKX$:G\!?'USH]R'GTN4F33[UEP)HL\9[;AT(H \LHHHH ****
M"BBB@ HHHH **** "BBB@"2VN9K.=)[>5X)D.Y)(V*LI]01TK[#_ &7/VV_&
M.G>)M%\(^)/^*BTZ]G2UBN96Q<09.!S_ !#V-?'%=U\"_P#DL7@__L)0_P#H
M5 '[8UY[\:OB=)\+?"\=_!:"[N9Y/)C#-A5..IKT*O!/VP?^1&TS_K\_]EH
M^9O&GQ#U[Q]?M=:Q?//S\D*G$:>P6N;HHH **** "BBB@ HHHH **** "BBB
M@ HHHH 5':-PR,58'(93@BOMG]FF/Q+)X&%WK]Y+/!.P-E'.,NL8[Y]#VKYV
M^ WPCE^)/B-9[J,KH=DP:X<CB0]HQ_7V^M?<5M;QVEO'!"@CBC4(B*,  =!0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM=?E:WYWT-6[\7Z%8:U!H]SK-A;ZM/CRK&6Y19Y,]-J$Y/X"M>O@_P <>.=
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M!+F/EH+A1B:W?'#HW4']#T/%?F#^T+^R3XK^!=]+=")]8\-,Q\G4H$SL'82
M?=/OTH \*HHHH **** "BBB@ HHHH *[KX%_\EB\'_\ 82A_]"KA:[KX%_\
M)8O!_P#V$H?_ $*@#]L:\$_;!_Y$;3/^OS_V6O>Z\$_;!_Y$;3/^OS_V6@#Y
M"HHHH **** "BBB@ HHHH ***.M !78?#7X7ZQ\3=96TTZ(I;(1]HNW'[N)?
M<]S[=:[+X1?LZZMX\EBO]5632]$R#N88DG'HH[#WK[!\->&--\(Z3#INE6J6
MEK$,!4')/J3W/O0!D_#OX;Z1\-M$2PTR+,C &>Y8?/,V.I]O;M75T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(\6\2?LUQ:WXGUC5+7Q3J&E6NL1>7?6<$*-YIQC(<\@>P_.M71/@7'H^H>
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M-K;:-'KFG/JZ\M8+=1F<?5,[OTKYE^'?BC4K+X@-X>\(>,+[QSX=FT^5GGO
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M0?!=/%]_H?VC69[-KRWTFQA>)I<J"B .S')/\6<$<XHULWV_X/\ DPZI=_\
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MGM4>F?M#Z%K.B6.IV6B^([B/4,-90)IC>;=)MW%XQGE0.I)%-73YNO\ G?\
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MTQ;&,(.IKV[P9X[T3X@:,VJ:'=M=6B2O!()89(98I%.&1XY%5T8=U8 U\X^
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MP3\%M,@L]%;5?$FFZ/#%'I*W$<?FW"Q*NSS&;8!NZG., XS7=T4-WBXK2_\
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M:2$+$N]G=W8E5 !^52 ,\"M.5IM?U>Z5OQ1.ZO\ ULW?_P E9];45\X_LO\
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M:J^FC4;&YTNSDB &_;(KP;W9MO4;3EAV%8EU\8-5U30;)I==T#Q$PU_2K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20220930x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220930x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #I!#@# 2(  A$! Q$!_\0
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ML<\WE2!HF8@+N0KN&2>N,5/X=^)WAGQ7>-:Z7J8N)A USAH)(PT2MM+ NH!
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MT?VC;_W_ /QTT 6:*@BO89G"(^6/;!J>@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJ*:YCMR [;<].* ):*K?VC;_ -__ ,=-']HV
M_P#?_P#'30!9HJM_:-O_ '__ !TT?VC;_P!__P =- %FBJW]HV_]_P#\=-']
MHV_]_P#\=- %FBJW]HV_]_\ \=-']HV_]_\ \=- %FBJW]HV_P#?_P#'31_:
M-O\ W_\ QTT 6:*K?VC;_P!__P =-']HV_\ ?_\ '30!9HJM_:-O_?\ _'31
M_:-O_?\ _'30!9HJM_:-O_?_ /'31_:-O_?_ /'30!9HJM_:-O\ W_\ QTT?
MVC;_ -__ ,=- %FBH8KN*=MJ-DXST-34 %%%% !1110 4444 %%%% !1110
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MJX9?C9X"&/\ BK-*_P# E:?_ ,+M\!?]#;I7_@2M/V<^S#^T\#_S_A_X$O\
M,[:BN)_X7;X"_P"AMTK_ ,"5H_X7;X"_Z&W2O_ E:/9S[,7]IX#_ )_P_P#
MH_YG;45Q/_"[? 7_ $-NE?\ @2M'_"[? 7_0VZ5_X$K1[.?9A_:> _Y_P_\
M H_YG;45Q/\ PNWP%_T-NE?^!*T?\+M\!?\ 0VZ5_P"!*T>SGV8?VG@/^?\
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M1_POCX>?]#EH_P#X%+1[.?9A_:> _P"?\/\ P*/^9WE%<'_POCX>?]#EH_\
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MO/SXY)-=_P#L\ZO=:Q\(]$>[<RS6_G68D;JRQ2O&A_[Y4?E3E323:>UOQO\
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MVV?5*Z[K5&;1116AYP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&33]5>WDAVJ 8R2C*R'&?NAAG[U;?_#)7Q"_Y]+'_P #%H_X9*^(7_/I8_\
M@8M"E03NI?CZ?Y()87B645"6'DTG?^&M_>_N].9V[7TV1FS_ !R_MII!KNB?
M;HDU"34+6.TO6MA$7P6B?Y6\R,D X^4Y)YYKS;5]2?6-4N[Z2..%[B5I3'"N
MU%R<X4=@*];_ .&2OB%_SZ6/_@8M'_#)7Q"_Y]+'_P #%IQG0A\+7WG-BLMX
MBQJMB,/.6M_@U^;2N]]+[;(\9HKV;_ADKXA?\^EC_P"!BT?\,E?$+_GTL?\
MP,6M/;TOYD>=_JYG'_0+/_P%GC-%>S?\,E?$+_GTL?\ P,6C_ADKXA?\^EC_
M .!BT>WI?S(/]7,X_P"@6?\ X"SQFBO9O^&2OB%_SZ6/_@8M'_#)7Q"_Y]+'
M_P #%H]O2_F0?ZN9Q_T"S_\  6>,T5[-_P ,E?$+_GTL?_ Q:/\ ADKXA?\
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M_#&_Q)_Y\]/_ / U:/;TOYD'^KF<?] L_P#P%GA]%>X?\,;_ !)_Y\]/_P#
MU:/^&-_B3_SYZ?\ ^!JT>WI?S(/]7,X_Z!9_^ L\/HKW#_AC?XD_\^>G_P#@
M:M'_  QO\2?^?/3_ /P-6CV]+^9!_JYG'_0+/_P%GA]%>X?\,;_$G_GST_\
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MDKXA?\^EC_X&+1_PR5\0O^?2Q_\  Q:/;TOYD'^KF<?] L__  %GC-%>S?\
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M@"W153[%+_S_ -Q^4?\ \31]BE_Y_P"X_*/_ .)H MT54^Q2_P#/_<?E'_\
M$T?8I?\ G_N/RC_^)H MT54^Q2_\_P#<?E'_ /$T?8I?^?\ N/RC_P#B: +=
M%5/L4O\ S_W'Y1__ !-'V*7_ )_[C\H__B: +=%5/L4O_/\ W'Y1_P#Q-'V*
M7_G_ +C\H_\ XF@"W153[%+_ ,_]Q^4?_P 31]BE_P"?^X_*/_XF@"W153[%
M+_S_ -Q^4?\ \31]BE_Y_P"X_*/_ .)H MT54^Q2_P#/_<?E'_\ $T?8I?\
MG_N/RC_^)H MT54^Q2_\_P#<?E'_ /$T?8I?^?\ N/RC_P#B: +=%5/L4O\
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M@)Z?[M:_V*7_ )_[C\H__B: +=%5/L4O_/\ W'Y1_P#Q-'V*7_G_ +C\H_\
MXF@"W153[%+_ ,_]Q^4?_P 31]BE_P"?^X_*/_XF@"W153[%+_S_ -Q^4?\
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M@""BH/LTG_/U-^2?_$T?9I/^?J;\D_\ B: )Z*@^S2?\_4WY)_\ $T?9I/\
MGZF_)/\ XF@">BH/LTG_ #]3?DG_ ,31]FD_Y^IOR3_XF@">BH/LTG_/U-^2
M?_$T?9I/^?J;\D_^)H GHJ#[-)_S]3?DG_Q-'V:3_GZF_)/_ (F@">BH/LTG
M_/U-^2?_ !-'V:3_ )^IOR3_ .)H GHJ#[-)_P _4WY)_P#$T?9I/^?J;\D_
M^)H GHJ#[-)_S]3?DG_Q-'V:3_GZF_)/_B: )Z*@^S2?\_4WY)_\31]FD_Y^
MIOR3_P")H T]*_X^3_NG^E:]8&F6LC7! O)E^4\@)_\ $UJ?8I?^?^X_*/\
M^)H MT54^Q2_\_\ <?E'_P#$T?8I?^?^X_*/_P")H MT54^Q2_\ /_<?E'_\
M31]BE_Y_[C\H_P#XF@"W153[%+_S_P!Q^4?_ ,31]BE_Y_[C\H__ (F@"W15
M3[%+_P _]Q^4?_Q-'V*7_G_N/RC_ /B: +=%5/L4O_/_ ''Y1_\ Q-'V*7_G
M_N/RC_\ B: +=%5/L4O_ #_W'Y1__$T?8I?^?^X_*/\ ^)H MT54^Q2_\_\
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MGW)IO_'XGX_RK:KY \.?&CQ7J5A;W8U=E=E^;$4> >A_AK:_X6]XO_Z#+_\
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M_P"/M_H/Y55KF)-=O9G+-.2Q[[1_A2#6+OO,?R'^%'(Q^WCV.HHKFAJUT?\
MEJ?R%/&J7/\ SU/Y"CD8>WB=%17/C4[C_GJ?R%.&I7'_ #T/Y"ER,?MHF]16
M(-1G/_+3]!3AJ$__ #T/Y"CD8>VB;-%9 OIO[_Z"G"]E/\?Z4<C'[5&K168+
MN7^_3Q=2'^+]*.1C]HC0HJD+E_[U/$['O1R,/:(M457$I]:>)#ZT<K#VB):*
M8'IP-+E'SH6BG#'I3P%/:CE8^=$5%6 B'^&E,:;3\O.*.4.9&CI__'G'^/\
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M #_A_P $_.G8W]T_E1L;^Z?RK]%_^$9T?_H$V/\ X#)_A1_PC.C_ /0)L?\
MP&3_  H^MKL']BO^?\/^"?G1L;^Z?RHV-_=/Y5^B_P#PC.C_ /0)L?\ P&3_
M  H_X1G1_P#H$V/_ (#)_A1];78/[%?\_P"'_!/SHV-_=/Y4;&_NG\J_1?\
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M )\X/^_2_P"%']EV?_/I!_WZ7_"CV@_JS[GD :G!L5Z[_9EG_P ^D'_?M?\
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MJL;%_NC\J78OH/RHYP]F^Y"&J16YIVT>@HP/2ES#4&;>G_\ 'G'^/\Z*-/\
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M?]^7_P */ML?]V;_ +\O_A4]% $'VV/^[-_WY?\ PH^VQ_W9O^_+_P"%3T4
M0?;8_P"[-_WY?_"C[;'_ '9O^_+_ .%3T4 0?;8_[LW_ 'Y?_"C[;'_=F_[\
MO_A4]% $'VV/^[-_WY?_  H^VQ_W9O\ OR_^%3T4 0?;8_[LW_?E_P#"C[;'
M_=F_[\O_ (5/10!!]MC_ +LW_?E_\*/ML?\ =F_[\O\ X5/10!!]MC_NS?\
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MU]:\YKII8.A.-W'OU?<XZ^/Q%.?+&71=%V1[]_PTY:?] ";_ ,"1_P#$T?\
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M6$.M/6E[.(^>1N?VQ#_=D_(?XT#5X3_"_P"0_P :QQTI5ZU/(BN=FQ_:T/\
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M6D)JHKHQJ4Y4GRR"BBBM#(**** "BBB@ HHHH ***T- TXZIJ]M;X^5FR_\
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M #%F_P# ?_[*E_X4W'_T%F_\!_\ [*O2**/K=?\ F_(/J=#^7\SS?_A3<?\
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M'.#P<H_Y>C_W[_\ KTX>$5'_ "]'_OW_ /7KH:*/;U.X>PI]C 'A,#_EY/\
MWQ_]>E'A11_R\G_OC_Z];U%+V]3N'L*?8PQX74?\O!_[X_\ KT?\(PH_Y>#_
M -\?_7K<HH]O4[C]C3[&*/#0'_+P?^^/_KTO_".C_GX/_?'_ ->MFBE[:IW'
M[&GV,<>'@/\ EN?^^?\ Z].&@@?\MS_WS_\ 7K6HH]M/N'L8=C+&A@?\MC_W
MS_\ 7I?[$'_/8_\ ?/\ ]>M.BCVL^X_90[&<-' _Y:_^._\ UZ7^R!_SU/\
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M_:A_YYC\Z/[4/_/,?G5&BBX6+W]J'_GF/SI1JI'_ "S'_?54**0R_P#VL?\
MGD/^^J/[6/\ SR'_ 'U5"B@1?_M8_P#/(?\ ?5']K'_GD/\ OJJ%% S1_M<_
M\\A_WU1_:Y_YY#_OJLZB@5C1_M<_\\A_WU39-5+HR^7C((SNJA10,VM/_P"/
M./\ '^=%&G_\><?X_P Z* +-%%% !1110 4444 %%%% !1110 4444 %%%%
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M^=7:* *7]E0^K_G1_94/J_YU=HH I?V5#ZO^=']E0^K_ )U=HH I?V5#ZO\
MG1_94/J_YU=HH I?V5#ZO^=']E0^K_G5VB@"E_94/J_YT?V5#ZO^=7:* *7]
ME0^K_G1_94/J_P"=7:* *7]E0^K_ )T?V5#ZO^=7:* *7]E0^K_G1_94/J_Y
CU=HH I?V5#ZO^=']E0^K_G5VB@!D,0@C"+G ]:*?10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>plx-20220930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:07:37 PM-->
<!--Modified on: 11/13/2022 9:07:37 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2021" targetNamespace="http://www.protalix.com/20220930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20220930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalDetails" id="DisclosureShareCapitalDetails">
        <link:definition>40501 - Disclosure - SHARE CAPITAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" id="DisclosureCommitmentsDetails">
        <link:definition>40601 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40701 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapital" id="DisclosureShareCapital">
        <link:definition>10501 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>10601 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10701 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" id="DisclosureShareCapitalTables">
        <link:definition>30503 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="SevenPointFivePercentageConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AlfataligliceraseMember" name="AlfataligliceraseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" id="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromExpenseReimbursements" id="plx_ProceedsFromExpenseReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReacquisitionOfEquityComponentOfConvertibleNotes" id="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquityComponentOfConvertibleNotesNetOfTransactionCosts" id="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CertainOfficersDirectorsAndOtherEmployeesMember" id="plx_CertainOfficersDirectorsAndOtherEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExtendedTermOfAgreement" id="plx_ExtendedTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>plx-20220930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:07:37 PM-->
<!--Modified on: 11/13/2022 9:07:37 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638039704559619800" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638039704559619800" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638039704559619800" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638039704559629815" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638039704559619800" xlink:to="plx_ShortTermBankDeposits_638039704559629815" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638039704559619800" xlink:to="us-gaap_AccountsReceivableNetCurrent_638039704559629815" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638039704559619800" xlink:to="us-gaap_OtherAssetsCurrent_638039704559629815" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638039704559619800" xlink:to="us-gaap_InventoryNet_638039704559629815" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638039704559629815" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638039704559629815" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638039704559629815" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638039704559629815" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638039704559639839" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638039704559639839" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638039704559639839" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638039704559639839" xlink:to="us-gaap_LiabilitiesNoncurrent_638039704559639839" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638039704559639839" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638039704559639839" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638039704559639839" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638039704559639839" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638039704559639839" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638039704559639839" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638039704559639839" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638039704559639839" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638039704559639839" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638039704559639839" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638039704559639839" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638039704559639839" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638039704559639839" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638039704559639839" xlink:to="us-gaap_LiabilitiesCurrent_638039704559639839" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638039704559649844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638039704559639839" xlink:to="us-gaap_AccountsPayableTradeCurrent_638039704559649844" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638039704559649844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638039704559639839" xlink:to="us-gaap_AccountsPayableOtherCurrent_638039704559649844" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638039704559649844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638039704559639839" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638039704559649844" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638039704559649844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638039704559639839" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638039704559649844" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638039704559649844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638039704559649844" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638039704559659860" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638039704559659860" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638039704559659860" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638039704559659860" xlink:to="us-gaap_CostOfRevenue_638039704559659860" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638039704559659860" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638039704559659860" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638039704559659860" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638039704559659860" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638039704559659860" xlink:to="us-gaap_Revenues_638039704559659860" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638039704559669816" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638039704559659860" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638039704559669816" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638039704559669816" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_638039704559669816" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638039704559669816" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638039704559669816" xlink:to="us-gaap_OtherNonoperatingExpense_638039704559669816" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638039704559669816" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638039704559669816" xlink:to="us-gaap_OtherNonoperatingIncome_638039704559669816" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_638039704559669816" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherIncome_638039704559669816" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638039704559669816" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_ShareBasedCompensation_638039704559669816" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_Depreciation_638039704559679811" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638039704559679811" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638039704559679811" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638039704559679811" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638039704559679811" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638039704559679811" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638039704559679811" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638039704559679811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638039704559679811" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638039704559689804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638039704559689804" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638039704559689804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638039704559689804" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638039704559689804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_IncreaseDecreaseInInventories_638039704559689804" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638039704559689804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638039704559689804" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638039704559689804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_ProfitLoss_638039704559689804" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638039704559689804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704559669816" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638039704559689804" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638039704559699798" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" xlink:to="plx_IncreaseDecreaseInBankDeposits_638039704559699798" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638039704559699798" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638039704559699798" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638039704559699798" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638039704559699798" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638039704559699798" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638039704559699798" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638039704559699798" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638039704559699798" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_638039704559699798" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704559689804" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_638039704559699798" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704559709789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704559709789" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638039704559709789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704559709789" xlink:to="us-gaap_RepaymentsOfNotesPayable_638039704559709789" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638039704559709789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704559709789" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638039704559709789" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638039704559709789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704559709789" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638039704559709789" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_638039704559709789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704559709789" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_638039704559709789" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638039704559709789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704559709789" xlink:to="us-gaap_ProceedsFromWarrantExercises_638039704559709789" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638039704559719797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638039704559719797" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638039704559719797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638039704559719797" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638039704559719797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638039704559719797" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638039704559719797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638039704559719797" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>plx-20220930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:07:37 PM-->
<!--Modified on: 11/13/2022 9:07:37 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureShareCapitalDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20220930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalDetails" xlink:type="extended" xlink:title="40501 - Disclosure - SHARE CAPITAL (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CertainOfficersDirectorsAndOtherEmployeesMember" xlink:label="plx_CertainOfficersDirectorsAndOtherEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_CertainOfficersDirectorsAndOtherEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_AlfataligliceraseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromExpenseReimbursements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>plx-20220930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:07:37 PM-->
<!--Modified on: 11/13/2022 9:07:37 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">OTHER INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition of equity component of convertible notes</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity component of convertible notes, net of transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable-trade and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Decrease in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts paid (funded) in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment for convertible notes redemption and transactions costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">The transaction costs in connection with exchange of convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Transactions costs in connection with the exchange of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">SHARE CAPITAL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Valuation Assumptions</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum entitlement of development costs to cover per year</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional amount payable for achievement of regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change in amount receivable for achievement of regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Performance obligation number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price (USD)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt Instrument Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt Instrument Fair Value</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">New director</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CertainOfficersDirectorsAndOtherEmployeesMember" xlink:label="plx_CertainOfficersDirectorsAndOtherEmployeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CertainOfficersDirectorsAndOtherEmployeesMember" xlink:to="plx_CertainOfficersDirectorsAndOtherEmployeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CertainOfficersDirectorsAndOtherEmployeesMember_lbl" xml:lang="en-US">Represents information pertaining to certain officers, directors and other employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CertainOfficersDirectorsAndOtherEmployeesMember_lbl" xml:lang="en-US">Certain Officers, Directors And Other Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CertainOfficersDirectorsAndOtherEmployeesMember_lbl" xml:lang="en-US">Certain Officers, Directors And Other Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">New employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Option to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting Period</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (USD)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (Years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted stock granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Value of restricted stock granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance under share-based payment arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentsAndContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExtendedTermOfAgreement" xlink:to="plx_ExtendedTermOfAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term  of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term of agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AlfataligliceraseMember" xlink:to="plx_AlfataligliceraseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">This member stands for the product, alfataliglicerase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">Alfataliglicerase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromExpenseReimbursements" xlink:to="plx_ProceedsFromExpenseReimbursements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">The cash inflow from expense reimbursements in a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from Expense Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from expense reimbursements</label>
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>plx-20220930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:07:37 PM-->
<!--Modified on: 11/13/2022 9:07:37 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureShareCapital" roleURI="http://www.protalix.com/role/DisclosureShareCapital" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureCommitments" roleURI="http://www.protalix.com/role/DisclosureCommitments" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureShareCapitalTables" roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureShareCapitalDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638039704560259822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638039704560259822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638039704560259822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638039704560259822" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638039704560259822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638039704560259822" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638039704560259822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638039704560259822" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638039704560259822" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638039704560259822" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638039704560269813" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638039704560269813" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638039704560269813" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638039704560269813" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638039704560269813" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638039704560269813" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638039704560269813" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638039704560269813" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638039704560269813" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638039704560269813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638039704560269813" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638039704560279796" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638039704560279796" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638039704560279796" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638039704560279796" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638039704560279796" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638039704560279796" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638039704560279796" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638039704560279796" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638039704560279796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638039704560279796" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638039704560289797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638039704560289797" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638039704560289797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638039704560289797" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638039704560289797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638039704560289797" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638039704560289797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638039704560289797" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638039704560289797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638039704560289797" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638039704560289797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638039704560289797" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638039704560299795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638039704560299795" xlink:to="us-gaap_AssetsCurrentAbstract_638039704560299795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638039704560299795" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638039704560299795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638039704560299795" xlink:to="plx_ShortTermBankDeposits_638039704560299795" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638039704560299795" xlink:to="us-gaap_AccountsReceivableNetCurrent_638039704560299795" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638039704560299795" xlink:to="us-gaap_OtherAssetsCurrent_638039704560299795" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638039704560299795" xlink:to="us-gaap_InventoryNet_638039704560299795" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638039704560299795" xlink:to="us-gaap_AssetsCurrent_638039704560299795" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638039704560299795" xlink:to="us-gaap_AssetsNoncurrentAbstract_638039704560299795" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638039704560299795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638039704560299795" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638039704560299795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638039704560299795" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638039704560309806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638039704560299795" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638039704560309806" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638039704560299795" xlink:to="us-gaap_Assets_638039704560309806" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638039704560309806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638039704560309806" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638039704560309806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638039704560309806" xlink:to="us-gaap_AccountsPayableTradeCurrent_638039704560309806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638039704560309806" xlink:to="us-gaap_AccountsPayableOtherCurrent_638039704560309806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638039704560309806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638039704560309806" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638039704560309806" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638039704560309806" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638039704560319796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638039704560309806" xlink:to="us-gaap_LiabilitiesCurrent_638039704560319796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638039704560319796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638039704560319796" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638039704560319796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638039704560319796" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638039704560319796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638039704560319796" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638039704560319796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638039704560319796" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638039704560319796" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638039704560319796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" xlink:to="us-gaap_LiabilitiesNoncurrent_638039704560319796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638039704560329794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" xlink:to="us-gaap_Liabilities_638039704560329794" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638039704560329794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" xlink:to="us-gaap_CommitmentsAndContingencies_638039704560329794" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638039704560329794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" xlink:to="us-gaap_StockholdersEquity_638039704560329794" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638039704560329794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638039704560309806" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638039704560329794" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_638039704560339813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560339813" xlink:to="srt_ProductOrServiceAxis_638039704560339813" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638039704560339813" xlink:to="srt_ProductsAndServicesDomain_638039704560339813" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638039704560339813" xlink:to="us-gaap_ProductMember_638039704560339813" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638039704560339813" xlink:to="us-gaap_LicenseAndServiceMember_638039704560339813" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560339813" xlink:to="us-gaap_StatementLineItems_638039704560339813" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_Revenues_638039704560339813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_CostOfRevenue_638039704560339813" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638039704560339813" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638039704560339813" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_OperatingIncomeLoss_638039704560339813" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638039704560339813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_OtherNonoperatingExpense_638039704560339813" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_OtherNonoperatingIncome_638039704560349798" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_NonoperatingIncomeExpense_638039704560349798" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_OtherIncome_638039704560349798" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_NetIncomeLoss_638039704560349798" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_EarningsPerShareBasic_638039704560349798" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_EarningsPerShareDiluted_638039704560349798" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638039704560349798" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638039704560349798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560339813" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638039704560349798" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_638039704560359796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560359796" xlink:to="us-gaap_IncomeStatementLocationAxis_638039704560359796" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638039704560359796" xlink:to="us-gaap_IncomeStatementLocationDomain_638039704560359796" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638039704560359796" xlink:to="us-gaap_CostOfSalesMember_638039704560359796" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638039704560359796" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638039704560359796" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638039704560359796" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638039704560359796" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560359796" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638039704560359796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638039704560359796" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638039704560359796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638039704560359796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638039704560359796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560359796" xlink:to="us-gaap_StatementEquityComponentsAxis_638039704560369807" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638039704560369807" xlink:to="us-gaap_CommonStockMember_638039704560369807" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638039704560369807" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638039704560369807" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638039704560369807" xlink:to="us-gaap_RetainedEarningsMember_638039704560369807" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638039704560369807" xlink:to="us-gaap_EquityComponentDomain_638039704560369807" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560359796" xlink:to="us-gaap_StatementLineItems_638039704560369807" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="us-gaap_StockholdersEquity_638039704560369807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="us-gaap_SharesOutstanding_638039704560369807" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638039704560369807" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638039704560369807" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638039704560369807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638039704560369807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638039704560369807" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_638039704560369807" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638039704560379797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638039704560379797" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638039704560379797" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638039704560379797" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638039704560379797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638039704560379797" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_638039704560379797" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638039704560379797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_638039704560379797" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638039704560379797" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638039704560379797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="us-gaap_NetIncomeLoss_638039704560379797" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638039704560389797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="us-gaap_StockholdersEquity_638039704560389797" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638039704560389797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560369807" xlink:to="us-gaap_SharesOutstanding_638039704560389797" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638039704560389797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638039704560389797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638039704560389797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638039704560389797" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638039704560389797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638039704560389797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638039704560389797" xlink:to="us-gaap_ProfitLoss_638039704560399804" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638039704560389797" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_ShareBasedCompensation_638039704560399804" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_Depreciation_638039704560399804" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638039704560399804" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638039704560399804" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638039704560399804" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638039704560399804" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638039704560399804" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638039704560399804" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638039704560399804" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638039704560409796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638039704560409796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638039704560409796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" xlink:to="us-gaap_IncreaseDecreaseInInventories_638039704560409796" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638039704560409796" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638039704560399804" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638039704560409796" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638039704560389797" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638039704560409796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638039704560409796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" xlink:to="plx_IncreaseDecreaseInBankDeposits_638039704560409796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638039704560419806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638039704560419806" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638039704560419806" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_638039704560419806" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638039704560419806" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638039704560409796" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638039704560419806" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638039704560419806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638039704560419806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638039704560429793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" xlink:to="us-gaap_RepaymentsOfNotesPayable_638039704560429793" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_638039704560429793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_638039704560429793" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638039704560429793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638039704560429793" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638039704560429793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" xlink:to="us-gaap_ProceedsFromWarrantExercises_638039704560429793" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704560429793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638039704560419806" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638039704560429793" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638039704560429793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638039704560429793" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638039704560440167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638039704560440167" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638039704560440167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638039704560440167" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380397045604401671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380397045604401671" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638039704560440167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638039704560440167" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_638039704560440167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638039704560440167" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_638039704560440167" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638039704560449804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638039704560440167" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638039704560449804" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_638039704560449804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638039704560440167" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_638039704560449804" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638039704560449804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638039704560449804" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638039704560449804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638039704560449804" xlink:to="us-gaap_InterestPaidNet_638039704560449804" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638039704560449804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638039704560449804" xlink:to="plx_InterestReceivedNet_638039704560449804" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638039704560459798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638039704560459798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638039704560459798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638039704560459798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638039704560459798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638039704560459798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_638039704560469806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_638039704560469806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapital" xlink:type="extended" xlink:title="10501 - Disclosure - SHARE CAPITAL">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638039704560469806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638039704560469806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="10601 - Disclosure - COMMITMENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_638039704560469806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_638039704560469806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10701 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638039704560469806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_638039704560469806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638039704560479802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638039704560479802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638039704560479802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638039704560479802" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638039704560479802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638039704560479802" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638039704560479802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638039704560479802" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638039704560479802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638039704560479802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638039704560479802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_638039704560479802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638039704560479802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560479802" xlink:to="us-gaap_DebtInstrumentAxis_638039704560479802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638039704560489807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638039704560479802" xlink:to="us-gaap_DebtInstrumentNameDomain_638039704560489807" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638039704560489807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638039704560489807" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638039704560489807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560489807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638039704560489807" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560489807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638039704560489807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560479802" xlink:to="us-gaap_StatementLineItems_638039704560489807" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638039704560489807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560489807" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638039704560489807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638039704560489807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638039704560489807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalTables" xlink:type="extended" xlink:title="30503 - Disclosure - SHARE CAPITAL (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638039704560489807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638039704560489807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967854703" xlink:to="plx_SignificantAccountingPoliciesTable_638039704560499802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638039704560499802" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638039704560499802" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638039704560499802" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638039704560499802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638039704560499802" xlink:to="plx_AtMarketEquityOfferingMember_638039704560499802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638039704560499802" xlink:to="us-gaap_TypeOfArrangementAxis_638039704560499802" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638039704560499802" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560499802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560499802" xlink:to="plx_AmendedPfizerAgreementMember_638039704560499802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560499802" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638039704560499802" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638039704560499802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638039704560499802" xlink:to="plx_ChiesiAgreementsMember_638039704560499802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638039704560499802" xlink:to="plx_ChiesiUSAgreementMember_638039704560509802" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638039704560499802" xlink:to="plx_ChiesiExUSAgreementMember_638039704560509802" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638039704560499802" xlink:to="dei_LegalEntityAxis_638039704560509802" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638039704560509802" xlink:to="dei_EntityDomain_638039704560509802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638039704560509802" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638039704560509802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638039704560499802" xlink:to="srt_StatementGeographicalAxis_638039704560509802" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638039704560509802" xlink:to="srt_SegmentGeographicalDomain_638039704560509802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638039704560509802" xlink:to="country_BR_638039704560509802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638039704560499802" xlink:to="srt_RangeAxis_638039704560509802" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638039704560509802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638039704560509802" xlink:to="srt_RangeMember_638039704560509802" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638039704560509802" xlink:to="srt_MinimumMember_638039704560519794" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638039704560509802" xlink:to="srt_MaximumMember_638039704560519794" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638039704560499802" xlink:to="us-gaap_DebtInstrumentAxis_638039704560519794" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638039704560519794" xlink:to="us-gaap_DebtInstrumentNameDomain_638039704560519794" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638039704560519794" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638039704560519794" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638039704560519794" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_638039704560519794" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638039704560519794" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560519794" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638039704560519794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638039704560499802" xlink:to="plx_SignificantAccountingPoliciesLineItems_638039704560519794" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638039704560529793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638039704560529793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638039704560529793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638039704560529793" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638039704560529793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638039704560529793" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638039704560529793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638039704560529793" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638039704560529793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638039704560529793" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638039704560529793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638039704560529793" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638039704560529793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638039704560529793" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638039704560539793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638039704560539793" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638039704560539793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_PaymentOnNetSalesPercentage_638039704560539793" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638039704560539793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638039704560539793" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638039704560539793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_AgreementAmendmentPaymentReceivable_638039704560539793" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638039704560539793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638039704560539793" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638039704560539793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638039704560539793" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_638039704560549805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_MaintainOfMinimumCashBalance_638039704560549805" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638039704560549805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638039704560549805" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_638039704560549805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="plx_RevenuePerformanceObligationNumber_638039704560549805" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638039704560549805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638039704560519794" xlink:to="us-gaap_SharePrice_638039704560549805" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638039704560559801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638039704560559801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638039704560559801" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638039704560559801" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560559801" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560559801" xlink:to="us-gaap_DebtInstrumentAxis_638039704560559801" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638039704560559801" xlink:to="us-gaap_DebtInstrumentNameDomain_638039704560559801" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638039704560559801" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638039704560559801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560559801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638039704560559801" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560559801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560559801" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638039704560569799" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638039704560569799" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638039704560569799" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638039704560569799" xlink:to="us-gaap_FairValueInputsLevel3Member_638039704560569799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560559801" xlink:to="us-gaap_MeasurementInputTypeAxis_638039704560569799" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638039704560569799" xlink:to="us-gaap_MeasurementInputTypeDomain_638039704560569799" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638039704560569799" xlink:to="us-gaap_MeasurementInputSharePriceMember_638039704560569799" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638039704560569799" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638039704560569799" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638039704560569799" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638039704560569799" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638039704560569799" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638039704560569799" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_638039704560569799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638039704560569799" xlink:to="plx_MeasurementInputYieldMember_638039704560569799" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560559801" xlink:to="us-gaap_StatementLineItems_638039704560579790" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560579790" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638039704560579790" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560579790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560579790" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638039704560579790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638039704560579790" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638039704560579790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638039704560579790" xlink:to="us-gaap_FairValueInputsLevel3Member_638039704560579790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560579790" xlink:to="us-gaap_DebtInstrumentAxis_638039704560579790" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638039704560579790" xlink:to="us-gaap_DebtInstrumentNameDomain_638039704560579790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638039704560579790" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638039704560579790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638039704560579790" xlink:to="us-gaap_StatementLineItems_638039704560579790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638039704560579790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560579790" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638039704560579790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560579790" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638039704560589921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_638039704560589921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560589921" xlink:to="srt_ProductOrServiceAxis_638039704560589921" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638039704560589921" xlink:to="srt_ProductsAndServicesDomain_638039704560589921" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638039704560589921" xlink:to="us-gaap_ProductMember_638039704560589921" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638039704560589921" xlink:to="us-gaap_LicenseAndServiceMember_638039704560589921" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560589921" xlink:to="srt_StatementGeographicalAxis_638039704560589921" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638039704560589921" xlink:to="srt_SegmentGeographicalDomain_638039704560589921" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638039704560589921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638039704560589921" xlink:to="plx_PfizerMember_638039704560589921" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638039704560589921" xlink:to="country_BR_638039704560599800" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638039704560589921" xlink:to="plx_ChiesiMember_638039704560599800" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638039704560589921" xlink:to="us-gaap_StatementLineItems_638039704560599800" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638039704560599800" xlink:to="us-gaap_Revenues_638039704560599800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalDetails" xlink:type="extended" xlink:title="40501 - Disclosure - SHARE CAPITAL (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" xlink:to="us-gaap_PlanNameAxis_638039704560599800" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638039704560599800" xlink:to="us-gaap_PlanNameDomain_638039704560599800" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638039704560599800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638039704560599800" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638039704560599800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" xlink:to="srt_TitleOfIndividualAxis_638039704560609806" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638039704560609806" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638039704560609806" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638039704560609806" xlink:to="srt_ChiefExecutiveOfficerMember_638039704560609806" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638039704560609806" xlink:to="srt_ChiefFinancialOfficerMember_638039704560609806" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638039704560609806" xlink:to="srt_DirectorMember_638039704560609806" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CertainOfficersDirectorsAndOtherEmployeesMember" xlink:label="plx_CertainOfficersDirectorsAndOtherEmployeesMember_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638039704560609806" xlink:to="plx_CertainOfficersDirectorsAndOtherEmployeesMember_638039704560609806" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" xlink:to="us-gaap_GranteeStatusAxis_638039704560609806" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638039704560609806" xlink:to="us-gaap_GranteeStatusDomain_638039704560609806" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638039704560609806" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638039704560609806" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638039704560609806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638039704560609806" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638039704560609806" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638039704560619798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638039704560619798" xlink:to="plx_AtMarketEquityOfferingMember_638039704560619798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" xlink:to="us-gaap_AwardTypeAxis_638039704560619798" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638039704560619798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638039704560619798" xlink:to="us-gaap_EmployeeStockOptionMember_638039704560619798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" xlink:to="us-gaap_SubsequentEventTypeAxis_638039704560619798" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638039704560619798" xlink:to="us-gaap_SubsequentEventTypeDomain_638039704560619798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638039704560619798" xlink:to="us-gaap_SubsequentEventMember_638039704560619798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638039704560599800" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_CommonStockSharesAuthorized_638039704560629789" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638039704560629789" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638039704560629789" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638039704560629789" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638039704560629789" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638039704560629789" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638039704560629789" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638039704560629789" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_SharePrice_638039704560629789" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638039704560639794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638039704560639794" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638039704560639794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638039704560639794" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638039704560639794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638039704560639794" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638039704560639794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638039704560639794" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638039704560639794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638039704560639794" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638039704560649817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638039704560649817" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638039704560649817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638039704560649817" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638039704560649817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638039704560649817" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638039704560649817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638039704560649817" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638039704560649817" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638039704560619798" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638039704560649817" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638039704560659801" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638039704560659801" xlink:to="us-gaap_TypeOfArrangementAxis_638039704560659801" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638039704560659801" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560659801" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560659801" xlink:to="plx_ChiesiAgreementsMember_638039704560659801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638039704560659801" xlink:to="plx_CommitmentsAndContingenciesLineItems_638039704560659801" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638039704560659801" xlink:to="plx_ExtendedTermOfAgreement_638039704560659801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638039704560659801" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638039704560659801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638039704560659801" xlink:to="us-gaap_SubsequentEventTypeAxis_638039704560659801" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638039704560659801" xlink:to="us-gaap_SubsequentEventTypeDomain_638039704560669803" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638039704560669803" xlink:to="us-gaap_SubsequentEventMember_638039704560669803" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638039704560659801" xlink:to="us-gaap_TypeOfArrangementAxis_638039704560669803" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638039704560669803" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560669803" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560669803" xlink:to="plx_PfizerAgreementMember_638039704560669803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560669803" xlink:to="plx_ChiesiAgreementsMember_638039704560669803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638039704560669803" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638039704560669803" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638039704560659801" xlink:to="srt_ProductOrServiceAxis_638039704560669803" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638039704560669803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638039704560669803" xlink:to="srt_ProductsAndServicesDomain_638039704560669803" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638039704560669803" xlink:to="plx_AlfataligliceraseMember_638039704560679808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638039704560659801" xlink:to="us-gaap_PlanNameAxis_638039704560679808" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638039704560679808" xlink:to="us-gaap_PlanNameDomain_638039704560679808" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638039704560679808" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638039704560679808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638039704560659801" xlink:to="us-gaap_SubsequentEventLineItems_638039704560679808" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638039704560679808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638039704560679808" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638039704560679808" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638039704560679808" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638039704560679808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638039704560679808" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638039704560689793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638039704560689793" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638039704560689793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638039704560689793" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638039704560689793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638039704560689793" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements_638039704560689793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="plx_ProceedsFromExpenseReimbursements_638039704560689793" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_638039704560689793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="plx_ProceedsFromSaleOfProducts_638039704560689793" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638039704560689793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638039704560679808" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638039704560689793" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647240092336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,665,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647235373072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,720<span></span>
</td>
<td class="nump">$ 38,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">10,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">8,651<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">14,562<span></span>
</td>
<td class="nump">17,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">45,760<span></span>
</td>
<td class="nump">61,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,677<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">4,854<span></span>
</td>
<td class="nump">4,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">56,709<span></span>
</td>
<td class="nump">73,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">5,639<span></span>
</td>
<td class="nump">6,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">12,870<span></span>
</td>
<td class="nump">16,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">14,793<span></span>
</td>
<td class="nump">8,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,302<span></span>
</td>
<td class="nump">33,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">28,111<span></span>
</td>
<td class="nump">27,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">33,921<span></span>
</td>
<td class="nump">46,525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">68,223<span></span>
</td>
<td class="nump">79,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(11,514)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 56,709<span></span>
</td>
<td class="nump">$ 73,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647235218128">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,183<span></span>
</td>
<td class="nump">$ 12,054<span></span>
</td>
<td class="nump">$ 39,021<span></span>
</td>
<td class="nump">$ 29,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,074)<span></span>
</td>
<td class="num">(3,703)<span></span>
</td>
<td class="num">(17,195)<span></span>
</td>
<td class="num">(13,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(7,386)<span></span>
</td>
<td class="num">(7,282)<span></span>
</td>
<td class="num">(23,732)<span></span>
</td>
<td class="num">(22,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(2,848)<span></span>
</td>
<td class="num">(2,954)<span></span>
</td>
<td class="num">(8,613)<span></span>
</td>
<td class="num">(9,263)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,125)<span></span>
</td>
<td class="num">(1,885)<span></span>
</td>
<td class="num">(10,519)<span></span>
</td>
<td class="num">(14,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(639)<span></span>
</td>
<td class="num">(2,410)<span></span>
</td>
<td class="num">(1,879)<span></span>
</td>
<td class="num">(6,613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">197<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(442)<span></span>
</td>
<td class="num">(2,314)<span></span>
</td>
<td class="num">(668)<span></span>
</td>
<td class="num">(6,210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">OTHER INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,567)<span></span>
</td>
<td class="num">$ (4,199)<span></span>
</td>
<td class="num">$ (11,187)<span></span>
</td>
<td class="num">$ (20,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,498,105<span></span>
</td>
<td class="nump">45,556,647<span></span>
</td>
<td class="nump">47,582,733<span></span>
</td>
<td class="nump">43,761,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,498,105<span></span>
</td>
<td class="nump">45,556,647<span></span>
</td>
<td class="nump">47,582,733<span></span>
</td>
<td class="nump">43,761,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,812<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 21,222<span></span>
</td>
<td class="nump">$ 12,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 7,548<span></span>
</td>
<td class="nump">$ 17,799<span></span>
</td>
<td class="nump">$ 17,541<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647239349904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647234510640">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 320,280<span></span>
</td>
<td class="num">$ (347,352)<span></span>
</td>
<td class="num">$ (27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,915)<span></span>
</td>
<td class="num">(20,915)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">368,434<span></span>
</td>
<td class="num">(368,267)<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,863<span></span>
</td>
<td class="num">(364,068)<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">368,434<span></span>
</td>
<td class="num">(368,267)<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">368,852<span></span>
</td>
<td class="num">(374,934)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">4,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,841,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,187)<span></span>
</td>
<td class="num">(11,187)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">374,557<span></span>
</td>
<td class="num">(386,121)<span></span>
</td>
<td class="num">(11,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50,158,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">372,616<span></span>
</td>
<td class="num">(382,554)<span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,712,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,445,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,567)<span></span>
</td>
<td class="num">(3,567)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 374,557<span></span>
</td>
<td class="num">$ (386,121)<span></span>
</td>
<td class="num">$ (11,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50,158,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of September&#160;30, 2022 and 2021 &#8211; 144,000,000 and 120,000,000 shares, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reacquisition Of Equity Component Of Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReacquisitionOfEquityComponentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647239382032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647234279280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (11,187)<span></span>
</td>
<td class="num">$ (20,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(391)<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">2,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="num">(5,547)<span></span>
</td>
<td class="nump">13,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable-trade and other assets</a></td>
<td class="num">(5,692)<span></span>
</td>
<td class="num">(4,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="nump">3,392<span></span>
</td>
<td class="num">(1,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(4,438)<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,389)<span></span>
</td>
<td class="num">(5,198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(37,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(415)<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Decrease in restricted deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts paid (funded) in respect of employee rights upon retirement, net</a></td>
<td class="nump">427<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(9,988)<span></span>
</td>
<td class="num">(18,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment for convertible notes redemption and transactions costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,163<span></span>
</td>
<td class="nump">16,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(28,265)<span></span>
</td>
<td class="num">(7,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">38,985<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">10,720<span></span>
</td>
<td class="nump">10,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt', window );">Transactions costs in connection with the exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">2,198<span></span>
</td>
<td class="nump">3,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The transaction costs in connection with exchange of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647240863840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 Phase&#160;III clinical program includes three separate studies, referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. In addition, the Phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On November&#160;9, 2022, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), resubmitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) a biologics license application (&#8220;BLA&#8221;) for PRX-102 for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, includes the final two-year analyses of the Company&#8217;s phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102 (the &#8220;<i style="font-style:italic;">BALANCE </i>study&#8221;), which were completed in July 2022, and long-term data from the Company&#8217;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 to the European Medicines Agency (&#8220;EMA&#8221;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#8217;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternation treatment for adult patients with Fabry disease. The submission was supported by the 12&#8211;month interim data analysis generated from the <i style="font-style:italic;">BALANCE </i>study. Data generated from the Company&#8217;s completed phase&#160;III <i style="font-style:italic;">BRIDGE</i> clinical trial (the &#8220;<i style="font-style:italic;">BRIDGE</i> study&#8221;), the Company&#8217;s phase&#160;I/II clinical trial in naive or untreated patients, and from the Company&#8217;s extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA includes data from the Company&#8217;s completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage (the &#8220;<i style="font-style:italic;">BRIGHT</i> study&#8221;) to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of the Company&#8217;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of September&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $15.6&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) under the initial Exclusive License and Supply Agreement (the &#8220;Pfizer Agreement&#8221;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The novel coronavirus disease (&#8220;COVID-19&#8221;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">not include 33,922,624 and 33,295,154 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2022, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647240733712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,166</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,526</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,954</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647239002592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of September&#160;30, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of September&#160;30, 2022, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $30.9&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647238951296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.9pt;"><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:bottom;width:40.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,883</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,188</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,260</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,541</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647237764192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; SHARE CAPITAL</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;30, 2022, the Company held its 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 120,000,000 to 144,000,000 (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on August&#160;2, 2022.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Stock based compensation</b></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On February&#160;25, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">637,531 shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $523,000.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">121,951 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $100,000.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June&#160;30, 2022, the Company&#8217;s stockholders, among other matters, adopted amendments to the Plan to increase the number of shares of Common Stock available under the Plan from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5,725,171</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,475,171</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares and to amend certain other terms of the Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June&#160;30, 2022, the Company granted </span><span style="-sec-ix-hidden:Hidden_Zw_3KOfSQU6x2J-upO1Hdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">40,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock to a new director serving on the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.09</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share and vest over a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. Vesting of the options granted to the director is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$32,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On August&#160;1, 2022, the Company granted <span style="-sec-ix-hidden:Hidden_TR-D_RlREEGMWjkHWnc9rQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span> options to purchase 160,000 shares of Common Stock to a new employee of the Company under the Plan. The options have an exercise price equal to $1.06 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $124,000.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On September&#160;7, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, <span style="-sec-ix-hidden:Hidden_IAM58yfoSUWi7YyjTPtjww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span> options to purchase 3,280,000 shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers, directors and other employees under the Plan. The options have an exercise price equal to $1.03 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to executive officers and directors is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $2.5&#160;million.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><span style="background:#ffffff;">The fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 85.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the nine and three months ended September&#160;30, 2022, the Company sold, in the aggregate, 3,841,479 and 1,445,656 shares of Common Stock, respectively, under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $4.4&#160;million and $1.6&#160;million, respectively, in connection with such sales.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647237864720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; COMMITMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647237783568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During October and November 2022, the Company sold, in the aggregate, 506,990 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $530,442 in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On October&#160;13, 2022, the Company collected approximately 1.7&#160;million from sales to Brazil. In October and November 2022, the Company collected approximately $2.3&#160;million, in the aggregate, from sales to Pfizer. On October&#160;26, 2022, the Company collected approximately $1.2&#160;million from expense reimbursements in connection with its collaboration with&#160;Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647234267136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 Phase&#160;III clinical program includes three separate studies, referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. In addition, the Phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On November&#160;9, 2022, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), resubmitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) a biologics license application (&#8220;BLA&#8221;) for PRX-102 for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, includes the final two-year analyses of the Company&#8217;s phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102 (the &#8220;<i style="font-style:italic;">BALANCE </i>study&#8221;), which were completed in July 2022, and long-term data from the Company&#8217;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 to the European Medicines Agency (&#8220;EMA&#8221;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#8217;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternation treatment for adult patients with Fabry disease. The submission was supported by the 12&#8211;month interim data analysis generated from the <i style="font-style:italic;">BALANCE </i>study. Data generated from the Company&#8217;s completed phase&#160;III <i style="font-style:italic;">BRIDGE</i> clinical trial (the &#8220;<i style="font-style:italic;">BRIDGE</i> study&#8221;), the Company&#8217;s phase&#160;I/II clinical trial in naive or untreated patients, and from the Company&#8217;s extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA includes data from the Company&#8217;s completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage (the &#8220;<i style="font-style:italic;">BRIGHT</i> study&#8221;) to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of the Company&#8217;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of September&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $15.6&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) under the initial Exclusive License and Supply Agreement (the &#8220;Pfizer Agreement&#8221;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The novel coronavirus disease (&#8220;COVID-19&#8221;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">not include 33,922,624 and 33,295,154 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2022, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647238773360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,166</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,526</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,954</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647236129088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647237829344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.9pt;"><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:bottom;width:40.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,883</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,188</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,260</p></td></tr><tr><td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,541</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647237781136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 85.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647229939008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,161<span></span>
</td>
<td class="nump">$ 8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,922,624<span></span>
</td>
<td class="nump">27,962,842<span></span>
</td>
<td class="nump">33,295,154<span></span>
</td>
<td class="nump">26,847,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Performance obligation number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change in amount receivable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647234156000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,664<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">2,619<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">8,279<span></span>
</td>
<td class="nump">11,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 14,562<span></span>
</td>
<td class="nump">$ 17,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647239370256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">1.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">4.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">75.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">14.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647237758016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 28,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt Instrument Fair Value</a></td>
<td class="nump">$ 30,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647235355952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 14,183<span></span>
</td>
<td class="nump">$ 12,054<span></span>
</td>
<td class="nump">$ 39,021<span></span>
</td>
<td class="nump">$ 29,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">21,222<span></span>
</td>
<td class="nump">12,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,541<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">11,279<span></span>
</td>
<td class="nump">7,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,708<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">7,162<span></span>
</td>
<td class="nump">4,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 7,548<span></span>
</td>
<td class="nump">$ 17,799<span></span>
</td>
<td class="nump">$ 17,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647229375744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 25, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,520,000<span></span>
</td>
<td class="nump">$ 4,161,000<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445,656<span></span>
</td>
<td class="nump">3,841,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,475,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,725,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | New employee | Option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 523,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | New director | Option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Certain Officers, Directors And Other Employees | Option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_CertainOfficersDirectorsAndOtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_CertainOfficersDirectorsAndOtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647237943408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS (Details)<br></strong></div></th>
<th class="th"><div>Aug. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139647229786384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 26, 2022</div></th>
<th class="th"><div>Oct. 13, 2022</div></th>
<th class="th"><div>Nov. 13, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,520,000<span></span>
</td>
<td class="nump">$ 4,161,000<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds From Sale Of Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chiesi Agreements | Alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromExpenseReimbursements', window );">Proceeds from expense reimbursements</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Brazil Agreement with Fiocruz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds From Sale Of Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from expense reimbursements in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_AlfataligliceraseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_AlfataligliceraseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>plx-20220930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20220930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20220930.xsd" xlink:type="simple"/>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_1vc1iVN5MUuWqVvagT41sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_oDtUP6CxnkePQUEErUteKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWdI5ZA6vUyC15HD3EjNzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o3NakbeXoEead8-t7k-62Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kCsglji7kOkuf4CbzkCjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6b9M0fMDnE-ONxperA-Nqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NsMLImWFUkKskcZiXRX0ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_csxCWMqCMUKoZEBkfV_2Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u-zmvKk_nE-TsUTpTrb0yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TSLrDFkfsUiXaEXbJNE19Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oi1iFnUfUk2j89URToy_FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li6VzojNEkm79l_inaRUZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_oaSi65tpAEmtBYUa7viC5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eR0GjrjuNk-nDafPkPNl-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf5bZps_2EenQQ2ZpXcHZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bD4jRYV9p0SrHNp39PFY8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AdqKFA4TTkyOitbYq9oh_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v6SRUqykhkq9NDJkMs8VCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_RB19xNug80KwnklS6AmRlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_7Y9PKaad7UCQjX_1X3wmIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mpZ3bzeTFkeJouERtLBqfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ULcGA7VYNkCKoZuU0B0qrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_rBqFi8FTzEq1WlKuF9bz3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_E6HX3L8o1UORIsdQUL7dMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_ivy2EExMakeWgn87BPkvjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_MXh1QMX0OECsjpG02kpLTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0crLeupio0SwfGQZ9ZvUtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_FrWFE9O6FU6tzt749aUeMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_weDWoM4FaEy6cA5rEgSlaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pveYO1f-lkC05eDMbh02IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_GM0fNZn86UWpPaTCwWm11w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-4dgoH7cSUStclwbyHvr5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_63ussK77mkmthjFePYZl1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jSgenlSB70S_SqMhXL6RSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KItA5s_IX0OM8e34BU2fSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FTvwbQ8tckqFhCmnA1b1uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ukBSADqu40uHabngZO-BlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_BukwyZ3SXUKm2PtgAfi0lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nMiBJOmnlUya-eSouKgGFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_D5y751RR1UqvCc-Q5th3_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_O1a6ViT3C0ewVHZtdm2T7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3bFqnnwhSkCeJGvIIsUgXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8IZaBt_-TE-hj4hdLTni3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kCjfzxrofkaqU5KXQCoK5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eooI9ZYRYUK3xtjGWM-3Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0XmRqyM5IkSNgT9vMbeyqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_HH1mRiFsa0qJN4a4_yJ33w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_fpSaaWnM_kqRxthhVgZ0dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sjuUQKwTikGShcjRQ3wqGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NzJ2ZKx5l0SOQAjJS-KHfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_lyC38x65I0G8pUXc-Tn39A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_IaxJhLjT5EG26liBngcw3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2022_uKl9eMIZyU6wmrR6-IFDvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_rxA6MsPFmkGcr9wRVnhiBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7H_2K0nM006KXiMtIxq9sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_7nrXjB6c6Eq4cT3hYF-X6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FZ5IV3EHuU2VQz4Oea9P-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_D2abpIHIxki6wHgQcLCQlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_TpBThY-o1UO9jj7QH2sP0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__e2stD8DXUakAd6Cgk7bXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Vftn1tQ1hUCzVmrnQgfT1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_OZrCQjIzZEa_Imuc6kFkfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FoX-isrF7k-mTWZnrW05yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P__KdEwYTE-FwaUrq-H-4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_6dFVaa8MP0mBiDmzAt8Y9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_-CFgg0SHbEuiMRjiTw4qOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0sCNP7rIoky5QN2CONKd6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_b3jRdtg_20SDBBcjXHfzTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Htz4Xmw9BUOG0UfER5r48w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_FwE5KZrKh0-_yTQHyIr5xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iwDdKv5AH0-AHSnrWhC_JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-13</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qayOenlWNEakzQ457tclgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_CpKx-mzFKEGNxFx6wijT_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainOfficersDirectorsAndOtherEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-07</startDate>
            <endDate>2022-09-07</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_GZzd7j7xTUuaSCT_sh1p-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainOfficersDirectorsAndOtherEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-07</instant>
        </period>
    </context>
    <context id="As_Of_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_kkHU2uv0R0yTrJf1B14ytw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_QEMAQN-BDkGbFVEHLs5KjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Dh9X97v5V0KmJgH7rEd7Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_13_2022_To_10_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_46nzZWDXz0C-Ml2n7Gftvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-13</startDate>
            <endDate>2022-10-13</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_QWJZhKTEsUGVicty8qY70w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-13</endDate>
        </period>
    </context>
    <context id="Duration_10_26_2022_To_10_26_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ci7oO7k4IkeIa7oHLUkBFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wwuvWu9CNkGPR5tF60aEww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wMq9gBW5wk-NkT7WyGmXVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_S8KAN140aUmNwYXLjfuU2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3mw68fgma0ShyyRQq7AwBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_W1rR-tiQQ0WX0Mrz4mB2wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_BAHkbJYPMkyDVzUoFG5QDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_5rkf-nGdtka3BrgWc-Tu5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r9AEUZN090WxWVevOrEmew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_NS6ZViowGUycZBQ7Si9mxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2022_IeK4AGoGu0qrXYZvP3Bvig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_3n4b8unPO0K-5i9HzEyFQQ">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_6_2ecVNG4kOwBZw8VWtz7Q">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      id="Hidden_5Rf5OZGRIUui7KVBnG-3-A"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      id="Hidden_MYDvw0JFgECXtpuniwnZrQ"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="2"
      id="Hidden_SD_ZzPZry0Kn3wCxqHuvyw"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="2"
      id="Hidden_ph-RG_FF60KNyDOGP_Etkw"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="2"
      id="Hidden_nea46fNOSkqHFDBXe51eTg"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="2"
      id="Hidden_whOWA2mtCEmlBgl3O8lO9w"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="0"
      id="Hidden_dhtmIVfIYUWGH9gC4uv-ZA"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">47582733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="0"
      id="Hidden_kjEdenobfk2zKJAT8Z4QIw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">43761769</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="0"
      id="Hidden_rjgj7ZAm2UWpwyaBeAd0eg"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">49498105</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="0"
      id="Hidden_pYAP2pu4iESAJ3e-bVKQng"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">45556647</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_-glfFb_BQUi1hQXr-UW1Xg_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_6ADnnZ4bZEa0hu_MENJrSw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_a14RITmB_EyJo7axC-HhpQ_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_kHJ2GcRpek2AN05n2ytBcA_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_mCU0xgIxckCE0uVkoQwDug_6_1">false</dei:AmendmentFlag>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg"
      id="Hidden_Zw_3KOfSQU6x2J-upO1Hdg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA"
      id="Hidden_TR-D_RlREEGMWjkHWnc9rQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw"
      id="Hidden_IAM58yfoSUWi7YyjTPtjww">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_zx-h1tHTZUWtTMSHmeH1LA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_xMV-tZNFrU-eU9Ye0neZFg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_3bFL7MIrAUmO4XNmFNWV2Q">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_VfgSy4ret06xXCAbOLfmuw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_k73lkkc3REOJJmom0N62JA">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_1QUUT5kkxEGRHxQitcKBGA">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_Hsvlicwjjkaeg3L269EWrw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_BxKfVRjce0GtMa6Cl1s01g">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_sitv5Zki6kq6MOTv1-xRrQ">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_VkVDMYWi30eXrfPjDz60GQ">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_QWBDTa8qJ0yPbPATIDftDw">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_LJBg_Q6i2kKc7zgS-xm6GQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_erPekCCUoESpudkfHih9Rw_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_hpS_-fnBSE2EhTYBXk42wg">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_ld0-rSrvmkuXyz9WTAHKEw">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_CrTO3okJXkK3PFT1ZKRKKQ_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_SOeTcccVPk2RRhS0eCqcyw_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_qpYkbw-kzEmJp5z32ZacLg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr__ALARe9TYUC3u88fdQwcTw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_fppt8WI7uUmVNH7OH0VNjA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_Sj58F-tmmEmv6zaChQLgeg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_bTwJXo1HQES0_LnonEWzpg_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tc_ZERjyU-whkiDj-Vjv6GSFw_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Narr_Hnc35Pwd7Uybi4N558L-nA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_10_2022_IeK4AGoGu0qrXYZvP3Bvig"
      decimals="INF"
      id="Narr_GLzCV75lf0ebd9urpohZLQ"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">50665598</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_Ofl9_3hG2UyAGqAqfiYuOA_6_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">10720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_dTgsqtDioUexMbZyra5HpA_6_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">38985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_gUYWRHHb_0msK9mPxvLqfA_7_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">10091000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_yj4dVReS1UG9xfzC_xBbYQ_8_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8651000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_GU0TuqHxPkSdLIwtOwaQIg_8_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3442000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_uawvH_eg7Uu4_WeGIt8lPg_9_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1736000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_aw4PnQm8wUinAK8Q1nPtxA_9_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1285000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_VCxIiSk96E6hof81eUS0Ww_10_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">14562000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_RLbyw3gQmkCw48Qlop-Z6w_10_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">17954000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_X5_sIb1Do0ejExaSLetsoA_11_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">45760000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_Qk-fUvbBFkmfUqutiVGfUg_11_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">61666000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_UgVYvf2G5ESPQQc8ia1oOg_14_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1418000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_W4sPMiHNHkysK-bsHTtm5A_14_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2077000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_HNd3qDTpXk2fMkqKTu9mmg_15_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4677000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_mtaKzQsJnk-PEi8mZlySwA_15_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4962000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_2p6pYu-kGEO_AFkwdueREw_16_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4854000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_FpgT-Dl9D0uXNKeiNsOL1Q_16_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4960000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_YYJrj0D8HEGooFyUtefCEQ_17_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">56709000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_Y1uXdFXdd0ujfIAoJe1O6w_17_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">73665000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_wjtiHY31UUmeoFqkMqSBpw_23_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">5639000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_Ed_-EMGn70O3SXM4r4K0VQ_23_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">6986000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_Fva7Ttx-BUexQmdZ-Kx4Kw_24_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12870000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_lIe7IWU0X0GQQ25P09keuA_24_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">16433000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_ThJakNhTpk67-BQVP6u_HA_25_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_Z7T04om8r0CuCaUtxrPKAA_25_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1207000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_P0W7ZyeUf0KmRI8wfHz3AQ_26_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">14793000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_Q-mYtmZhR0eINfXBxUrVfA_26_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8550000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc__VIDpftrfEmtGuvHVgKyKg_27_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">34302000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_wgrSOXc-x0WjO1mz-uhDtQ_27_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">33176000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_kb8iRORtqkOFZgc7q7Cs7w_30_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">28111000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_V_gJrwZ-REmNioVsVGejow_30_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">27887000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_r6J4a8TQL0mPD-Y20yGlOw_31_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">11790000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_6wB0O595b0KMnaWoGLFVXQ_32_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1779000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_o0WuplLQl0WsePbKGthceA_32_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2472000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_SYiW7xGTuUCYX2bAjnvv_A_33_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4031000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_OMvQ9BsQe0iQ3Y6taAwPTw_33_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_S3cSbeOUe0qyxYml6nsKLw_34_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">33921000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_yV-x86T1REyjrDA4syw7MQ_34_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">46525000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_RSwatuqNzUGT5zBwojc0eQ_35_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">68223000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_UZ-ue90350GGDp6LKe6EAA_35_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">79701000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_TYPzDLzmkEy_3KQLh9d0fw_39_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-11514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_8CL8iLb6wU631bK5rPBK2g_39_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-6036000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_PZRKeHnDJ0-dsH_z-tA37g_40_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">56709000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_xP9vfPiAz02YfCjjYWZMKQ_40_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">73665000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pveYO1f-lkC05eDMbh02IA"
      decimals="-3"
      id="Tc_EZSHOwnsF0uCjOkngPu9Zg_3_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">21222000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_D5y751RR1UqvCc-Q5th3_Q"
      decimals="-3"
      id="Tc_TcIUYR_PlkynUfKX5c48RQ_3_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12260000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_ivy2EExMakeWgn87BPkvjA"
      decimals="-3"
      id="Tc_-TYW6nhElUKF6mDGLEiNhQ_3_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8812000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KItA5s_IX0OM8e34BU2fSg"
      decimals="-3"
      id="Tc_dIF_8dTb3kKDFOJ7FdoKug_3_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4506000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_GM0fNZn86UWpPaTCwWm11w"
      decimals="-3"
      id="Tc_xit7HQzmdE-XQGubCEefWQ_4_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">17799000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_O1a6ViT3C0ewVHZtdm2T7w"
      decimals="-3"
      id="Tc_9T5ITSyDoUWn88sB76IITw_4_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">17541000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_MXh1QMX0OECsjpG02kpLTg"
      decimals="-3"
      id="Tc_MxKayJPnak-7OvSiOCaxQQ_4_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FTvwbQ8tckqFhCmnA1b1uQ"
      decimals="-3"
      id="Tc_bv992tnw2UaNJ7Fq0UhRXQ_4_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7548000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_wPfEh7lMB0i_Q_8i6PlGAg_5_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">39021000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_edfP_d1Ql0ew2IoDnK46CQ_5_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">29801000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_yOB7wYTdEU242qBvwc6Y9Q_5_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">14183000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_YF48IRUzjEOkUtedluU_3w_5_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12054000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_n1C5k2ZMdEuoT8DpSwmt6A_6_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">17195000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_T0gb_nfGqUeRzjM7fAUKPw_6_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">13201000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_18eLu7jalEK2GyS3JEZ_ag_6_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7074000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_qlSyO4TcwEahO_lTGSCRZA_6_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3703000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_CtU7fJlFLUWK-2ZJEB02fQ_7_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">23732000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_PZ1_rxCXYEaxToDczyclvw_7_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">22093000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_WaAF5qNXF0-z5XWCXH-7Ig_7_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7386000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_qjIjttn8v0KRquu6KCJZJw_7_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7282000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_I4Sv3meE2EW6qmi-m0GhGQ_8_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8613000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_bnjj10L9rkeBXEn0PgCW6g_8_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">9263000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_Yj9I9ljr_EWcICY-fdWM_g_8_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2848000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_gSI0-d_O5USkjePB25wk1w_8_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2954000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_xjx9-fNKUkSq2EDRAmZsiA_9_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-10519000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_PuqC1fUoH0ef4ydQUDxEvA_9_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-14756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_bS1bEpfyPkOgcFHGluAxGA_9_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-3125000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_efKIWs1db06MzLH8iL4MqQ_9_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-1885000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_RQwaO38BxEm4hwxHjrBkGw_10_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1879000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_vk4HyRGE7k20PqhX0gGOZw_10_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">6613000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_yJ853HzSG02cuXA6uzc--A_10_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">639000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_L47NrjXzMUGbctSz9wek9g_10_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2410000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_98cXCMwywkuOjdzwTfQhtg_11_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1211000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_dRrXZYDG-ECVNoETLI-Uvw_11_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">403000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_37w64IB5HkS-gpMbRoNJaA_11_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">197000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_S1bJCfcQnUuZkqV9L3TDaQ_11_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">96000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_9XD4gPllm0-1uyP2ukaXjw_12_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-668000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_QznMrvU8EkaLuJcZoZBUuQ_12_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-6210000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_VTxWv498r0aPBhsjZQ0leg_12_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-442000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_uFw60wrAQ0u9E63TqCU9_g_12_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-2314000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_anByqlOInUyYo0hDG5WaNw_13_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">51000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_3cPXCfD7Qk-vZnMgEk1raA_14_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-11187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_s3sZ2DD0jkOWh9gUYZM_kQ_14_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-20915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_eg2SJBeJrUi7PSB8n3ZI_Q_14_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-3567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_1PixscLaQEGtybV57VOpNg_14_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-4199000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="2"
      id="Tc_MuYLdn-R2UKBtpRphH99sg_15_3"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="2"
      id="Tc_5ftVwfeC9UOen-aznHt5ww_15_6"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="2"
      id="Tc_UgeAggBo-EihCwZdaOcxCg_15_9"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="2"
      id="Tc_TK71XM1vMEKqGLgYBrX6GQ_15_12"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="0"
      id="Tc_w8JuZnaHRkifTb5c9G8VzA_17_3"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">47582733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="0"
      id="Tc_ueCx8a7Mg0uHeQ_aXst_HA_17_6"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">43761769</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="0"
      id="Tc_KiLXB6HwU0-xEVwybacoSw_17_9"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">49498105</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="0"
      id="Tc_LBuSW30SIkyo8rS3ZMB1Ug_17_12"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">45556647</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_OZrCQjIzZEa_Imuc6kFkfg"
      decimals="-3"
      id="Tc_9m3GgFyeGkOKTsjPcMSwKQ_18_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">58000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_b3jRdtg_20SDBBcjXHfzTg"
      decimals="-3"
      id="Tc_yuH7ZF9D_UOS6PmX_nYLfw_18_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_TpBThY-o1UO9jj7QH2sP0A"
      decimals="-3"
      id="Tc_GynBVznkQk6KxCQcjPI4hQ_18_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_6dFVaa8MP0mBiDmzAt8Y9Q"
      decimals="-3"
      id="Tc_aaFtaJkdn0C4LAsolG99VQ_18_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">65000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Vftn1tQ1hUCzVmrnQgfT1w"
      decimals="-3"
      id="Tc_E96rwd8OuUKc_ShsXgj2ew_19_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0sCNP7rIoky5QN2CONKd6Q"
      decimals="-3"
      id="Tc_E_SFV4k4zkq13CX1ROXf5g_19_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_D2abpIHIxki6wHgQcLCQlw"
      decimals="-3"
      id="Tc_aaV5eG7DnUaezNaaBd5lnQ_19_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_P__KdEwYTE-FwaUrq-H-4w"
      decimals="-3"
      id="Tc_uKuYati1uUyEOfi412cXzA_19_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__e2stD8DXUakAd6Cgk7bXg"
      decimals="-3"
      id="Tc_n9GUemzmekaWQ2xsmS1kVg_20_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1213000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_-CFgg0SHbEuiMRjiTw4qOg"
      decimals="-3"
      id="Tc_zrCMdVORKkWYUrY5s29hvA_20_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1216000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FZ5IV3EHuU2VQz4Oea9P-A"
      decimals="-3"
      id="Tc_zycUQBq5S06lADvguNE2Hg_20_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FoX-isrF7k-mTWZnrW05yQ"
      decimals="-3"
      id="Tc_M6lqVvPe7kGeIbShr-nlFg_20_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA"
      decimals="INF"
      id="Tc_7myOcM5WM0WoI1yAP70r_w_6_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA"
      decimals="-3"
      id="Tc_KGRKar0xoUmwtm9LJk4j5A_6_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf5bZps_2EenQQ2ZpXcHZA"
      decimals="-3"
      id="Tc_CMGnZ7Oep0WGKGlVt4RrMA_6_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eR0GjrjuNk-nDafPkPNl-Q"
      decimals="-3"
      id="Tc_mIcl0M0QMUeYDhnUetVV2Q_6_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_7nrXjB6c6Eq4cT3hYF-X6A"
      decimals="-3"
      id="Tc_tXe0MMCA1keCKw7eJnnKOw_6_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ"
      decimals="INF"
      id="Tc_bhYLgp5R10uXYjtxmQhObQ_8_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ"
      decimals="-3"
      id="Tc_R3wJKlPAakWygqXSnMEfsA_8_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw"
      decimals="-3"
      id="Tc_tyJmVHjNa0-pNBV72zGKgQ_8_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_ZgkYx7NcpUiYE4Bw2kovNQ_8_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ"
      decimals="INF"
      id="Tc_nmq4JRk3-EORS1MItaKcMA_9_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ"
      decimals="-3"
      id="Tc_cPTbRcieVEOAU4O1ilHpxg_9_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw"
      decimals="-3"
      id="Tc_91oiHKU0n0y9Eg-iczczQA_9_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_uTksoCEPNkWp5u42OIbXfA_9_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw"
      decimals="-3"
      id="Tc_W-YL_y-zPUyc6RiZbFbfEA_10_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_fJkrft4PukyyA21jA5DqYQ_10_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw"
      decimals="-3"
      id="Tc_YPiKBNlrMkO87pM4KJ_lgQ_11_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">781000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_RyC5PoQdNkWuJscZI0vS8w_11_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">781000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7Z2dPZ1-AkWklZt1jKEITQ"
      decimals="INF"
      id="Tc_thi13ixbeUuHkrsQiITRkA_12_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw"
      decimals="-3"
      id="Tc_PPq59OJZ-EyHeTd1IR5Caw_13_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_B3baeuMlikq0uFyJofYr7Q_13_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ln5xt5_as0q5DTkZVDl1Cw"
      decimals="-3"
      id="Tc_v_r3xsIAj0eD42fSIB9b8A_14_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_ybT63lB5e0WWphMjr76Eug_14_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eooI9ZYRYUK3xtjGWM-3Xg"
      decimals="-3"
      id="Tc_tX5Ka78j5E2pm6rz_lqnDg_15_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-20915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_4WEtThlMqEW3J01lwrZabw_15_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-20915000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg"
      decimals="INF"
      id="Tc_Vg3ciLhkvU2HwfGsU6fBMA_16_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg"
      decimals="-3"
      id="Tc_eeqY-m3ZiU-YUW0ep9Lz2w_16_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TSLrDFkfsUiXaEXbJNE19Q"
      decimals="-3"
      id="Tc_8LCe2ZU6KkaCh2aoS0xo8w_16_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">368434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u-zmvKk_nE-TsUTpTrb0yQ"
      decimals="-3"
      id="Tc_6xpW-4a_Fk6CiNMuzpCJzw_16_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-368267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ"
      decimals="-3"
      id="Tc_UwYGfqxlCkGpZ00qg_Wclg_16_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">213000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AdqKFA4TTkyOitbYq9oh_w"
      decimals="INF"
      id="Tc__yTrLzsAdUy18I39T73gtQ_17_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AdqKFA4TTkyOitbYq9oh_w"
      decimals="-3"
      id="Tc_gjTJeEqezEGiFL1IssL4jg_17_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_csxCWMqCMUKoZEBkfV_2Hg"
      decimals="-3"
      id="Tc_3KLWemeVG06RqEp1SS6lKQ_17_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NsMLImWFUkKskcZiXRX0ZA"
      decimals="-3"
      id="Tc_SOaWnn2EmUi1CftS6s91tw_17_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_CYY-GljXhESdP1dv-9xdVQ_17_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-6036000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ"
      decimals="INF"
      id="Tc_ITEbUeMAOE6-Yk33cXimLQ_19_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">3841479</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ"
      decimals="-3"
      id="Tc_5uwPQ0KnEk-9goFriGSvJw_19_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw"
      decimals="-3"
      id="Tc_lCOe0y3Dr0y5Z5D8f-zmGA_19_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4157000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_IUPJCUiZT0-lNKaZaJrtaw_19_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4161000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw"
      decimals="-3"
      id="Tc_lGwBzCUooUWKc33CTF038A_20_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_f9Br8VV0YkmPF-6Ovh63Og_20_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ"
      decimals="INF"
      id="Tc_HAxVYURivkuRqA9qj9Po-g_21_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw"
      decimals="-3"
      id="Tc_BAXt6XMF1UGOrfGOBqzkAg_21_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">954000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_xfIJ_MzbKEK_S386o7fpRg_21_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">954000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Zcrk9Cdk0-h4B2rXbCRKQ"
      decimals="INF"
      id="Tc_mHwqVUwizEODPiRPsC9Dbg_22_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ia23T9zc_k6TufsByJcWRw"
      decimals="-3"
      id="Tc_P5P6jQKJgE2mzGjdDLYxtA_22_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_mb5g8jYmhk-30wN-tX-0fw_22_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8IZaBt_-TE-hj4hdLTni3g"
      decimals="-3"
      id="Tc_qD4gD_E27EqZfW7VJ0o8_w_23_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-11187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_Pp-WMPNCJU-TjS2zToGNHQ_23_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-11187000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ"
      decimals="INF"
      id="Tc_OYKLN2fRrECF_oKOrOvfaQ_24_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">50158608</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ"
      decimals="-3"
      id="Tc_5y1nSnqiEEqfy6zyHDQrGA_24_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o3NakbeXoEead8-t7k-62Q"
      decimals="-3"
      id="Tc_zeMKtK-RBkmUMikY3iA97A_24_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">374557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWdI5ZA6vUyC15HD3EjNzg"
      decimals="-3"
      id="Tc_SpswBqUiwkGp_o4eZ-rlVA_24_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-386121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_8IFasy3qMUGlJyrEoWWYlA_24_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-11514000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v6SRUqykhkq9NDJkMs8VCQ"
      decimals="INF"
      id="Tc_rTnP4f7RQkGQNUF9AcRd8Q_25_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v6SRUqykhkq9NDJkMs8VCQ"
      decimals="-3"
      id="Tc_nrCiS1Y-XE-DdNlpzQ7UJA_25_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li6VzojNEkm79l_inaRUZg"
      decimals="-3"
      id="Tc_YhZ3EhcepkKHfsYBSlU8DQ_25_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">367863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oi1iFnUfUk2j89URToy_FQ"
      decimals="-3"
      id="Tc_kptODVYgX0mL6B8lGviJlw_25_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-364068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_oaSi65tpAEmtBYUa7viC5w"
      decimals="-3"
      id="Tc_NjILO9nWN0WI5I4x8zenVA_25_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3841000</us-gaap:StockholdersEquity>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug"
      decimals="-3"
      id="Tc_iRU2qM9aSUySigd3KNbnDQ_27_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_SY0ra7Hs706F3C5FBfRG2Q_27_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug"
      decimals="-3"
      id="Tc_Ob-peZxaKkeF9-dU-GSE_w_28_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_WoykLfytokyxzBbzOpdomw_28_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug"
      decimals="-3"
      id="Tc_P7fcpNZZ-EyInOdxRP8bqA_29_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_JvjNxrNZlkm-ufvETJjYEw_29_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f47OupcqeUuXXDe-24nFug"
      decimals="-3"
      id="Tc_PihsPEe2U0aD07V-tIscVQ_30_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">219000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_xpOE2tuRQUKYh_zHHT4q4w_30_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">219000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kCjfzxrofkaqU5KXQCoK5Q"
      decimals="-3"
      id="Tc_wTWFXxBmZUOoFXkiKY8T2A_31_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-4199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="-3"
      id="Tc_RgsnQjbavUq4BJiIjCro7w_31_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-4199000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg"
      decimals="INF"
      id="Tc_3tg0jVyZPkSbuRThcWb5oQ_32_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ecmY16DCHkutdU2GRW3Nrg"
      decimals="-3"
      id="Tc_LIPnC2DdPE64sd3NDchhog_32_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TSLrDFkfsUiXaEXbJNE19Q"
      decimals="-3"
      id="Tc_9luqNn20m0eS2s28mMEweg_32_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">368434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_u-zmvKk_nE-TsUTpTrb0yQ"
      decimals="-3"
      id="Tc_u5ytG0BakEK1ZunrzPY_DA_32_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-368267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ"
      decimals="-3"
      id="Tc_eYI-y1XQBE-JOZdlMUcSsw_32_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">213000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bD4jRYV9p0SrHNp39PFY8g"
      decimals="INF"
      id="Tc_IdjnDwkcNU2CiDqYLit86g_33_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">48712952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bD4jRYV9p0SrHNp39PFY8g"
      decimals="-3"
      id="Tc_LX47omDL5UqlTxT2hjqP9Q_33_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6b9M0fMDnE-ONxperA-Nqg"
      decimals="-3"
      id="Tc_Et5b-R_OK0-u8sRHWFEMvQ_33_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">372616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kCsglji7kOkuf4CbzkCjA"
      decimals="-3"
      id="Tc_dn4gO1fkA0O2mZ-2604r7w_33_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-382554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_rxA6MsPFmkGcr9wRVnhiBw"
      decimals="-3"
      id="Tc_7JBrTbU5qUiyyB6h3oYM6g_33_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-9889000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qayOenlWNEakzQ457tclgA"
      decimals="INF"
      id="Tc_AuSuHn18CUWgsioZExaEAA_35_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">1445656</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qayOenlWNEakzQ457tclgA"
      decimals="-3"
      id="Tc_pw7Guwmle0aRhN6-TkqufA_35_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ"
      decimals="-3"
      id="Tc_d4QSbIpXOEmchVx5bEpnVQ_35_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1519000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_LjbQKHzndEC4jmWbqgL34w_35_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1520000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ"
      decimals="-3"
      id="Tc_pEkxcLDOoU6SGO7OdDNZ-A_36_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_o-CvDYmPuUavoJH67yXGlw_36_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qsEWb1woIkWFUE-6wXisQQ"
      decimals="-3"
      id="Tc_V2dXKXqBWUeq5UEfxZL-vA_37_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">124000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_6STBZSAljkGwF88ODcTFSw_37_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">124000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3bFqnnwhSkCeJGvIIsUgXQ"
      decimals="-3"
      id="Tc_Oif1c2ZFbEqnGoi7mauoJg_38_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-3567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="-3"
      id="Tc_rlR2AEimJ0C0eMHm9-vWNw_38_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-3567000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ"
      decimals="INF"
      id="Tc_EepnTc1-w0y2oIaq8ImdXw_39_2"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">50158608</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_04yQIpEqOU6SVPrIqRCXoQ"
      decimals="-3"
      id="Tc_uKpjFerMJEqOAAMx4ICcBQ_39_5"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o3NakbeXoEead8-t7k-62Q"
      decimals="-3"
      id="Tc_yRGulH5T_0W-LN2z4M0S5w_39_8"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">374557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWdI5ZA6vUyC15HD3EjNzg"
      decimals="-3"
      id="Tc_SKP1agIYPUm8mPQTOfceOg_39_11"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-386121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_osfgZ77GXkWLxQUf1W4IYw_39_14"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-11514000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ"
      decimals="INF"
      id="Narr_dl7uBDirjE6QS0BEmdnRCA"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="INF"
      id="Narr_jQ8XkMNsYUqPiCTxzMSACg"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="INF"
      id="Narr_HW07niUoVUSdDPm97WCYQQ"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ"
      decimals="INF"
      id="Narr_1cmgsjsZs0yEwB6kJxw1jw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_und9JNrMq0Wpan1HiBx4Zw_4_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-11187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_SUgayADK2UqxZlziqSiYqg_4_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-20915000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_so5Pf5GFEEy6RsKTNHMBAQ_6_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1546000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_rPHuO55oHUGcGwH01AhGwA_6_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1957000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_XfraYtw6MEGW0Kk3xMBW_w_7_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">811000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_O4fkfoU8VkaW_9QCLaWJgA_7_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">859000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_1911ZquTo0GJe5BQsyqtxw_8_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1083000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_iq8YVkI2P0CkTz_cxKhZLw_8_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-118000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_6F8Xc_h2Ck-44jFkVauUNQ_9_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-391000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_FuEeyAa5LUiIUA_480SdlA_9_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">100000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_V8xX1m1dl0-nLlJSV8hZaQ_10_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-6000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_JRAsaNkXukWTaXKOlITptQ_10_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">75000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_k1F78r-GDEa57alkdKuLIA_11_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_mk43WsM4iE2QiN_fx6Zz_A_12_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-831000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_6OgvB-oh1UuEpHKT9aXLIg_13_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">224000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_Xodw0bCoukOeBmWOpddDtA_13_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2569000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_8paqUBBu_UK9JlVTaTuTxQ_15_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-5547000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_ATRTQe1hAkmUF8N_kW9zug_15_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">13945000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_VlyWizq-bkuhdEmexg5Mqw_16_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">5692000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_SEQY8tWjeE6BjxkNCDlPEA_16_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4075000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_q0uoV8HLGkKeo0Iuq8ipdA_17_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">30000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_UWQsajy2wUiOS5Rf-nMOkQ_17_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-168000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_cSp6UH4TKUCzvSf20RviTA_18_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-3392000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_hWJvIybNzEqlXLedP5ijZg_18_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1648000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_3eoLl999a0uE3duiKqrOpw_19_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-4438000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_qCPguKFn1Ee4V3_HRGD0vw_19_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1070000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_lt14_SqQh0irlPIF47sS2g_20_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-51000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_hV8ko67q10SGZbRo4gMplA_21_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-22389000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_m_DVSFqa0k6ku3XReqXCsQ_21_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-5198000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_6U-GTyFlckWP_qgDMu-Euw_24_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_aHHuv8tgpEmmlDiZ1TVgVQ_24_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_xK_1MLv9Mky3R02cq6JuXA_25_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">6000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_2NnXUMsYzkO4X33_L460DQ_25_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">20000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_i2we3Zq-Z0mQjKOcGL4yrg_26_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">415000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_I-DMJ1uHvkmMVZJBfHk58A_26_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1011000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_BjSr7bBh6EqujICF3Y7Rbw_27_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_zPquRW_LEki0Rb4LIsBVBQ_28_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-359000</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_W5TvRX_aUkWWxmTdSNC_Fw_29_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-427000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_gQBT22reBEm-M4G_-acXTg_29_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">81000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_L7u--7LnSkSMUsOB9R0cHw_30_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-9988000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_ympvYt_Lc0-QJP5CRKDKeg_30_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-18515000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_W1Bkfb_TOUWnWlDvZoW1sQ_33_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">25990000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_RSIyUKY3AUG2Ge8n_n8I8w_34_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4086000</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_2wa6P2AHOk-FCM8KoqawJQ_35_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_rjC-jG41ikuBoCxZJlDaBg_36_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4161000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_FNbpIszMpUyL4ajGxHYdPQ_36_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_jZwnrtdOJEWWj0g81spgtg_37_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_0y1XOPCgcE-NoFg69KNB2A_38_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4163000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_aLq1MqgMZE6IffkjFrrwHw_38_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">16124000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_cvSDSkXu1keo-Iy9tTzsMw_39_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-51000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_nsNQ7Kvb3kCu1uMynxoDTw_39_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-34000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_BZb-irv9rU6FgXncSmGNXg_40_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-28265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_kgR-P5nbeECTyNVQ2vh_rw_40_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">-7623000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_pQUYs3QBjEujjcG5hYd2vg_41_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_7nrXjB6c6Eq4cT3hYF-X6A"
      decimals="-3"
      id="Tc_6PBbo82BQ0O-U5rOBXBqYg_41_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">18265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_JxMgTLfLCEmjAlrrRC0bgw_42_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">10720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_crAfM3EDDEq4Ht9MjRfloQ"
      decimals="-3"
      id="Tc_Hit-50D2HkmekcppCUzdSQ_42_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">10642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_b6c6TzAAMkeRYzJ4TVvKbQ_4_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">205000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_B7mXlaprYkG9BKHIbF1U4w_4_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">387000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_rrNgfABxzEuEWpf3gzVBvg_5_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">396000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_LvRMQeGMZEqcO0j0q1jCtA_5_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">309000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_cP87xFECJkWg69RujBiPfg_6_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">774000</plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_Csh57hkiZkKFdq1qVG3v1A_9_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2198000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_XfzTcCdk_0aZQdZ5eCN_6w_9_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3288000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="-3"
      id="Tc_Iqi26jmaRkqqfFsP5SLaTA_10_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">136000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="-3"
      id="Tc_UATxAef26ECCmgTA-f8w8g_10_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">445000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_YJbpsfEshEGcuSugvqRu_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 Phase&#160;III clinical program includes three separate studies, referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#x2019;s drug/therapy. In addition, the Phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On November&#160;9, 2022, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), resubmitted to the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) a biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, includes the final two-year analyses of the Company&#x2019;s phase&#160;III &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; clinical trial of PRX-102 (the &#x201c;&lt;i style="font-style:italic;"&gt;BALANCE &lt;/i&gt;study&#x201d;), which were completed in July 2022, and long-term data from the Company&#x2019;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 to the European Medicines Agency (&#x201c;EMA&#x201d;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#x2019;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternation treatment for adult patients with Fabry disease. The submission was supported by the 12&#x2013;month interim data analysis generated from the &lt;i style="font-style:italic;"&gt;BALANCE &lt;/i&gt;study. Data generated from the Company&#x2019;s completed phase&#160;III &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; clinical trial (the &#x201c;&lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study&#x201d;), the Company&#x2019;s phase&#160;I/II clinical trial in naive or untreated patients, and from the Company&#x2019;s extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA includes data from the Company&#x2019;s completed 12&#x2013;month switch&#x2013;over phase&#160;III &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt;&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage (the &#x201c;&lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study&#x201d;) to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (the final Clinical Study Report), and an interim analysis of the Company&#x2019;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of September&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $15.6&#160;million remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) under the initial Exclusive License and Supply Agreement (the &#x201c;Pfizer Agreement&#x201d;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The novel coronavirus disease (&#x201c;COVID-19&#x201d;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2022 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, &lt;span style="font-family:'28mugxoulnobhnx';"&gt;under the terms of the Company&#x2019;s &lt;/span&gt;outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, the Company is required to maintain a minimum cash balance of at least &lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;$7.5&lt;/span&gt;&#160;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;million.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;not include 33,922,624 and 33,295,154 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2022, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_Ri8qS6iMRU2_XmJtduzsxg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 Phase&#160;III clinical program includes three separate studies, referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#x2019;s drug/therapy. In addition, the Phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On November&#160;9, 2022, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), resubmitted to the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) a biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, includes the final two-year analyses of the Company&#x2019;s phase&#160;III &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; clinical trial of PRX-102 (the &#x201c;&lt;i style="font-style:italic;"&gt;BALANCE &lt;/i&gt;study&#x201d;), which were completed in July 2022, and long-term data from the Company&#x2019;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 to the European Medicines Agency (&#x201c;EMA&#x201d;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#x2019;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternation treatment for adult patients with Fabry disease. The submission was supported by the 12&#x2013;month interim data analysis generated from the &lt;i style="font-style:italic;"&gt;BALANCE &lt;/i&gt;study. Data generated from the Company&#x2019;s completed phase&#160;III &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; clinical trial (the &#x201c;&lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study&#x201d;), the Company&#x2019;s phase&#160;I/II clinical trial in naive or untreated patients, and from the Company&#x2019;s extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA includes data from the Company&#x2019;s completed 12&#x2013;month switch&#x2013;over phase&#160;III &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt;&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage (the &#x201c;&lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study&#x201d;) to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (the final Clinical Study Report), and an interim analysis of the Company&#x2019;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of September&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $15.6&#160;million remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) under the initial Exclusive License and Supply Agreement (the &#x201c;Pfizer Agreement&#x201d;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The novel coronavirus disease (&#x201c;COVID-19&#x201d;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2022 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, &lt;span style="font-family:'28mugxoulnobhnx';"&gt;under the terms of the Company&#x2019;s &lt;/span&gt;outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, the Company is required to maintain a minimum cash balance of at least &lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;$7.5&lt;/span&gt;&#160;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;million.&lt;/span&gt;&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7H_2K0nM006KXiMtIxq9sA"
      decimals="INF"
      id="Narr_RPt2DDYQRU62gQfZ0yIQDg"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw"
      decimals="-5"
      id="Narr_4BUPV6Fg9kK-r1fyiHpRbQ"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw"
      decimals="INF"
      id="Narr_NRMsIbDPfUyPE-dWTLIODg"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_7XtIUOB_GkCxWXA36LcIUw"
      decimals="-5"
      id="Narr_3HDMzFrIR0uAQbC3b6d1VQ"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q"
      decimals="-5"
      id="Narr_G_g56DQMmkWLBHrysfc_vg"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">15600000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_FwE5KZrKh0-_yTQHyIr5xg"
      decimals="-5"
      id="Narr_RFU60S1LzEC0Wm768K0U5A"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Htz4Xmw9BUOG0UfER5r48w"
      decimals="-5"
      id="Narr_gYlPS88PVEqstvsnCvggHw"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A"
      decimals="-5"
      id="Narr_qUrxS0DELk2GgkQuFLAI4g"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A"
      decimals="-5"
      id="Narr_K5ozBnhhpEiNlu38nXGTBw"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r7_2kCqW3U-SMvg7bMkN_A"
      decimals="-5"
      id="Narr_h48aN9U8zUaCSNssI4BjUw"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug"
      decimals="-5"
      id="Narr_s3ONBNXOzkuZ29vgWTNy5A"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug"
      decimals="-5"
      id="Narr_O2USIXmUuU-a7GuKpO6aXw"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6EuAvpW20UKGavIVUWTaug"
      decimals="-5"
      id="Narr_VP_fYfvDoEWMW1Qlxkk5pQ"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_S8KAN140aUmNwYXLjfuU2Q"
      decimals="INF"
      id="Narr_GECO7avwe0SiRvpGwYoS3g"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3mw68fgma0ShyyRQq7AwBQ"
      decimals="INF"
      id="Narr_3Pd79iVMAEOJeUyfKITImg"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wwuvWu9CNkGPR5tF60aEww"
      decimals="INF"
      id="Narr_i4qkWrMZT0ygcjRujv_Z_Q"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wMq9gBW5wk-NkT7WyGmXVA"
      decimals="INF"
      id="Narr_UYV6PHztD0uoUBzIvlxzbg"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_NS6ZViowGUycZBQ7Si9mxQ"
      decimals="-5"
      id="Narr_86dyIn3gtUCgFiwVsZdE0Q"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r9AEUZN090WxWVevOrEmew"
      decimals="-5"
      id="Narr_7wB6naf8lEmHxL6xswf8YQ"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_5rkf-nGdtka3BrgWc-Tu5Q"
      decimals="2"
      id="Narr_t7QPcoLFAU2c9DaoYp_RwQ"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_W1rR-tiQQ0WX0Mrz4mB2wg"
      decimals="4"
      id="Narr_AnTZrCvQUk2Fe5qRz0H3ig"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_W1rR-tiQQ0WX0Mrz4mB2wg"
      decimals="-5"
      id="Narr_3oVU---160KOAGOOhZlydQ"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_Aa6rexGZbkaKfxVNmZsvTQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_hVOIBFE_RkGmz5l7llkb3A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;not include 33,922,624 and 33,295,154 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2022, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) and the exercise of outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ"
      decimals="INF"
      id="Narr_Rb9S1U42FkyR6mC94pBnlw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">33922624</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      decimals="INF"
      id="Narr_F_ZUvHwY10OBJRxyQj8M5w"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">33295154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_bGac4PHQXk29zw5m8jNh1Q"
      decimals="INF"
      id="Narr_pyWn_rqPR06AEa-Pyy9BCw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">27962842</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_NfV3bTe4F06X2BeEJVnSbQ"
      decimals="INF"
      id="Narr_AIbyXx1F9EOIExuL7l55Xw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">26847081</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_IaxJhLjT5EG26liBngcw3w"
      decimals="4"
      id="Narr_llWVDVcbjkqCjQK5PGKyyQ"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_IaxJhLjT5EG26liBngcw3w"
      decimals="4"
      id="Narr_aPMRnZQXT06f4SvapTWl8A"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_xh1bRm0L5UKyrVUGnwwVuQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Dh9X97v5V0KmJgH7rEd7Iw"
      decimals="INF"
      id="Narr_GuiCDyV5ykCq9CNc2g2HRw"
      unitRef="Unit_Standard_agreement_3n4b8unPO0K-5i9HzEyFQQ">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_0rROMhs5yUKYXdSh3nzpYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_MKwPLLA64E-8LZ0CbMdc4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_SNbibtJdJUCfk3pR8CT63g_3_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3664000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_lMwaNDS0KUeSQnkdeckE2A_3_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_uveb0I0CcEyoL6iH3Go_kg_4_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2619000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_tzvd7DmcikeePD3KdwPYcQ_4_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3262000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_mbxzAIBomkuWnsvUiR4O9A_5_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8279000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_hG1hTdLa1kCRQyJB2sgVFA_5_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">11526000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ"
      decimals="-3"
      id="Tc_zahFTfabn0mF98SR09PIXg_6_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">14562000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_6Q5S8xRY_06h0vyN2RiG6g"
      decimals="-3"
      id="Tc_JVvcAwfEgUqVJo5fb96pXQ_6_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">17954000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_pk1VPtFh3UCkuewwPXK1rQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;As of September&#160;30, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level 3 measurement, as of September&#160;30, 2022, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $30.9&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A"
      decimals="-4"
      id="Narr_3cme8TQWb0uuWwkHHBva4A"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">28750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A"
      decimals="-5"
      id="Narr_S2Y0b5ZTZkmPW2GU9ojF9g"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">30900000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0XmRqyM5IkSNgT9vMbeyqw"
      id="Tb_xu_ttNOxXUyCW9-c5VBGyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_HH1mRiFsa0qJN4a4_yJ33w"
      decimals="2"
      id="Tc__ZGQz-Q560-IAR0-3jwQeQ_2_5"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">1.04</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NzJ2ZKx5l0SOQAjJS-KHfw"
      decimals="2"
      id="Tc_RLyurxSGOkujZeQsjW2Uhw_3_5"
      unitRef="Unit_Standard_Y_6_2ecVNG4kOwBZw8VWtz7Q">1.92</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_fpSaaWnM_kqRxthhVgZ0dQ"
      decimals="2"
      id="Tc_y5Ywga-qgUabhJgCK9fx7g_4_5"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">4.26</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sjuUQKwTikGShcjRQ3wqGA"
      decimals="2"
      id="Tc_e6HeHGqNkUKLEXK-ReKaOQ_5_5"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">75.32</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_lyC38x65I0G8pUXc-Tn39A"
      decimals="2"
      id="Tc_3exXkAOOmUutXdqPwrW3sg_6_5"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">14.18</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_R7YaULuqk0iif382_B2mVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.9pt;"&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.95pt;"&gt;&lt;td style="vertical-align:bottom;width:40.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_HJo-5E27hE-2oJacYOcBhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.9pt;"&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.95pt;"&gt;&lt;td style="vertical-align:bottom;width:40.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ULcGA7VYNkCKoZuU0B0qrQ"
      decimals="-3"
      id="Tc_3aApgYNfzEOB4ZRktHlqDA_3_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4541000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-4dgoH7cSUStclwbyHvr5g"
      decimals="-3"
      id="Tc_yoqEzBiy40StRdu-alcfDA_3_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1135000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0crLeupio0SwfGQZ9ZvUtQ"
      decimals="-3"
      id="Tc_wkA3Hr2gx0-br9C9a2E00g_3_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">11279000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ukBSADqu40uHabngZO-BlQ"
      decimals="-3"
      id="Tc_7wQKkNagFEi0Ep2JDzSZcQ_3_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7883000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_E6HX3L8o1UORIsdQUL7dMg"
      decimals="-3"
      id="Tc_uyqiw41Xj0GymmCNpAJS_g_4_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1708000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jSgenlSB70S_SqMhXL6RSg"
      decimals="-3"
      id="Tc_mNM3BrX8TEaq3zGyFhMK4g_4_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">3200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_weDWoM4FaEy6cA5rEgSlaA"
      decimals="-3"
      id="Tc_LeRj3wYB2kmS8TKzlLu5Ww_4_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7162000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nMiBJOmnlUya-eSouKgGFw"
      decimals="-3"
      id="Tc_IQaIOzSFp0mORkYHV_Kung_4_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4188000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_rBqFi8FTzEq1WlKuF9bz3g"
      decimals="-3"
      id="Tc_8RdYwoUDqEu8tnzs3AUbZw_5_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2563000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_63ussK77mkmthjFePYZl1A"
      decimals="-3"
      id="Tc_XG2VqIXYwE-OYcTpmpfKCg_5_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">171000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_FrWFE9O6FU6tzt749aUeMQ"
      decimals="-3"
      id="Tc_LPFqt4ekoEa3NB-nvgcVQw_5_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2781000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_BukwyZ3SXUKm2PtgAfi0lQ"
      decimals="-3"
      id="Tc_P8uI-_5Smkm3o2YOnOyLxw_5_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">189000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_ivy2EExMakeWgn87BPkvjA"
      decimals="-3"
      id="Tc_bcQo-y4wa0-0rnLQVBk5cw_6_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">8812000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KItA5s_IX0OM8e34BU2fSg"
      decimals="-3"
      id="Tc_-3oz1Qf2TkC_9U6f4yFagg_6_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4506000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pveYO1f-lkC05eDMbh02IA"
      decimals="-3"
      id="Tc_Xclba8Z4q0GNleTzUXt-UA_6_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">21222000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_D5y751RR1UqvCc-Q5th3_Q"
      decimals="-3"
      id="Tc_0JD-vWFSc06skTRrZKxuUQ_6_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">12260000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_MXh1QMX0OECsjpG02kpLTg"
      decimals="-3"
      id="Tc_arTf3lozzEmt7I9t2D_-kA_7_3"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FTvwbQ8tckqFhCmnA1b1uQ"
      decimals="-3"
      id="Tc_t88abspYtUKaUx69sqhxeA_7_6"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">7548000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_GM0fNZn86UWpPaTCwWm11w"
      decimals="-3"
      id="Tc_Tdl7xBwsaECDGWJUTyCI8g_7_9"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">17799000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_O1a6ViT3C0ewVHZtdm2T7w"
      decimals="-3"
      id="Tc_fuIiPlHxakuXDTurIo8wYg_7_12"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">17541000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_o_wbBkSYlU6dJZTCknE1ag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; SHARE CAPITAL&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Authorized Capital&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On June&#160;30, 2022, the Company held its 2022 Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;). At the Annual Meeting, the Company&#x2019;s stockholders, among other matters, approved an amendment to the Company&#x2019;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 120,000,000 to 144,000,000 (the &#x201c;Charter Amendment&#x201d;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on August&#160;2, 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Stock based compensation&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On February&#160;25, 2022, the Company granted, with the approval of the Company&#x2019;s compensation committee, the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:108pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;I.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;637,531 shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $523,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:108pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;II.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;121,951 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $100,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On June&#160;30, 2022, the Company&#x2019;s stockholders, among other matters, adopted amendments to the Plan to increase the number of shares of Common Stock available under the Plan from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5,725,171&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8,475,171&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares and to amend certain other terms of the Plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On June&#160;30, 2022, the Company granted &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Zw_3KOfSQU6x2J-upO1Hdg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; options to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;40,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock to a new director serving on the Company&#x2019;s Board of Directors under the Plan. The options have an exercise price equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.09&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share and vest over a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; period in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;equal quarterly increments. Vesting of the options granted to the director is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$32,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;4)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On August&#160;1, 2022, the Company granted &lt;span style="-sec-ix-hidden:Hidden_TR-D_RlREEGMWjkHWnc9rQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10-year&lt;/span&gt;&lt;/span&gt; options to purchase 160,000 shares of Common Stock to a new employee of the Company under the Plan. The options have an exercise price equal to $1.06 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $124,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;5)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On September&#160;7, 2022, the Company granted, with the approval of the Company&#x2019;s compensation committee, &lt;span style="-sec-ix-hidden:Hidden_IAM58yfoSUWi7YyjTPtjww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10-year&lt;/span&gt;&lt;/span&gt; options to purchase 3,280,000 shares of Common Stock, in the aggregate, to certain of the Company&#x2019;s officers, directors and other employees under the Plan. The options have an exercise price equal to $1.03 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to executive officers and directors is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $2.5&#160;million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"&gt;&lt;span style="background:#ffffff;"&gt;The fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 85.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;At-the-Market (ATM) Offering&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;During the nine and three months ended September&#160;30, 2022, the Company sold, in the aggregate, 3,841,479 and 1,445,656 shares of Common Stock, respectively, under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $4.4&#160;million and $1.6&#160;million, respectively, in connection with such sales.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_rxA6MsPFmkGcr9wRVnhiBw"
      decimals="INF"
      id="Narr_jCd5bgYm9kyI8oxwEsATZA"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_8_2_2022_uKl9eMIZyU6wmrR6-IFDvA"
      decimals="INF"
      id="Narr_r4R02ZrYQEOIo4IgLAwBrw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_oDtUP6CxnkePQUEErUteKw"
      decimals="INF"
      id="Narr_Q-tQfECEFU2WVCV46bIkkA"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">637531</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_oDtUP6CxnkePQUEErUteKw"
      decimals="0"
      id="Narr_g5k5lGhrJkiE2KlCus6_pg"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">523000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_1vc1iVN5MUuWqVvagT41sw"
      decimals="INF"
      id="Narr_FPXxvNz5MU6q9wCUPO52Nw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">121951</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_1vc1iVN5MUuWqVvagT41sw"
      decimals="0"
      id="Narr_JQ6W7Tu5VEebAWAmpwDPWg"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_7Y9PKaad7UCQjX_1X3wmIw"
      decimals="INF"
      id="Narr_f67nnpjx7kKOI1iPsPPneQ"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">5725171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_RB19xNug80KwnklS6AmRlA"
      decimals="INF"
      id="Narr_PbKHoomVqU-btTfJSJX98A"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">8475171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg"
      decimals="INF"
      id="Narr_y__ZEe8fgEqyBdBR1-S96A"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_QEMAQN-BDkGbFVEHLs5KjA"
      decimals="2"
      id="Narr_IlOsrubOTES2ftl-7wPWLg"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg"
      id="Narr_TD7EUWxoPki89QexLLiv-Q">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_3emG3piDO02uQkqX7v4lwg"
      decimals="INF"
      id="Narr_fAhm8lm22E2EYMnAe9mM7g"
      unitRef="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_QEMAQN-BDkGbFVEHLs5KjA"
      decimals="0"
      id="Narr_65pXLzKZ30iLIMjy4v3Syg"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">32000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA"
      decimals="INF"
      id="Narr_l-yYUr9g3U-c7zaxkaU30g"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_kkHU2uv0R0yTrJf1B14ytw"
      decimals="2"
      id="Narr_7FW1xmNx3EmqgbAQcSRNGg"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA"
      id="Narr_s6KjabaNz0W-6zus78VulQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_1_2022_To_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_2eoxf_4SZE2cFPbem8crGA"
      decimals="INF"
      id="Narr_5OICmi3ZNEKf0N21WY3-8g"
      unitRef="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_1_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_kkHU2uv0R0yTrJf1B14ytw"
      decimals="0"
      id="Narr_F2zJKj1wWU29HU3Ws6He6w"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">124000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw"
      decimals="INF"
      id="Narr_IgEOe0BT0EafEvMdbj1kng"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">3280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_GZzd7j7xTUuaSCT_sh1p-A"
      decimals="2"
      id="Narr__FFCTlH2KEuyzKdhwopi7g"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw"
      id="Narr_c0kv3_C8_UyEiNGNLwyO3A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_9_7_2022_To_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_yKp4IjZcPk6v0LTgVjjgqw"
      decimals="INF"
      id="Narr_tw0So6hprUi7hYpEgGSdZA"
      unitRef="Unit_Standard_item_LejqcGwnNkSY1Ic5gZgOgg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_9_7_2022_srt_TitleOfIndividualAxis_plx_CertainOfficersDirectorsAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_GZzd7j7xTUuaSCT_sh1p-A"
      decimals="-5"
      id="Narr_DAqI2HJqfk-4mNoVpc65aQ"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2500000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_vtkGUUeMak2EPx72q3jGOw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 85.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mpZ3bzeTFkeJouERtLBqfA"
      decimals="2"
      id="Tc_PERS53waJkO8vJqFPGVZYA_1_2"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">1.03</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mpZ3bzeTFkeJouERtLBqfA"
      decimals="2"
      id="Tc_fX5iwZZNjEWEpJ-fu_pXLg_2_2"
      unitRef="Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw"
      decimals="4"
      id="Tc_RBxXLZXdpUWP6rCj2Ca55g_3_2"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.0332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw"
      decimals="4"
      id="Tc_vYYAnqKCQUu7stDPNSzhAg_4_2"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0.8594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw"
      decimals="2"
      id="Tc_k9Ji8coPBUyYAocIiLpYSw_5_2"
      unitRef="Unit_Standard_pure_LQpF1lTS0UGyRdhSfsTGHQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_FZF3YFQlPUq0rHQOmeloSw"
      id="Tc_pYzP7OjHl0qnwQudx7raJw_6_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q"
      decimals="INF"
      id="Narr_9_lLD4kCwUiDAd4_7k1YZQ"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">3841479</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_CpKx-mzFKEGNxFx6wijT_g"
      decimals="INF"
      id="Narr_wqts_cYMfk2M9voVkbElJw"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">1445656</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_jMFiAHN-7ESrkEx8MQ_u1Q"
      decimals="-5"
      id="Narr_jl78AfJAYE2sWV2w-KBE5w"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">4400000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_CpKx-mzFKEGNxFx6wijT_g"
      decimals="-5"
      id="Narr_FYWeAOdeEECsH-9dwErF9Q"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1600000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_Xb_AHrGTM06qKOP3T-GG_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; COMMITMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_BAHkbJYPMkyDVzUoFG5QDA"
      id="Narr_VfYjBAyhvk-MPDnwaY97Qw">P7Y</plx:ExtendedTermOfAgreement>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA"
      id="Tb_jiyaq4WzcUCBldI257BBNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;During October and November 2022, the Company sold, in the aggregate, 506,990 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $530,442 in connection with such sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On October&#160;13, 2022, the Company collected approximately 1.7&#160;million from sales to Brazil. In October and November 2022, the Company collected approximately $2.3&#160;million, in the aggregate, from sales to Pfizer. On October&#160;26, 2022, the Company collected approximately $1.2&#160;million from expense reimbursements in connection with its collaboration with&#160;Chiesi.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iwDdKv5AH0-AHSnrWhC_JA"
      decimals="INF"
      id="Narr_b9MGIeoLXEGGhN4R-w_WDg"
      unitRef="Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g">506990</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iwDdKv5AH0-AHSnrWhC_JA"
      decimals="0"
      id="Narr_PSsx75_sLUSFAEmKjFrTzA"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">530442</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_10_13_2022_To_10_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_46nzZWDXz0C-Ml2n7Gftvg"
      decimals="-5"
      id="Narr_Qn31QENUDUGqHb68e9jO1w"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1700000</plx:ProceedsFromSaleOfProducts>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_QWJZhKTEsUGVicty8qY70w"
      decimals="-5"
      id="Narr__oFTAXL0MkyoPgZl6hcL7w"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">2300000</plx:ProceedsFromSaleOfProducts>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_10_26_2022_To_10_26_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ci7oO7k4IkeIa7oHLUkBFA"
      decimals="-5"
      id="Narr_avRuuJw2-UK9s7bpAvCmHA"
      unitRef="Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA">1200000</plx:ProceedsFromExpenseReimbursements>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_HAxVYURivkuRqA9qj9Po-g_21_2"
          xlink:label="Tc_HAxVYURivkuRqA9qj9Po-g_21_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of September&#160;30, 2022 and 2021 &#x2013; 144,000,000 and 120,000,000 shares, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_HAxVYURivkuRqA9qj9Po-g_21_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_nmq4JRk3-EORS1MItaKcMA_9_2"
          xlink:label="Tc_nmq4JRk3-EORS1MItaKcMA_9_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_nmq4JRk3-EORS1MItaKcMA_9_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ITEbUeMAOE6-Yk33cXimLQ_19_2"
          xlink:label="Tc_ITEbUeMAOE6-Yk33cXimLQ_19_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ITEbUeMAOE6-Yk33cXimLQ_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_AuSuHn18CUWgsioZExaEAA_35_2"
          xlink:label="Tc_AuSuHn18CUWgsioZExaEAA_35_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_AuSuHn18CUWgsioZExaEAA_35_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_thi13ixbeUuHkrsQiITRkA_12_2"
          xlink:label="Tc_thi13ixbeUuHkrsQiITRkA_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_thi13ixbeUuHkrsQiITRkA_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_mHwqVUwizEODPiRPsC9Dbg_22_2"
          xlink:label="Tc_mHwqVUwizEODPiRPsC9Dbg_22_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_mHwqVUwizEODPiRPsC9Dbg_22_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_7myOcM5WM0WoI1yAP70r_w_6_2"
          xlink:label="Tc_7myOcM5WM0WoI1yAP70r_w_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_7myOcM5WM0WoI1yAP70r_w_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rTnP4f7RQkGQNUF9AcRd8Q_25_2"
          xlink:label="Tc_rTnP4f7RQkGQNUF9AcRd8Q_25_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rTnP4f7RQkGQNUF9AcRd8Q_25_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_3tg0jVyZPkSbuRThcWb5oQ_32_2"
          xlink:label="Tc_3tg0jVyZPkSbuRThcWb5oQ_32_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3tg0jVyZPkSbuRThcWb5oQ_32_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Vg3ciLhkvU2HwfGsU6fBMA_16_2"
          xlink:label="Tc_Vg3ciLhkvU2HwfGsU6fBMA_16_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Vg3ciLhkvU2HwfGsU6fBMA_16_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc__yTrLzsAdUy18I39T73gtQ_17_2"
          xlink:label="Tc__yTrLzsAdUy18I39T73gtQ_17_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc__yTrLzsAdUy18I39T73gtQ_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_IdjnDwkcNU2CiDqYLit86g_33_2"
          xlink:label="Tc_IdjnDwkcNU2CiDqYLit86g_33_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_IdjnDwkcNU2CiDqYLit86g_33_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_EepnTc1-w0y2oIaq8ImdXw_39_2"
          xlink:label="Tc_EepnTc1-w0y2oIaq8ImdXw_39_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_EepnTc1-w0y2oIaq8ImdXw_39_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_OYKLN2fRrECF_oKOrOvfaQ_24_2"
          xlink:label="Tc_OYKLN2fRrECF_oKOrOvfaQ_24_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_OYKLN2fRrECF_oKOrOvfaQ_24_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_bhYLgp5R10uXYjtxmQhObQ_8_2"
          xlink:label="Tc_bhYLgp5R10uXYjtxmQhObQ_8_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_bhYLgp5R10uXYjtxmQhObQ_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_T0gb_nfGqUeRzjM7fAUKPw_6_6"
          xlink:label="Tc_T0gb_nfGqUeRzjM7fAUKPw_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_T0gb_nfGqUeRzjM7fAUKPw_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_qlSyO4TcwEahO_lTGSCRZA_6_12"
          xlink:label="Tc_qlSyO4TcwEahO_lTGSCRZA_6_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_qlSyO4TcwEahO_lTGSCRZA_6_12"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_n1C5k2ZMdEuoT8DpSwmt6A_6_3"
          xlink:label="Tc_n1C5k2ZMdEuoT8DpSwmt6A_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_n1C5k2ZMdEuoT8DpSwmt6A_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_18eLu7jalEK2GyS3JEZ_ag_6_9"
          xlink:label="Tc_18eLu7jalEK2GyS3JEZ_ag_6_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_18eLu7jalEK2GyS3JEZ_ag_6_9"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_PZ1_rxCXYEaxToDczyclvw_7_6"
          xlink:label="Tc_PZ1_rxCXYEaxToDczyclvw_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_PZ1_rxCXYEaxToDczyclvw_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_qjIjttn8v0KRquu6KCJZJw_7_12"
          xlink:label="Tc_qjIjttn8v0KRquu6KCJZJw_7_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_qjIjttn8v0KRquu6KCJZJw_7_12"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_CtU7fJlFLUWK-2ZJEB02fQ_7_3"
          xlink:label="Tc_CtU7fJlFLUWK-2ZJEB02fQ_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_CtU7fJlFLUWK-2ZJEB02fQ_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_WaAF5qNXF0-z5XWCXH-7Ig_7_9"
          xlink:label="Tc_WaAF5qNXF0-z5XWCXH-7Ig_7_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_WaAF5qNXF0-z5XWCXH-7Ig_7_9"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_bnjj10L9rkeBXEn0PgCW6g_8_6"
          xlink:label="Tc_bnjj10L9rkeBXEn0PgCW6g_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_bnjj10L9rkeBXEn0PgCW6g_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gSI0-d_O5USkjePB25wk1w_8_12"
          xlink:label="Tc_gSI0-d_O5USkjePB25wk1w_8_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gSI0-d_O5USkjePB25wk1w_8_12"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_I4Sv3meE2EW6qmi-m0GhGQ_8_3"
          xlink:label="Tc_I4Sv3meE2EW6qmi-m0GhGQ_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_I4Sv3meE2EW6qmi-m0GhGQ_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Yj9I9ljr_EWcICY-fdWM_g_8_9"
          xlink:label="Tc_Yj9I9ljr_EWcICY-fdWM_g_8_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Yj9I9ljr_EWcICY-fdWM_g_8_9"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>44
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6.]8?3'9RTND\O("JJ9"Y(43Q*5&?(+T0\BH.'4DXV!JU WQ&8)@&K9ML:H
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MVY,BW52O];^E19&NJ\,%B^<L*P'\^D.:%J\G90>[CU6#?P%02P,$%     @
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M=1L#CH!*@/A_0PA_;L@!JN.FZ7]02P,$%     @ ]#AN516(_N!U"0  &40
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MDK"N7FW OK\K"OJT40?8OPWD]/]02P,$%     @ ]#AN5>/EGK2Z @  L0@
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M..Y5,[^B?)$6@F0P1ZS5^80DO&Z0=2!9J3O /9/83_0PP6\*X"H!U^>,R:=
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MB0_;*4;164#SIW,Q,>"Q/ .ZP/:2YQD4A&@;B-E*TJ3I;[-,^/=&N$2::*O
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M3K#O>*3>O3L=Q6IK6Y:>:0+V;.U%";L>R-%Z3;K)6_0O:&.L+IK*-UR8"P;
M,=<MDMEBO"^2-<AX"H$2VFWP%_ZYJERSE'3,#"F/6"$(B0H^0J=@Q-<N^S*B
M,$2HH3'JQZ/QT=$$17<E"WHG.Y5%E[2HJ^A6^IJ-%]:X7%)*)R>/ZD# SEC;
MS89X^W$*^H#51;%=ULVNWJM+9C%2'JO/*"*4N359$_L8WQ0)"0\^70= 3E3/
M8+XP^=9"+M^3H46P,^$:8/)DJ(\3"HYMRSN[13)C!/(NUIQX^1+I&;8[;'^!
MTMGMX>?+ 3/<)"8@!M-G)M9O>!PH:1),9".6OHPM8 X243PYFT?9$@77 ]1$
M*ZWRS6"C)?')8Y;3TVTY_4WA),!Q2%"#4MJ.BAQMA[I=0R<9K"I@8EQZ&PV1
MQ]IA4%5\BN1Q[]G^#E]XNWTU:?.%1X+!2_@'G+@D5'@G0=EM"1KL_3A]E'@/
M];A<68890@N^>_["!]-Q]W$*YT9)VV'XS-NJ1H(A*%,7H0F5MP5D8-JGCK[%
MZJ!.TK93YGP-?(@*<$,0K%8_3M)801&):CWI?& 'Y&]#9O9U-H[3@#.*1M &
MJI%T*]J,U^]]T3J#$ DH&TE'B]EC"M\0V2Z#FB8F=MVL1;_IB=E! 7IVI<2.
M/MP7C6W)'=)/QH_^35ENT7O\GQ;LE:/2Q6R+D'!ZX$\\D- ZE1&-]"1VI=,&
M45OW%+!C[YU;IFIM\^\<5<I65.A6;+-Y8SGPQH+3<" .BP=MOS0F[S&E$]J)
M&C-3,>9"N#<;AN>C-#GQOL@?&5<L@SLQ.HC<#M*6(XN.2C&!(4O?B0_A<]L'
MB6O]!5*TG!92,YH\^@<]/L:/@$)*(#>&4:, 72D_!^C::1B LJ'ZB?/^UW(:
M0S6<@%Y(NHL1.7M.0M_TX+]UJ(='_\ZAACM>WW68CX(F)\=#F#G4*]0F%S9(
MT4I&ZFD&WL4?>WJO$<,.N@0=@T<E'.JD9=HCQ%N6"#R'S ="O85-2E;*,BRE
MB5&7R3IFM[+E=FKH4F:O)A>A>D,VK?YH4&H;;C]Q<TL\2IJ1TD'MIRSHN9',
MRBUF*O?H8,12$M9VXE@[V0H>\Z^>QXS5C*("-S_^2G#$RW2+ <%".,[[)1?<
MW;5]8P<)+UUM"89'_^XWPF(QNM;4M8>C7UJ2.]EN6X&FC6Z*&\NB ;$VI%!0
MGAM3!J@I/:F+!6!D%>:N 0#)9RV$ZZ)=' G\#3 =]MD!B&Q($=<#JSX:G,W*
MXFW8&@U[%U1SXT?8T8/LS,+2?6Q]P[N\*UAK83E/I[GRBOV$7D<HHV9(+VUL
M;]MV[@>A\5EA:+2Y,_&@.+0U<6GMJ4;UX1>!-RZ1.<<&4L3GN:^T*9)3X)B%
M4<O0X>",W2VT["4O*_VG+=)HO$^0HU8V6P"TR[ 50$#9F) :K8\3*#LOQ+TG
M1Q*@S>V&M.K5LG!S[CC1TW"4D:B?(Z6PAX-0UVFKU;=-G!AI"1,#E2&W\_P@
MLA9**7CUA!OL%+'W]S>B!Q"UJZ[I=Q55,>P9@>D]I=-K&(W^Z8?I\>0$_TZ?
MG#CUT=_H(D=5635_MC[[VKH,OR<W$N ?U3K*6C:Q-*20&>T=/7EK=($]=KGA
M%]W;CAK;YTY(&:MD6^G?!5##:?:E=>\1^1I;KISG!4+"!A*U@$=J1AB)3)3[
M+#5ON0$]ISM>;3P4VSYLJ+_08J<V[+(.1R$EP19B3=?.0$)#2+I%Y""QZ9#(
M)PWZ'UQ-"O"U#EDX)#<;I@-,:+1E92/% T"Z;F#7\,U^?SE$I.\02Q"K](OC
MR"$0XQ?F8<@'VV,S^1;-Q'<I"96H4:CUC.I57]NJ\;')V5T!^/CK^:O#R;/.
M!+JF6&ZR0E?=3.,W5R$<!F/Z6"UU&8.7<*J#X^(HB!5KFTD[#2I4DXF,TT>L
MH)7.5=D@ %*?6^>HH\"162R ?'U$8X$4 02WODLJD,&Y4)P U15"JA=+HTXG
M6UO8@3R6]Y 3Q9./:!BTXH9<-,%-19W/S/A^T,T=S^]SR=1<S^NJL-2.J_6R
MFW"VQP<IRTATP<1(R\CTU.6U BRI4[18T-!74-G:T:T2QT@#FH)-9@(*?%.$
MB3H,TU'96>B[%INB9N1[EJ6T\W1R0>,Z[>)N _3MBRY;W>+<80E)\4L)_Z0%
MA2F7H>Z21F:8@[<GE@#;]M.K1JHBJ82B88L.+3:1.SI+JJ1+<D==1.C%JQQU
M?[R)$^[TT<!%!AR8V3.<U[#VQJ ND%_ZBN&!$\_O#04">DPL4$9H1T+4&S<D
M4ZY=&=GYT-;Q9+HP+6JN,B%(@=J]<(%,\_6OX#!QO[Y8$>XL\HZ7A=SPU7XE
M0)/^0X4-8%Y[/\&O8"""RN>Z_$*%B_,,"-GBNAL3\;8CWU+S#5F=#=C;0VQ^
M<3?L/ +UN>B5]@78HM%<K293M99KF>V ,I=0*HKW,NTO,YFAX5&X5D$0B:^D
M[&UK]3KIVRQMQ]NM:@]IF#,%.0,W/5AN"!>M!\0#I*V5L9J/U4M-@U>93'NR
M.(Y?I!Y**;P?&4Q3:D -LF(J4 @\\/^ !\/T?O#8_=,D^4[NU(0K,5O5%/W>
ME'5HR,M-DS@:+M)[0T.%:!O'W\QF%[W+"W'BW#%J2[F,S:*8;250\G;V]3 -
M3@%<LI -$J^91"4P=MI=+$<JYR'IL"7PF&D#K0GBA7LA< J.I UU_GOC:Q'F
M/;Z]5]+./$=N*@Z[2,M-9>ZWU3<8Z.9C4BPNM*VZC3L82D'4MQ \"@A>;EWN
MHT& 7J>W>($(^'##A7X;C/?18=,G.4:F;-&-;Z_--C-I[""4RLDI4F9H3KU
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MV@!SOA)"[PR;H/G;&/\!4$L#!!0    ( /0X;E6?%\%(B@4  ( -   9
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MV@"S7@BA+X;=H'MM5[\ 4$L#!!0    ( /0X;E7Z-9AG?@8  ,(0   9
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;+U8:V_;-A3]*Q?>5C2 8ENRG7<"
M.(]B&=8UB+,.^TA+M,5%$C62BI/]^IU+/6*G;KIVV#[$DDC>RW//?9$Y66ES
M;U,I'3WF66%/>ZESY=%@8.-4YL+V=2D+S"RTR87#IUD.;&FD2+Q0G@VBX7!O
MD M5],Y._-B-.3O1E<M4(6\,V2K/A7DZEYE>G?;"7CMPJY:IXX'!V4DIEG(F
MW:_EC<'7H-.2J%P65NF"C%R<]J;AT?F8U_L%'Y5<V;5W8DOF6M_SQW5RVALR
M()G)V+$&@<>#O)!9QHH X\]&9Z_;D@77WUOM[[SML&4NK+S0V6\J<>EI[Z!'
MB5R(*G.W>O6C;.R9L+Y89];_TJI>&XY[%%?6Z;P1!H)<%?53/#8\K D<##\C
M$#4"D<==;^117@HGSDZ,7I'AU=#&+]Y4+PUPJF"GS)S!K(*<.YO].+V]HHOI
MS?7=].>3@8-*GAC$C?AY+1Y]1OR0WNO"I9:NBD0FF_(#0.GP1"V>\^A5A3-9
M]FDT#"@:1M$K^D:=?2.O;_2M]M7BX^WBG!)'MA2Q/.TAYJTT#[)W]N:[<&]X
M_ JX<0=N_)KV+X-[7?R7#W=7-*$WWQU$87A,&]I([-"T<JDVZB^9T(4HE1,9
M?2CHIZJ0'<,!N532A<Y+43Q1*K.$E+-^BJ9%44'D/4)+%4O2"YHY'=^G.DND
ML?26)7GO:'B\N=0/AL<[?9HZKW]S>F-/#W[_V))=TQV0R#5OB84&T>Y</5B6
M1C_ &H%L1F%(\(<-]%9]%](XM5"Q<)*A7Q>Q-J4V@FL!5-E:@TP"5J"*&!7-
M2J^IJ/(YMH60306<SF_0#D0U 22>>455)&5M)8I8TL+HG,)H& R'_H\UA^-Q
M][G.V 54PRJ:MG8\DW;'UKR<IA4@+U2&/5?*I1[H3 *U0RFM?=-8ZF?:CTN9
MB16,(("?5DO4$XIJS_=IOM/8PU4MH1@$HMAZ@BC<X5!Y)^>F8OW19%NX+(TH
M'#/8(:H]!%<W.%XZ96,/?.0*KI6UUH7.T"$0'T=TW:>]T7XP&85K+L##&14[
MCN9U;[#[$+(WF%<)F I GI(+NGJ4<<4EGSXL$ <@LX*_S59<TSH6$%@)W6(?
MP;MP7Z.KO,STDY3-9@@C;,%*;S*Q$4<;WN7)%PYM.(-RE7OUWF:A#(&OJO/<
MFI4^(]AQ/)XT#O6<L\WSANU'KRY[HN\GT8C#K$_7X"^,PN!P\A7\S4R?/H*F
M3XE\IPJ$M^+J\0F1;.C_9F!8YU&?HIW7"]E7%95$EPRF*RBVK2ALVS<4AP>A
M,C'/Y N6ZNHP"?:12^%^YQCH/PC&^QMC'(48]X@(?#N<K1K8P)S;ELJ:_-$7
MR&C3E,+A[I,4P%YR^OFMR\K$*9LVKBO49VQB,%3@A)4H@],4:AYW0M\4BJV\
MGVMA$E]_&@&[-69:)*E 0H$B^2A-K "G-!R)\D_N&MC\^[ _/*02\AZ@)^@!
M<43H!@;0%KHRM6U8HS1Z&"K87B./'RZE""#O2.]BA#K':=W5W!J2EJLF!#I[
M%6*IFO^!#T]&A6,9BEB,0V6, V;=57C7195E5)5\W 0I=<.1= >M5M3'4,V
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MD-H;$+"42L5+J:6KX*:TB'3A//S$"&;/DNMEO/RV$N;2ZY]!Z(+0OZ$GMC>
MWR\>L"/*#2CR"G*Z3G3>?06+2J*38W@^4BH86 #)=&W3J'T?U $*VY8TOW9>
MZ!R!NA,\//[U2YID+&U$$XKZC=0E=0Z%6T':/.:5-LJ4^Z ^#&4N%,GIFAMW
M"6^%=AN2'=J%])1Q=$A<"=>+&H&H#7$;*M>2O92'PDAI8\U6%OC*\: W-W6-
M-I>4;L.6;SK+^53)'-UQ >Q/KMJ"Q??%&^L#)94A<]D(3[Z4RJR)38E6DY5F
M<X!W)K[:-7"54(HT$%RWR/Y3/K*MI0D%GS#'>DV%3-)P8LY'M*#0.?+(4L\)
MZ5!8)2E&<B?-C2V"[Z$V5L:1CE7X?R4/9O<AU+KVL$; %X_<,V"]A[KU+14B
M!@![(2A-44C>$UIKT$I3,+W#+6K8DQH';4,;UJ-W5M)ITT<L#4$L&X@OC;3=
M[O;ZR'O/.\&*QC^ZR_%10Z5M*\.SX<A ,JSKK</L\#+== WY6WCWK*V$+:5V
MH'!#T&3\X3P"VST5W<";)K3GM?'4[,-G1:\K6@Z@]8TQ_C#@!,-[/?\'4$L#
M!!0    ( /0X;E6Z3F*O] (  /X&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;*55VV[;, S]%<(M^A3XEO2>!&BZ#.O#VFYINV?%9FRALN1)<M/N
MZT?)B9=@:=!A+[)$\1P>RB(U7"K];$I$"Z^5D&84E-;6%U%DLA(K9D)5HZ2=
MA=(5L[34161JC2SWH$I$:1R?1!7C,A@/O>U>CX>JL8)+O-=@FJIB^FV"0BU'
M01*L#=]Y45IGB,;#FA4X0_M8WVM:11U+SBN4ABL)&A>CX"JYF R<OW=XXK@T
M&W-PF<R5>G:+FWP4Q$X0"LRL8V#T><%K%,(1D8R?*\Z@"^F F_,U^V>?.^4R
M9P:OE?C!<UN.@K, <ERP1MCO:OD%5_D<.[Y,">-'6+:^"3EGC;&J6H%)0<5E
M^V6OJW/8 )S%[P#2%2#UNMM 7N4G9MEXJ-42M/,F-C?QJ7HTB>/2_929U;3+
M"6?'L\?);/KM<7K[ -,G&F?#R!*MVXRR%<6DI4C?H3B'KTK:TL!4YIAOXR.2
MTVE*UYHFZ5["&=8A].,>I'&:[N'K=SGV/5__?W)L*0:[*5QI7)B:93@*Z.X;
MU"\8C(\.DI/X<H_ 02=PL(_]8P+W4]S>/4SA%(X.SM(DN82_&.%3H[DLX"ZS
M:HX:F,SA5KU@Y1;NG'M@2X1K5=5,OH%1(N\!E][(BD)CP2SVX#@^Z9V?QV!*
M1L< :N$0%577S*KL&1JZ =IC9DS0_A4!D4K8AO"PP5Z@1$U\^1]J*+0R!FJM
M,L3< /YLF "K@-5D>^54?RC>X/"8[L5@D#IIF9)R5=M+;DOJ*QD-+FX(=[++
M-.GW=B1(=>,:@Y.P%2 )3ZG,A'"L"ZVJEM )F6CVBXL0;N1'#_&]&(=IV%\'
MV77(VW'O%_P7ZJV4TI-_2>DP"=/MG/"5>KI!:JJ\FC?:^%]D=ITI)[/C97-%
M/ZPS7Y<<#0_]=8O[.TL@VNA)%>K"=UY'UDC;MJ?.VC7WJ[:G_7%O7X:O3!=<
M&A"X(&@<GAX'H-MNVRZLJGV'FRM+_=)/2WJ@4#L'VE\H9=<+%Z![\L:_ 5!+
M P04    " #T.&Y51)%A)BT7  "H10  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6R]7&MSVSBR_2LH[^Q44B4KEIS$R>11I3A.XGOS<,7)S'Z%2$C"
MA"(T!.G'_/I[NAL@08ER,K-W]TL<BT2CT<_3C9:?7[OJFU\94ZN;=5'Z%P>K
MNM[\\N"!SU9FK?W8;4R))PM7K76-7ZOE [^IC,YYT;IX,#TZ>OQ@K6UY\/(Y
M?W91O7SNFKJPI;FHE&_6:UW=OC*%NWYQ,#F('WRVRU5-'SQX^7RCE^;2U%\W
M%Q5^>]!2R>W:E-ZZ4E5F\>)@-OGEU0F]SR_\:LVU3_ZOZ"1SY[[1+^?YBX,C
M8L@4)JN)@L:/*W-JBH((@8T_ LV#=DM:F/X_4G_#9\=9YMJ;4U?\9O-Z]>+@
MR8'*S4(W1?W97;\SX3R/B%[F"L__JFMY]^'Q@<H:7[MU6 P.UK:4G_HFR"%9
M\.1HSX)I6#!EOF4CYO*UKO7+YY6[5A6]#6KT'SXJKP9SMB2E7-85GEJLJU]>
MGK_]>/[F_'3V\8N:G9Y^^OKQR_G'M^KBT_OST_.S2W7OPA4VL\;??_Z@QGZT
MZD$6:+\2VM,]M)^J#ZZL5UZ=E;G)^^L?@,^6V6ED]M7T3H*79C-6QT<C-3V:
M3N^@=]P>_ICI'?^]PP^=6 @^'"9('O2+W^C,O#B BWA379F#ES__8_+XZ-D=
M[#YLV7UX%_67;TUI*ET,L77W0CU68:VZJ%RM"WNC7EGW986/-J:I;>9'ZKS,
MQNH>[(D=YLH4MS#%>J5L[>&R<V]SJRL8PDC5*Z-^_L>3Z?3HV:E;;W1YR[]-
MGMU7NLQYP?4*=&X/W75I\JW5+0?OZWS,"SJ>QK]NL=#;[#*A$W<<*5T9-;=N
ML])PTHQ/@W-FS!A>5 L'-P(7" %$*S>@ZS:(*S5OCA?7ILHL&/A3<Z!P"T0;
M?#RWI<9+=2<EM0&GQI:> T%+,A'"Y.29I[<VX+%&D*.S4<@YN\$A)B</GVW]
M@ K4VGFPDE_I,@--6UX97]LE\X*#Y%6SQ(?[-LJ;K%8;NS&D<V7QF5DV)987
M$!685+I8Z)%RE;KX_*_#R=$4 ALZDLH@#*RH#016\6XU@GS-<H)$WN@Y3I-;
M;T"4:%20^T@M859$I;CUSKLU\6N]JW)3C6 #-EL12T0,-O [E$JDM(*NP-GY
M^;G*P#;K"VPL*[T>LT0"J^IB[WN02%8TN2'BE0%YL]$5,>_K)F<S0W W506!
MUDYIX>'5[/WLX^F9>O7Y_/5;_O'VW1?UJ50?W959STVEGDIH&:72QB]N:4AD
MG3]\WXC 3@V/8V&VDC]=@34+6;:6:M7E>#.>P>JC0_$KG74CBC3SM:UK.0GQ
M]75\.59OG,MYZ]=D'[,<J<'ZNI+-[R5.\^;UK/-.<I3"+>'O"E$=J17VL=G@
MOV%=6//J?;<F.4!K&1N83%GCM'T;T3E2(4Y>6WS@15H]NQ'M@E->BUUZU*\U
M!YK^8<$^N=D'?:NF)ZR=(]4@G53Q:>L,LRQ#KB<CR-5L SNY(G/1]>I:0X<D
MJK"!-W\T8!#Q36/)AMZ?W[:;T8NPL)(^OJBLJVQ]JSZ;*P(8L#>[+%E68_7.
M7<,*8.=PGAG\O2#F)J.6D/6^ 0W-=E08V.9GXS>.9/[>X(B5NG?Z^?U]6E[%
M!^'0B83&B,LP>C%OTE'4 4DO&(<GA-2S63Y%L#:R1!C:A@6#S;3Z<KLQ:J;N
M(2V3VN1P]]4:&,*62]%;(OM+DE'B'I.QFGDF2ZOIQ;@21MC4AN/2E<U[<FW#
M@?AM+G94(6QA$05*=B$R&V(]$H3=('AWQV-"E@0".A92A6*7\'\BIVN)[T!!
M8"[[!DC)D=CYOC61 /6.^-0J!(G$MAVL9;-Q."="9J5S&T*RCM:%XV^[QOZ@
M*<;?8R^$]5U5+I'\Y%FVTF7W9H7@7NC:@6H!.?D,43P^^PJCP4DO:RC:C](
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M?=9S"TMV [67#3N,B^:1AE]&,P98!789 T9 57YE-SX KZ+0<Q=R8P"'P42
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MNQB1L^<D]%T/_EN'>GCT[QQJN./U0X?Y)&AR<CR$F4.]0FUR88,4K>1R/,W
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MVH;A**3A\%N+/DETO&^5@N^20BB9"DTE=(G--56*RWOA((SE*P:%/JOL7,(
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M.MZ*"COW@2G+9%S!HVB\L[YV>Z4&7N-U8T=+4R0K"G<=9H6Y591<T5!!PVU
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M088YJ9F>B?43;N>YLGRI8,H]8=WT]FX\2&NE1;D%&P4EY<U*-MOWL ?H!T<
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MOIZ@XREH0IDZ05_1_6**CH].T!&B'-VMQ481GJO$U4:+972S-N]EDQ?OR;N
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M=&3LR:9W-A,MRKK]/ EMFED]7)O?#4@;8/:70NBWB>UHW0\L_0-02P,$%
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M\:]RE!VM.E*W@#$D=--(:7SW7*)FIJO5:E^X<!*L F9LTTQ&^^'7!@?G@'/
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M\U$M0+60TM1XUK474U][.7CMFGY\ZW2A/98#STUS)9R-[HB#:BZJ>:CFHUJ
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #T.&Y5U;33;ML"  !U$@  #P
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ]#AN59E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #T.&Y5PW.>'NX%  #D'P  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ]#AN50%CL?F,!0  DQ<  !@
M             ("!,0X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( /0X;E5'P21N_@4  +@:   8              " @?,3  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #T.&Y5& V$3<8#  !Z
M$@  &               @($G&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ ]#AN516(_N!U"0  &40  !@              ("!(QX
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /0X;E7CY9ZT
MN@(  +$(   8              " @<XG  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #T.&Y5"R"0BTL)  !,*0  &
M@(&^*@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ]#AN
M5?A.^E#Y%@  5$0  !@              ("!/S0  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( /0X;E6IS$%NI (  $(&   8
M      " @6Y+  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /0X;E6Z3F*O] (  /X&   9              "
M@;EA  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ]#AN
M5421828M%P  J$4  !D              ("!Y&0  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #T.&Y5E$7/%(L"  #D!0  &0
M        @(%(?   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( /0X;E7B#2U8< (  /0%   9              " @0I_  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ]#AN55J?LO?N @  ,P<
M !D              ("!L8$  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #T.&Y5,[(XS&T"  !K!0  &0              @('6A
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /0X;E51W.:4
M"PT  %:A   9              " @7J'  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ ]#AN5<I4!>>, @  S 8  !D
M ("!O)0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #T
M.&Y5^KN%*<X"   )"0  &0              @(%_EP  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /0X;E5!D;UO%@(  "\$   9
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M970R-RYX;6Q02P$"% ,4    " #T.&Y5O+IF92L#  #N$@  #0
M    @ &>M0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /0X;E67BKL<P
M !,"   +              "  ?2X  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M /0X;E75M--NVP(  '42   /              "  =VY  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #T.&Y5?SW?:4<!  #8$   &@
M@ 'EO   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #T
M.&Y5VG)9V'@!  "Q$0  $P              @ %DO@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     (P C &P)   -P      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>172</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30503 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapital</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40501 - Disclosure - SHARE CAPITAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalDetails</Role>
      <ShortName>SHARE CAPITAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitmentsDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureCommitments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept EffectOfExchangeRateOnCashAndCashEquivalents in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. plx-20220930x10q.htm 14</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  plx-20220930x10q.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  plx-20220930x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="plx-20220930x10q.htm">plx-20220930x10q.htm</File>
    <File>plx-20220930.xsd</File>
    <File>plx-20220930_cal.xml</File>
    <File>plx-20220930_def.xml</File>
    <File>plx-20220930_lab.xml</File>
    <File>plx-20220930_pre.xml</File>
    <File>plx-20220930xex10d1.htm</File>
    <File>plx-20220930xex10d2.htm</File>
    <File>plx-20220930xex31d1.htm</File>
    <File>plx-20220930xex31d2.htm</File>
    <File>plx-20220930xex32d1.htm</File>
    <File>plx-20220930xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20220930x10q005.jpg</File>
    <File>plx-20220930x10q006.jpg</File>
    <File>plx-20220930x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="317">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>50
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20220930x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 115,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20220930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 282,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 13,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 18
   },
   "keyCustom": 36,
   "keyStandard": 136,
   "memberCustom": 17,
   "memberStandard": 22,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - SHARE CAPITAL",
     "role": "http://www.protalix.com/role/DisclosureShareCapital",
     "shortName": "SHARE CAPITAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - COMMITMENTS",
     "role": "http://www.protalix.com/role/DisclosureCommitments",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0XmRqyM5IkSNgT9vMbeyqw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0XmRqyM5IkSNgT9vMbeyqw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - SHARE CAPITAL (Tables)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalTables",
     "shortName": "SHARE CAPITAL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_HH1mRiFsa0qJN4a4_yJ33w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_HH1mRiFsa0qJN4a4_yJ33w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_o94eVrew4E6wDw6CMs244A",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesDetails",
     "shortName": "REVENUES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_ULcGA7VYNkCKoZuU0B0qrQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_6_30_2022_rxA6MsPFmkGcr9wRVnhiBw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_xBpFrb_itUa-m-dTgglm6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - SHARE CAPITAL (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalDetails",
     "shortName": "SHARE CAPITAL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_CpKx-mzFKEGNxFx6wijT_g",
      "decimals": "-5",
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodValueSalesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_BAHkbJYPMkyDVzUoFG5QDA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:ExtendedTermOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - COMMITMENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureCommitmentsDetails",
     "shortName": "COMMITMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_BAHkbJYPMkyDVzUoFG5QDA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:ExtendedTermOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodValueSalesAgreement",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_10_1_2022_To_11_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_QWJZhKTEsUGVicty8qY70w",
      "decimals": "-5",
      "lang": null,
      "name": "plx:ProceedsFromSaleOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_DF5dJh_q9EC8NgSUTADEqQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_TpBThY-o1UO9jj7QH2sP0A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_TpBThY-o1UO9jj7QH2sP0A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_meO3TiU780u98xVJPMWPNA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_mQhLCnpXrEikVmEPdum5DQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_H2Tv44kWkUugcx4cSOye1w",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZbbjgFPzN0emebI_hQ2CAA",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_EsVSLBcYpUm3kncQIbEaZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Additional amount payable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AlfataligliceraseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the product, alfataliglicerase.",
        "label": "Alfataliglicerase"
       }
      }
     },
     "localname": "AlfataligliceraseMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CertainOfficersDirectorsAndOtherEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to certain officers, directors and other employees.",
        "label": "Certain Officers, Directors And Other Employees [Member]",
        "terseLabel": "Certain Officers, Directors And Other Employees"
       }
      }
     },
     "localname": "CertainOfficersDirectorsAndOtherEmployeesMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Change in amount receivable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "localname": "ConvertibleNotesDue2021And2024Member",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction costs in connection with exchange of convertible notes.",
        "label": "Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt",
        "terseLabel": "Transactions costs in connection with the exchange of convertible notes"
       }
      }
     },
     "localname": "DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "localname": "EmployeeStockIncentivePlan2006Member",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "label": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "terseLabel": "Equity component of convertible notes, net of transaction costs"
       }
      }
     },
     "localname": "EquityComponentOfConvertibleNotesNetOfTransactionCosts",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ExtendedTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended term  of agreement.",
        "label": "Extended Term Of Agreement",
        "terseLabel": "Extended term of agreement"
       }
      }
     },
     "localname": "ExtendedTermOfAgreement",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Decrease in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaintainOfMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance"
       }
      }
     },
     "localname": "MaintainOfMinimumCashBalance",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year",
        "terseLabel": "Maximum entitlement of development costs to cover per year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement [Member]",
        "label": "Pfizer Agreement [Member]"
       }
      }
     },
     "localname": "PfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromExpenseReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from expense reimbursements in a collaboration agreement.",
        "label": "Proceeds from Expense Reimbursements",
        "terseLabel": "Proceeds from expense reimbursements"
       }
      }
     },
     "localname": "ProceedsFromExpenseReimbursements",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost",
        "verboseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProducts",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ReacquisitionOfEquityComponentOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reacquisition Of Equity Component Of Convertible Notes",
        "label": "Reacquisition Of Equity Component Of Convertible Notes",
        "negatedLabel": "Reacquisition of equity component of convertible notes"
       }
      }
     },
     "localname": "ReacquisitionOfEquityComponentOfConvertibleNotes",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number",
        "terseLabel": "Performance obligation number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz"
       }
      }
     },
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20220930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director",
        "terseLabel": "New director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r150",
      "r172",
      "r205",
      "r206",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r312",
      "r315",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r150",
      "r172",
      "r205",
      "r206",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r312",
      "r315",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r118",
      "r189",
      "r191",
      "r291",
      "r311",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r118",
      "r189",
      "r191",
      "r291",
      "r311",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r150",
      "r172",
      "r196",
      "r205",
      "r206",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r312",
      "r315",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r150",
      "r172",
      "r196",
      "r205",
      "r206",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r312",
      "r315",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r189",
      "r192",
      "r314",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r189",
      "r192",
      "r314",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r122",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r123",
      "r124"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r226",
      "r227",
      "r228",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r208",
      "r211",
      "r231",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r211",
      "r224",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r68",
      "r163",
      "r167",
      "r168",
      "r266"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r107",
      "r110",
      "r116",
      "r126",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r240",
      "r244",
      "r255",
      "r273",
      "r275",
      "r293",
      "r304"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r42",
      "r77",
      "r126",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r240",
      "r244",
      "r255",
      "r273",
      "r275"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r212",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r32",
      "r70"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r70",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r258"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r135",
      "r297",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r187",
      "r188",
      "r190"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r187",
      "r188",
      "r190"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt Instrument Fair Value"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r52",
      "r77",
      "r126",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r255"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r76",
      "r78",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r267",
      "r294",
      "r295",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r164",
      "r295",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt Instrument Carrying Amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r76",
      "r78",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r14",
      "r193",
      "r194",
      "r195",
      "r204",
      "r292",
      "r303"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r68",
      "r130"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE CAPITAL"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r50",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r93",
      "r95",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r249",
      "r250",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r50",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r95",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r249",
      "r250",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Option to purchase shares of common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r104",
      "r127",
      "r184",
      "r185",
      "r226",
      "r227",
      "r228",
      "r236",
      "r237",
      "r248",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r316",
      "r317",
      "r318",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r156",
      "r165",
      "r166",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r251",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r156",
      "r165",
      "r166",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r251",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r156",
      "r165",
      "r166",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r69",
      "r256",
      "r257"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r68",
      "r169",
      "r170"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of convertible notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r207",
      "r209",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable-trade and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r67",
      "r289"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r62",
      "r65",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r128"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r40",
      "r275"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r128"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r128"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r77",
      "r111",
      "r126",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r241",
      "r244",
      "r245",
      "r255",
      "r273",
      "r274"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r77",
      "r126",
      "r255",
      "r275",
      "r296",
      "r305"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities net of capital deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES NET OF CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r77",
      "r126",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r241",
      "r244",
      "r245",
      "r255",
      "r273",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r17",
      "r18",
      "r77",
      "r126",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r241",
      "r244",
      "r245",
      "r255",
      "r273",
      "r274"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and R&amp;D Services"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Share Price."
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r44",
      "r47",
      "r49",
      "r69",
      "r77",
      "r83",
      "r85",
      "r86",
      "r87",
      "r88",
      "r91",
      "r92",
      "r96",
      "r107",
      "r109",
      "r112",
      "r115",
      "r117",
      "r126",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r250",
      "r255",
      "r298",
      "r308"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "NET LOSS FOR THE PERIOD",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES, NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r107",
      "r109",
      "r112",
      "r115",
      "r117"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r41",
      "r275"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "OTHER INCOME"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts paid (funded) in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19",
      "r193",
      "r194",
      "r195"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r212",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Goods"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r44",
      "r47",
      "r63",
      "r77",
      "r83",
      "r91",
      "r92",
      "r107",
      "r109",
      "r112",
      "r115",
      "r117",
      "r126",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r239",
      "r242",
      "r243",
      "r246",
      "r247",
      "r250",
      "r255",
      "r300"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r131",
      "r275",
      "r301",
      "r306"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Payment for convertible notes redemption and transactions costs"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment for promissory note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r233",
      "r290",
      "r331"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r127",
      "r226",
      "r227",
      "r228",
      "r236",
      "r237",
      "r248",
      "r316",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r48",
      "r77",
      "r105",
      "r106",
      "r108",
      "r113",
      "r114",
      "r118",
      "r119",
      "r121",
      "r126",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r255",
      "r300"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r212",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price (USD)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under share-based payment arrangement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r210",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r209",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "New employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price",
        "verboseLabel": "Stock price (USD)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Term of award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r219",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r39",
      "r45",
      "r46",
      "r47",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r104",
      "r127",
      "r184",
      "r185",
      "r226",
      "r227",
      "r228",
      "r236",
      "r237",
      "r248",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r316",
      "r317",
      "r318",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r104",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Number of restricted stock granted (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r184",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r20",
      "r21",
      "r184",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "verboseLabel": "Value of restricted stock granted"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r77",
      "r125",
      "r126",
      "r255",
      "r275"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "SHARE CAPITAL"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r265",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r265",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r265",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r265",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r94",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r93",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r332": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r333": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r334": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r335": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r336": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r337": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>51
<FILENAME>0001558370-22-017554-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-017554-xbrl.zip
M4$L#!!0    ( /0X;E6DM" TPPT  )-V   0    <&QX+3(P,C(P.3,P+GAS
M9.U=W7/;-A)_OYG['WAZN?1!UH>3=NR)VY$E.=&<);F2G#9/'8H$)4PH@ %
M6^Y??POP0Q1%@A3E)+PY/;2FB,5B%[_%8A<?S/O?MAO7>$*,8TIN&IV+=L-
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MW?>YH)O>%O,!W9B8A#W-&P:&GCFN2BQ>)*"-'$RP4@;FEG;;:!H[CO C8FH
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MO</48O[?T:B/#:U:]1.=1+4>"FAUYZ#B("@\U#)#>+/T&8_6Q+)"JQS2VEA
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M-H0Q[@B2N),(Y0Q/F.,]G1 PK. +\FW5AD[_E7[@0S8GK(+=\0<"2$].5$0
M[S:0B>PMVZ9+-,D^ 6>WRLY2,CL[)M"2>IOFP5U3S%.V$+P5. /*,\ &-*JW
M"6M;JT&ZD+^I?Y=^(+F*,Y#"WNX(Q*+><9T)OA(#(MLGV2*F O6$<DS)%K(.
MS7<H:.YDB]B)R;83,HY&3S>(XC)-F'NKV:/(<A*=B.P _J-W1,6R"FAMA";L
M%ERQ7I??'/V>0JV$U8GSNZL'CN.X?(AWO530,6G9T!E2E'C(;5(0*5W!">OD
M0,Y0.-5BZR'(K1/Y&LY!*'MZXSC.[ H>!W$.>@BPGT4O&Y+FK.4<U', CWQ
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M 70KCLB#_O +(9-\'"=;'CG'.8')?Y]0W/#YJ;)V,OQXA-C@]_\!4$L#!!0
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MK_<+1BZ8@D6/L>)]L-V #Z]\N-ZXM$/VW0J#Q8=7&_?EC$KUXMW5!<7NNUE
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MK#^97/$T[B:P_(Y@3.:%/?I2Y@NA.Q7#FYIB$%)A@D#VKQ1"#XS(Q\*W_U*
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M;4UD1OL GME/E:Y:IQJ;48BHS'Y"D;!**>2_G$>\)/^A(;M__C]02P,$%
M  @ ]#AN5=1UFN;800  DV<# !0   !P;'@M,C R,C Y,S!?;&%B+GAM;.U]
M?W/C-K+@_U=UWP&75W4[J9(SF<G>>Y7<[GLEV_)$]6S)*\F3S:5>I6@1LGFA
M286D/'8^_:$!_B8 @A2%IE-7M;7QB-V-;J"[ 30:C;_]Q\N33YYI%'MA\/>O
M/GSS[5>$!MO0]8*'OW]UB,^<>.MY7_W'O__W__:W_W%V]L_SU35QP^WAB08)
MV4;42:A+OGC)(]F$^[T3D!L:19[OD_/(<Q\H(1^^_881_>8[<G:6TCAW8H83
M!H03^_C-A_S+14HO#'X@'SZ\__#=^X_??OQ(OO_AVW_[X;M_([<W.>0-8W#G
MM8/Z7O#;#_!_]ZQ1PD0-XK]_]9@D^Q_>O__RY<LW+_>1_TT8/3#L;[][GP%^
M)2!_>(F]"O27[S+8#^__>7.]WC[2)^?,"^+$";8%%I"1X7WX_OOOW_.O##3V
M?H@Y_G6X=1+>^:U\$24$_.LL SN#G\X^?#S[[L,W+[&;\=5@JT5X]M5-<H0R
M\/]Z+SY^Q;J8D+]%H4]7=$>X:#\DKWOZ]Z]B[VGO RW^VV-$=_*F_2AZ#_CO
M _H 8P^\?P^\?_A7X/U?TI^OG7OJ?T4 \FXU5TKQ?856BO1><"E4 7ZZ9G]5
MF*4O"0U<ZF;L A%-3_$V^#!RRD [W%8(^C"F8=04/\YZ,J;;;Q["Y_<N]4!S
M/_S^5_CS3/S))6?__/4B9)8YO8^3R-DF&34NP]^_DGQ_G_,#(-.HRI03;3,2
M[,\6&5.(]]N0:?8^.?-%7PKT710^21E(FPLE'W_U[_TZAQ7V(AJ'AVA+.PU"
MF2M5OXB6F5(S"'!J-#B[6W_U[Y>9%W,"E\R"Q$M>R3S8A=$3-\>_">*G'N&,
MBPVC*A&D^MG^^,K8RX:W_,WJZ#8;5@\NP%@>RG\<G"BAD?^ZHOLPDIFM$A)O
M@!5,U\>Z!H8R[%(>U!J0@Q,!;]NP(R>(/? HK>K0!$4T> 7;#>.OP>$X BD3
M&J>0P^/HQ"V-O-"=!>XE6Z9HY*K!X6F#E.&Z*E2 4/1 PH%:"00PF_E= N"6
M5$ L-*X\GRX.3_<TDDC3!+$_\"HVLS&O?[<ZW/+&&R.=KND C@A JV.\H@\>
M+$"#9.$\R:Q<#H8UUG)VJ^-=A4$8<QD#JG$O8 D 6QW[>; -(S:Q\)W$.F'N
MY2(\!$GT>A&Z:E5HP<+2#"-AJHJB14'0&P-^5&I409T0CDS"B*0$"%"PJEL;
MYV7NL@G,VWDB<-0RD2CAL?2I18"J)BF $71(RXE*>Q@2J6)A3$53UV7]$:?_
MN?8"^D$IIA062U4TC%?51 *(H")*+E3JD4).LC\(X)!E8->C--G^V$'$CV-2
MCX^FZO%Q%.KQL8]Z;+Z$&.IQP?Y<1IOP2] F8!D2636:3$L5HP##4XLZ#ZU*
M 0BP$@$4#(7@2Z%E=!N%SUZP52]K5>#(JJ%@7ZH?-5@\)9$RTJHI^:(UP\-0
ME]LP3AS__WA[[1Y(#HRL*E+6I8I2@<13$PD;K4HB< A#LKFG 2<VC:BC4(KJ
M9X3S30E[^?%FZ9O=T\U&PXW!Y7,#P-@<2\AD\&\?PT =VVR"V!]3%9O9N-:_
M6QU;>>.-\>5@A,/9W5"NZ?80,>7Z\/%^XR6^S&:;(/;'6,5F-L;U[U;'6-YX
M8XSY-Q+NR(>/[^Z_)AF6I8'>1 [D@*U?G^Y#F1"U[_:'6,I@-KZ5CU8'5])R
M<V0%#!% EBUW]K)]9,Q0Q:F$' S/@F7LUJVX#(-BR4T&&F.>@9(,UOZIQ,4A
MBFB0B"-OT%&V+3C$RK6D"AQK,:YGO[H<E\,B+,AUC*B6Y"D.R9&(P+)\A)50
MR)[SGNFEDS@I3YH3%CDXWJ&5COWZ:94,%N682LV(^GPJQX$\!B?3'NOY#-&%
MD]"','K5GMB7H#"S&AK,-A,;<A"DW(9:^[KTAHADL%9'??WD^/[Y(?8"&JNG
MD1H4UJA+F:V.>@4$8=0E[:M&G8.2#-;JJ,^>:/3 )J5/4?@E>;P(G_9.H+9Y
M!326%FB9KVJ#%!1!*S1\J+0C0R$"AZ1(=IW#(_7]-NVH J&Y!@FK-<]0@L!P
M#(WFE7X!(%'&F[7Y!+DUX?:W]:/#^F!Y2.!>%&QTU:MC+1+:1L- E-IV0X.!
ML>EH94>Y]>"8A*-.B$ F)6R[*L66L9'CSP.7OOPG57N1!AR:XL@9KNE*%0A#
M/60<*#5" !,.31BXK8,AL8VY\N*MX_],G4B=+J\&13@P:F$[/SQ2P-D]2-(R
MT3Q42N,2 IX @NWT^2Q[OV#YBOTBVWPH(?%N42B8KM^CJ(&AW*20\J"^2U'6
M"(Z H@[B1H>90E1@L55"PKA<*4J B&K1X*)5,=*[-C958\K:=SG/OB-;@-:^
MVU<!*8/9L%<^6AUJ2<N-X<UA"  =/: [)[[GW!WBLP?'V?-1?4_]),Y^X8-[
M]NV'M*+!OZ0__\H3FX"1Y>[*"YQ@ZS'M#,75/L6U^6ZH=M6BCUB@,5WPK"E3
M=Z::"X[EXG*V6,\N"?MKO;R>7TXW[!_GT^OIXF)&UC_.9IOU&-1OX]PW4B%4
M0,@J56%5JCP< D]-2LTW#U$S(/(+!_NO,0S^M1?0.?NSONC0 2(K08-EJ2+D
M4'C*4&-!IQ  2C@LIE9,XY@F<<O<4P?"T08YJV5-J$)8UP)9\\VU" <BOV1@
MC<$?A,V$1C&]/IK7]1IWPA)<IOMX(R5MP&+JJH+QILK6 )$T5\J%0H$G>=;'
M.#39C/>+N]5JMM@0H=@_(&KVA1,_3@,7_C/[_> ].S[C/IXF%TX4O7K!PV?'
M/ZA6:(:X.)K?2;"R)1@A6K>,#EPUM8TA\6I=_(\2^H0X"<DH$$X"QW8&D6X+
M?] "O8]5[?T7L)2/WW[_W;?<3M@/OZX?PRC9T.CIW E^NZ1[V(35%ZT:.+OZ
MW\HPZ+H2Z"1ZG=6]Y/>X3?M-.=JIMCZ#2D"6MYLBD$?JIR4U[QF=F.S"B,1
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M-ZNAT*__2NC+]A'>KB"NM]M1: 3WKO4MF[S@K8[ 72:/-+H-V>*0)FS1!RO
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MS)#*O+._\\;85/<;^S'[B?T?'#+_^_\#4$L#!!0    ( /0X;E7O)LUGXRT
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M!^^UA67X1F_B+;),4!O*\X$</9:U<@RK=JRJ+3:LHDXDY8<,452ZAMQ"$X9
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MA,EB@*X 6H*"S6IB66U0E6I^^46E.K^5P+G7XR!V?!J[;_;H'1!'<,E6M*&
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MZLP-<=*21>1:!IZ;NR;LG1VB/Y)SP_%UYY2#E.*-M(\K$O5 W7V3>K:ZVL&
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M?]3L0NK$)G$HI>Y"ZDT/^;N0.D%?&JT*NY!:XBTMT%4G=-6])CBUI)<CNI9
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MF[B@M-Z8EL FB[:HY)H@>VN[AHMN_.9"EESZ+2 K(+GZ/;8;VP<F;) *9K9
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M__ZO%/PO^I-*_?W_(4A*[V7;U93J*($%;#^EN$#V@9I:Z/[X-B4XTZELIVK
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MD=_/^=\%8;X8MM*^8LP*XYQEL]@0"RXPG/39_O>7RL#QJPK.ZW\'1I9G\[.
M1(.2/+1'@P:2-2]04+Z?__W6=>#%RN$C_SL;&(O5@.![8L7"F_Z(U70TD<,X
M^-_?6@[W_&^[IF?O&I9MBBL9 ;P35$;%P@6&K+Z3_WWALI>G5@R%M=N8.)OG
M%*1%^6-"^K9&[2?R^SG_NX')=$<7B!P*%IW2P%<M7& NT)A\@?_]=3)P/ ?I
M)/5PB&%A9MN+,6_DP%UQ7BY[XJ@7.TL0NWHX<<]-.HELI,L#.>M+B, AXPDY
M5JN"K<<O]3KVLA&W?;.3R(:1FVCKI>MHACP3J4JOE7,J5&(W+CVF<YH::XY3
MS@SZ[;Y8(9;^I-BM(40OL1N7XV^\/*?DP= OVY[O!B%J]U$3'LR!W73T\$:^
M.6@"-SQS)X\ #VS=@4Z<$KCA55/V'+B^/C1!W?&!EP\ [)O<Y;SVK/9L5:/*
M!E\?"9EY;0A6L]@YISN).*3#)O[Q<4)\J]GHN1.TYQ.CW0@%67<[LAF [.K^
M8PFR7':5\:H*QS$?6;/[-F5[&OA>U(!XTF4-R!X$((0X:G5P OAI@^@*M:;[
ML  KE3"KK1<\&9W=U4F9E%9W!)'(^&\<^GT;>Q\L^ O\_3@PSPG&P_"O2<8I
ME?XS+^WY&7K<UCVCX +8IP]<X/EM: RW?6I37I:[=DTR9NVE/QYW1@-4C:TK
MG&CTV33Z>1E)=#O.NAT9X8YC0N?7A&3?[<], K%560BZ4>3'RJ3=(A:S8NP2
M[Q*U/KM:'Q6/1*/CK-'<<@H4'Z@"<*UM7_7U'3ZH+"D3Y1LM=G+'(Y62EOC=
M/T^=#V4CT>4XZ'((^M.'?1V8ZK8#<Y4CTDN:*J/%]%3L*8A@$YED/OZ^"AR2
MZP6!N"RMQ7Y7:Y_*PE8;RO+R;ER="!17Q&E3S]HC9?%]PDC'D3X3Q\]TU=J%
MVFDG0X*."Q8D1R_R"SI7\W"23,QL3,ULK&Q=6L*W@E\Q,Z!6'JQ$>F&Y;1HI
M%_+SL\O0NW%/(RA^*MP?*GJ[2Y:N><V"9105-[-H=^RQGHW9)5TG+BG-;!B_
MMWT<##U=U65WQ<LF:&A1%<Y[P\?Z-=DUP';#M:%I<#A[M+4_3$G"*ZA=@ZA6
M>GK-+R]G&2^V]N=91#=FZ"5,SS>;,2>4ZP?_17%9K49P^3PW(TM^IC9I:^;Y
M[UOZTJE\[_8%QG9[DRRMT!![12#&_0+2HV-FTDYV2<$;$P_+MN)8X#Y_HNHH
MT5N/7 T>F"84^2*PX<1GLK;*JI9NZW#&EL."O.%BW/;NO=K"@"IW"*X4B'BG
MM28;0,XTD=@J_POX/\SJ[R+ ]TQ1_+@4M8$'0K<)DB\?ND7.-$K8V=!NE]..
MR\-IN51>&CJ]*(U:2C77,F.[(GJ3[+P![41BCDM,SO%\.!W#27EG6X1I5ACW
MD;",:V8R85HEW&NBEVU;#I#\GM+P<CK:Z6<A">">GT_G>Z)LL"J=&QG,,+[Y
MBY<U"\6MD-2I9Z&.YMN8W\+&8F[=L5R[-=*$^-67NJ19Z)(EYG 6:@S<7&M2
M7@\X62I;@4(;!4.[;-ORJ;-07 ]3G&$MY/00W7,+C(%80G=@NUV46L4VK>R"
M9J$8EE,Y]2S4E*2*RBWZ H<4%K+HSI 20B:ST ^5F,-9B%8+'5E.UYJHE=7S
MUIKUT_W,9=N6SYN%8GQLZ_2S$)(KC$8H7QIR@5YK3W1A0<X:E^VOQ&86^O(#
M7F>>A5 O5V\R;MDQ5E2KCN<:]8I*7[:5^>)9Z)(EYG 6&A*3MNJ/8%=\/IM5
M)KV2MH[?72CQG84^71J>[(IA$MVB^/2RW9=0>HS.5W6\K1?ILW/PO7N")[VZ
MFY%P B*/I>\%.\Q8:VBLZ\KV"#S*\-E4PA(]=N2"S1-;W?S&+?=^W9T,]-=D
MSUIDLF*CB(H:UZ9<,AU;I_THUOL%P-Z(]GFVP;%TZ*3AQ,EV@E$)"V_-QIB3
ML[VPX*C*P*V,441:":W2JNQ2R]A:P9BSG4$P%,%.>E\UNA<%Q. T2#RIL!(,
M/3 +0B]@#O\<'$UX\GS+='V15RMSBBVA"%OB;;<[SDEWL=V,>@;'/9?Z&))G
M# -")K\U#(A!^T]\?.H[:2TF^+/EV%&NT%8>9O*J 6RS6^=D8]TB*<97S%%\
MY>%M)3,.T/R>VY.O2,3OI\+EII4E8JT+%:Y87Q:6]$*?"%)L9X:8I,+%1RY.
M46'GT%(P UQM#C"$-;J&.?"Q284K"[%=5,?.4GS=LNG!-%BM<35G3WLNIQL=
MBVNJ@47E8Y9)>?I+[$]1J.Y0'=(#Q34R.=5 D3&9Q=W>,->N).IP23NJ'Y((
M5E7UL#/9;,JZ6K9S\E3W97/G5GE<=X@MG++1+8@<0B]ZNM>Z=.EX$>7O.94>
MEY1\@5+OQM(LP^72]1$O"FR>F\7!CL:'<*<PNB^KF"[CA)!9*Y)!"X'F95=W
M2K<=VZA5W%7LZXQQ)HQLWDL*\W#-HJ#[H3M?ME5]KJO!_CT)P UK(D)?7E>
MZ^5U%RB^XWJLK3;\,7 Y:VHZ*W ?[[\7J(7LJ@>!DEWK:-IK3$.@GKS7-&6[
M+EL/Q\4?O5*VPS-^X6D_V R'HK-]>U69DN7)0&D:]!RM"J/.9#**7U'!L.+U
M44IO8VOO(_6S(OIF17G$HP?%>)9)'Q]QG[L;I-_"WG,J8P9:[C<KXT/3$RAC
M>L]LWW_^J/H47>C!@V@'*WALX:-2=%G9 VI37D61VX?X[J[?D^@B#IRE)I'\
M@,.50G,(K+3BQK>FTN?KP &+]D*L;^;1=U3%]-OGQ?VF)U#%AX.]4!<?OCP_
M,X9/=O;Y2R<^ EA%8JKG&R@>M(Q9CYF3YB)VX<,7)K[PT6-*)O/:*91I_^CW
M*\I$GS0 ]HV\RN)@K3(39BF(@<SG!,D;8]/XG51-O,JOU[ZG0=4'1_'C]3:^
MCV=H&"41#^9H&UT)[IV&93%RY<=NE99XAC%3IWUG[W0E7"[ N6MQ-;951[)Y
MHS@L=+A2U:,JDTN:?Q+G[ASZ<)JJ/F\-'_]^:L.D5M#94AUA.-XUN&6ZUI("
M++X;,_%,;?C*G3O\/K7AI,6?>GY9;&2EHI%;=GLL05>5LAA;+R".8O&D_-,K
M^0W[34]_P\MK&;+W*:&[I5Q^G.EEF#G502O6W:C$N)S*E&/+_E=389_B=\Y5
MQ6G-/GJ?YAHFO:(G2GI]72[X8#HU5W#Y*0!E;#NF,X*K =GVH.K<$[.K^^."
M[BANL-[V2]+V>M#-]]9H#JF9N,T4-7\>NT#7F9)I3R&NOT7V,\YL80XW\;:9
M[5'34VR8GR7=^W7);VKZ>H_:.R^_>S<85P3.$XL=7?%7Z5F?06-K$&,HV4?)
M>E[)_:K$="BY.+UOM'??GKTK.G+'3$WV95,?F6$(4/:>1G/.)>_/> "*SC@-
MQB#+!BC+C%.JBD:V$,ME[?'KJ2._[SA)/R[G,=2O\SLZAPJ&TV^>&AZ:GF;1
MLSWYMUGU;+^$ZM4.*7,?(*KIMFX%UCMU0>2?6O_%(IAW@TRN;A2;;<HOT*C,
M+6)G_4-EN,=_$]=Y1(!/D+\#TIU+ )\>*WQ! )\V_50!E)>G$<#:+#/*=JF%
M@=0-@>FNBE:O$TMK_%0 ]PF0". IG>/M*=CMNG#[[50VD%L>"B&?KK!UC$1E
MT:HO^KWJ1 M$/':APAA8P2/$.YL8/CEG^Y(8/FGZR6+X6Y;PF!@2UH).:R-+
M1OGQ:M5NS1AVD;T(,?QD6_C=Q?#S;WGI8FX;\?56"^WVT)J[)JTL'K]$KIV
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M73?X/E96J-%@U!@=<C,<,VS__N'RX9DG$/%Q*T E7)B3I-$UQ&"D+$F%;ZS
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M#^ZX+(IK+0@^<0G0=V6V0,WJO0**K*E>-]<K(4QY!*'/7 +T0WLRP=!JQC5
MML?9:'.4ZT)G)_U(\&F29"@5@\[_4*,D$C"4- 0J(6&D"H:T3&14BOH2Z$=\
M&454J4&)O#$!S2Q.+0QL$996PR\!_#+)SPD+<#C7I6>6CEAH<5P,G07B$J#O
M3S+EC#EQ):ZKE'-]1%.[-2D4G<QIH=_\XCF!JP!O\W4,9#7:A5#U^;]_PS\I
MSU^%"%GR$EGHJC^^Q5#T/W]-9575[1%B LV_I6[2Z8>?7'TTOO_-\:*4NNW
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M&*=N8,\;&[BQN#N*IN3 =\(Q-U["YN_ELO'CD-,?U)!"HUW[O_^#T>A?D59
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MI2\/H7_P.$,$RI0I3SUPN_OPU#AOQ2S,8(HLKWW/KRA8$$G/]H=-MEGTRZ.
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MI(RR R0#2 8WK92\F0RF[F*!H4W6MXWB2'#1SHP?TK.$#.@OW]D\3D,R@&0
MR>"VA),WD\%XP=989^$KPE"K\6/$U(<M!9 !^^4[GF=.W,*'9 #) ))!EH64
M-Y/!K%]#$5T1*;EO+XQ.$:=B&XL3,@"*"IYG3]P7>9.B<J.A)6)' +I)NY)K
MBGU8<>;CI>3/1)>9>_N,,.B'""WBR@!?Y\YJKN8MC:87@/MUR:LGSSF5/W6Q
M91&SW9#M_AH72CUN.0DL#G3ORW<,S5/8<?Y4> X%R0.2QUT*,Z\DCTZTYC%3
M]JJH89([O2N7ML(&D >=7N(O4/ 0&Y(')(_KD\>'"#FO)(]I'YL**W/7L<69
M5JY6G(C;5@!YL.!Z (9?\O(LY [('9 [,J3[O)([#+-1&P:8/D7IUKY99:PF
MV5IWD^ZEZ4'R#/,L>=Q7>I!RK<VU^1K7_!$2 \-AX.7'SWOY\6-4EG!N^&W/
M]1YYZVEENM>-59%@BEMA2<[C;77A%^U*K&!H*K'DF<(E%9:, AKB%^+WND+'
MR_&[L<GJKE<1"C:.=M;S$3JKB),4O_27[S2,0(/XA?C]>*WAY?C=U1F*J.[[
M%137HA%'1WL-03B 7S;!+P%77XA>B-X/WNV_'+U-LM#V%Z-]2ZY,M;"_9V/#
M9F< O8? #A)#/W5@Q\_=?ZW-BRU8< 6*I% D?1B..RN\<L2:!ZWT5+5+1AOQ
MK7@7VY&XT/>Q9';G84*:V$%RP#%8AP4>K4#6R AK?+#2\21KZ#U_-!F7*HC
M#]J>(#5KB+R) 6O07[Z3)]*U0<Z G $YXV,YXSKJRI.<011BFJP5J:K=1V:K
MUK3GM>LJ!S@#U'%A"Y S(&= SL@&9WRPIO,D9_2Q:9TWM:XK1Q-[/6";A%12
MNX S@*3#'L>,?I[(C7RN+4@P? ,*T)]7@/X0*>68IWXJT$\&G;&C$CGK.,X2
M1;!HU\$C6QTMDOT1#E05FH;7C2&.(8X_5MQX$XZ[>[?E;V1&L-5F5-<FWJ0H
M1UV XS2@ W_^1 DB&2+Y<R'Y0R2'-R%Y(&V'&Y)E?%3M%.?!8M)%'6,&D,Q^
M^4Z2E\R>#G$,<7R;.+ZL#/ F'$?EF$9CG^NB$2O0A+3F959)<7P(\B"P3YZ]
M0ZH*/1C@\0DEU.RO!7<AO2+P6 )B*CN#=A>8NH.PB2>/,%2WN%L[8LV5=V,/
MG9<JU%!MQPI&  F!@M%5D%ZR/&AW02]PR8:8RM"@W1NF[K[&2%N0TER8N;+8
MRR7[ZUQ'Z-7$$CQ\OUB.8"*Q?=V+IHZ1A>"C_[Q4?N"/?\V,Z(L?<W)OA"]+
M$4-HG1%OE@I=&]E,W-9,L#$?1":2Z1T(+(\QQ\&)\'@ 8A]B/[-[\A=C/R""
M"5XJH0M;',[9F3R>M!2["[ /2JNB>1:[9'(YB/UK@P)B__[B UZ*?6.&]^M%
MH^[+5J'3+S(N,:DI*?;3O)(4#9=]"'T(_5L**7@I]+&.M0VTIMH5*N%N.J *
M W'5G@'H@S ",H^QSR9[.9OD<4.1!:D"TA%ZN7Z5ZPDYL9SCQ59+;.?ZDL@W
M<H D,.S?N2+7K_%I%=92K2E+PCMDDMM16S,=A7""<AX:A-XJR^(L$A@:8FV1
MPPA^JZ;_40#Q[#L3?X<V7"+FM^MJM-G%)^?GC1 Y_ D\)QGOA'F<W^;WX:-T
MC7B8R8^6AC,THV=?84K6QM*-='T)YJIO!$H5ES8D:0]M.9II6U+KBSL#B\^L
M+.&O6&4$U7>3,0PZAM\'72RJ@:4=KS;HC]6F%8V;NHOT<+E1#%>]U;S*LD&R
MVE! 8$*_XL^&K,$C*\B9[^7,U1SI591RF48;[5U)K'04(;0A9T+.?)<B=U'.
MI,QP$)L&S\JBX2+JWJV&5!P#SJ0!9UZT9"?D3,B9BFNH)&VVQ;Z]KI9+Q9%!
M888T@YP).?,]2N9%.5.>&=QL5O00P9KS\41716W+IWXF"S@3O:2>"3D3<J82
MS\4AAR]#7E@ZQ9E#B(PCLM#/A)SY+@GXHIPI-0K8J(5M6D)C76G.QD5_1%>Z
M@#.!$IP,S\<(P5E5?8="K5*5A%*.&P@]KB+DVG*K*/2 _)OJP/TC(1B&Q=W&
MS=GL+Z$7OW&;#L&K&/+J8P+/CB$N("X@+B N("X@+B N/C<N/F,<CMQ/=F.U
M-MAT=62IUJ[D_HC,@9$X-Q2)<T>ID3+X^A?)0O @?6V+J[(_5:Q05I$EHDNS
MF;.D9V<.2T%?(7T-4ZLW="Z9/G5FM*/EU/!%,Y7! C$* _ "R0@_2F)_*F$Q
M4X\FKEKMV98I32F-K3"#/:=@!1"E0A;R%(/G"P2L[9#](P1(*I^)5%X=M_&1
MI!(9_)91"ZT9&E6-KJ*.@E"IIJ0"*L40^0*-)?\_UM@AJ4!2@:1R!5)Y:V##
M1Y)*PVJ.BG0UEE%D*PSB73*?7C\&I *2N;)YDF7R&'I\<1.2"B052"K7(Y57
MG_Q_)*DTBU%_2*#]FKWS&+]/3%I%3)X!4DFOA%%YBJ+S-/E<G:K,U9QYACEP
M\O =R<N8GA>Z7FCDMDOGFZ.ZL__]8KB(W#\,C9*,MVE2E*9,:1-3R"EI*JQ&
M:LD<3DT-5S&#98TCS>II0>;+]W]A_^1JKN9$>O(>J3DA4S4P],1VEB !<&HS
M!['JE][=5%#!X^B^0J@Z/ AQ##-,>WBUF[B9*OQUL8NXF8K$NG;YX0<.50Z7
M9Y.GA\FCW+#I:>F_XK96\*,-[P5A0JL)>P8M W"L(DY\OKNH[2>"JM26D4;;
M9=N<O?D2+^<XX'L-_3& R]#Y7XCAZ0+P[)*HS,H[HV*+#2E8=+16/VYT%8P!
M A9U?&$ GJ]!!H$,<I[\/>]CD"FQZ.GA+'E4OU0L:HM1U=Q+5V"0750M3,IL
M29'%/MU9CA1WW#1CP" @&Q!VP1JED$(@A7P:"CFM,;V/0J1549J/$0^317:Q
M*'2K>-!!WYX\\,T44MFYQ<'>M;LVW=CR76W1J9'SU D!286>JU@*&00R"&20
M]V03>A^#T'IYH*I,JX,NBU9IN>="9LR^/1?1FQE$5<NA6K=U%^7))I=,;H5E
M!RF# "&*?D[6OH7R1F?1I!B*0#65)15:8TB%-,F$7AG25 J:1JDX2[$DBKY.
MD\(_4)/*W(#?B$R5N93I'T7YF7OQ;*P"[Q>S>D9@J+XVYUR]9&P,QUN!I@_<
M_+ N#,S0Q<(N-I?Y_6#IN]V9*8$[CA^]+@@L[<<Z(T9R0U/Z\V T6^!&LCEE
M@;R%%^!Q)V0CR$;79Z-W^*0O82,TX-N=@E_S[!W5;>.\V&[H]!6\5$'IEP>D
M3>[M-4;P(ZPGCDQJ!M@(U+4ZD=(,LA%D(\A&-Z2QO82-2K@Z7=6JM:UMT7%U
MUM6:?->Y@F^DJ@/*J!1*KJP:^[:J%G7*<;N C5A0P@.R$60CR$;79Z,+^T8=
M16GH0CR6!*0<J[*_1JH(>04VBAK1.&F"1?).$$V+Q'!M!&[2L*F"AU'/T=%]
MQI#1)%F@=(Q2\*E)*:11H)2IH1,*1NK&E%8)5J>HU^EU!(PARY8X]SGX'9+Y
M.62WON$XR=A4#-?P52>A=$Y?6JX5A. ;-L8#LSX>S"@&'H0EIC2259O3:7YF
M%Z:C*T2'N&Q%-I;[I6&KPRZ^#99]S!Z H)6T3EP>QRYX-Q+ZE)!@/AO!O,-;
M?!W!('QY-D/[U:D06:W>PI)B<BU>@6#V/M_2!V*O80_'LC^F IR=;SA ,/2!
M8&#X""082#!9$,=>1S#E"54;$$(UDO%!=T^*ALIVD"L$I^UWFMPMKJD^2CM<
M:3.+V@)>33T8%APAXI!>(+U >LF VO5*>O%&B!7XY8*-+*7AQ/6'*+6[PIE@
MBW;6@TW'*-@5HS;MSWW$=<HIO0#=BR#_JGO]OU"=.L;Y.>%/$GC021ZM%'\Y
M$YP]5YJ6F(#A_PE/T*67) .3YD9.U8#FI;J[Q&!R0.4*<LFTY9*WM9)'SQ+[
MR:U4/\QY9BY,FB<6JX/Y U*9FX(33'7.M%S5U:RD<?!HF<'7'QG#+CTA+^5A
MW=I\_Y_DQ^._TQQ#]0$WS?_]^YP2X$L>F0G]K_,M-,]-7?(MQ"_]3'_^W__S
M:W]_G@\@FN=X_K='7OSE1>:'&<93BIP9R-0W5!M1S>2[OJE.K.Z"AQ=CF*\X
M^4BYWWYP*WCU'/658?XK]_-7, !'H[=4M\@O8_1 R ?Y\/"O'C]*R?3Q,R^P
M 'B_^8:3LA%X]F]/32<"I+N_V"S\ 1<"_0D7-3?W 1O_AR3R)]=^\/NSQ0,D
M0$( +CP@]P0'/TQ0?8D9_CZFIP9+?;A8S;"&H5&&0E %52$Q#%,86C,4!L.-
M*4GH!(;B7P[?>IY1.R*0OQASIR=*7+,VRA5KHE05>EQ'D*4:W\\?<B?4VOS7
M=#P.[\.+[9+0[@NEY)>^V*R5.$DH]:7D9TMH2WVQS%>Y=D7H7_65?G0R]VLO
M<S^[F>:S/W0T5VN?D?Q>V],TFWY5;):$7C]-Z5CX=T[HRC5IG/L7SW5JR<SD
M2D*YQM>$-C_^YX-6)W#T(G_M?\WIGN.H?I"L,<FJXD5!XBL%^9RQU8P$BNF!
M3"Y96-0/[9>K1GKBGNH?^*5G<BL>&('"IJBIX@5%1^F$$<@"JC"D3BDH1DQ9
M$T]^ZLP#?-1'IPOEQDYGY<UB-&)JFP6.JV+=Z"8>:.'/EL-25U^W:TT.5?F)
M$/7C7H$?=!5<P?]L.>E(JA7&@Y7<WV-UQ>Q3^P$>)RW)/UNV_,&VP_G>6H[:
MD_;0UX-MDT]<ON-O+V\*[CH>(+2\&QE*B^NWV:D/GHFA?S;MV75#-FLU"376
M19KKDHU:N<(IQ'%'17*'S*OC4!<J.[507K<(8UL"+8\ZNF9VI(MO<<0V& /W
M!0HQEZU9TO*HHPN2M5OZNJ*C"5VCQ:(H[^@M:'G<4:EM50N=S1"U*S'*DO*
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M>3Z6I^E2VY!2U !=4R7)G@Q*#L;''\Y X:Z^'%07;15%5NWBH(#O*XT9\']
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MM\JKV&J;"SS'TC^B\.H-+ L9/K>ZJHQT/:/)#GX>_,TKX^=<SN>US"G#"(.
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MOKEPM9<(6?Z/TK</FI::%K^%(6NW$+*6CL#KKL->?:F!1SWPP!,>>$(40!3
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M_ 9AD%9\3C_7K4 #(@?<M\!]RR?(3'@G!Q"/1/DKU$7S(8+;G?$ XYRKEQ[
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MEL@>5MU'@9 (0XX7(SGWS"\+0XYK>7T.ALR'Q7ZGM!#H67KF).[:TN*N8+4
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M>A_.CO8U%3PB[%2-9C:S+O&%F]E 3N?:SF->:4[D(3X^.I/YQ".,+BU4<SZ
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MB"]\K$9T+,;AZ.J-+M\A(^DVJ&<.R7 ;^'#5P'$99X+<_;,I?O>H%-)3'JC
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MT::ZA:\E=RONW6BL>5-X4M08U3/4C:4?B3!0L88N$M"_.BPA585*/XK#JD&
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M._!F59D0+A#&C@IY8[8"7C:Q#G88@4QR[Z66,)'(@\)X%OCY/X0!-U?(!J'
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MQD$237 <N$?5-3F.I&Q.J#TQ]7GH-)&+I\55880\@UT-N@F.'.1F%^)V%)A
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M6%/%L-RM%L34B*?<;1:R_^4BQ4A!SQ*G&FQO;+R=J>>R82 "I%B'N_KXIZ6
M3'+'PE:W8I(0:V ;?)O=?9"Y%$GD,262O32))-*7>@;>?1F,NWE)2':"TMCD
MRQL5JS,'LG&01/WEX%UZ?8W3%/ZFW.@!!.BFTMQ-[9CK8V6BP(ZU]K29D\TB
M4(N4!?I/HF2T[/\ _U\0FWXG+DU<)I?FWL&E6\X,T1YUC/TAT#F2<#0XF'<!
M5B#\-$4**XY3*-SPFZB8(NQ>>5N9=;YKQ;&IC^YTK3W(-WJ.@\-=8<;+YL5^
MQO%W5' [?;S9Z:LL?S\0ZR30()#A UDV2 \>T@RL7FWCYN%A13F6D+D\QIN&
MX3D9;G]^>*8"*AE'T'#FH03:FN2*^5N#EBT9H,D6CN*F^Y#3A4"Y3_W1[B6_
MH?%I.H3E!$O7$,%AY+!!0]Z#!!8QA>1:_F"-0)XJ/H'H=%M9L,WGY@/$ CON
MW@RP9XJCO9CT%&?C"9*M*ZHQF4AXZX*##6-,P&#(LR.H>"/*_6V[_P1+>GU5
M<!,P!HB,*W)^T_\*<^,?]/*K&%6M%F)>2M5!FA]^,/)&]EX(>UYVR#:7, =6
M&.^F/Y!=NRNJZ9B6@W-S=2^9<NZ[8WM3V"4.I.188!N2J+;B*A'\[]34'9GX
M5GA4E(6,*+([#+DOL#./O3==G,7 /H/=-T>B_OUR"6Y1@1P 7(!+GC>\9KO+
M9'(VF/4<65PGQ4YC(S&KW3I<SAHV)L/,D"5UMVZ%R-#/@-[ +!N3#@R&6RO6
MT%#70\XFBPR'D-D;;Z5K."([S%P/V5M:J]%T^O9.J=F5]2)G[93G5^JE=[04
M*6!RX $T!;-AX@WW<1](TI3,#DS5K^>E26U$73#-8;MIL\7B?:O=2[-R:_)
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M/@LW]]TG\>MXKQ-B]1L!.YN8YKN#\;*$T<]^(@*<">8.P\NRQOE)R.9VJXW
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MUT@8Z[CC]WA;5B8)IJI H>7.61X^#="C%+SE,L$/PZTJ!1%*L=T>^Y#U/YE
MPT,2-9WK<.""CJUOM%PVG&*)#67+4=U>Q4@"=,BY486-'Z0V)!.K+(T4:@J!
MON[+8*GU_D[4_JD >R7=8QW= E2<:0@(X 95TF1W(YU4_KI-L_T9$Y7AE^2;
M#MGF)EO;G@21-5302\A!%C)DO&@@]X+JN2/X+AT2["W):X<=_"FD]3F:,!Z>
MA.TP=.]*$F;NA]V%P:UKX(NQ!(@#/\,00,?YS66@@%T"FN*$!^SM6&YJL06L
MBU@+RF;Q@Q 5H#X:R8$HX".37*GQWG<ZJ?>6#F$W^*SNL0VX"ENPIL3!@S]@
MEQ"Y/I+7,-V:(B8DD?F1H,U@EP2"619L>#Q?QH6/D;$<8&_%#3U8:'VLR29<
M2DG,'Z=+D"0Q-#;H)@0!. IWN;2V75/'1#D0#K.DT$-=\0!(M_R]'.[G.V:P
MV;DCKW5'U?315%O_?XARSF'"2-CXW7 O")&GEC[;U";AK,.RLZ(TLBL:XG!G
MQ]3M@$76U)']4T*2OC4Q.XCM=1.7LTKC@J[A^ER<F6]+5M&1T+.3KD$\8,QV
MW%9:+7IP1]?,I^0\SZYVTJ:2[Z@SW!VG?U0U6B]2YOZ:%<QIW0>SL&SU9FQ)
M2BW:3_1U0I%Q;EN8&4SF2;D3I0(SI?!4$5;C)JW)'2,+?X%_]U3?N[AEW^K8
MVW-'BX'M)4!JG#6'!0[I,A^>/:;WM@_>\_+CQ$\OB^'>D5!)B-V8N D%!43J
M/*%T>$&KWN_%XW&$8;<-KMQH3!_4S;@5GCKIK@Y!O'>MD5<#NW.B\\&>Y6G.
M1-T[^73SW-F;G) VI77Y8303;B?K?GW^8"V[K>@TS==/J\R&'58YNIC#-$.'
MAYG#[=?O'YE[TI,UV5V[9>?<=\?;@7O/^>Y[2CO@U9(C<-P3;/92#01?/+9G
MPGA]^M7@,3]AZ2"^)U7FN.;.D15>Q]/M0!6-(!JIC=]SD\'4QH:VV\,S&.T+
MW(@M-0WK-5_E($L3WDZL*9*_$D8=;!WA1DP&0DH2'D7+)LANT!%>*(P?'<LF
MQ/P+GR]'=KXA+=@QL<^CX;-\__9S8-  MAVDR/[11%#,[8L#S<B1!V/Y\5J/
M0*23N>7Q(7K>=MV\ON57E'MTL.\)/?<<; X"';U!*>JV"^-2VA],T'"'H)<8
M/,@0QW$A6?Z8=>R[4H",W(^Q/K+>'15.H(/V6V/72WETM+T*R,"C7WF@R^T<
M82C2SQ<<\Q)B"(JAX[<^F7"/>!+*+B*B!WP$QDM*FN S/D8[/L%V4-O#R;;=
M5\C)HMZ^).RRN2WK]UL9D:\#Y[.2K0!RXA7PD6MUD:PGM-KA8]QN\2">Q@GP
MOA?BT2S<^[ )#P$E\<O-8#1- VL0V!/ZB&X=2-TQ@X&V'0AR#R>G< 3&$DUE
M1* '[GE]U=Z\)E>A3?V/;)#P@@F^N.4UN7K.$IGV&Y5\B1^V9^7Y4TK-J.IL
ME. .<R+"KXM. 7_S*=MLF&4@7HSA$CZ^*NX*X_4V.Z7)$DB^!/.)Q+K&BNJ
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M&"'C$EF_8*62@S[&OEE[< ZD6_+FQM#&IG/*Q0OCG>VQSK([S&#[ >]DR>"
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MJLY="5LWCK<,>SB2H+?FA$!-35!W_^HV"J$2 G\CP40(K^[D_+M?_?B%.WQ
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M<RV,-/FA$<^K1X&,S*IU.ZL+<HE7:-Y@;XI/G0<1EV^S/WYE8MELX@7(^%C
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MC,9>]="-+[V9L]8]/US'3GH>-F/[AK;A3P=-EL8CW"Z.^VCY(1<VS<88_Y_
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MHL,9YO@-[B:*1V[H?Y6+@HQM*JI1-X$[P+8AO%RR2OIB682'H,PX&NB$A8A
MI) ME4L5&:A'EQC:=(*'&%K(/33EX7D3V'*!841RHZ"9-R(TXL#0GJNMHB\*
M4@CQY5+I1"@S(>>D/(X](3(-E3DC=8:/6/5RZW7SP9.Z-P<993TN/^W/#';
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MM?SIU#?6W/6UC75E5E_4SFI\[O>] ;GM^U$TJ#B[<3KBU=J)0/ PPM-E\L_
M]U(%</"J7 &679#R,T/M)P;YW9U,4E16,Q22B=2&,K>Q6D=[[<@2(:,9E!*N
MU&1*U0Q1D.HH$1P.9%FA!X%CD=!H5$\!_5 X&J0M=3/:1><;[6L7PV_+$D\/
MSS,Y:ZX) O>\F;M>H0)<Y+28:Z @W:;YP-H:QRC8!3ISPVCH6[U3W#X<28G>
M8!B(8XCP=#S%7 Y#*)80A\AOP>):XWC(20DQWA#JWDI7KA^P!N AZGY!4K.=
M)C,*<@P&$C?5E-S42%?OD-;-&0>)Q"KGF7\WW/UQZ.Q[O3@%SY%/2.?V8$:V
MC$W=,(?=KA(\(DFVVR=P<;,5$8"UE\9M^E82:-!YYF?:2*K6,9N>Z9;,)4 -
MXWAC%"T8+!JZ]LM/77)(O53H)J.J]1M1&SART]Q+&VS=F>VKYT,%XFFKF?51
M#<KS[!X]N%K6-)77RWH31!&<4/1?U2(N'2ZYC[HN2/G::#*J&A+P<</"2WFM
M<P/1WNY36Y^,,5M@S"DB7[/L7!!L3I3=JL&$"B@D<;<064[&9-%,J*71)!NE
M\1(N9(0_BGU+\])M#GG19_8,[Q0",*:N#@&0P@H\-U$! +BE.4:TBZ_,O4D3
M5=!:WL^ZKA0*DDI< !A"Z)(((8&N<G34JK)@ZI%DO0%?!>Z7V=JJG"F)C,-C
MVZ@BH=:MQL-&<=4R:GR#['KD]BZ!T6#-(/T*J1AN7[#7;\Y-RT7Q26Z3JZP[
MB".ZNT-HA\A"NSE061Q8>I(PUG&9G.>BBZS/;#[XO/)B/TETUZX[AY6L@RV4
MT".H<9$"X"OYM)KMT,VJHZ\J-(<ZV(/IE8:><42^%1VE)SIKIK^HZ[2JO(E]
MS(G#3D532K]$@W687^C@_2OT3JCS+*"P&D@F4)J]ADU$SVY<2G:MBO#=\S@[
M:^:9.^I$G=%?N#'HNB170ZU1\J_6L;[*?<-[3R.;3]TWOJ[JF/^$"T2;(<TZ
M5O<J4U4E"O9=$,7S&).M5HZ F*/4[;S@(Y3D%:F7/X@]J.L?..IM$_2'A%KV
MX#"J?EYT>(2X*I&&-_T^U3N0&R599-WM5J@XQ?T!30I>ANX9@D6[*UM=U4D6
MCEBC4\D:&SO@H<BI4"M]'$^QM0MZ2/!5LXXXRV(X,#/B*H_6 "<D\G>GT/Y3
MO/=+ZE*10:+4')D)1+5#K2 <]!/ =B)4@]67@\E#N)R"96= .5V+I21/I&@Y
MS'Q%<MM-ZNJ" 0Z?\_=PL0F#"4^7>-!RXJK X6@K66WH'KH(?F*ZVW!=B9JG
M7+MYTQ-[E5'#T8H%:R%I?N@0A,(_](;@&M.UW:A3LV/NI,/):.\&%C=!DIBY
MW0 X.SHVX4J_8;<20"?,5&:7*$1)E$E1M5X?5R9*R(,G/J!E=1YW E>]]>:@
MYZAZ'"6-#\LJ\7G'=BF^K3<)W^).4.1L39N,P<NF=54WUSAGU.NG*2'15ULF
M*@#?F&JFIFOLF4QU*C&_AONBHI.I0P?9G><@ =JPV: $7\SF=VXP=%7&..^A
M5/0<<%:(BS*LPD0V$(Y U8[A$54B")90%I;0>;&,0&&I9G-=.C50!$D4",H.
MVR5!IB:H(VR[C3 T">K!S-.^;?QH5)''?C<WO&*2*R[3\3$F!2XRS(H&(-UG
ME=.,@52]+S@A:OT>J2JP@8DQJWH?!=JQ7T@9'<(K40 @MT37W$!I8K!/\+8J
MJ4+\5R_BA09=U=WM)E3G>>6SVE7]P,'DM O3E"J3@"F^E'0_UT721ABLB[:6
M>AXMHVT@J<V-/43&L9+($$<;F14E%)'QGH;PKJ?1&'+@R&V[&T9.^L6S1LB0
M3J@#>J^TNYT(1P()C,?#?J3F4#!E\+T=X#M\J2P_=*>OB1^G7H7T%S O%G:Z
M(GJ>J _R'.FX@X'4ICO/"E8\?-UO2:\9[]]%>]L3$!I/$P/II^?5T/WO_S1;
MVR_Q1BMJPT1'HA=QC,AV5Q3M,CV<9!Z\<2/)V8Z7B1V>?.DT'C#W4L??BL&9
M5P^YL7-.M9@L(&@!K#S@&NN?!L:P]0QC>(8QK ;&L-A*RP1*(S"6L?45G".Q
M0>"&"UQI(CI3).,<HVA^XY''<((^\Z)Q2Z!ATDA4WSN]%$0X)'1YFICQVO8Z
M$Z<B,@ZT9H\3JK=?]*MQM4\T. 0M77.%W/EJK#C6=8=3O=<EIW<O&Y>U6:@>
M>HNI>#4&;DD=RZPLT\>B0C*)(;.U E+&P5Q'%JAM89S+1\#RCC+H*TZCN:F*
M*&2!\\A,*L"6%Q?L';KQ(T2B6K>0.\"F$3KP1_07R-T[GB?P8#>LW'E25!R2
MC=XY-*M*V;3.D*:Y&#D7*\O9[A@+5<S:1[N#"]'$M9-7.*OJ_F9]7:&99EC\
MYZCJ!&Y$&1'+70&/O5&O:]^,_?DU\.RS&V5G?@KOUS'\QQ#0QM;"5]_?U&3F
MB,WM;WEDWN25&'#SFQZ:LVV5C"P(Z]ZV[^W&0_:]T<CM>\TYOXXT![F>'1J=
M)5[6H\GSRH*H*E6N:2<7Y9E5XR62=LW%GH6%*Y?K0,!_)][ =Q'%(PD#+*]U
MUOR3LY/U#%2 8E^?(Y\BU/P:?G@V59[M!VX X$EV%!P4Z'O^5%J.A$-?^>3Z
M6!+.GB@O(V)\@=$*5L+0IC)=:A8I$:4S160G^/)J.HTL[%&>Y4] ;!1Y+T>Q
M3?4JY=QX@N7G/"TN1C'PHMY<A8!+>E>2K',9WE,+5*?YT(I*QFR"LE-@<I*5
M[T8B4<KOB_(Y]:](CZB1W5U#WOY\.AWL,C<WY 75V[]&><0*.MB#B,AB*N#R
MIL0H U(#/S%>CAEDHR"3:+O[6S(9N9R(DM!1LWN?!(Z\;4P5#N$0<R:+&K?!
MU'1')Q,_O<M!R:3<;5)1Z2E-1EO>&K"CI_F8Z)J&AJW?/G=630%FX-2UD,DH
MTU\REM-L[">\T#I/$2J C]3Y,!\K-\!378JU8N(]8BR!5KEVH9"HR])<K-;
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MBG2E3&=B4*]M/MKX,H]&E=9HUMJW#!;3!LJI)<(A56$#7Y)68)D75KC06>7
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MCA\K[O%LC??!7RPY!JV6U^&8K%EP[@H4;KAS#?5I28GHN5A;:HC]+8X<G?:
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M"/T*[6T7)J 4J-$LW 2S4C:I[)!A7DCG4TP0/#[Q@!1UK35JK6TURS5<6V.
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MJ- C.7Z<NM/MGC##H.?A3L#@XGXKZ*96%J(+7%7JPJ[]3+^*ZA#@EH/C$M,
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MDO7ZSU9M*\L5:EEZR]8^GQICFA[N*HW/W:BU<BR[<'RW-W_/%NWIT?%7<J3
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MU25:)61)07-#Q2A8:TZ)^CI,)ZQV[/7UJ5\WK2(..6MEL#L'BYB&U-8)[,O
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M)<DKKFJEUMLK'X/'CFS72L9/CKB$IKS82B&>[+LY#T/"ZH)LS86%H*<,-9*
M;PS'C*D8- 21J%0.IES*%:UBF>M0Q?.=04:_FN9H_%9$$R759*$B9*>R4B(X
M&:>E "&R(.??KFXA&FLDV,"^X>5M</^!B(NA6<*F&4D;4/)[4;QS]_>"7LB?
MRUXV>OQ.#SWD?''R5N%8#U ,3.R]V' Q. N/FP\EX*:G FY4P,V^ VXPQ@;=
M'QC!R#4 6$-%!"/X7YY8J'V 9K80\_ ^KG[$,N1+4&P2X2$8PB]*<Z3D :*F
M,8$4,<GXC<?Z+Q74>E05E!<[#T5G Z@""7=:,7#"\.RTE,'+A]_ Z&P">]$
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MSK:-FF.:6?. I]9TU-2NPYF#G5M+7YK; ]AUW0"8D%1@29.&V\.3PY3#-0>
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M"8/:M1NMQ4TVNZ].GI#/%R'2NBWEJQ-WSI"WGEB[#:G$M-7++ YYMMEG9EM
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MJ-FJMRW]@2&VY^P+L2\CZ$:F(!NZ7BK,?GTJ-E:<M<-L7H)9(+;#6VHHQ#X
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M#;,[!O 4 R#^CP(N^*Z>8P"4],(80)[X_0CP->>Y6PQJ"P.("$/&8@!*KAC
M#G1=]3_*4+PW&G"#8WOU; =\+8(!<(7&3UAEY_U7=N7]5P'3I<L$J)?FK>C@
M,0S@\;VA$_]/F.&]^7+[_=_$_)N8?Q/S;V+^3<R_B?DW,?]_(8:_/^]6%:4R
M=<+QBXVG^=?IG&C,NN'$7=2 AI5>V3*9?W1ZDX,&V/N?Z;1C>N"J41C NC \
M-+Z* 97>T9#@&^=M9(>;."8!(C$:OU/)49OY[*QD7]UAGYO_0ZG$['HJA?J]
M)7[ 4[*2.M<@N1Y*Z[W\!%6&IXD(\E,Y$0KWM$:^;R"__)T*?PW_$YREWO6K
MES3)A^8CE!J&=L\U5S4N3^V/LZ<--1W/I7RL'ICMTZ68:[),5KY)22K9 3[/
M' 12>8=/\DP;FQ<]>,&3;"HH6\:XG]LQDR,P*CM<&[$]."C3YV7)/S6.]+(P
M'E+GJ>$W]EX#&597)X0ZA&AFNA\]7CLRZ3;+NN3:S'H'-MTSV^B/J GX;''4
M#Y[& "X.MW/TNZ_RR$XJC=MDT]JB4AHGMG_A4E@20;S@P_LK?.-T02HFDO&U
M?.9BDK)/_KH0BWFUI.]-:KG%"RE=IL)]OXDF^$+)Y4C>80"FPZUW52@<V]:B
M$$W&@1&G[-"&;0S@ 8HZ_N518MD!7H!(;##_I<=/[T?,S;3A&JFE<@HQ\9F*
MQ>Z+!.L'X=RNFF2#&,!+#.!P:NJR'1G"H][ CL*]_X1UT_./4U.3?I$F6$B?
M??5SI]9G)^=;>9RI%GL@Q<)(I]:DA1(&@ 6^.0?WF/@3@D=<__/G!8)4CS6-
M9"RB#^C^9%MU23QT%@WXQ).\/?WBQ]!_GFE&@>=R!.E3I7+B*ES:0$X4) \V
M1?KUTH=J1_O.=YT.XI<C)2D=OA=ZBZ7L7AO>.GDV4P\WIZBN\EPVP F!AS[L
M*+Q[*>- %RM *KKI-0;0:85N#^9[NLJ3^<&9P:TAK/?WU'SAB?==A3P1C_K]
M@H738P 0_=(CX-HWQ</5O%O?_X2/KB6"7N['K/R;%O+L*UR"U"*GO+;E\,?1
M/RZIXXQ*EPHO?\*9G6-+*S-CE_.N[1N_H1LF%H)]X%6KJ,:62'3+8K)5GA6%
MI9;4[VF(K= /BYR_9N44&A<GI,B47</VF#]_N%M^!:?%B*9+,^Z;MFGJU8+$
MME)!BOU3'8^000:=8?J?4^>SG.Y<W)AO73Z0Z@\\!"Z_<=D9U>PQ78VT,?$A
M(?S,A;/C;O4JM^/+G=)+5S%F]:<J%H++&, /XJ,.I3WLL\P]P\>S'+H.XV>'
MET:K+F)#V\60&Y@;K3\!9'QRSL7W)K[-ZR670>KQB581(GMSW])];95,LN*[
M.EV)_2+_#[6=QS&H&,,Y*:-]6+'Y3%N 0XFYDZEK_2>7)KLH+)@7^85T]JLG
M$]IF[1F>9=V&K,GS^Y8"/V=Y<IE]D^3%U*G=S;%??YB['*H\1R87=#1X%5^G
M5(VVY9JEL@]E.X0A85'L[.:.N3+3YU$&U\E+SHP"TTF& ^SP1Y8V"/'^ENK4
M-2TYJYH$AYD&HK=?^\N5TI-^X+#]&MBUU'KEQC\3D@,,EX3,5$>^>S+AQC(Y
MT8#,<]+:,".D9"P9;OV,IQ*@P*]4/?^9;&>+[2OD<YO99EYT+B7<-:T?6C1:
M4EGWTLCZFB3]-4X@FY;U*LH/H1U6O?!RQ$LA[:A(SVR)] L/N]0!Q;;5D[JE
M6;'MBN<\)?<>_%/@ZKQ!,9OC3 M,_YS@-4(A(LN-^]OB6^_$;489>V*@OG96
MK^]KJP''W_V@3YK)'Y-KB"-V83NT<.VR6Z65E8,G<_4))HE99\'0]_1C\A@
M875/-YB]!(H@Y58//M>T#WNOD,>% >QAU_4@5,0,;8B1+GQ6!JB_AN8INK%?
MN'.JD'G&[-&RLJO&INSU1.Z?OGK1XU)_\,I<:H-)W,EO[%P24A2E\.<-9E[/
MN&] $9$?"Y;LU%V_6\=Y=5E[6*9NC.*H*HI/Y&I)$@E/I(ZD16B0#12')A/Q
M5>0)W\'LO4^#->'G?@+NESL!>1X&:N;I_>(),OVJNQ9D\7]-PXM 3])%U<1:
MOY0-C,^R;GE 8L\-" OI8%QO@OHLZ#5^$MMT\/WV,.3)<'/$.5N]3)#KD/3_
M@0%,=8/WBB V=W'G0N+&\*L8)@Q N[[#<3?1QKRSEO::0JMSH\WA,LIUE4G^
M=8B#SAU-VAZX=K=OC#18<J+A,"04<91[;.O8K6+UD(^@.,B'.IUI)(CS&LI7
M]2*2UJ L.B6.YL"BU>S(3UZ@YX8EEPM!FYM&6F/6/KWQ2/ W[0/J$>H]O! %
MBK].WU?GY(T4A3)W7U.>F.@!QO.TGP\<FJ,"$SL3B0XDF?Y\\1%Z<3IY(/.2
M>OM+_%(V95AB^P7MX1/T#)B"VFCX0&J#.XJ4@3 "^(9 YCZV]5>9UFK.EW2H
M5J78,0HS&B2XF'[96F@H+= YAIU<LVFNZ<Q[J<*"280;J@^G'*_HFJA[?'W+
M8H#\*BKW4;/52")Q7J=G(3<RI+(I=F%5,R@B4J?%_XO@!\G.T3&5=YNL*A2!
MH5!$:7>&%7ZPV3I29,M5^^;FV,S[]"N^:HL3S6ZCP4[KZH<?'5)(^N)]V=E8
M+S\[W-+!='R+VG=?TOZ0&WQZXC5->E7VY>!'<Y,K"$4]WF5WS<;?+LC*))K=
MGI4:/'H[M#"Y'>@7Z"L_UF]5^\74+TY>--]QH6B*5>MQRD;09V9K@\4445B5
M.S+O4JBA8=S-;J)A,39';T%A1R!*LJB(=(UM'N52CSQ$**ZN._2ZXUH-L><1
M/Y?WDYQ(LK!V#7M_0XE<FU6-A3J=X"XZMH3/)@94.C-5;=GVN'*=J=((@EAQ
M (##CR;E7Z.5I:_1#A;O6B.>S-1(U/"+?G$M3#4RC[YM7T;[[04CUJ'AIE49
M4=[-;8:%EOLKK%*\37Y>*GI/7P2F_Z6H"JD KP$I3/:3%YTZ\"9\7&GS>1[T
MT9T&(I+_A'AEPP;AZ,E0SMG1DJR-9-=*?_??S[UL+GV4N&P:U\-N8+5(ATW5
MKA-\F1EOU1GO*U%:67,MD13MP&N[F..K*I?^RJK?'9M_UMM4M#X;<JH4;/NV
MECF.^C7&:RB"M*^D@42AHXV68E $6_./I=%U$5*3%4V6U^8?=SG*KL.HWF.?
MCP4;@>*@#EIR.C/UC]9/Z.:< RW+I,-+4PR,FG#I2-\O56/M)H0V+/O[7>;#
M!V+6$)*QFP)$5=XAV@Z.I@!MCC?XL(&'B.Q$TZZ,#5 W!3&RM4>U9X79J?)O
MZ9EP Z/A-T3#IS71ZR@NR9"R?L/IM"ET\H@924\#+X^&P8*[B8R&.%1*K0@F
MU$YE%0#UN&7::S+5&IQLTU>8+<8UZV$@2-DEP'EX-6#M!%G[*@RUXXI@%9YI
M&&B.F7<P!HT*NZ5Y0!GO7#K"+LN1P4^9BYEROUNG*#*IZ7R)_-A@$,K#W=9B
ME=#!-A5*DL/??U0,^SY-=<QKRMGP:9E(%@-H$> ZU!A6/X:*+T!T(G_&%/U,
M_;13JB<\"55VL6CW:_)R&[A\7./*+=&&8.T-K.MGN3:ZCM9A9!Q3<-D!,R$U
MSCI7>*<EY#:J/!P>O3B<B+1GU[6R3%S(ZF3*R68J7MZI<0UBD6/6_J1.2<)N
M]X:(Y6P?";H_I3R0-UZ10D245DFX4RUKF' &D-1"E/&BN1 6TGXFH[=:B2D;
M,8QD@D(\Z=)GJW^'H+ZK+G70W[=U/1TL/\,Z.RC3I[J9[*N$?DL.>9ZX4WW=
M%-TNYH*,?B)@/3-I7"5O>UR"<DT6DHB7T?J38I?[VRP_3NI;SU$_EF)/0P!%
MK_L"VV P)WPG8YW5]WC$LN%6UISY_41.+#4^<VO\HDO*70Y:>-X?-!!8W;!Q
M9W3@T-)PVC$EXY23]7XM-76R>8:QP^D&-59?ULMHW;O^TS>N W_W^+1_Q,(/
MJAJZ<_49 W#(X1QH&8ANL-"WU.*?5=#>D:YTI32UJ. D/6+YN <H\X',*XXI
M(R/7[QXU?-N=?&J7\:[[26W_(%:_+.5@=>KZR1'E&I#<47:FH6?%Z<KS0'SI
M^O+]<5"XDR;?$(O'!]6WIK(G1XQK.2Y];*0SJ:\S><_/Q,T'N 1-I+[CY*+B
M]/6JB]+O4Y4/ 8@N^,PK03N^Y].N4B<NE1<Z%E4A0GO65J']F?+)+@_V5_A3
M+#1F_ ;<$,+4 FE4;[8<6%T<>M@).MBT;H%=8#^AA@K+A0&AV5][3,9%7%0Q
MVK[K'=JBFNL8P )/%YWB4T1ZOF0^_\(!!Z7;BA+KXNNP 3>7>*0/(K73':Z$
M?@"ANVL$BKRW;7H1/+'CKL?@O7MM@$:_#H;M8P"X"\"#2S;H,>WC4:8*$TLI
M+=[EY<5O4N6SBVP"\+KN)/_-#;KP_*76Q^W;G>K$<-\/QA\O<-CC0PPW$QE0
M$DBMC2 @O@62H]^,42C=I-1,>NOA@V>##^OR,E*T7;;<<?W+-[O8A"8O%FU-
MN&N^:E"V/-GK0>#&W.1N;H*[3BA=+A7%IH_<.1&TV<\I2=^I;99@+<PM!517
MOC1+F6C8"H:26+^?_NGSENG+_JRGZ;3&4HX>=$Q+04<6#NXBP]ET2&BH@)*:
M+SFQ43;Q=FK2V8+>_G8DVN_:RA43\.L'U_ZVQ,M2A=7G:&CIZ,2@E]U<C]>)
MNU[%B!_+["F;P(%'H((%Y%6O^ '3V\ES5ITWX96;V&K#<6XAOT8D/75T/\@9
MK%*!'<'$YOLW]HG?EP\"/S$/<K6TM^<:D5 -5B[172>RI:4=EO5Q'97F58U9
MTOQR,V9J*)66;4HO1_A!6T>86Y4O%Q9SJX"?O1\ANH?G'%O>-[F2+?5<JEW2
MG:E*]XN?6%&A7GV2<X]:X8EAF.1-U?]E$$_#_X-*$H#S'5+V^*Z@C1P#H'/U
MJ?DQ<I?'EG)9Q9,T?T;ZX6/B=\@75$"YV6&H%.R"657,=-EJ5/Z5"I&*Y_.!
M\8G/<84B =YWVHJB?6]J&+Q_3L7EU;LO.^T/MGHW7]TU14C,28#)LW0(G0*C
M?AG/'A@U1;_BU7]\;965[7%B:;')/@_I5GR*+/YA:CQZ%\$QE?\K':83_4(P
M[E3XJ)W^$0$.J_A*LU6<5;U=SNJ'>@$1O,.K],!*\EC/V?6"Q[BVE+D8@*1
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M+&+Y*)8AZQWAG%#N0!J#XDY-F]"M,I*;57] TK0W@T!S^GC%\7$"Y^W<-X#
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MMT@]0;AL.L^NW._]DH+(*>R%4;05='UJ=^EOPVJBKZGR:E3ZZO/I!CDA;+F
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M_?5=[[/?Y_G%?O9^F2 B!P3KH% _%?]BY)RI27*I\OGY\8@MNXO(]B.(ZB^
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M"EKG@Y?,V?[H]KL[3_7C/6JM924'AN/@,O;J=HE1)5Z]]KT[0'#.^W'L<,Q
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M)MI:.PY*JWSU,:&K>61+T-RR-1)A]=87[,?\CA/,MMO.RA)5OO*8N=5;I=Z
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M%9)PS_@J,/Y&N$+%+\T(F^5YSCWF_FN1C>:9AT!(!\V16H4C?=:I'G[B^AV
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MG:$E2!&C*0GV4XAZ*+>::NVXO;[[,[?[=\9&B_U7&YJ?[;1_7F4-OB]UWK'
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M' !#V7QRDVC3>]BC5R&_NRM?/P".(#>\[;?;N['2;:^K[H:?6D(Z=8MRR!X
MG1*L;%IWO$OXAJI8OG6[D@+9,^=M(1+TC.%@66=[^('.',_ZJ7:UU4Q%W<".
MU2=Q1?VZ?FS1 3/7?B'>=NB?G)XV(G=[$T[KV4LBK"5OW3GGJAQG_H0F4$**
M4XOW*,>T(VL3Y&H-%0<'>N@^>N\2Y(9II;+9VYHHY@C%35 XLY-W]0  _=S@
M>W:4-XHIM:LCR@1X77T)T)6OZ=V(["^G+,5R-A5%:9T>3J+4$3T[(46]X/?@
MUU5/>VKQKA)7;73>M#NLJA._=1W7\8PP[=+5N<T'2U 4 ]7P;#DK(%:53$1;
MZ"/K/A1L)3/LYG;G;TONR-9C?GP ).3%[ [M(0O1UE.E'!]QE70Q@VMW0I*I
M!W$TNWX']U>2;EB'EJ/$3S.45 A[5WN/=Y6#K+YM/K?*;&^3^$[T,V)?36BK
M];D8)ECP3# D'/S5F $NWAUHM,_I_><F=)<N&K;,CQ@\W"0OF&,N9%@[A0R9
M:LDS2GR]^^_PX?"MME7,M7V"ZFH]4UR%R-';]1RAMV*HKL@;5VU'PF4;'Z?3
ME\%'"=]2N[J_#G^5-_W[9\D[5G[5X2WSS7E3G>U)J#^]EXLQ:*- \UM=%<&C
MKQ^SM,;D#ZXT%K;VIC%>1C<M/3U3]"KU,1U"%3P KB8J['?_VWL;*Z+Q&G\R
MR1'$S]^N*UKN=37T :%2'-8ZY.E=NC*O5M*9 G];1?<I<JAA1>:KA9%U;,/K
M5JO3ROP-G6DI"N7-A2-#52G*:2;%F5@S+IXOSQ@]AZX5*3W!YIE:-)>MN10Y
MQ=R'KL4HC49$'3  W%,GHDZ%:9UYX^LE,7X!NV]!ND+.1&AFEJ80CR6YP.&S
M8^W\B(+[KOY?-R[\QPS+)+BWI&H"BI7$C6&29-F@G2/J9DZ<R$M9!+V]G+)Y
MD4A8S*DY4_=+VMEQC/I^EM$-"M/D,:I*:;A)1?$R;X3CY,Y@7_=5^K3BXJ@>
M_N*P>GF)Q,K(>1?&Y\P 8LP!YO164]_4VQ7>.4W29N^VBK@RP3@*F\:=XG(]
M [4=HST!+DJSRB?BK^L!V<UO=Z Z6A:KE872S43D9SG1@O_<CJSA7 8J+2$Q
MJ$9TEGM)7(T_XJ*&S@346$3_BS=KB\X)?<G%U^]F;'N@VCKEV(Q[7U4DA#*A
MKW6;2IGGNU/^'F9_@"X9J'T*D#;-((8JW_H+STV9=ORX:!N[G)I3ZV%4^(<6
MFKH<(STP(/^3MK+'B:=ZF#_TA2/%N(!$#3,ST- ?;%AW$]$TY33B!6GWEA 0
MZ6&,X/>2-\@BO@\>! &DAOL&[=+J4(60%?@C^=,YS?[IF0?R*4AAOR]YK*V7
MHK8'1_^T+//U1VXFZRB:R;Q[F3GU\2S:=PEAXY_G,# $NQ&Y9=0K+^DW$DMF
M["8BP\VW6*7_>+'\.'UT37%E3"4R_U/0_*(7QUB/&#B],#G3\DODQ*^AQ(A)
M:8$AWEB^^FP!+0EWQR);,<56"?Y7D"<CE?_X%K,$X2,[=Q9?S3'44AV$MXJI
MQWQ>-Z0#RX GL!LT!J\'6KEM##%^FW*G*9S2^8V[<!HW@8EO2<(L^L_3" ^-
MP,QLU\!VMB>_OYEP34DH\92D"-R$J32"Q!.[ONF3R[ZT+NDB!.U418BIP,+
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M*AR2-)20D,'4,,@K!--/;XL07'E^\JFNM9'B?%^7T;+V?3EXP2-EJ?W=AO)
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M]%1)L%2F+:0 ,S*^*4ZDL-G&__)D<_QX1Z4X9-(W*FK[<Z=MZ4P(&OGAC_&
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M>TOS4JE?9IV\AP;U %@W>*R$5\,*45#4B?DN+Q$RPV *['T*E_T]RH20++R
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MA#T"E!N:9JBL6KR]-0!K>(JZ(_8+*&6.U*@2XLR!@AE2=^>[1(VSN^>:E(\
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MS-Z4)2CLC%@]AK&MP=#C5&8\O1+]A=WVE=GO>E7GU-//V;9_D.TEW U4S8\
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M=3*'7]$[+DL()-VQ8@QEH0(FY'/'EM/VS+637VJK"F7S(W^94%'P-<J;-__
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ML8O<KNPEO_S&:19A#@DZX(9]_H EP@DC#V&%1FB/"57"M-@'#0;<#L:O T4
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M>9<X"&M,2ZQ5J^SRG+?T+B)0@N)X!T1.U)0-QZ'5#_8X;O-7)0\<'IP5O8\
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M?7GA<".)THVO 9]C1ZZN)#- 072HV(,8D2KA77.Z-!+S=[PVTGB_7[([W.K
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M(E9PK_D!_HH>1MTS_H+0ZAJP)'\-".- Q>QP'-]INP9\\[X&W+ETCOH;R-]
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M3*J8">%SWTCXX2=^SH ?C0_(_6TSNY#7 $>0"R48+F><GG_0FD:7!@;MJ;,
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MHYP4:K%&(0;9G<S),:A]SOW!YYD7JP;-[9D[S]K&#A36K8_?>PH N4O92!X
M\&.,7R-VVXI /M) U,6.]#!<Z@S5,!<%$]K85A:>O_JV=5R$(_6LN]R_!A#
MSLXI=/V/.Y9?7XGI81PRA.VC=3I0K?"9JT.S]O32?K]:TOQWIIR.4B%,EG&@
M]\&M]L6>[228:.]54@KJJPKU0!K]46>[NC2&[&>5VR$(08!8*1>K"0>:8:G1
M%Z:@6L*;7PYF#J"GGTR<;@4*$<W_CAS[><_RZ^Z=1X!07[IJE'5GYD9\(:8
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MQ;GB&&U#*9BV+!%AK8J095%RQTSA+'GSWZ#B>IU[@W3Z@.]8_A:P\X4?^!J
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M@?^H9&0C)5;C@&@YW8C8BX1S,QT"V3JO/B)NN((2NN_(M@)+9C%1LX^3_HC
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MAKH:P[P[XBG1OBM9^1'S_G&0H7NN"K'DX>9N6P$(M#-E/EQ8#K0E<&5<@8?
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M[+7V1[JVVI!=086??\SZTQ8%G,_.Y*JB3GJR^8AV@Y<,F+'30\<WB7JSSCE
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MAN <DOIDT0? 8V,C;[8M28^W'4L/@&J909WK)G3C T"@42L:39[\KGYZJB=
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MYLDGI,1IS/_UNTH\'MO4@]O<4@7_+%3 ;Q>NE[GH%>WPX::P#=UT;C6%TE@
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MGPA->$XD$'>(ID:]G^ID&"CYZ7PBV*%YKAZOIQ;8K,J54DN=)2SC+T]C\RF
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MM85DR-AG-5PE]M<*3W63B7F$NR.$1<JY&S.9]::TM/H? .GA: (4)C?(X0&
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MJ[J"2XN+BR%[M#G=@T:+/Q*-OR;@-7\PA"U5!["7L__S!L?_:H\5H"#N;X2
MB^BV3J*IBS(RCTH@64TY6)FX96H?L-S\B)H=-A@W=(O"1@:Q)O<S?3.7#P6A
M4G)Q-[H$B7\12RB$<T&"6TVK-=WU>+.IN;,C6Q^:P;Z1&*&]J,;LO,,;9CSR
MG.;5$:@_CS9(K0HIW^M2LI^E&.K>RMC:U'A6'+C-.JUI&QL>"OF8R:(HOID"
MF:FIB8"J7#X ).@U=2SY%T,F0EXWTC&ELGM35P8+:'5DT7EP0E[XQXJ]D>!+
M_(,OG$3Q?E0%'.2$L S?F''9ZI@P-;I3JQ_AAJ#?AKIL>% IL<R2I"+7^CT^
M1VRG^1H&UQ!>5[N63DX;)@&C-_"+Z:-0Y&4FBWM41$ZM;E<1K5%5R=P0C<W*
M&$.GTE]],5A0!4GB/H<@0F3DNDRLMJ-);K6;78EQ[_LD*7$)/W+"MH4^3K>4
M/)S'<GRUWJ1!-6?FT+NCFUB)8I;I2RKV@OSW_P-S//Z_DO^1>2 8:](\IYWY
M>@-9ZKF4K;-"+@%;Q5-"P'4\&E5KA7CO"/3!\$<VNGF:K%^SWK!8,B7CJ2+T
M0L>4X%"Z"R\7V$8%7)#3FZ BWW[#Y W4I:;H>21@^79"A9.YS5Y@:QS?'BT>
MW0//+5_/L;28U(RUEIS577+46Y ]SDP3_*#]T9K!/JCQ_D"LBY(Y8<[US.D6
M_%.BVE)?1 U4^4N(,]N8-K:QT3\]@D/@+#*"G<$C9Z %[)#UY)C)?BOQ8V)K
MX:<W*#S_\3YP++D,P?&%*&/<4C5O0B5?ZN*O81*>1V4I. BO-(,\K8- &$RK
MV: -=CEO.F79ON/=P2AXI&51/QU$[0,>JG LN!W7BQ("6CPJW[+55<K<PEZ
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MTP,@#/VR!1E8L>>GC6S31G#GYE0HUL4'/CED2S7:U'X;^VB4/<V=43TBJC_
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M+KZ?Z[]\U"VB2? PY)%^@E1=$VUH#=-CGA0:;?HAJ2>3Y?42$K?VS>CLW?=
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MA$Z;A<#4C@ 78']]W/V=R0]XCR&^"B/Z@\1Q"(6U#-JXW'EL=Q !*HI[*)G
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M=B9T<)QM5*'FKM58RJ&N;<I?>E/G-R=X$GY;V!9N SD4K.!>DIQ'1"HUGE_
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M#-0AYADT#]3;/,'<MLQ.V:"YJC[:BAH4Y2YFS?]TC_X.%.-I/Z#S8@NY2PE
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M"1E3VNOYIYRDK:K9K-P/'-DB3TD7:L<K8>J,67[N/@U.X4?S"?VZ=4[:4E\
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MH8BN%7++*D>1/(2^XIUPO?W""MW>K'L&3"!J_AA_6Y7T1.#F_DGNWS5N&H,
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M>;PFR\>")#R[H=8Q$U080Q,KE>7:V45FG=B!8)LF[%.FM+Z_9/7[)A=']Z;
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MJI0#W,E24>Z$_:?CBD%8@YN;!5Y->O1Z$<8Y9O7I_UQ/DGL!V,I6N8,:R%;
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MNUA&1,LML:-\QIZ>= /_K&7:U?< QYK=L0,@*C]C(Y08[=Y[C-/EM2NS1)/
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M)NG(\^V/F=^!GIEOE&-V#)X^/'7X<&,.NV^3AO-D2G3^=*)]2#[>L*8I5(/
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M:M'3)":'#X#':LL"1L[EQF?#41D^I2Y_3U/%#YER<@F $M:[K!?,A)/?6=4
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M4<+2\?K;8Y/FC8KD^8/QE?$#57^"33(_ H_ UC94CPB9.T4\!WP+87IQ8R[
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M;*.6F;]S= ')WV\G=@,4DVR@2TPQ)._0]H4^CN-0H16UVSD>0#66K#P\?^5
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MCS0R?#E*YH$-B&_?$]/WL/8Q)=?M3;L%(LZ]D,KI3J"5W;]#&$.@ZAA9R(Y
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M!/.7OJSZWHWTV,5MJC4 TQ"23SC\YA\4:Z3NV0Z(6--/[J 5_UYW53@RY]4
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M4FAD)EFNY9!V':[[C%Q<-[>I:DRR68LZJ?IP_7:_1;H<X")X_\'Y(JK2:,5
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MW[9=!7C((V,0I"6"/50V1R8HK^.9%_K%;W\U[P,M;%8C:6JL.#J!I[0G*1F
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MQV:]P>^XECS<B;'>WY0CZ :7&T+UQXK<6ISS(![@B?TRB5:,-'#R91VS.D.
M]ENJ*85^%ACUJH/&H<ELLR[WNNW7]RYQ$\D"8E1\^"F@]*EZH1,ZS0 TL%>V
M-Z;J.>+ [[H0&+%](MN@X'12,4E!MWO2;E)6@4TV#19M/.;/!]"@;(7*/_DA
MYE'5M69J[ ]6X$N-Q2<9[LZ?" ,!]:ISSI*F:0QR+&!\JC5G<_98RJN;#)]/
MAIM._D!+JBF*L_AX4G,J,Z\#J?>W[W4I3[C)Q-^_UXS]751O*P[#8UIPR @%
MJ1,!\TJ;/J4C[H"Y2^+T.KQB(@$:OY:^9V_A!'; 6.<3=TP^1%*J!VHSXMO
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MU33WT$+:T Q+O0SJS.B%U8,<?E-"MN]-0N+J5#/O\9IT5POYS*$I'?/8%B(
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MY_1#R/5'EX 5/2D.P4&CK_V(&GA+F.SAP2,3)N +*M/<C,4#(2'CPG/I3)R
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MQYG^W,T+/#_S+R92[ZW3J.W#=8!^RTE90\=9K$'31,;Q9D4.7"0<63Z.^#(
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MPR5N[1_F5CYRV(WHF=+^5[LXT0QJLZ6I(6Y'PK7P7*B,,H6#,/#WKX";$GD
MV<$@CV?HME.5)@<\C!DD7TMK5QX.JJ]ZKU8=>W<Q]NCF@ O_V'.K:5+M4?)6
MO>+!Z%8#!N?139$[T2%_M)#/,#KN6GPYO'_93UJHBCB7#3E-$VC[0_"XX^<A
M V!5W._I?XA#3%EU^-0T*#9ZH*Q=+(U0O-:&J"E?CV<?UH?]'+4\_&[YO: '
M7./5!ET.5]@0X"0K*85K57_)E!R'4=2=RY#':L&L"MJ7WGD_X]$"I%\1>6G+
M21:A<M56CHQV^E</ADDF+]8,6[W1+O\II#V0"X^X\,M4Q'/O1R!TA^*)"$<\
M#[!;I4*.;<._^,9US:F..Y)?XTL?'?]A8G*Y/V5XFH4223!DL[)RT5TF20BY
M*Y8QWL?JH.!.I!Q?@W8-U9;/^DGMMD(9PH9WN*RM)[LEQ,3E.#O"@^N]I>5:
ME4O)9P#'$[="WX!^DG:16ZZS$N;=SQ$1W3X][))43)^&?73FG:Z,$U5S"[%O
M* .TBU(0UPA*B2<H7 )T9[9^>C>XOFUI05;(.#_59JM9OB$(AGHU<1A8NCLQ
M+QH(4AT-4H0_'9,?O+KQQH[IJII.J5Y.M^N[909::0YWJE-_3%/!%;?#,-\]
M4/@9@-L^5O"&I>^VU;!G;S.369(!=2A1J^+CYO6RDF+A#!0D.J8[P73O#/ A
MU3$CS_<%R-"(L$@\*/%RMOZQ8B8:V[6(ZO/WZ/2T92-#4&0S$Y+"3@^VM&Q#
MW!BI&O*\7$7+L+C[J<3FIJ&5719U&G;:>/Q3(PN[&Y2.&1\H&-AA>#0!3+-8
MK*])?MPM+\W/#WIT=2$J-;6P,/OE9>-?@%?7O73;_F_T!_W9Y(53AOLL$)S:
ML4HW+!\63>DY[TZGZP:/%0&W^UV']?)%1N](=1;4JET?/'@SEO9B&*8@R&6I
MWV":X5;P&(I:@X!98LW;7(6>SBO_^CW ]/1ZU.#!X]'%2E]I-1TW8>EDR.M+
M0]-7YZZ5KNXNICM\9>5B^A(["UF[<Z=L.PASKGPK/175F+*LI;B;@A?*JM?W
MB\\ G+Y?(%/-U*^>7QUK?IY(<OS<<2_GYD/.N.NYM@=;:#"=)LMCKMOY7B%4
M]Z:M-TGQ]=Y,9-:LXN]Q\-.P_QC-'F[7 )P%RFF3%%/PU]#X45AV4V*;!]2S
M7/'IO07^TNV/$D8#F\?SE/G^3WK%ZI@%1"*%Z6[:@B*JA(S6&:,\QO=4%QO>
MVINW=-+5A=5Z5(O46]S]<Z'K$B3]^J;::^(?&4[R:IO&+23YEYK&(=,!"/B^
MCO47B=GJ_73,T9I'%*%8QH0DG9:SP6,30YAZZ%/4]ZHJ,JY?+L1)*)#=G,K6
M('$&L D[=*>6^$F%_YM6KPY+QIW$<1AX+&2(+5G_73L#O*:[GY 1*=K]U2=G
M]0,+Z&GJ=@L;1<TNE,IB>$UF((=C)2!.K7/Y#%"2D,7U>[V1N]_3W[32H<Q*
MH3.F;::M0DUKC)FFF/WU8/8EDRD?R(I8$@*;=539O8>>G)CHTHPL!Y6!Y#64
M&A)70&*"MPE*$KPFM?Q_NVV!O><!.T$!1..,39W)5!F#6P7FDSV>CTJ]$QEE
MO3MLX&HB'*T]27^5+Z.S;MW.W-CBC]+GJ%$#^'\.R,[):LK;/P_HJJBC//BG
MD_M!O?ZEV- @@4U;29)1M716WJ\4[Q863*6Y5L9OON4!09J*GXL3C<#YOP<J
M:G>ADFH.?GGDC_,=2@(W1ZM[K13FP2*Y#-S1]8QU/4O1Q][H;)EMPE[C[6WI
M97.I[X]%$NO;<H(3#77R7 [\#[Y!"M</K_G8>W$AN?$J%LQ[PE,U7^K3("!R
M !5"E(M:-D5,Q 2AM]5J%YQ^66$^'==&*:@_[L3:2H\IK(_@ ])Z34+;+P-.
M)X16^3]T/F\Y3<UI;B37:U)$&+.(/Z5R:QU.N#1?3_**Z0R>]&T-:-@F$SQ?
M&LR9!I;N$,CL'(NU 91##8\)S;=6>3:W5MLPS%Z"5UV(X/CU^S'+^8GZ#2$L
M9<-?'(]X^<]A1^ ]L!Z!*^ 'PWE:4HH-+V,^O6YZ")6\I=,<$-K>L^/*:^0>
MM#[@UAG@Q0[?65G9+#[9IL(,JX63W7?VJC$R.Y9;\&'2XP.E1G*H>!2U>_$D
MXXH,\P:X<$:+(UV4RP2@/?G%E9M[55!_*.[ %*M@=R&&MF/^!JRZ60?4^/'P
MX?C""*XJ4,P\^0LTAJNXB.$CXWVSH3U3L'MW,A2%@P1.:/W>5<5H=B.:CBHV
M#Q3O8T,5BJ$!W693AU%>D82E!A+#;"+-<ELK4B'4_#(?PK]AD#VH']DB2?Y4
M2$8NVB EMN&WQ4/G!E1?)YM!Y]X'SB(FI\G8RF'#C=)3EWJ$S,9"FA7"\C];
MY)>FO?I;<U]C,WQ9$0?J^V.I1#N=@L<GO69J3UB^AKQ2GO]=%OX+4Q%B>Q5#
M#KCOFP-9(@9VY<H;2'UE\I1N5(4MH MI?;ZC@W+0F68KFZ>(M)/?_\%(=Q;E
M-=FMC*(SA*\8@H.]%J9#WE4-F[?[\16OD7I4*%?1LI6GT?\\M\,.[O.G?$;_
MHQ@Z%&O4P_"Z4O;:L>M#PNRU@D*/OL,_4-6+US: \J4!7F> <,JPX1QV_0S
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M5C9%SG&&[O7+/*A,TH[NK5#UE"U'FM]UP_CRQ7J\Z'<0.X8<G0$23#%2#6>
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MMADGC$N3*-U3YP'G0HHA= XQCA%W'3_3?<@F?7SO*[YY_M38=E:KC@3M;&.
MB?'?ZX%LSWC_EYJL_'\X!,\F_PM02P,$%     @ ]#AN58O-3$4D:   XHL
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M5W)N"3TT_4./OK,,/)+(RYB?IOUFV?\[PY[^ARS[FV%_MVL<H"0F H-'?!Z
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MV;.$YSZW4?A>]O_H3(/*68@H*G:8%GW:U*0EWN>:MG8G8>GY;6U9IJFZ"?I
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M)EE%4'MPAH(2 ';)OU\1/8HJ/LEV/2$ .*^^OU[TDB0+5/WGB3X#MWK7Q+T
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M4>F0P8^$C899;::)3CBLA,H?MB%U/AU9+U9<:"FQFN@H;/.@2-J6\R(O%_&
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M=4IPTUV$.[MS]5C6XT.=N:(#;[#_XQHSA PJF#K)3=V=AT+26?Z!1 L3P]V
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M[6'*V2@XV,$A?M <4XA!M]>*S(I'I(8)P%32U"*,)ZM!50E[93SWO6N^3G!
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M:OFRJJ[=_#>^94R]AJS,CG>W^3%PD$\S#\WQ?8*J'T!.O=<JZG#_IG875J!
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MA.D/L\%VI4X&#;YN2'\,]:AVE1X&#?N7 F/0BA' 2P_YBP35]':3N!7N$B:
M.\G@J2R:0>1 YJ<\O HAN>DA:/ G#_I3--CV&$MGW3(8D/JT>@"47FY41 =C
M7S*!0MEY\L*?+,"KDX1E(I0T!II#L6]YP\B"CZD$0LM.U7U&'51>CU</;/(+
M@^;MML=E&PS[7W]:%:,UW(>6+ZS?)JS^3U@X"Q;^#]C#G>AMMO/_H%!%:AC^
M;KAYUMT*N.L((A<Q=DX<6BC\TDC*(;3U 9"0Q9J="F<0X\T$!AV^;DS*?\.
M_)"P,'A'CXUWE@GT\2&61]TAO>-IXHQ&J/>DG02I*SBB3C^9[2MA641B_QWC
M;;;#61,DSEL7"DN/.$_O@X2Y,(&KSG\S./]-@"X3D%[N]3>N,6]']";>I:U;
M,@%"W(9X3\A/I9M^\C/M!4T"V@!./<[0-<*,#8+A+_FG_B3Y-":@(D]8&P6K
MXTN6N/-4QH.@%1SKPZC_AV?L?J%0URNXIU#E1*#SH?E[)F#?"[(<0_GI& QN
M'@\Q%NEL!$T#VCBAQ=>60$>QFIL1UB8A(531!@C%!#9A'=[<>57C3X)SMYF7
M@ [0FM 6A]MD=AR"S?Z$;7+CY]1CPU<F44^T_$6"DTSC:>0!R&R6UVTW^87O
M1(=@KS):BB#/*B(V<+ ^;W!YDFV#=S_W5%OYR);<3X6V%?073I!ND2 !ZE-[
MD#,M"/+*0P8=]1-D58[>B?WCZRG)YY/WRYYP<&WEUL:03H)D(C]]09STD%(Q
M=XN8^[''C:2(&'\$KGW,HAZ%+=<CJ(.&L]NFYLOK=M:=DW<M^O/BB"'I,CC^
M#%QKA+CWJHR+"H5&(>6Z I[#R"-I:XU95%G$<A-B/DJCF/L*-9F5J4P&?N&G
M+>FS6OK@QJ-!@FB\(CUL[LZK7&+^RR51)I#JS 3\0\\]@6*5^)-Z!>K:&-QQ
M!'D,%YG1A**&D0U;$0[4!"+4R+Q9?PX^JC,JML:_E)$<V+0FH^H()8Q@B_X<
MJCD\C-[!PCI2XWBA5*F^CC%!R_6&OZ3EC',[4B.#<WG+T6XB0<^XM:UK#!Q_
M0#U'Y#8#T1HJ^S,_,CG(R>@,H<;#UCDW_O=%2D9\>P?-C<Z(]<0R-<#D_Q/_
M/<1[L'JKWM%R_$+, G;MY>UOOJ$CG@./#@9:@/.=X..[:0(Q7JWQC&EH,K&.
M2(%I P3\G($X^1HT>^@R>-L';+()%7 Z&5PHJ)0+-+0J'68_OP\SXT-]"Q+B
MH5$3,PO-8-[NU"4H_]#7BSL&7"!! [E"@=4BXV\TXX[SOP64(N:^0/,7DB9.
MO0%^3V+0<.LF*P;;86ZHG^Q4!F!KCI!H.(-7F6<+VX ]8P::>*!<#%7:0._#
MS4/+Z6-]M7^W$'8T0;U,4UN7D,GE%W 22=6#S5F#@[)I-%V#3G!X$0$;M3+9
M8ORWR[#^6TS 8QC*!3)96W"^\_R7ICJYO'^DUT$4F_#].$PQ&_USO\E+CK^Y
M_V_12@T%'O[-_1I_A0N=?O_0KQ@;_A6MW(F7N_Z*,<]?/>*$K_A6[G^KD)A+
MN'"IW1(*WY4/W:&?_+M3C/&XX1$F\![,<FW?H3^K");?AO),/+@H"SK7T%M0
MM)VL#0;YG@;_58AL9W.0]3V7+NJV>SUH<,\R_Q4$LPAHM8>YK\":\]K_WYL[
M_C<*N3$9<;3PZ?U#0O3!"U-^@A*_;E48[ CPJ^53$2SD3WR4??".:-V[P^XO
M(H"/(B49M@&+K28//U8Y/-LG6UGF:-^^Y5!3SKD[BSL[+R^HE$$U0S:&DY3%
M<3C!HI1\Y-D;KH]<Q#LV>S/'M_>8NTNEC=W1+GJLI6ZS+] =7%(6#5T0F#\U
M:UPK[6-N_*&J(^+!N3(/'9G&(^_8ER*_=*#.;,6N>[>.U_23'GE2*YK07_V5
M)6OSS\T>NG<Q*'.KSZ?AT [B3!*..,6P$FC@_=Q3L4[.6B8L*U?E3@M69C_,
MMI[BQY/EGT\X1"WH 22A1/):37RIAOD">_]4SYH@IFX9=%&5;371*AXYG<I#
MY>J:0 IBL?##'>?.9/?3J]:,WN^K+$LX0N! GMW:\+B)O6D-?4KAU##[/.4F
M$S"(D-!+1KO%CQ>M3D[=51%>Y T)+<XID3P-%EOJ1+XVR6U4/!2TA=?>I$O2
MTVHWUMW1RN^R^9W&[P!VUT/+GG-GLGP&+KJR=;A_DT*[NF^O=HS@OU4T<PT0
M\AJ\*TN_VE*C\&/K(H\@'R;7Q4[R:GDB_XN18(7MUQ[N36E(?CU?$XH.MNZI
M2KPWB49.FURLJ[*2FW<=S5ORG<9E*+^7]&T-,)4=<>9LL0I[1<WNM1<#YNIE
M4ON^7.]YC/GR0:FVPUG!0PL-?]A2^\?GX;L)'A[Z2-]SRO:(D%7]G=\NV]KJ
MWLV;W-]TZ^TWV;"3!=K&0;=^UW<QJLFW04PCEX1NZQ8G0OES*9T)[)V+T[#L
M+J AT#H! ? 8-Q$%>7:AF/N 4$QJ]8=M%S\4.M,.R@J6T/IGZZ$2:+_FL91&
M[N5;S3[6WJN\DP3^,KFR$$/<<-^JWVV%;)EZ4,CH.>SY[3"_"A#YRK!VN3,6
MWX>DT/5*&VKEE9[G!Z O2/A5'#Z0>OJ1&U=%?/3O/BMY/TXNIL8,)@G,K?K%
MN&U'%6K7MVK5^XH??V<%X[]>Q;^>/WPXW\6, B:7IB)3J7>O'DXV<X^ SWVX
M,ZQCY<:O@ZI-#$A-Q3<&S5ZYZ&1]<N>5>_UW.BO%VS]D!"3J+U11[W%=#E,W
M"USRIKF5,ISRK'U0^B4QNEI2 */CK-MEB9.'!]YQK!P0EM%;Y'YRRA^>:>WB
M&YO-K@B<UORM\, A+D LEW=H[U39'7\XOGB@9*GD.[=E66&OWN73N);&Z0:1
M=>S%]9G;"V^M$#,-3""#+SE'O%6Z*L*,[(S]5L?Q!WJW=G\.81S3\R,<Y*)I
MMI\S]+TQ<Y,P:Z7SY.:A:+YKPMHAVQ"/E0A#4@^\TJ<L"\P'9HK'K\\EJ ]D
M'!JDO6NB[;C='_]$%G=@O>?3\(7W88:)S1;'RU,)8WO51B-5%<J'>4?[4QX3
M0FB<!=/R+OC>J7A^>87%AVL'OQR70*AP=Q='B)SN-"%H3%-6EJ5]<AML!*=Z
MT%B]*HVO9O&&/_IK;K/?#'78=\3^@-'I$Y9D[)!Z,;Y ?J%%LO+[\RCW4Y+*
M(U&OO8,N2:OCSMYNNJKQIDY_^(NV1IH>KJ+K0[>@]3[)_.^ZKN(QUX\1;^W1
MK"4=6HX0IV1X]X#3E%[0ILCW1OPDW4LE/,^W"N/V:C)>Z?%(\$DKS].:1!T[
M#>,'3=A4?[# I?]Y^<W.J=V9_:^3.+K!_NC6"&M4 CH:N"?3&Q%PLNN<]<VD
MP3IR9:RNMV>U0]2%+1$_WAV"?38SJED2+UUS7*C-BXXUZK.><[MI7UD2.L3W
MG2='F$LZ4EU-QR+U !.(NJ/#!+"7F<#*7DNOEF,MQZ.Z=I]1TUK=(YZ>^28]
M5'Q;#>@,"FL,HF;..+QU+3P3==YBZ[" 2O"'GD\P 03Q5(]D<;[RD99W26<M
M_9(/?12+_BWU1UPEU55J&LD!]FB!D5B>];-'O7\H%D=K\1W=J[M< 2"ZRGQ)
MXL3)-JXI.<P+XE5I4[NG)NDSKW$'16:S_:V3Y4N$WK-;M62J.[R+L"J0/AA$
MO!6B')"?WJ4BU;ON0;(Z2"H,GI/CZ-C]^N !X$&4>T1(]P?<Q9X;_EH+:[6"
MCS\OUKVN08>=Z7K"Z?$J-H/Z9AO;I%F5:#86' KKZ5P98!]0B/@]'N88I(ZH
M &@C3J(8N]SRI2:K\0G5NBX3\O!)0N,*%1%&4K 4HA25A/9]$M4X*=MS0,,N
M4IH4Z"OR@O<A?);G2;0.+$3*J?2B1K]]+/F&\@5Q1<K0A[>:B8H,GO4@OB@^
M>_#F']>"AX ;@^96Z:W]/8]G9TOXXM6"A)7^T-6K)G-(/11S:$\MT!?ZS=>L
MJ-HP1.;V>WU<W&?[<*QQG(1%2<#[[]BH 1_SX>3 4Q4509S'W'9@"N(]6NYX
M>C_I/%@U<T-K'(^N7._B$.1X7Y?R3 GS3.;4?CE,2_#3I+-W3T5)?/HTXO@!
M2\Q\?SPI -/B?E=NS-/JY0)A /->NIIXP2*A]!YC$@-RNKR7(X1X-MT8+,'/
M'/KZ*N#FQPKIR&U+F@4S6A=BXF9[$HVK.XSP4OUWY^;')\>4?)J70BJ/!?AY
M:O^PK=*XED'SBKG<?<IS=.$;Z:VMYI&G<T[BCU+)?9T3)XIQQ8?#Q]F)8>5&
M_ [W[),D(F_=ZS.8I"3+]^=)#MVP*$FX5I;*!$QU@@7$)/<4G"S9$\EEU8E!
MU"Q?X,O-V.%5\?9WO6L5?K6AN\)D'O+'OOOV_<Q5K;:7!2DG3MKJ-S0S@07.
M.-]Y?>=U*1(3>$BWKLRCN;_K&.JT!3FLTV9W[:@]$3,R>_0^=U//L^'VT%8F
M$!P.<Z8B:*)K:=>90*KMW2]DMR_FQ54/ZAX5M3I)OI3#8.-]"M^4[RL=-;OR
M">ET0#3?QF6O;F:3W=:LM*<[8^V#M+QVI(Y@DU(BAF0-J'>>.0QCC#(TG+CK
M6%]_@N]%>AF7J8TRG#2&X!$:-7LGP^^]DO=B-ZT(WS<^IG;TV>_BOQ,D5@O<
MUYU;]"F +A-X< 3*WU[#AH]V:O[@T<E/F,->[1C2^GZ4.X2+O/UA3_>'L??.
M5R;T%&[/=ZTI3@\O\HRW'/"TX7?P6Z/)CJ+IP'&H=(UB[<-E IQGG)G ^=VX
MA:/@HMR@K!G!H(8)P(=:P=E3YLN!N];F_RDT@R'HT<FXOQ\<U&3M4OQX/6-*
M !RE70:=K^*2%C1P8(V>)=B^U9VV&T;3O;%N/\Q(&6)ODASME)(\8.PQ&^7P
M?7HRE)R.G?!]@%]U=8U:,ZR?7]-G6\E<X)%,IUD8?EY4,(\?1.7CB([.(0R;
M.2; VN4TE M"YVG+\W=9.ZZ8 *^MXZ/305P71@0MQRAQ(@VO5J>^MT$ST>,7
MV6!;)8&^@*.9PFFG,#(,'QLF0&!G G7F+SHG*'&_459OCJ/[_0WP@RDVF/E=
M!R:>0C13**FS%D30* 20L!LZ[XGLT/B:$]*3?U?9WQ_9T4:K0&X26*]$]--@
M FFN\U0B8OW]$N^D#H0,MX>0=QE\)!034.DAK%6#BYZXA3)9D$RJ8@)5^YE
M&/8P.B(V=<\31L7E5=RZ52*"1OV3)Q[*.;_AN6D5MI"F&]*C\!'%55F:*IM0
M7PT:]2?)$)+/NL>=YDI@R<];<F&S5,G2Y),OG$8NE'JBR*3*37FA4/K^N# S
MC>S]\P+V.)HK]CE7%-(ZS[>!)NDFQ@C @O./-K?0/L9 -61;R3Q](8UF>L^&
MIPJMR7<Z=PJW4"*+):]]^,D3QK.2P02DUM)8%IJ.>HY.ZDS%AJPVHW,A&_!X
M%*WB!_A+3PTH'FE^;9MZ$KM3-+HD.*].I;Z"2*HZB*7Y>ZS-AE HM57$G)W^
MBG1^2XAEE'. 422CS&1E?MWBO043B/?#48G@>EYNP#!=93(R4^'(=<8Q)./$
MAW4O- :>UREQ=2JEC';<&[G<#%)'P?H'PR=EF, I],;N-]=P80DS]%1Q?:$I
M5PMC_T$$>11!7\(-0^KM#DBC+:4QR+!AZUO3>ID+7YLI7U2Q3.#1^W8FT"(!
M:13%D"4.5:A"S,9H(>L]AY1,\KOCNW)1TW)<6,:^).,_":P8&KJ H\F$2"8@
M.!JB?6M:BY@;TNTBK+DH!SGG^9U 51HT<SR*ADJ6EC/@88;<9RP$TIE:D+QZ
MW+.FUJQA_=B??"ZXTYM8@%:XML^D\<PAD1].%^6H=VC[&*HT9_7R+8S="(C:
MAM&LS/7;Q6G^XKU<#O>"%IE[,8O1%T(M@@2Y[O7M#+'4>\9.ZI2OQ^YF\$.<
M.^@8[C7D$FS8@EU'I_>C2W$X5?@F^[VPTYKJTA]AP^90X216@EAJ=6\$PSWR
MNS.%3P3$:LPZ> [7=C<P+%I8[/^I/MPRTC-S\@^7@HA8GV#H\G8<RW3DNJ8D
M$RB'CR#JR[MF];)FAA#.1UXQ?I0Q1C;H.RMN@D'ZD(PK> S<:6]>M *N[!#B
MDQB$CW4U@ W&0!I>5L4H._LIHE+5QTFUB.^L2^>[B(AJ)L#BT" L88[1%SV9
MD@3KAZ+DQ00.,V0SC)] W0IRD.LAKUR^B#]4'%U 9S5ZSZ9+KS= 1X^O=4YZ
MO!QS1)&>@=_!1B-Z%4*=EB^?IG$")@,/FVASI.4&#L R DTO^!I]77KU_:EW
M\)"WUT<V81=8$2ZO*VY26ZG#X6Q162^ARSFPEI%/[GI_:U+K9;G.C)$O=ER'
MM)O;BS8UJNB9_LGC2><(HA;W(HO1&D-M(B=653I_+3C[@M"'!^\A9#1(GFD_
M]#]WA_-<EG)B HXM]!%:V[HA/0F^%K.,(%J:&%XI3_IYIBW;I+\H-@96%SNW
MX&,.O*#';U[7(%GC(":L_UD8:DI=8P+7?K+Y$V 9:R C0SWN/L]JC)IY@?N0
M]@(J>KN$):X?'],G72)LMCXR&9TNPW=I2RJ:=M(VXQT3,!2CHLD&AGS__:UG
M@^UO!^KN'(BXCC=1-OVZERP8P:G2_;4PN%] AV._D)T'8L^XRG&?Z.D:$=YH
MMW-Y4^:G&YQ=/F]A/U*Z[<K"[::&$FB\AYUSS9O\(?UUI<G?BS_$[FWITW2+
M M&$;V>,*W(:FV!8[0FTNBEOYSPAJP)9WF+V0>*LW%WTS;*Y'D>_H][R[?6+
M61\T46MQ!@#!\,?34R^CO!-BY@0^L0?QD-A*?$I+%F%(-X5/**_7&D3]6?%L
MUQ;T6RT>7IA$[_"SQ6]>&-QNUZKCB_(Q0V=U= /DV$IW]0>^?ZXEV%SK\.KB
MGJCZT\JN6G;C N4*Y+4R]W5YF8@3^Z(?&=/.(BL9?LC<DI?^PAW^ROD#R :O
M7!MZ7+^.JVO^_<7SGW_7OO]R7"2SYV:[.KX@6^YT3G6Y8:1R^+WX&N3!:=QO
M):4I!.K92YVB?&O>Q+WA7WH";VGG3'\2SG^]./<V;R)5)#5 I-'FA]N-LV],
M'NTX6N'T6KJS/!<CF#PE<Q?LH9WQ/*;UJ3GY1B4"JQJ 2;_GW_V4(\E[_H0,
MZA+%6+2H+%@A0E$T'#9_XN66JO0//1:+N">S*OM[7;I_8\=HN^Z_K;P\8_(0
MV#=P.TC/1Z!A9_JB>[A7PIS_6;3E-!]E=T5G(L5-?6Q'I.94QMH5>1ZG:+\E
M:8TW*;.!F(!J2NVI+*<\_?DBY(O):?L;:=X_CI&];]WWKTK3=S$K>M!E4IU@
M*O[.0/[AIVWX#P-:Z^$YMC6#*7KF%Z[EGWMN;I#.676KM8EG==N);TX"<I.K
M<=H>V;-P1(VJI:F=J:T*,@+7\ZKZ.HY-UHW;/(ARME)[U&W4>;"X_!TGAY$0
M[:/;]E1](]\>PR$XM^5ZFH[?P:+I ]>B')[<GVB^P)$9='K7"D9)0BDF1K?2
MT#!KEY@ YH"1[HE6;X)<@8S6??8FP><(X]#$@Y?=FJ15A?ZXOUMMVR'/W.LY
M%;)%TJO(/;W3_*7\,OG;G!']9K)[^+2 CT[#8@<:QTH<@\\^^>R1WG1@ZO5I
M;J)^>EAIP3&>) <^DAGIQ9+D4(BR?S%[6G-LWT""Y?[MCL?/2,\<U)K&9Z>'
M%?;]IAQ>_.P 9LB1O7C?_4AEE=CHRY:??]-R8W^R?KZ1BX#.NIP>]J;H<"*>
M/2CXLGTL^KO4_5F*2;1Z]"L-4\\C.RX["'KQ!(OFJ.UY"2C^<SL+.8G48=VW
M#BT?G:R"Z(5D=-5+^EM^+U0P$Y@NP#6:A_L+/%&(F%EZ5<A3Z^ 4== <3SS6
M%#P^Z^W_7.G<>I4>"1D0X?C]U@[K9_XEWWS4*<-U_? G;G+W^F?=,"H]VY=H
M;1RA-8_MVSYS2=N8819Z--V<C)]]<_']/G/7\7C0P1RST?U7(T<M$+Y:RCM_
M[/!6:N9^KD/II+7N"/$Z\H4-34.01=34?(/C%][JRR=J?K4EG?&2')\5O9X>
M\465UUCT]V/E0L1@-HS%PEJULHRAW\FSN7-U7?A+:GA]H=OYQV?<PF.+0[WI
M@QI(%_>]NE"^ANP.NFP9T4)AE)Q+#%UYH2(T&3UQ6]>.-*M'Q'3]F,)?3U1T
M$-OA$+*E2V.M#)9EU:7"ZRPO9ESBUQ)V,%S9,'%I:NAX\'#DT=T"6V*?C3@D
M#ZZ@9XE^;%TNEN-Q'3:$"/_]Z G!>^6==KC$'<GJ9;/GC <N9=[R>'#)+8UX
MAM*SV_*B2_I[Z5P]D[130:'B&(Z@?VP_.ZEZOC,B-W_ :GC4L84)O#^#R#J<
M==>^2W:+>,<-VOQJJD';"OT$7?29^+8'.M;H[.(+^MG&$P*L[Y3DXY]'^1JU
M&^WQF;P$I8,)U;%>F5G"+N>]MF%XN(HYN: ,K1]:5'BTU'B,!(7U;&/[/59R
M!*#<25?8^2LG,&TDJ:[T-4PK5A%*>WZ'?EJ:D9Y9EA?P<2[:JB&67K)>:).B
M2"(^R[;DMTDCK*4:M[!$#4;6$\U5G,!M&TOL3JR$SK72C]K&+N(3*B6&L\XW
M2&I6YLGE\I=HMJ].ZPD[YW<G*^$=GT0Y._,]S\S4K'2Y@,^P+3DT:21MCM%4
M,G&%$@,)Z72U6;ULK(N7ENJD672<BR]/"%?Q:C;TRZQ_RJ9M.JVI! F/;N J
M$?UJC]$L3F@OIEQ3R;3;<,.F"[X6A<"U#;NAHXCB^P&*GMF=(=J7 BXF*QD[
MUV0);\L9G88$6'H=?LQC>)Z+]?4X-%S;[8RO2>$*7ZAXYBYH5.P14C+"<\46
M[^,5;J \17Q'-&?FS"&^:C$F&28\:K^VD87_?._VEB9_&_QK.=AN3%TF_/8=
MM(VJ_YN7+8KA1>>%6V7JK/#GQ(WK^JLJ%&+D2E]QG.2Y$>+KQG:F<1CCY6F6
MEV$P8@N&XQJK33(DEG%P*!$9:S6N%>$,<*\7$>FZ>]Y-=C3E6M!YK8 )DROV
M0G[=O+B:[W[G.VFJV=>5PDNJT@('"FKKROJ>(SZPWU>73O857 F5R"O2B4?3
M#C[,8!.3PBU(DD6\B&V/Q3[YSA93Y)JEXI6Q?:MG+5Z\/;NE-D]#O?7.C*Y[
MWSK[I?9B3GW=CI?R0:L""DGGHL/K;G'9)*"JW[N(IUBT#=GMD9VDG62PO6I
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M(S7N\?EHL6ZEM1]X-#6$W\,A\1[1Z;RO!/\/NW(=]P3;>BPYU5FM][% HIJ
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M!-YK_I _GO!T \>5 00>/7A$7@ O_-^BTI_H!'C-\&GEW<]:3BW<Q4GH@SG
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MI!S4F51"^'BNX\&[I3:5:*NG7H :;QEXIIXLJL4#U)EXUET29!F'(S<P ZO
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MJ\/$V.O!*KR^@ME3?!QY'Y+,@&R89Q1#@/WY?_.(B]#WEK/D<=\4W=M\79H
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MU>)G"^6BEU9-N<BL,7-JXO;C\LN0.9CJM;+FRV3-Q,J:;^LU*EE3VS)IB93
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M.SW#?/<F">)$QUHIW5?A7R" 91#=QH$'UK44OQH3;(:/2Y+;K--65NGT\'C
M#@;!@0HVUVG<K9G5;S.KNV =4R%(BZ:,- [9@H>B"1+(:G9#?07*BYZEBM[J
MIP1FQ;G*8N^])%ZB/;/(P_?P>" 4;K@K.?:I'H)EL)FB?+W@"9*KRBR]9%Y
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M+1',,6V02B;.4V358X'_O-1YUFZ[OFT[KVO;KJ*,,  @M 3VL(5QN6;D5&W
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M&@_#9DL"Z19D+1PC9";KHL$.('U(9?P@U[EAUA :P(@%KZG("_F/EDO! VD
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ME@N+Z"J26JU@TR',W3J^Y:((>2,;4>R\/EI'B,:MO9FR?8OMF\P*Y$<WMVU
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MKBSK=>((ZVOQ)P;-\T<>XB,C5A2E&(PW@LI@MMV(@5$"4E<P%74PI(#1VHO
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MX.D=R ;+&.,)[\4)URY<AS(K",R5Z 6;W7),0W"8:W>''6!A8!$4A7K9ZKV
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M0#71T3OSR8R:RA2SC")(\=O_V-#_8&7]S]_^]K?_+6I9O\,YK75"575"N7N
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MQL](T8<[[B?@?59VN);(1J9*D-98@B0UEV[XQXUZA$>&MMW@22("3FYW-L,
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M_3@\*<I'TUK 19 %:?UPDL\- 21X)LMCV!:,@V4LAP-D]+,C+G$D0Q=AFZT
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M[6=1"M/ M/<O6%)4271_8 ZF4(U3-P1SVGX7JXTHPR;XR$QJ$O#!=I<T3LR
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M(7I5OQZ-3OM(K](X-LQ;$UG:XZ]7)]8K+GR1Y. %2-^\S'J[DJPO92B6S.3
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M5$>SL3P_(*J4@#F\G.7DF68O<XW%=&6G=]+MQ2T;.:7Z6GPCSSL\SZGEF+O
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MP NG&5XH<G#!"<I76G19'R-O/G& UGTF0[8>V&XPVN$B^.XH&Y+<E48]+E:
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MRW-[KU==P;4\Y BN8^MDF^\\U@VZG^?"H#:!<1PI?AVY'O%UPANS_A BSE@
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M'_B2@:<H(@=\JF32P'YXV-W=7_*];^NYU]K\NV_N9;KC_P-02P,$%     @
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MK>'>%X3E3R=:8,WIV509O[@'>V^"]NKU:$YV2[=[H?@:IWT*FS:O+051'UJ
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M&[>/1KW^<%-LZC'/7B77]\WV OOX;U!+ 0(4 Q0    ( /0X;E6DM" TPPT
M )-V   0              "  0    !P;'@M,C R,C Y,S N>'-D4$L! A0#
M%     @ ]#AN553,W=O-"@  38H  !0              ( !\0T  '!L>"TR
M,#(R,#DS,%]C86PN>&UL4$L! A0#%     @ ]#AN53P<"#*L(   Q_4! !0
M             ( !\!@  '!L>"TR,#(R,#DS,%]D968N>&UL4$L! A0#%
M  @ ]#AN5=1UFN;800  DV<# !0              ( !SCD  '!L>"TR,#(R
M,#DS,%]L86(N>&UL4$L! A0#%     @ ]#AN5>\FS6?C+0  >0L# !0
M         ( !V'L  '!L>"TR,#(R,#DS,%]P<F4N>&UL4$L! A0#%     @
M]#AN53'KF%4@B0$ Y7D/ !0              ( ![:D  '!L>"TR,#(R,#DS
M,'@Q,'$N:'1M4$L! A0#%     @ ]#AN5:^UZ#/K@P$ H[L! !<
M     ( !/S," '!L>"TR,#(R,#DS,'@Q,'$P,#4N:G!G4$L! A0#%     @
M]#AN5?!VK/)H>0$ >HD! !<              ( !7[<# '!L>"TR,#(R,#DS
M,'@Q,'$P,#8N:G!G4$L! A0#%     @ ]#AN58O-3$4D:   XHL  !<
M         ( !_# % '!L>"TR,#(R,#DS,'@Q,'$P,#<N:G!G4$L! A0#%
M  @ ]#AN540+<H:ON0  ::$( !<              ( !59D% '!L>"TR,#(R
M,#DS,'AE>#$P9#$N:'1M4$L! A0#%     @ ]#AN5::/D^V:'   ">   !<
M             ( !.5,& '!L>"TR,#(R,#DS,'AE>#$P9#(N:'1M4$L! A0#
M%     @ ]#AN570'4_]E"   N28  !<              ( !"' & '!L>"TR
M,#(R,#DS,'AE>#,Q9#$N:'1M4$L! A0#%     @ ]#AN5>0L_,UY"   (2@
M !<              ( !HG@& '!L>"TR,#(R,#DS,'AE>#,Q9#(N:'1M4$L!
M A0#%     @ ]#AN51ZG=+20!0  >Q<  !<              ( !4($& '!L
M>"TR,#(R,#DS,'AE>#,R9#$N:'1M4$L! A0#%     @ ]#AN565A08^3!0
ME1<  !<              ( !%8<& '!L>"TR,#(R,#DS,'AE>#,R9#(N:'1M
64$L%!@     /  \ ]0,  -V,!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
